id	sid	tid	token	lemma	pos
work_izjlueimqneiljcxm4zmi6kuna	1	1	3783	3783	CD
work_izjlueimqneiljcxm4zmi6kuna	1	2	The	the	DT
work_izjlueimqneiljcxm4zmi6kuna	1	3	tale	tale	NN
work_izjlueimqneiljcxm4zmi6kuna	1	4	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	1	5	lenalidomide	lenalidomide	JJ
work_izjlueimqneiljcxm4zmi6kuna	1	6	clinical	clinical	JJ
work_izjlueimqneiljcxm4zmi6kuna	1	7	superiority	superiority	NN
work_izjlueimqneiljcxm4zmi6kuna	1	8	over	over	IN
work_izjlueimqneiljcxm4zmi6kuna	1	9	thalidomide	thalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	1	10	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	1	11	regulatory	regulatory	JJ
work_izjlueimqneiljcxm4zmi6kuna	1	12	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	1	13	cost	cost	NN
work_izjlueimqneiljcxm4zmi6kuna	1	14	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	1	15	effectiveness	effectiveness	NN
work_izjlueimqneiljcxm4zmi6kuna	1	16	issues	issue	NNS
work_izjlueimqneiljcxm4zmi6kuna	1	17	A	a	DT
work_izjlueimqneiljcxm4zmi6kuna	1	18	narrativa	narrativa	NN
work_izjlueimqneiljcxm4zmi6kuna	1	19	de	de	FW
work_izjlueimqneiljcxm4zmi6kuna	1	20	que	que	NNP
work_izjlueimqneiljcxm4zmi6kuna	1	21	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	1	22	lenalidomida	lenalidomida	NNP
work_izjlueimqneiljcxm4zmi6kuna	1	23	é	é	NNP
work_izjlueimqneiljcxm4zmi6kuna	1	24	clinicamente	clinicamente	NNP
work_izjlueimqneiljcxm4zmi6kuna	1	25	superior	superior	NNP
work_izjlueimqneiljcxm4zmi6kuna	1	26	à	à	NNP
work_izjlueimqneiljcxm4zmi6kuna	1	27	talidomida	talidomida	NNP
work_izjlueimqneiljcxm4zmi6kuna	1	28	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	1	29	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	1	30	questões	questões	NNP
work_izjlueimqneiljcxm4zmi6kuna	1	31	regulatórias	regulatórias	NNP
work_izjlueimqneiljcxm4zmi6kuna	1	32	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	1	33	de	de	NNP
work_izjlueimqneiljcxm4zmi6kuna	1	34	custo	custo	NN
work_izjlueimqneiljcxm4zmi6kuna	1	35	-	-	:
work_izjlueimqneiljcxm4zmi6kuna	1	36	efetividade	efetividade	NN
work_izjlueimqneiljcxm4zmi6kuna	1	37	Resumo	Resumo	NNP
work_izjlueimqneiljcxm4zmi6kuna	1	38	A	A	NNP
work_izjlueimqneiljcxm4zmi6kuna	1	39	Agência	Agência	NNP
work_izjlueimqneiljcxm4zmi6kuna	1	40	Nacional	Nacional	NNP
work_izjlueimqneiljcxm4zmi6kuna	1	41	de	de	NNP
work_izjlueimqneiljcxm4zmi6kuna	1	42	Vigilância	Vigilância	NNP
work_izjlueimqneiljcxm4zmi6kuna	1	43	Sani-	Sani-	NNP
work_izjlueimqneiljcxm4zmi6kuna	1	44	tária	tária	NN
work_izjlueimqneiljcxm4zmi6kuna	1	45	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	1	46	ANVISA	ANVISA	NNP
work_izjlueimqneiljcxm4zmi6kuna	1	47	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	1	48	aprovou	aprovou	NNP
work_izjlueimqneiljcxm4zmi6kuna	1	49	em	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	1	50	abril	abril	NNP
work_izjlueimqneiljcxm4zmi6kuna	1	51	de	de	NNP
work_izjlueimqneiljcxm4zmi6kuna	1	52	2017	2017	CD
work_izjlueimqneiljcxm4zmi6kuna	1	53	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	1	54	lena-	lena-	NN
work_izjlueimqneiljcxm4zmi6kuna	1	55	lidomida	lidomida	NNP
work_izjlueimqneiljcxm4zmi6kuna	1	56	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	1	57	LEN	LEN	NNP
work_izjlueimqneiljcxm4zmi6kuna	1	58	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	1	59	para	para	NNP
work_izjlueimqneiljcxm4zmi6kuna	1	60	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	1	61	mieloma	mieloma	NNP
work_izjlueimqneiljcxm4zmi6kuna	1	62	múltiplo	múltiplo	NNP
work_izjlueimqneiljcxm4zmi6kuna	1	63	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	1	64	MM	MM	NNP
work_izjlueimqneiljcxm4zmi6kuna	1	65	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	1	66	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	1	67	síndrome	síndrome	NN
work_izjlueimqneiljcxm4zmi6kuna	1	68	mielodisplásica	mielodisplásica	NNP
work_izjlueimqneiljcxm4zmi6kuna	1	69	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	2	1	A	a	DT
work_izjlueimqneiljcxm4zmi6kuna	2	2	ANVISA	ANVISA	NNP
work_izjlueimqneiljcxm4zmi6kuna	2	3	havia	havia	NNP
work_izjlueimqneiljcxm4zmi6kuna	2	4	ne-	ne-	XX
work_izjlueimqneiljcxm4zmi6kuna	2	5	gado	gado	VBD
work_izjlueimqneiljcxm4zmi6kuna	2	6	o	o	NN
work_izjlueimqneiljcxm4zmi6kuna	2	7	registro	registro	NNP
work_izjlueimqneiljcxm4zmi6kuna	2	8	em	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	2	9	2010	2010	CD
work_izjlueimqneiljcxm4zmi6kuna	2	10	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	2	11	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	2	12	indeferido	indeferido	NNP
work_izjlueimqneiljcxm4zmi6kuna	2	13	um	um	UH
work_izjlueimqneiljcxm4zmi6kuna	2	14	recurso	recurso	NNP
work_izjlueimqneiljcxm4zmi6kuna	2	15	apresentado	apresentado	NNP
work_izjlueimqneiljcxm4zmi6kuna	2	16	em	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	2	17	2012	2012	CD
work_izjlueimqneiljcxm4zmi6kuna	2	18	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	3	1	O	o	UH
work_izjlueimqneiljcxm4zmi6kuna	3	2	motivo	motivo	NNP
work_izjlueimqneiljcxm4zmi6kuna	3	3	do	do	VBP
work_izjlueimqneiljcxm4zmi6kuna	3	4	indeferimento	indeferimento	NNP
work_izjlueimqneiljcxm4zmi6kuna	3	5	foi	foi	VB
work_izjlueimqneiljcxm4zmi6kuna	3	6	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	3	7	falta	falta	NNP
work_izjlueimqneiljcxm4zmi6kuna	3	8	de	de	FW
work_izjlueimqneiljcxm4zmi6kuna	3	9	estudos	estudos	NNP
work_izjlueimqneiljcxm4zmi6kuna	3	10	comparativos	comparativos	NNP
work_izjlueimqneiljcxm4zmi6kuna	3	11	de	de	NNP
work_izjlueimqneiljcxm4zmi6kuna	3	12	efetividade	efetividade	NNP
work_izjlueimqneiljcxm4zmi6kuna	3	13	demonstrando	demonstrando	NNP
work_izjlueimqneiljcxm4zmi6kuna	3	14	que	que	NNP
work_izjlueimqneiljcxm4zmi6kuna	3	15	LEN	LEN	NNP
work_izjlueimqneiljcxm4zmi6kuna	3	16	era	era	NN
work_izjlueimqneiljcxm4zmi6kuna	3	17	mais	mais	NNP
work_izjlueimqneiljcxm4zmi6kuna	3	18	eficaz	eficaz	NNS
work_izjlueimqneiljcxm4zmi6kuna	3	19	do	do	VBP
work_izjlueimqneiljcxm4zmi6kuna	3	20	que	que	VB
work_izjlueimqneiljcxm4zmi6kuna	3	21	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	3	22	talidomida	talidomida	NN
work_izjlueimqneiljcxm4zmi6kuna	3	23	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	3	24	TAL	TAL	NNP
work_izjlueimqneiljcxm4zmi6kuna	3	25	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	3	26	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	3	27	um	um	UH
work_izjlueimqneiljcxm4zmi6kuna	3	28	medicamento	medicamento	NNP
work_izjlueimqneiljcxm4zmi6kuna	3	29	rigorosa-	rigorosa-	NNP
work_izjlueimqneiljcxm4zmi6kuna	3	30	mente	mente	NNP
work_izjlueimqneiljcxm4zmi6kuna	3	31	controlado	controlado	NNP
work_izjlueimqneiljcxm4zmi6kuna	3	32	pela	pela	NNP
work_izjlueimqneiljcxm4zmi6kuna	3	33	lei	lei	NNP
work_izjlueimqneiljcxm4zmi6kuna	3	34	federal	federal	NNP
work_izjlueimqneiljcxm4zmi6kuna	3	35	10.651/2003	10.651/2003	NNP
work_izjlueimqneiljcxm4zmi6kuna	3	36	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	3	37	dispensado	dispensado	NNP
work_izjlueimqneiljcxm4zmi6kuna	3	38	gratuitamente	gratuitamente	NNP
work_izjlueimqneiljcxm4zmi6kuna	3	39	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	3	40	pacientes	paciente	NNS
work_izjlueimqneiljcxm4zmi6kuna	3	41	através	através	NNP
work_izjlueimqneiljcxm4zmi6kuna	3	42	de	de	NNP
work_izjlueimqneiljcxm4zmi6kuna	3	43	unidades	unidades	NNP
work_izjlueimqneiljcxm4zmi6kuna	3	44	de	de	FW
work_izjlueimqneiljcxm4zmi6kuna	3	45	saúde	saúde	NNP
work_izjlueimqneiljcxm4zmi6kuna	3	46	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	3	47	hospitais	hospitais	NNP
work_izjlueimqneiljcxm4zmi6kuna	3	48	públicos	públicos	NNP
work_izjlueimqneiljcxm4zmi6kuna	3	49	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	4	1	O	o	UH
work_izjlueimqneiljcxm4zmi6kuna	4	2	recuo	recuo	NNS
work_izjlueimqneiljcxm4zmi6kuna	4	3	não	não	UH
work_izjlueimqneiljcxm4zmi6kuna	4	4	explicado	explicado	NNP
work_izjlueimqneiljcxm4zmi6kuna	4	5	da	da	NNP
work_izjlueimqneiljcxm4zmi6kuna	4	6	ANVISA	ANVISA	NNP
work_izjlueimqneiljcxm4zmi6kuna	4	7	em	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	4	8	relação	relação	NNP
work_izjlueimqneiljcxm4zmi6kuna	4	9	ao	ao	NNP
work_izjlueimqneiljcxm4zmi6kuna	4	10	registro	registro	NNP
work_izjlueimqneiljcxm4zmi6kuna	4	11	da	da	NNP
work_izjlueimqneiljcxm4zmi6kuna	4	12	LEN	LEN	NNP
work_izjlueimqneiljcxm4zmi6kuna	4	13	foi	foi	NN
work_izjlueimqneiljcxm4zmi6kuna	4	14	um	um	UH
work_izjlueimqneiljcxm4zmi6kuna	4	15	inquestionável	inquestionável	JJ
work_izjlueimqneiljcxm4zmi6kuna	4	16	triunfo	triunfo	NN
work_izjlueimqneiljcxm4zmi6kuna	4	17	do	do	VBP
work_izjlueimqneiljcxm4zmi6kuna	4	18	lobby	lobby	NN
work_izjlueimqneiljcxm4zmi6kuna	4	19	que	que	NNP
work_izjlueimqneiljcxm4zmi6kuna	4	20	sucedeu	sucedeu	NNP
work_izjlueimqneiljcxm4zmi6kuna	4	21	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	4	22	recusa	recusa	NNP
work_izjlueimqneiljcxm4zmi6kuna	4	23	inicial	inicial	NN
work_izjlueimqneiljcxm4zmi6kuna	4	24	do	do	VBP
work_izjlueimqneiljcxm4zmi6kuna	4	25	registro	registro	NNP
work_izjlueimqneiljcxm4zmi6kuna	4	26	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	4	27	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	4	28	frente	frente	RB
work_izjlueimqneiljcxm4zmi6kuna	4	29	do	do	VBP
work_izjlueimqneiljcxm4zmi6kuna	4	30	qual	qual	JJ
work_izjlueimqneiljcxm4zmi6kuna	4	31	estavam	estavam	NNP
work_izjlueimqneiljcxm4zmi6kuna	4	32	políticos	políticos	NNP
work_izjlueimqneiljcxm4zmi6kuna	4	33	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	4	34	membros	membros	NNP
work_izjlueimqneiljcxm4zmi6kuna	4	35	do	do	VBP
work_izjlueimqneiljcxm4zmi6kuna	4	36	Congres-	Congres-	NNP
work_izjlueimqneiljcxm4zmi6kuna	4	37	so	so	RB
work_izjlueimqneiljcxm4zmi6kuna	4	38	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	4	39	associações	associações	NNP
work_izjlueimqneiljcxm4zmi6kuna	4	40	de	de	NNP
work_izjlueimqneiljcxm4zmi6kuna	4	41	pacientes	pacientes	NNP
work_izjlueimqneiljcxm4zmi6kuna	4	42	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	4	43	sociedades	sociedade	NNS
work_izjlueimqneiljcxm4zmi6kuna	4	44	médicas	médicas	NN
work_izjlueimqneiljcxm4zmi6kuna	4	45	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	5	1	Dois	Dois	NNP
work_izjlueimqneiljcxm4zmi6kuna	5	2	ensaios	ensaios	NNP
work_izjlueimqneiljcxm4zmi6kuna	5	3	randomizados	randomizado	NNS
work_izjlueimqneiljcxm4zmi6kuna	5	4	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	5	5	fase	fase	NNP
work_izjlueimqneiljcxm4zmi6kuna	5	6	III	III	NNP
work_izjlueimqneiljcxm4zmi6kuna	5	7	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	5	8	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	5	9	três	três	NN
work_izjlueimqneiljcxm4zmi6kuna	5	10	estudos	estudos	NNP
work_izjlueimqneiljcxm4zmi6kuna	5	11	observacionais	observacionais	NNP
work_izjlueimqneiljcxm4zmi6kuna	5	12	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	5	13	caso	caso	NNP
work_izjlueimqneiljcxm4zmi6kuna	5	14	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	5	15	controle	controle	NNP
work_izjlueimqneiljcxm4zmi6kuna	5	16	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	5	17	coorte	coorte	NNP
work_izjlueimqneiljcxm4zmi6kuna	5	18	de	de	IN
work_izjlueimqneiljcxm4zmi6kuna	5	19	base	base	NNP
work_izjlueimqneiljcxm4zmi6kuna	5	20	po-	po-	NNP
work_izjlueimqneiljcxm4zmi6kuna	5	21	pulacional	pulacional	NNP
work_izjlueimqneiljcxm4zmi6kuna	5	22	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	5	23	compararam	compararam	VB
work_izjlueimqneiljcxm4zmi6kuna	5	24	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	5	25	efetividade	efetividade	NNP
work_izjlueimqneiljcxm4zmi6kuna	5	26	de	de	FW
work_izjlueimqneiljcxm4zmi6kuna	5	27	terapias	terapias	NNP
work_izjlueimqneiljcxm4zmi6kuna	5	28	para	para	NNP
work_izjlueimqneiljcxm4zmi6kuna	5	29	o	o	IN
work_izjlueimqneiljcxm4zmi6kuna	5	30	MM	MM	NNP
work_izjlueimqneiljcxm4zmi6kuna	5	31	com	com	NN
work_izjlueimqneiljcxm4zmi6kuna	5	32	TAL-	TAL-	NNP
work_izjlueimqneiljcxm4zmi6kuna	5	33	e	e	LS
work_izjlueimqneiljcxm4zmi6kuna	5	34	com	com	NN
work_izjlueimqneiljcxm4zmi6kuna	5	35	LEN	LEN	NNP
work_izjlueimqneiljcxm4zmi6kuna	5	36	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	6	1	Em	em	UH
work_izjlueimqneiljcxm4zmi6kuna	6	2	conjunto	conjunto	NNS
work_izjlueimqneiljcxm4zmi6kuna	6	3	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	6	4	esses	esse	VBZ
work_izjlueimqneiljcxm4zmi6kuna	6	5	estudos	estudos	NNP
work_izjlueimqneiljcxm4zmi6kuna	6	6	mostraram	mostraram	NNP
work_izjlueimqneiljcxm4zmi6kuna	6	7	que	que	NNP
work_izjlueimqneiljcxm4zmi6kuna	6	8	não	não	NNP
work_izjlueimqneiljcxm4zmi6kuna	6	9	havia	havia	NNP
work_izjlueimqneiljcxm4zmi6kuna	6	10	diferen-	diferen-	NN
work_izjlueimqneiljcxm4zmi6kuna	6	11	ças	ças	NNP
work_izjlueimqneiljcxm4zmi6kuna	6	12	quanto	quanto	NNP
work_izjlueimqneiljcxm4zmi6kuna	6	13	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	6	14	eficácia	eficácia	NN
work_izjlueimqneiljcxm4zmi6kuna	6	15	de	de	IN
work_izjlueimqneiljcxm4zmi6kuna	6	16	tratamentos	tratamentos	NNP
work_izjlueimqneiljcxm4zmi6kuna	6	17	com	com	NNP
work_izjlueimqneiljcxm4zmi6kuna	6	18	LEN-	LEN-	NNP
work_izjlueimqneiljcxm4zmi6kuna	6	19	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	6	20	aqueles	aquele	NNS
work_izjlueimqneiljcxm4zmi6kuna	6	21	com	com	NN
work_izjlueimqneiljcxm4zmi6kuna	6	22	TAL	tal	NN
work_izjlueimqneiljcxm4zmi6kuna	6	23	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	7	1	A	a	DT
work_izjlueimqneiljcxm4zmi6kuna	7	2	LEN	LEN	NNP
work_izjlueimqneiljcxm4zmi6kuna	7	3	causou	causou	NN
work_izjlueimqneiljcxm4zmi6kuna	7	4	menos	menos	NN
work_izjlueimqneiljcxm4zmi6kuna	7	5	neuropa-	neuropa-	NNP
work_izjlueimqneiljcxm4zmi6kuna	7	6	tias	tias	NNP
work_izjlueimqneiljcxm4zmi6kuna	7	7	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	7	8	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	7	9	efeitos	efeitos	NNP
work_izjlueimqneiljcxm4zmi6kuna	7	10	adversos	adversos	NNP
work_izjlueimqneiljcxm4zmi6kuna	7	11	hematológicos	hematológicos	NNP
work_izjlueimqneiljcxm4zmi6kuna	7	12	mais	mais	NNP
work_izjlueimqneiljcxm4zmi6kuna	7	13	graves	grave	NNS
work_izjlueimqneiljcxm4zmi6kuna	7	14	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	8	1	Ela	Ela	NNP
work_izjlueimqneiljcxm4zmi6kuna	8	2	é	é	NNP
work_izjlueimqneiljcxm4zmi6kuna	8	3	muito	muito	NNP
work_izjlueimqneiljcxm4zmi6kuna	8	4	mais	mais	NNP
work_izjlueimqneiljcxm4zmi6kuna	8	5	cara	cara	NNP
work_izjlueimqneiljcxm4zmi6kuna	8	6	do	do	VBP
work_izjlueimqneiljcxm4zmi6kuna	8	7	que	que	VB
work_izjlueimqneiljcxm4zmi6kuna	8	8	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	8	9	TAL	tal	NN
work_izjlueimqneiljcxm4zmi6kuna	8	10	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	8	11	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	8	12	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	8	13	substitui-	substitui-	JJ
work_izjlueimqneiljcxm4zmi6kuna	8	14	ção	ção	NN
work_izjlueimqneiljcxm4zmi6kuna	8	15	da	da	NNP
work_izjlueimqneiljcxm4zmi6kuna	8	16	TAL	TAL	NNP
work_izjlueimqneiljcxm4zmi6kuna	8	17	pela	pela	NN
work_izjlueimqneiljcxm4zmi6kuna	8	18	LEN	LEN	NNP
work_izjlueimqneiljcxm4zmi6kuna	8	19	aumentará	aumentará	NNP
work_izjlueimqneiljcxm4zmi6kuna	8	20	muito	muito	NNP
work_izjlueimqneiljcxm4zmi6kuna	8	21	os	os	NNP
work_izjlueimqneiljcxm4zmi6kuna	8	22	custos	custos	NNP
work_izjlueimqneiljcxm4zmi6kuna	8	23	da	da	NNP
work_izjlueimqneiljcxm4zmi6kuna	8	24	assistência	assistência	NNP
work_izjlueimqneiljcxm4zmi6kuna	8	25	pública	pública	NNP
work_izjlueimqneiljcxm4zmi6kuna	8	26	à	à	NNP
work_izjlueimqneiljcxm4zmi6kuna	8	27	saúde	saúde	NN
work_izjlueimqneiljcxm4zmi6kuna	8	28	no	no	DT
work_izjlueimqneiljcxm4zmi6kuna	8	29	Brasil	Brasil	NNP
work_izjlueimqneiljcxm4zmi6kuna	8	30	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	9	1	Palavras	Palavras	NNP
work_izjlueimqneiljcxm4zmi6kuna	9	2	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	9	3	chave	chave	NNP
work_izjlueimqneiljcxm4zmi6kuna	9	4	Mieloma	Mieloma	NNP
work_izjlueimqneiljcxm4zmi6kuna	9	5	múltiplo	múltiplo	NN
work_izjlueimqneiljcxm4zmi6kuna	9	6	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	9	7	Custo	Custo	NNP
work_izjlueimqneiljcxm4zmi6kuna	9	8	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	9	9	efeti-	efeti-	FW
work_izjlueimqneiljcxm4zmi6kuna	9	10	vidade	vidade	NN
work_izjlueimqneiljcxm4zmi6kuna	9	11	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	9	12	Câncer	Câncer	NNP
work_izjlueimqneiljcxm4zmi6kuna	9	13	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	9	14	Custos	Custos	NNP
work_izjlueimqneiljcxm4zmi6kuna	9	15	da	da	NNP
work_izjlueimqneiljcxm4zmi6kuna	9	16	assistência	assistência	NNP
work_izjlueimqneiljcxm4zmi6kuna	9	17	médica	médica	NNP
work_izjlueimqneiljcxm4zmi6kuna	9	18	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	10	1	Abstract	Abstract	NNP
work_izjlueimqneiljcxm4zmi6kuna	10	2	In	in	IN
work_izjlueimqneiljcxm4zmi6kuna	10	3	April	April	NNP
work_izjlueimqneiljcxm4zmi6kuna	10	4	2017	2017	CD
work_izjlueimqneiljcxm4zmi6kuna	10	5	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	10	6	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	10	7	National	National	NNP
work_izjlueimqneiljcxm4zmi6kuna	10	8	Sanitary	Sanitary	NNP
work_izjlueimqneiljcxm4zmi6kuna	10	9	Surveillance	Surveillance	NNP
work_izjlueimqneiljcxm4zmi6kuna	10	10	Agency	Agency	NNP
work_izjlueimqneiljcxm4zmi6kuna	10	11	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	10	12	ANVISA	ANVISA	NNP
work_izjlueimqneiljcxm4zmi6kuna	10	13	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	10	14	Brazil	Brazil	NNP
work_izjlueimqneiljcxm4zmi6kuna	10	15	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	10	16	approved	approve	VBD
work_izjlueimqneiljcxm4zmi6kuna	10	17	lenalidomide	lenalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	10	18	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	10	19	LEN	LEN	NNP
work_izjlueimqneiljcxm4zmi6kuna	10	20	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	10	21	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	10	22	multiple	multiple	JJ
work_izjlueimqneiljcxm4zmi6kuna	10	23	myeloma	myeloma	NN
work_izjlueimqneiljcxm4zmi6kuna	10	24	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	10	25	MM	MM	NNP
work_izjlueimqneiljcxm4zmi6kuna	10	26	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	10	27	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	10	28	myelodysplastic	myelodysplastic	JJ
work_izjlueimqneiljcxm4zmi6kuna	10	29	syndrome	syndrome	NN
work_izjlueimqneiljcxm4zmi6kuna	10	30	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	11	1	ANVISA	ANVISA	NNP
work_izjlueimqneiljcxm4zmi6kuna	11	2	had	have	VBD
work_izjlueimqneiljcxm4zmi6kuna	11	3	re-	re-	RB
work_izjlueimqneiljcxm4zmi6kuna	11	4	jected	jecte	VBN
work_izjlueimqneiljcxm4zmi6kuna	11	5	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	11	6	first	first	JJ
work_izjlueimqneiljcxm4zmi6kuna	11	7	application	application	NN
work_izjlueimqneiljcxm4zmi6kuna	11	8	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	11	9	2010	2010	CD
work_izjlueimqneiljcxm4zmi6kuna	11	10	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	11	11	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	11	12	denied	deny	VBD
work_izjlueimqneiljcxm4zmi6kuna	11	13	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	11	14	request	request	NN
work_izjlueimqneiljcxm4zmi6kuna	11	15	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	11	16	reconsideration	reconsideration	NN
work_izjlueimqneiljcxm4zmi6kuna	11	17	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	11	18	2012	2012	CD
work_izjlueimqneiljcxm4zmi6kuna	11	19	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	12	1	The	the	DT
work_izjlueimqneiljcxm4zmi6kuna	12	2	reason	reason	NN
work_izjlueimqneiljcxm4zmi6kuna	12	3	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	12	4	rejection	rejection	NN
work_izjlueimqneiljcxm4zmi6kuna	12	5	was	be	VBD
work_izjlueimqneiljcxm4zmi6kuna	12	6	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	12	7	lack	lack	NN
work_izjlueimqneiljcxm4zmi6kuna	12	8	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	12	9	comparative	comparative	JJ
work_izjlueimqneiljcxm4zmi6kuna	12	10	effectiveness	effectiveness	NN
work_izjlueimqneiljcxm4zmi6kuna	12	11	studies	study	NNS
work_izjlueimqneiljcxm4zmi6kuna	12	12	proving	prove	VBG
work_izjlueimqneiljcxm4zmi6kuna	12	13	that	that	IN
work_izjlueimqneiljcxm4zmi6kuna	12	14	LEN	LEN	NNP
work_izjlueimqneiljcxm4zmi6kuna	12	15	was	be	VBD
work_izjlueimqneiljcxm4zmi6kuna	12	16	more	more	RBR
work_izjlueimqneiljcxm4zmi6kuna	12	17	effective	effective	JJ
work_izjlueimqneiljcxm4zmi6kuna	12	18	than	than	IN
work_izjlueimqneiljcxm4zmi6kuna	12	19	thalidomide	thalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	12	20	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	12	21	THAL	THAL	NNP
work_izjlueimqneiljcxm4zmi6kuna	12	22	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	12	23	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	12	24	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	12	25	strictly	strictly	RB
work_izjlueimqneiljcxm4zmi6kuna	12	26	controlled	control	VBN
work_izjlueimqneiljcxm4zmi6kuna	12	27	drug	drug	NN
work_izjlueimqneiljcxm4zmi6kuna	12	28	regulated	regulate	VBN
work_izjlueimqneiljcxm4zmi6kuna	12	29	by	by	IN
work_izjlueimqneiljcxm4zmi6kuna	12	30	Federal	Federal	NNP
work_izjlueimqneiljcxm4zmi6kuna	12	31	law	law	NN
work_izjlueimqneiljcxm4zmi6kuna	12	32	10.651/2003	10.651/2003	CD
work_izjlueimqneiljcxm4zmi6kuna	12	33	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	12	34	dispen-	dispen-	NNP
work_izjlueimqneiljcxm4zmi6kuna	12	35	sed	se	VBN
work_izjlueimqneiljcxm4zmi6kuna	12	36	to	to	IN
work_izjlueimqneiljcxm4zmi6kuna	12	37	patients	patient	NNS
work_izjlueimqneiljcxm4zmi6kuna	12	38	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	12	39	at	at	IN
work_izjlueimqneiljcxm4zmi6kuna	12	40	no	no	DT
work_izjlueimqneiljcxm4zmi6kuna	12	41	costs	cost	NNS
work_izjlueimqneiljcxm4zmi6kuna	12	42	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	12	43	through	through	IN
work_izjlueimqneiljcxm4zmi6kuna	12	44	public	public	JJ
work_izjlueimqneiljcxm4zmi6kuna	12	45	health	health	NN
work_izjlueimqneiljcxm4zmi6kuna	12	46	system	system	NN
work_izjlueimqneiljcxm4zmi6kuna	12	47	units	unit	NNS
work_izjlueimqneiljcxm4zmi6kuna	12	48	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	12	49	hospitals	hospital	NNS
work_izjlueimqneiljcxm4zmi6kuna	12	50	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	13	1	ANVISA	ANVISA	NNP
work_izjlueimqneiljcxm4zmi6kuna	13	2	unexplained	unexplaine	VBD
work_izjlueimqneiljcxm4zmi6kuna	13	3	retreat	retreat	NN
work_izjlueimqneiljcxm4zmi6kuna	13	4	on	on	IN
work_izjlueimqneiljcxm4zmi6kuna	13	5	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	13	6	LEN	LEN	NNP
work_izjlueimqneiljcxm4zmi6kuna	13	7	approval	approval	NN
work_izjlueimqneiljcxm4zmi6kuna	13	8	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	13	9	marketing	marketing	NN
work_izjlueimqneiljcxm4zmi6kuna	13	10	was	be	VBD
work_izjlueimqneiljcxm4zmi6kuna	13	11	an	an	DT
work_izjlueimqneiljcxm4zmi6kuna	13	12	unquestionable	unquestionable	JJ
work_izjlueimqneiljcxm4zmi6kuna	13	13	triumph	triumph	NN
work_izjlueimqneiljcxm4zmi6kuna	13	14	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	13	15	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	13	16	lobbying	lobbying	NN
work_izjlueimqneiljcxm4zmi6kuna	13	17	that	that	WDT
work_izjlueimqneiljcxm4zmi6kuna	13	18	ensued	ensue	VBD
work_izjlueimqneiljcxm4zmi6kuna	13	19	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	13	20	denial	denial	NN
work_izjlueimqneiljcxm4zmi6kuna	13	21	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	13	22	at	at	IN
work_izjlueimqneiljcxm4zmi6kuna	13	23	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	13	24	forefront	forefront	NN
work_izjlueimqneiljcxm4zmi6kuna	13	25	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	13	26	which	which	WDT
work_izjlueimqneiljcxm4zmi6kuna	13	27	were	be	VBD
work_izjlueimqneiljcxm4zmi6kuna	13	28	politicians	politician	NNS
work_izjlueimqneiljcxm4zmi6kuna	13	29	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	13	30	Congress	Congress	NNP
work_izjlueimqneiljcxm4zmi6kuna	13	31	members	member	NNS
work_izjlueimqneiljcxm4zmi6kuna	13	32	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	13	33	patient	patient	JJ
work_izjlueimqneiljcxm4zmi6kuna	13	34	organi-	organi-	NNP
work_izjlueimqneiljcxm4zmi6kuna	13	35	zations	zation	NNS
work_izjlueimqneiljcxm4zmi6kuna	13	36	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	13	37	medical	medical	JJ
work_izjlueimqneiljcxm4zmi6kuna	13	38	societies	society	NNS
work_izjlueimqneiljcxm4zmi6kuna	13	39	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	14	1	Two	two	CD
work_izjlueimqneiljcxm4zmi6kuna	14	2	randomized	randomized	JJ
work_izjlueimqneiljcxm4zmi6kuna	14	3	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	14	4	phase	phase	NN
work_izjlueimqneiljcxm4zmi6kuna	14	5	III	III	NNP
work_izjlueimqneiljcxm4zmi6kuna	14	6	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	14	7	trials	trial	NNS
work_izjlueimqneiljcxm4zmi6kuna	14	8	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	14	9	three	three	CD
work_izjlueimqneiljcxm4zmi6kuna	14	10	observational	observational	JJ
work_izjlueimqneiljcxm4zmi6kuna	14	11	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	14	12	case-	case-	NNP
work_izjlueimqneiljcxm4zmi6kuna	14	13	control	control	NN
work_izjlueimqneiljcxm4zmi6kuna	14	14	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	14	15	population	population	NN
work_izjlueimqneiljcxm4zmi6kuna	14	16	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	14	17	based	base	VBN
work_izjlueimqneiljcxm4zmi6kuna	14	18	cohort	cohort	NN
work_izjlueimqneiljcxm4zmi6kuna	14	19	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	14	20	compared	compare	VBD
work_izjlueimqneiljcxm4zmi6kuna	14	21	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	14	22	effectiveness	effectiveness	NN
work_izjlueimqneiljcxm4zmi6kuna	14	23	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	14	24	THAL-	THAL-	NNP
work_izjlueimqneiljcxm4zmi6kuna	14	25	versus	versus	IN
work_izjlueimqneiljcxm4zmi6kuna	14	26	LEN	LEN	NNP
work_izjlueimqneiljcxm4zmi6kuna	14	27	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	14	28	based	base	VBN
work_izjlueimqneiljcxm4zmi6kuna	14	29	the-	the-	NN
work_izjlueimqneiljcxm4zmi6kuna	14	30	rapies	rapie	NNS
work_izjlueimqneiljcxm4zmi6kuna	14	31	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	14	32	MM	MM	NNP
work_izjlueimqneiljcxm4zmi6kuna	14	33	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	15	1	Overall	overall	RB
work_izjlueimqneiljcxm4zmi6kuna	15	2	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	15	3	these	these	DT
work_izjlueimqneiljcxm4zmi6kuna	15	4	studies	study	NNS
work_izjlueimqneiljcxm4zmi6kuna	15	5	showed	show	VBD
work_izjlueimqneiljcxm4zmi6kuna	15	6	no	no	DT
work_izjlueimqneiljcxm4zmi6kuna	15	7	difference	difference	NN
work_izjlueimqneiljcxm4zmi6kuna	15	8	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	15	9	efficacy	efficacy	NN
work_izjlueimqneiljcxm4zmi6kuna	15	10	between	between	IN
work_izjlueimqneiljcxm4zmi6kuna	15	11	LEN-	len-	NN
work_izjlueimqneiljcxm4zmi6kuna	15	12	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	15	13	THAL	THAL	NNS
work_izjlueimqneiljcxm4zmi6kuna	15	14	-based	-base	VBN
work_izjlueimqneiljcxm4zmi6kuna	15	15	therapies	therapy	NNS
work_izjlueimqneiljcxm4zmi6kuna	15	16	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	16	1	LEN	LEN	NNP
work_izjlueimqneiljcxm4zmi6kuna	16	2	caused	cause	VBD
work_izjlueimqneiljcxm4zmi6kuna	16	3	less	less	JJR
work_izjlueimqneiljcxm4zmi6kuna	16	4	neuropathy	neuropathy	JJ
work_izjlueimqneiljcxm4zmi6kuna	16	5	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	16	6	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	16	7	more	more	RBR
work_izjlueimqneiljcxm4zmi6kuna	16	8	severe	severe	JJ
work_izjlueimqneiljcxm4zmi6kuna	16	9	hematologic	hematologic	JJ
work_izjlueimqneiljcxm4zmi6kuna	16	10	adverse	adverse	JJ
work_izjlueimqneiljcxm4zmi6kuna	16	11	effects	effect	NNS
work_izjlueimqneiljcxm4zmi6kuna	16	12	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	17	1	It	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	17	2	is	be	VBZ
work_izjlueimqneiljcxm4zmi6kuna	17	3	much	much	RB
work_izjlueimqneiljcxm4zmi6kuna	17	4	costlier	costly	JJR
work_izjlueimqneiljcxm4zmi6kuna	17	5	than	than	IN
work_izjlueimqneiljcxm4zmi6kuna	17	6	THAL	THAL	NNS
work_izjlueimqneiljcxm4zmi6kuna	17	7	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	17	8	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	17	9	substitution	substitution	NN
work_izjlueimqneiljcxm4zmi6kuna	17	10	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	17	11	THAL	THAL	NNP
work_izjlueimqneiljcxm4zmi6kuna	17	12	by	by	IN
work_izjlueimqneiljcxm4zmi6kuna	17	13	LEN	LEN	NNP
work_izjlueimqneiljcxm4zmi6kuna	17	14	shall	shall	MD
work_izjlueimqneiljcxm4zmi6kuna	17	15	raise	raise	VB
work_izjlueimqneiljcxm4zmi6kuna	17	16	considerably	considerably	RB
work_izjlueimqneiljcxm4zmi6kuna	17	17	public	public	JJ
work_izjlueimqneiljcxm4zmi6kuna	17	18	he-	he-	NN
work_izjlueimqneiljcxm4zmi6kuna	17	19	althcare	althcare	NN
work_izjlueimqneiljcxm4zmi6kuna	17	20	costs	cost	NNS
work_izjlueimqneiljcxm4zmi6kuna	17	21	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	17	22	Brazil	Brazil	NNP
work_izjlueimqneiljcxm4zmi6kuna	17	23	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	18	1	Keywords	Keywords	NNPS
work_izjlueimqneiljcxm4zmi6kuna	18	2	Multiple	multiple	JJ
work_izjlueimqneiljcxm4zmi6kuna	18	3	myeloma	myeloma	NNS
work_izjlueimqneiljcxm4zmi6kuna	18	4	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	18	5	Cost	cost	NN
work_izjlueimqneiljcxm4zmi6kuna	18	6	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	18	7	effectiveness	effectiveness	NN
work_izjlueimqneiljcxm4zmi6kuna	18	8	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	18	9	Cancer	Cancer	NNP
work_izjlueimqneiljcxm4zmi6kuna	18	10	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	18	11	Healthcare	Healthcare	NNP
work_izjlueimqneiljcxm4zmi6kuna	18	12	costs	cost	VBZ
work_izjlueimqneiljcxm4zmi6kuna	18	13	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	19	1	Francisco	Francisco	NNP
work_izjlueimqneiljcxm4zmi6kuna	19	2	José	José	NNP
work_izjlueimqneiljcxm4zmi6kuna	19	3	Roma	Roma	NNP
work_izjlueimqneiljcxm4zmi6kuna	19	4	Paumgartten	Paumgartten	NNP
work_izjlueimqneiljcxm4zmi6kuna	19	5	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	19	6	http://orcid.org/0000-0002-6207-0149	http://orcid.org/0000-0002-6207-0149	NNP
work_izjlueimqneiljcxm4zmi6kuna	19	7	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	19	8	1	1	CD
work_izjlueimqneiljcxm4zmi6kuna	19	9	DOI	doi	NN
work_izjlueimqneiljcxm4zmi6kuna	19	10	:	:	:
work_izjlueimqneiljcxm4zmi6kuna	19	11	10.1590/1413	10.1590/1413	LS
work_izjlueimqneiljcxm4zmi6kuna	19	12	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	19	13	812320182410.28522017	812320182410.28522017	CD
work_izjlueimqneiljcxm4zmi6kuna	19	14	1	1	CD
work_izjlueimqneiljcxm4zmi6kuna	19	15	Escola	Escola	NNP
work_izjlueimqneiljcxm4zmi6kuna	19	16	Nacional	Nacional	NNP
work_izjlueimqneiljcxm4zmi6kuna	19	17	de	de	IN
work_izjlueimqneiljcxm4zmi6kuna	19	18	Saúde	Saúde	NNP
work_izjlueimqneiljcxm4zmi6kuna	19	19	Pública	Pública	NNP
work_izjlueimqneiljcxm4zmi6kuna	19	20	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	19	21	Fiocruz	Fiocruz	NNP
work_izjlueimqneiljcxm4zmi6kuna	19	22	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	20	1	Av	Av	NNP
work_izjlueimqneiljcxm4zmi6kuna	20	2	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	21	1	Brasil	Brasil	NNP
work_izjlueimqneiljcxm4zmi6kuna	21	2	4036/913	4036/913	NNP
work_izjlueimqneiljcxm4zmi6kuna	21	3	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	21	4	Manguinhos	Manguinhos	NNP
work_izjlueimqneiljcxm4zmi6kuna	21	5	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	22	1	21040	21040	CD
work_izjlueimqneiljcxm4zmi6kuna	22	2	-	-	SYM
work_izjlueimqneiljcxm4zmi6kuna	22	3	361	361	CD
work_izjlueimqneiljcxm4zmi6kuna	22	4	Rio	Rio	NNP
work_izjlueimqneiljcxm4zmi6kuna	22	5	de	de	NNP
work_izjlueimqneiljcxm4zmi6kuna	22	6	Janeiro	Janeiro	NNP
work_izjlueimqneiljcxm4zmi6kuna	22	7	RJ	RJ	NNP
work_izjlueimqneiljcxm4zmi6kuna	22	8	Brasil	Brasil	NNP
work_izjlueimqneiljcxm4zmi6kuna	22	9	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	23	1	paum@ensp	paum@ensp	ADD
work_izjlueimqneiljcxm4zmi6kuna	23	2	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	24	1	fiocruz.br	fiocruz.br	NNP
work_izjlueimqneiljcxm4zmi6kuna	24	2	T	T	NNP
work_izjlueimqneiljcxm4zmi6kuna	24	3	e	e	NN
work_izjlueimqneiljcxm4zmi6kuna	24	4	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	24	5	A	a	NN
work_izjlueimqneiljcxm4zmi6kuna	24	6	s	s	NNP
work_izjlueimqneiljcxm4zmi6kuna	24	7	l	l	NN
work_izjlueimqneiljcxm4zmi6kuna	24	8	iv	iv	NNP
work_izjlueimqneiljcxm4zmi6kuna	24	9	R	R	NNP
work_izjlueimqneiljcxm4zmi6kuna	24	10	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	24	11	s	s	NN
work_izjlueimqneiljcxm4zmi6kuna	24	12	f	f	NNP
work_izjlueimqneiljcxm4zmi6kuna	24	13	R	r	NN
work_izjlueimqneiljcxm4zmi6kuna	24	14	e	e	NN
work_izjlueimqneiljcxm4zmi6kuna	24	15	e	e	NN
work_izjlueimqneiljcxm4zmi6kuna	24	16	T	t	NN
work_izjlueimqneiljcxm4zmi6kuna	24	17	h	h	NN
work_izjlueimqneiljcxm4zmi6kuna	24	18	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	24	19	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	24	20	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	24	21	s	s	NNP
work_izjlueimqneiljcxm4zmi6kuna	24	22	3	3	CD
work_izjlueimqneiljcxm4zmi6kuna	24	23	7	7	CD
work_izjlueimqneiljcxm4zmi6kuna	24	24	8	8	CD
work_izjlueimqneiljcxm4zmi6kuna	24	25	4	4	CD
work_izjlueimqneiljcxm4zmi6kuna	24	26	P	p	NN
work_izjlueimqneiljcxm4zmi6kuna	24	27	au	au	NNP
work_izjlueimqneiljcxm4zmi6kuna	24	28	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	24	29	ga	ga	NNP
work_izjlueimqneiljcxm4zmi6kuna	24	30	rt	rt	NNP
work_izjlueimqneiljcxm4zmi6kuna	24	31	te	te	NNP
work_izjlueimqneiljcxm4zmi6kuna	24	32	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	24	33	F	F	NNP
work_izjlueimqneiljcxm4zmi6kuna	24	34	JR	JR	NNP
work_izjlueimqneiljcxm4zmi6kuna	24	35	introduction	introduction	NN
work_izjlueimqneiljcxm4zmi6kuna	24	36	To	to	TO
work_izjlueimqneiljcxm4zmi6kuna	24	37	grant	grant	VB
work_izjlueimqneiljcxm4zmi6kuna	24	38	marketing	marketing	NN
work_izjlueimqneiljcxm4zmi6kuna	24	39	approval	approval	NN
work_izjlueimqneiljcxm4zmi6kuna	24	40	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	24	41	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	24	42	new	new	JJ
work_izjlueimqneiljcxm4zmi6kuna	24	43	medicine	medicine	NN
work_izjlueimqneiljcxm4zmi6kuna	24	44	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	24	45	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	24	46	regulatory	regulatory	JJ
work_izjlueimqneiljcxm4zmi6kuna	24	47	agency	agency	NN
work_izjlueimqneiljcxm4zmi6kuna	24	48	demands	demand	VBZ
work_izjlueimqneiljcxm4zmi6kuna	24	49	that	that	IN
work_izjlueimqneiljcxm4zmi6kuna	24	50	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	24	51	applicant	applicant	NN
work_izjlueimqneiljcxm4zmi6kuna	24	52	presents	present	VBZ
work_izjlueimqneiljcxm4zmi6kuna	24	53	evidence	evidence	NN
work_izjlueimqneiljcxm4zmi6kuna	24	54	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	24	55	its	-PRON-	PRP$
work_izjlueimqneiljcxm4zmi6kuna	24	56	efficacy	efficacy	NN
work_izjlueimqneiljcxm4zmi6kuna	24	57	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	24	58	safety	safety	NN
work_izjlueimqneiljcxm4zmi6kuna	24	59	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	24	60	intended	intend	VBN
work_izjlueimqneiljcxm4zmi6kuna	24	61	clinical	clinical	JJ
work_izjlueimqneiljcxm4zmi6kuna	24	62	uses	use	NNS
work_izjlueimqneiljcxm4zmi6kuna	24	63	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	25	1	Along	along	IN
work_izjlueimqneiljcxm4zmi6kuna	25	2	this	this	DT
work_izjlueimqneiljcxm4zmi6kuna	25	3	line	line	NN
work_izjlueimqneiljcxm4zmi6kuna	25	4	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	25	5	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	25	6	best	good	JJS
work_izjlueimqneiljcxm4zmi6kuna	25	7	empiric	empiric	JJ
work_izjlueimqneiljcxm4zmi6kuna	25	8	evidence	evidence	NN
work_izjlueimqneiljcxm4zmi6kuna	25	9	that	that	IN
work_izjlueimqneiljcxm4zmi6kuna	25	10	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	25	11	drug	drug	NN
work_izjlueimqneiljcxm4zmi6kuna	25	12	is	be	VBZ
work_izjlueimqneiljcxm4zmi6kuna	25	13	effective	effective	JJ
work_izjlueimqneiljcxm4zmi6kuna	25	14	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	25	15	safe	safe	JJ
work_izjlueimqneiljcxm4zmi6kuna	25	16	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	25	17	or	or	CC
work_izjlueimqneiljcxm4zmi6kuna	25	18	that	that	IN
work_izjlueimqneiljcxm4zmi6kuna	25	19	potential	potential	JJ
work_izjlueimqneiljcxm4zmi6kuna	25	20	therapeutic	therapeutic	JJ
work_izjlueimqneiljcxm4zmi6kuna	25	21	benefits	benefit	NNS
work_izjlueimqneiljcxm4zmi6kuna	25	22	outweigh	outweigh	JJ
work_izjlueimqneiljcxm4zmi6kuna	25	23	risks	risk	NNS
work_izjlueimqneiljcxm4zmi6kuna	25	24	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	25	25	harm	harm	NN
work_izjlueimqneiljcxm4zmi6kuna	25	26	to	to	IN
work_izjlueimqneiljcxm4zmi6kuna	25	27	patients	patient	NNS
work_izjlueimqneiljcxm4zmi6kuna	25	28	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	25	29	is	be	VBZ
work_izjlueimqneiljcxm4zmi6kuna	25	30	generally	generally	RB
work_izjlueimqneiljcxm4zmi6kuna	25	31	provided	provide	VBN
work_izjlueimqneiljcxm4zmi6kuna	25	32	by	by	IN
work_izjlueimqneiljcxm4zmi6kuna	25	33	good	good	JJ
work_izjlueimqneiljcxm4zmi6kuna	25	34	quality	quality	NN
work_izjlueimqneiljcxm4zmi6kuna	25	35	phase	phase	NN
work_izjlueimqneiljcxm4zmi6kuna	25	36	III	iii	CD
work_izjlueimqneiljcxm4zmi6kuna	25	37	randomized	randomize	VBN
work_izjlueimqneiljcxm4zmi6kuna	25	38	clinical	clinical	JJ
work_izjlueimqneiljcxm4zmi6kuna	25	39	trials	trial	NNS
work_izjlueimqneiljcxm4zmi6kuna	25	40	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	25	41	RCTs	RCTs	NNPS
work_izjlueimqneiljcxm4zmi6kuna	25	42	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	25	43	controlled	control	VBN
work_izjlueimqneiljcxm4zmi6kuna	25	44	with	with	IN
work_izjlueimqneiljcxm4zmi6kuna	25	45	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	25	46	placebo	placebo	NN
work_izjlueimqneiljcxm4zmi6kuna	25	47	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	25	48	or	or	CC
work_izjlueimqneiljcxm4zmi6kuna	25	49	with	with	IN
work_izjlueimqneiljcxm4zmi6kuna	25	50	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	25	51	ther-	ther-	NN
work_izjlueimqneiljcxm4zmi6kuna	25	52	apy	apy	NN
work_izjlueimqneiljcxm4zmi6kuna	25	53	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	25	54	proven	prove	VBN
work_izjlueimqneiljcxm4zmi6kuna	25	55	effectiveness	effectiveness	NN
work_izjlueimqneiljcxm4zmi6kuna	25	56	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	25	57	active	active	JJ
work_izjlueimqneiljcxm4zmi6kuna	25	58	comparator	comparator	NN
work_izjlueimqneiljcxm4zmi6kuna	25	59	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	25	60	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	25	61	whenever	whenever	WRB
work_izjlueimqneiljcxm4zmi6kuna	25	62	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	25	63	use	use	NN
work_izjlueimqneiljcxm4zmi6kuna	25	64	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	25	65	an	an	DT
work_izjlueimqneiljcxm4zmi6kuna	25	66	inactive	inactive	JJ
work_izjlueimqneiljcxm4zmi6kuna	25	67	comparator	comparator	NN
work_izjlueimqneiljcxm4zmi6kuna	25	68	is	be	VBZ
work_izjlueimqneiljcxm4zmi6kuna	25	69	considered	consider	VBN
work_izjlueimqneiljcxm4zmi6kuna	25	70	unethical	unethical	JJ
work_izjlueimqneiljcxm4zmi6kuna	25	71	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	26	1	The	the	DT
work_izjlueimqneiljcxm4zmi6kuna	26	2	US	US	NNP
work_izjlueimqneiljcxm4zmi6kuna	26	3	FDA	FDA	NNP
work_izjlueimqneiljcxm4zmi6kuna	26	4	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	26	5	EMA	EMA	NNP
work_izjlueimqneiljcxm4zmi6kuna	26	6	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	26	7	most	most	JJS
work_izjlueimqneiljcxm4zmi6kuna	26	8	national	national	JJ
work_izjlueimqneiljcxm4zmi6kuna	26	9	regu-	regu-	JJ
work_izjlueimqneiljcxm4zmi6kuna	26	10	latory	latory	NN
work_izjlueimqneiljcxm4zmi6kuna	26	11	agencies	agency	NNS
work_izjlueimqneiljcxm4zmi6kuna	26	12	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	26	13	however	however	RB
work_izjlueimqneiljcxm4zmi6kuna	26	14	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	26	15	do	do	VBP
work_izjlueimqneiljcxm4zmi6kuna	26	16	not	not	RB
work_izjlueimqneiljcxm4zmi6kuna	26	17	require	require	VB
work_izjlueimqneiljcxm4zmi6kuna	26	18	data	datum	NNS
work_izjlueimqneiljcxm4zmi6kuna	26	19	on	on	IN
work_izjlueimqneiljcxm4zmi6kuna	26	20	comparative	comparative	JJ
work_izjlueimqneiljcxm4zmi6kuna	26	21	effectiveness	effectiveness	NN
work_izjlueimqneiljcxm4zmi6kuna	26	22	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	26	23	safety	safety	NN
work_izjlueimqneiljcxm4zmi6kuna	26	24	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	26	25	or	or	CC
work_izjlueimqneiljcxm4zmi6kuna	26	26	evidence	evidence	NN
work_izjlueimqneiljcxm4zmi6kuna	26	27	that	that	IN
work_izjlueimqneiljcxm4zmi6kuna	26	28	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	26	29	new	new	JJ
work_izjlueimqneiljcxm4zmi6kuna	26	30	drug	drug	NN
work_izjlueimqneiljcxm4zmi6kuna	26	31	is	be	VBZ
work_izjlueimqneiljcxm4zmi6kuna	26	32	clinically	clinically	RB
work_izjlueimqneiljcxm4zmi6kuna	26	33	superior	superior	JJ
work_izjlueimqneiljcxm4zmi6kuna	26	34	to	to	IN
work_izjlueimqneiljcxm4zmi6kuna	26	35	existing	exist	VBG
work_izjlueimqneiljcxm4zmi6kuna	26	36	therapies	therapy	NNS
work_izjlueimqneiljcxm4zmi6kuna	26	37	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	27	1	It	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	27	2	follows	follow	VBZ
work_izjlueimqneiljcxm4zmi6kuna	27	3	that	that	IN
work_izjlueimqneiljcxm4zmi6kuna	27	4	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	27	5	newly	newly	RB
work_izjlueimqneiljcxm4zmi6kuna	27	6	approved	approve	VBN
work_izjlueimqneiljcxm4zmi6kuna	27	7	drug	drug	NN
work_izjlueimqneiljcxm4zmi6kuna	27	8	is	be	VBZ
work_izjlueimqneiljcxm4zmi6kuna	27	9	not	not	RB
work_izjlueimqneiljcxm4zmi6kuna	27	10	necessarily	necessarily	RB
work_izjlueimqneiljcxm4zmi6kuna	27	11	better	well	JJR
work_izjlueimqneiljcxm4zmi6kuna	27	12	than	than	IN
work_izjlueimqneiljcxm4zmi6kuna	27	13	preceding	precede	VBG
work_izjlueimqneiljcxm4zmi6kuna	27	14	ones	one	NNS
work_izjlueimqneiljcxm4zmi6kuna	27	15	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	27	16	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	27	17	thus	thus	RB
work_izjlueimqneiljcxm4zmi6kuna	27	18	it	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	27	19	may	may	MD
work_izjlueimqneiljcxm4zmi6kuna	27	20	not	not	RB
work_izjlueimqneiljcxm4zmi6kuna	27	21	add	add	VB
work_izjlueimqneiljcxm4zmi6kuna	27	22	to	to	IN
work_izjlueimqneiljcxm4zmi6kuna	27	23	existing	exist	VBG
work_izjlueimqneiljcxm4zmi6kuna	27	24	therapies	therapy	NNS
work_izjlueimqneiljcxm4zmi6kuna	27	25	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	28	1	This	this	DT
work_izjlueimqneiljcxm4zmi6kuna	28	2	ap-	ap-	NN
work_izjlueimqneiljcxm4zmi6kuna	28	3	plies	ply	VBZ
work_izjlueimqneiljcxm4zmi6kuna	28	4	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	28	5	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	28	6	instance	instance	NN
work_izjlueimqneiljcxm4zmi6kuna	28	7	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	28	8	to	to	IN
work_izjlueimqneiljcxm4zmi6kuna	28	9	drugs	drug	NNS
work_izjlueimqneiljcxm4zmi6kuna	28	10	called	call	VBN
work_izjlueimqneiljcxm4zmi6kuna	28	11	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	28	12	pharmaceu-	pharmaceu-	JJ
work_izjlueimqneiljcxm4zmi6kuna	28	13	tical	tical	JJ
work_izjlueimqneiljcxm4zmi6kuna	28	14	jargon	jargon	NNP
work_izjlueimqneiljcxm4zmi6kuna	28	15	terms	term	NNS
work_izjlueimqneiljcxm4zmi6kuna	28	16	“	"	``
work_izjlueimqneiljcxm4zmi6kuna	28	17	me	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	28	18	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	28	19	too	too	RB
work_izjlueimqneiljcxm4zmi6kuna	28	20	”	"	''
work_izjlueimqneiljcxm4zmi6kuna	28	21	or	or	CC
work_izjlueimqneiljcxm4zmi6kuna	28	22	“	"	``
work_izjlueimqneiljcxm4zmi6kuna	28	23	follow	follow	VB
work_izjlueimqneiljcxm4zmi6kuna	28	24	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	28	25	on	on	RP
work_izjlueimqneiljcxm4zmi6kuna	28	26	”	"	''
work_izjlueimqneiljcxm4zmi6kuna	28	27	drugs	drug	NNS
work_izjlueimqneiljcxm4zmi6kuna	28	28	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	28	29	or	or	CC
work_izjlueimqneiljcxm4zmi6kuna	28	30	medicines	medicine	NNS
work_izjlueimqneiljcxm4zmi6kuna	28	31	sharing	share	VBG
work_izjlueimqneiljcxm4zmi6kuna	28	32	with	with	IN
work_izjlueimqneiljcxm4zmi6kuna	28	33	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	28	34	drug	drug	NN
work_izjlueimqneiljcxm4zmi6kuna	28	35	already	already	RB
work_izjlueimqneiljcxm4zmi6kuna	28	36	on	on	IN
work_izjlueimqneiljcxm4zmi6kuna	28	37	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	28	38	market	market	NN
work_izjlueimqneiljcxm4zmi6kuna	28	39	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	28	40	similar	similar	JJ
work_izjlueimqneiljcxm4zmi6kuna	28	41	chemical	chemical	NN
work_izjlueimqneiljcxm4zmi6kuna	28	42	structure	structure	NN
work_izjlueimqneiljcxm4zmi6kuna	28	43	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	28	44	an	an	DT
work_izjlueimqneiljcxm4zmi6kuna	28	45	identical	identical	JJ
work_izjlueimqneiljcxm4zmi6kuna	28	46	mechanism	mechanism	NN
work_izjlueimqneiljcxm4zmi6kuna	28	47	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	28	48	action	action	NN
work_izjlueimqneiljcxm4zmi6kuna	28	49	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	28	50	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	28	51	same	same	JJ
work_izjlueimqneiljcxm4zmi6kuna	28	52	therapeutic	therapeutic	JJ
work_izjlueimqneiljcxm4zmi6kuna	28	53	indications1	indications1	NN
work_izjlueimqneiljcxm4zmi6kuna	28	54	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	29	1	In	in	IN
work_izjlueimqneiljcxm4zmi6kuna	29	2	other	other	JJ
work_izjlueimqneiljcxm4zmi6kuna	29	3	words	word	NNS
work_izjlueimqneiljcxm4zmi6kuna	29	4	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	29	5	“	"	``
work_izjlueimqneiljcxm4zmi6kuna	29	6	me	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	29	7	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	29	8	too	too	RB
work_izjlueimqneiljcxm4zmi6kuna	29	9	”	"	''
work_izjlueimqneiljcxm4zmi6kuna	29	10	drugs	drug	NNS
work_izjlueimqneiljcxm4zmi6kuna	29	11	are	be	VBP
work_izjlueimqneiljcxm4zmi6kuna	29	12	not	not	RB
work_izjlueimqneiljcxm4zmi6kuna	29	13	truly	truly	RB
work_izjlueimqneiljcxm4zmi6kuna	29	14	innovative	innovative	JJ
work_izjlueimqneiljcxm4zmi6kuna	29	15	or	or	CC
work_izjlueimqneiljcxm4zmi6kuna	29	16	breakthrough	breakthrough	JJ
work_izjlueimqneiljcxm4zmi6kuna	29	17	medicines	medicine	NNS
work_izjlueimqneiljcxm4zmi6kuna	29	18	developed	develop	VBD
work_izjlueimqneiljcxm4zmi6kuna	29	19	to	to	TO
work_izjlueimqneiljcxm4zmi6kuna	29	20	treat	treat	VB
work_izjlueimqneiljcxm4zmi6kuna	29	21	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	29	22	morbid	morbid	NN
work_izjlueimqneiljcxm4zmi6kuna	29	23	condition	condition	NN
work_izjlueimqneiljcxm4zmi6kuna	29	24	;	;	:
work_izjlueimqneiljcxm4zmi6kuna	29	25	rather	rather	RB
work_izjlueimqneiljcxm4zmi6kuna	29	26	they	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	29	27	are	be	VBP
work_izjlueimqneiljcxm4zmi6kuna	29	28	just	just	RB
work_izjlueimqneiljcxm4zmi6kuna	29	29	“	"	``
work_izjlueimqneiljcxm4zmi6kuna	29	30	more	more	JJR
work_izjlueimqneiljcxm4zmi6kuna	29	31	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	29	32	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	29	33	same	same	JJ
work_izjlueimqneiljcxm4zmi6kuna	29	34	”	"	''
work_izjlueimqneiljcxm4zmi6kuna	29	35	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	29	36	or	or	CC
work_izjlueimqneiljcxm4zmi6kuna	29	37	similar	similar	JJ
work_izjlueimqneiljcxm4zmi6kuna	29	38	drugs	drug	NNS
work_izjlueimqneiljcxm4zmi6kuna	29	39	that	that	WDT
work_izjlueimqneiljcxm4zmi6kuna	29	40	are	be	VBP
work_izjlueimqneiljcxm4zmi6kuna	29	41	not	not	RB
work_izjlueimqneiljcxm4zmi6kuna	29	42	clinically	clinically	RB
work_izjlueimqneiljcxm4zmi6kuna	29	43	superior	superior	JJ
work_izjlueimqneiljcxm4zmi6kuna	29	44	to	to	IN
work_izjlueimqneiljcxm4zmi6kuna	29	45	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	29	46	pioneering	pioneering	JJ
work_izjlueimqneiljcxm4zmi6kuna	29	47	one	one	NN
work_izjlueimqneiljcxm4zmi6kuna	29	48	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	30	1	“	"	``
work_izjlueimqneiljcxm4zmi6kuna	30	2	Me	me	RB
work_izjlueimqneiljcxm4zmi6kuna	30	3	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	30	4	too	too	RB
work_izjlueimqneiljcxm4zmi6kuna	30	5	”	"	''
work_izjlueimqneiljcxm4zmi6kuna	30	6	medicines	medicine	NNS
work_izjlueimqneiljcxm4zmi6kuna	30	7	may	may	MD
work_izjlueimqneiljcxm4zmi6kuna	30	8	be	be	VB
work_izjlueimqneiljcxm4zmi6kuna	30	9	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	30	10	outcome	outcome	NN
work_izjlueimqneiljcxm4zmi6kuna	30	11	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	30	12	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	30	13	frustrated	frustrated	JJ
work_izjlueimqneiljcxm4zmi6kuna	30	14	attempt	attempt	NN
work_izjlueimqneiljcxm4zmi6kuna	30	15	to	to	TO
work_izjlueimqneiljcxm4zmi6kuna	30	16	increase	increase	VB
work_izjlueimqneiljcxm4zmi6kuna	30	17	efficacy	efficacy	NN
work_izjlueimqneiljcxm4zmi6kuna	30	18	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	30	19	or	or	CC
work_izjlueimqneiljcxm4zmi6kuna	30	20	to	to	TO
work_izjlueimqneiljcxm4zmi6kuna	30	21	attenuate	attenuate	VB
work_izjlueimqneiljcxm4zmi6kuna	30	22	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	30	23	toxicity	toxicity	NN
work_izjlueimqneiljcxm4zmi6kuna	30	24	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	30	25	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	30	26	prototype	prototype	NN
work_izjlueimqneiljcxm4zmi6kuna	30	27	drug	drug	NN
work_izjlueimqneiljcxm4zmi6kuna	30	28	by	by	IN
work_izjlueimqneiljcxm4zmi6kuna	30	29	altering	alter	VBG
work_izjlueimqneiljcxm4zmi6kuna	30	30	its	-PRON-	PRP$
work_izjlueimqneiljcxm4zmi6kuna	30	31	molecule	molecule	NN
work_izjlueimqneiljcxm4zmi6kuna	30	32	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	30	33	or	or	CC
work_izjlueimqneiljcxm4zmi6kuna	30	34	otherwise	otherwise	RB
work_izjlueimqneiljcxm4zmi6kuna	30	35	be	be	VB
work_izjlueimqneiljcxm4zmi6kuna	30	36	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	30	37	delib-	delib-	JJ
work_izjlueimqneiljcxm4zmi6kuna	30	38	erate	erate	NN
work_izjlueimqneiljcxm4zmi6kuna	30	39	imitation	imitation	NN
work_izjlueimqneiljcxm4zmi6kuna	30	40	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	30	41	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	30	42	pioneer	pioneer	NN
work_izjlueimqneiljcxm4zmi6kuna	30	43	medicinal	medicinal	JJ
work_izjlueimqneiljcxm4zmi6kuna	30	44	product	product	NN
work_izjlueimqneiljcxm4zmi6kuna	30	45	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	31	1	Some	some	DT
work_izjlueimqneiljcxm4zmi6kuna	31	2	authors	author	NNS
work_izjlueimqneiljcxm4zmi6kuna	31	3	believe	believe	VBP
work_izjlueimqneiljcxm4zmi6kuna	31	4	that	that	IN
work_izjlueimqneiljcxm4zmi6kuna	31	5	“	"	``
work_izjlueimqneiljcxm4zmi6kuna	31	6	me	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	31	7	-	-	:
work_izjlueimqneiljcxm4zmi6kuna	31	8	too”s	too”s	PRP
work_izjlueimqneiljcxm4zmi6kuna	31	9	are	be	VBP
work_izjlueimqneiljcxm4zmi6kuna	31	10	wasteful	wasteful	JJ
work_izjlueimqneiljcxm4zmi6kuna	31	11	duplications	duplication	NNS
work_izjlueimqneiljcxm4zmi6kuna	31	12	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	31	13	propose	propose	VB
work_izjlueimqneiljcxm4zmi6kuna	31	14	that	that	IN
work_izjlueimqneiljcxm4zmi6kuna	31	15	agencies	agency	NNS
work_izjlueimqneiljcxm4zmi6kuna	31	16	’	’	POS
work_izjlueimqneiljcxm4zmi6kuna	31	17	require-	require-	JJ
work_izjlueimqneiljcxm4zmi6kuna	31	18	ments	ment	NNS
work_izjlueimqneiljcxm4zmi6kuna	31	19	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	31	20	approving	approve	VBG
work_izjlueimqneiljcxm4zmi6kuna	31	21	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	31	22	new	new	JJ
work_izjlueimqneiljcxm4zmi6kuna	31	23	drug	drug	NN
work_izjlueimqneiljcxm4zmi6kuna	31	24	should	should	MD
work_izjlueimqneiljcxm4zmi6kuna	31	25	be	be	VB
work_izjlueimqneiljcxm4zmi6kuna	31	26	not	not	RB
work_izjlueimqneiljcxm4zmi6kuna	31	27	only	only	RB
work_izjlueimqneiljcxm4zmi6kuna	31	28	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	31	29	evidence	evidence	NN
work_izjlueimqneiljcxm4zmi6kuna	31	30	that	that	IN
work_izjlueimqneiljcxm4zmi6kuna	31	31	it	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	31	32	is	be	VBZ
work_izjlueimqneiljcxm4zmi6kuna	31	33	effective	effective	JJ
work_izjlueimqneiljcxm4zmi6kuna	31	34	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	31	35	safe	safe	JJ
work_izjlueimqneiljcxm4zmi6kuna	31	36	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	31	37	but	but	CC
work_izjlueimqneiljcxm4zmi6kuna	31	38	also	also	RB
work_izjlueimqneiljcxm4zmi6kuna	31	39	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	31	40	demonstration	demonstration	NN
work_izjlueimqneiljcxm4zmi6kuna	31	41	that	that	IN
work_izjlueimqneiljcxm4zmi6kuna	31	42	it	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	31	43	is	be	VBZ
work_izjlueimqneiljcxm4zmi6kuna	31	44	clinically	clinically	RB
work_izjlueimqneiljcxm4zmi6kuna	31	45	superi-	superi-	JJ
work_izjlueimqneiljcxm4zmi6kuna	31	46	or	or	CC
work_izjlueimqneiljcxm4zmi6kuna	31	47	to	to	TO
work_izjlueimqneiljcxm4zmi6kuna	31	48	pre	pre	VB
work_izjlueimqneiljcxm4zmi6kuna	31	49	-	-	JJ
work_izjlueimqneiljcxm4zmi6kuna	31	50	existing	existing	JJ
work_izjlueimqneiljcxm4zmi6kuna	31	51	therapies	therapy	NNS
work_izjlueimqneiljcxm4zmi6kuna	31	52	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	32	1	Others	other	NNS
work_izjlueimqneiljcxm4zmi6kuna	32	2	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	32	3	however	however	RB
work_izjlueimqneiljcxm4zmi6kuna	32	4	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	32	5	are	be	VBP
work_izjlueimqneiljcxm4zmi6kuna	32	6	against	against	IN
work_izjlueimqneiljcxm4zmi6kuna	32	7	imposing	impose	VBG
work_izjlueimqneiljcxm4zmi6kuna	32	8	regulatory	regulatory	JJ
work_izjlueimqneiljcxm4zmi6kuna	32	9	obstacles	obstacle	NNS
work_izjlueimqneiljcxm4zmi6kuna	32	10	to	to	IN
work_izjlueimqneiljcxm4zmi6kuna	32	11	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	32	12	development	development	NN
work_izjlueimqneiljcxm4zmi6kuna	32	13	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	32	14	non	non	JJ
work_izjlueimqneiljcxm4zmi6kuna	32	15	-	-	JJ
work_izjlueimqneiljcxm4zmi6kuna	32	16	innovative	innovative	JJ
work_izjlueimqneiljcxm4zmi6kuna	32	17	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	32	18	“	"	``
work_izjlueimqneiljcxm4zmi6kuna	32	19	me	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	32	20	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	32	21	too	too	RB
work_izjlueimqneiljcxm4zmi6kuna	32	22	”	"	''
work_izjlueimqneiljcxm4zmi6kuna	32	23	drugs	drug	NNS
work_izjlueimqneiljcxm4zmi6kuna	32	24	arguing	argue	VBG
work_izjlueimqneiljcxm4zmi6kuna	32	25	that	that	IN
work_izjlueimqneiljcxm4zmi6kuna	32	26	they	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	32	27	enhance	enhance	VBP
work_izjlueimqneiljcxm4zmi6kuna	32	28	competition	competition	NN
work_izjlueimqneiljcxm4zmi6kuna	32	29	within	within	IN
work_izjlueimqneiljcxm4zmi6kuna	32	30	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	32	31	pharmaceutical	pharmaceutical	JJ
work_izjlueimqneiljcxm4zmi6kuna	32	32	market	market	NN
work_izjlueimqneiljcxm4zmi6kuna	32	33	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	32	34	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	32	35	by	by	IN
work_izjlueimqneiljcxm4zmi6kuna	32	36	doing	do	VBG
work_izjlueimqneiljcxm4zmi6kuna	32	37	so	so	RB
work_izjlueimqneiljcxm4zmi6kuna	32	38	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	32	39	they	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	32	40	stimulate	stimulate	VBP
work_izjlueimqneiljcxm4zmi6kuna	32	41	lowering	lower	VBG
work_izjlueimqneiljcxm4zmi6kuna	32	42	prices	price	NNS
work_izjlueimqneiljcxm4zmi6kuna	32	43	what	what	WP
work_izjlueimqneiljcxm4zmi6kuna	32	44	ultimate-	ultimate-	VBZ
work_izjlueimqneiljcxm4zmi6kuna	32	45	ly	ly	NNP
work_izjlueimqneiljcxm4zmi6kuna	32	46	expands	expand	VBZ
work_izjlueimqneiljcxm4zmi6kuna	32	47	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	32	48	access	access	NN
work_izjlueimqneiljcxm4zmi6kuna	32	49	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	32	50	low	low	JJ
work_izjlueimqneiljcxm4zmi6kuna	32	51	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	32	52	income	income	NN
work_izjlueimqneiljcxm4zmi6kuna	32	53	people	people	NNS
work_izjlueimqneiljcxm4zmi6kuna	32	54	to	to	IN
work_izjlueimqneiljcxm4zmi6kuna	32	55	medicines1,2	medicines1,2	ADD
work_izjlueimqneiljcxm4zmi6kuna	32	56	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	33	1	The	the	DT
work_izjlueimqneiljcxm4zmi6kuna	33	2	National	National	NNP
work_izjlueimqneiljcxm4zmi6kuna	33	3	Sanitary	Sanitary	NNP
work_izjlueimqneiljcxm4zmi6kuna	33	4	Surveillance	Surveillance	NNP
work_izjlueimqneiljcxm4zmi6kuna	33	5	Agency	Agency	NNP
work_izjlueimqneiljcxm4zmi6kuna	33	6	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	33	7	ANVISA	ANVISA	NNP
work_izjlueimqneiljcxm4zmi6kuna	33	8	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	33	9	Brazil	Brazil	NNP
work_izjlueimqneiljcxm4zmi6kuna	33	10	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	33	11	policy	policy	NN
work_izjlueimqneiljcxm4zmi6kuna	33	12	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	33	13	“	"	``
work_izjlueimqneiljcxm4zmi6kuna	33	14	me	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	33	15	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	33	16	too	too	RB
work_izjlueimqneiljcxm4zmi6kuna	33	17	”	"	''
work_izjlueimqneiljcxm4zmi6kuna	33	18	drugs	drug	NNS
work_izjlueimqneiljcxm4zmi6kuna	33	19	was	be	VBD
work_izjlueimqneiljcxm4zmi6kuna	33	20	made	make	VBN
work_izjlueimqneiljcxm4zmi6kuna	33	21	explicit	explicit	JJ
work_izjlueimqneiljcxm4zmi6kuna	33	22	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	33	23	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	33	24	comment	comment	NN
work_izjlueimqneiljcxm4zmi6kuna	33	25	posted	post	VBN
work_izjlueimqneiljcxm4zmi6kuna	33	26	on	on	IN
work_izjlueimqneiljcxm4zmi6kuna	33	27	its	-PRON-	PRP$
work_izjlueimqneiljcxm4zmi6kuna	33	28	web-	web-	NN
work_izjlueimqneiljcxm4zmi6kuna	33	29	site	site	NN
work_izjlueimqneiljcxm4zmi6kuna	33	30	:	:	:
work_izjlueimqneiljcxm4zmi6kuna	33	31	…	…	NFP
work_izjlueimqneiljcxm4zmi6kuna	33	32	it	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	33	33	is	be	VBZ
work_izjlueimqneiljcxm4zmi6kuna	33	34	difficult	difficult	JJ
work_izjlueimqneiljcxm4zmi6kuna	33	35	or	or	CC
work_izjlueimqneiljcxm4zmi6kuna	33	36	even	even	RB
work_izjlueimqneiljcxm4zmi6kuna	33	37	impossible	impossible	JJ
work_izjlueimqneiljcxm4zmi6kuna	33	38	to	to	TO
work_izjlueimqneiljcxm4zmi6kuna	33	39	classify	classify	VB
work_izjlueimqneiljcxm4zmi6kuna	33	40	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	33	41	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	33	42	new	new	JJ
work_izjlueimqneiljcxm4zmi6kuna	33	43	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	33	44	medicine	medicine	NN
work_izjlueimqneiljcxm4zmi6kuna	33	45	as	as	IN
work_izjlueimqneiljcxm4zmi6kuna	33	46	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	33	47	“	"	``
work_izjlueimqneiljcxm4zmi6kuna	33	48	me	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	33	49	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	33	50	too	too	RB
work_izjlueimqneiljcxm4zmi6kuna	33	51	”	"	''
work_izjlueimqneiljcxm4zmi6kuna	33	52	drug	drug	NN
work_izjlueimqneiljcxm4zmi6kuna	33	53	on	on	IN
work_izjlueimqneiljcxm4zmi6kuna	33	54	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	33	55	occasion	occasion	NN
work_izjlueimqneiljcxm4zmi6kuna	33	56	it	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	33	57	is	be	VBZ
work_izjlueimqneiljcxm4zmi6kuna	33	58	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	33	59	first	first	RB
work_izjlueimqneiljcxm4zmi6kuna	33	60	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	33	61	registered	register	VBN
work_izjlueimqneiljcxm4zmi6kuna	33	62	because	because	IN
work_izjlueimqneiljcxm4zmi6kuna	33	63	some	some	DT
work_izjlueimqneiljcxm4zmi6kuna	33	64	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	33	65	its	-PRON-	PRP$
work_izjlueimqneiljcxm4zmi6kuna	33	66	attributes	attribute	NNS
work_izjlueimqneiljcxm4zmi6kuna	33	67	that	that	WDT
work_izjlueimqneiljcxm4zmi6kuna	33	68	would	would	MD
work_izjlueimqneiljcxm4zmi6kuna	33	69	allow	allow	VB
work_izjlueimqneiljcxm4zmi6kuna	33	70	us	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	33	71	to	to	TO
work_izjlueimqneiljcxm4zmi6kuna	33	72	make	make	VB
work_izjlueimqneiljcxm4zmi6kuna	33	73	this	this	DT
work_izjlueimqneiljcxm4zmi6kuna	33	74	classification	classification	NN
work_izjlueimqneiljcxm4zmi6kuna	33	75	can	can	MD
work_izjlueimqneiljcxm4zmi6kuna	33	76	only	only	RB
work_izjlueimqneiljcxm4zmi6kuna	33	77	be	be	VB
work_izjlueimqneiljcxm4zmi6kuna	33	78	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	33	79	fully	fully	RB
work_izjlueimqneiljcxm4zmi6kuna	33	80	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	33	81	assessed	assess	VBN
work_izjlueimqneiljcxm4zmi6kuna	33	82	after	after	IN
work_izjlueimqneiljcxm4zmi6kuna	33	83	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	33	84	product	product	NN
work_izjlueimqneiljcxm4zmi6kuna	33	85	is	be	VBZ
work_izjlueimqneiljcxm4zmi6kuna	33	86	market-	market-	JJ
work_izjlueimqneiljcxm4zmi6kuna	33	87	ed	ed	NNP
work_izjlueimqneiljcxm4zmi6kuna	33	88	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	33	89	used	use	VBN
work_izjlueimqneiljcxm4zmi6kuna	33	90	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	33	91	large	large	JJ
work_izjlueimqneiljcxm4zmi6kuna	33	92	scale	scale	NN
work_izjlueimqneiljcxm4zmi6kuna	33	93	”	"	''
work_izjlueimqneiljcxm4zmi6kuna	33	94	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	33	95	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	33	96	“	"	``
work_izjlueimqneiljcxm4zmi6kuna	33	97	...	...	:
work_izjlueimqneiljcxm4zmi6kuna	33	98	current	current	JJ
work_izjlueimqneiljcxm4zmi6kuna	33	99	Brazil-	Brazil-	NNP
work_izjlueimqneiljcxm4zmi6kuna	33	100	ian	ian	JJ
work_izjlueimqneiljcxm4zmi6kuna	33	101	laws	law	NNS
work_izjlueimqneiljcxm4zmi6kuna	33	102	do	do	VBP
work_izjlueimqneiljcxm4zmi6kuna	33	103	not	not	RB
work_izjlueimqneiljcxm4zmi6kuna	33	104	support	support	VB
work_izjlueimqneiljcxm4zmi6kuna	33	105	denying	deny	VBG
work_izjlueimqneiljcxm4zmi6kuna	33	106	registration	registration	NN
work_izjlueimqneiljcxm4zmi6kuna	33	107	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	33	108	new	new	JJ
work_izjlueimqneiljcxm4zmi6kuna	33	109	drugs	drug	NNS
work_izjlueimqneiljcxm4zmi6kuna	33	110	based	base	VBN
work_izjlueimqneiljcxm4zmi6kuna	33	111	on	on	IN
work_izjlueimqneiljcxm4zmi6kuna	33	112	such	such	JJ
work_izjlueimqneiljcxm4zmi6kuna	33	113	argument	argument	NN
work_izjlueimqneiljcxm4zmi6kuna	33	114	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	34	1	For	for	IN
work_izjlueimqneiljcxm4zmi6kuna	34	2	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	34	3	foregoing	foregoing	JJ
work_izjlueimqneiljcxm4zmi6kuna	34	4	reasons	reason	NNS
work_izjlueimqneiljcxm4zmi6kuna	34	5	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	34	6	according	accord	VBG
work_izjlueimqneiljcxm4zmi6kuna	34	7	to	to	IN
work_izjlueimqneiljcxm4zmi6kuna	34	8	ANVISA	ANVISA	NNP
work_izjlueimqneiljcxm4zmi6kuna	34	9	’s	’s	POS
work_izjlueimqneiljcxm4zmi6kuna	34	10	note	note	NN
work_izjlueimqneiljcxm4zmi6kuna	34	11	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	34	12	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	34	13	agency	agency	NN
work_izjlueimqneiljcxm4zmi6kuna	34	14	does	do	VBZ
work_izjlueimqneiljcxm4zmi6kuna	34	15	not	not	RB
work_izjlueimqneiljcxm4zmi6kuna	34	16	necessarily	necessarily	RB
work_izjlueimqneiljcxm4zmi6kuna	34	17	reject	reject	VB
work_izjlueimqneiljcxm4zmi6kuna	34	18	applications	application	NNS
work_izjlueimqneiljcxm4zmi6kuna	34	19	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	34	20	“	"	``
work_izjlueimqneiljcxm4zmi6kuna	34	21	me-	me-	NN
work_izjlueimqneiljcxm4zmi6kuna	34	22	too	too	RB
work_izjlueimqneiljcxm4zmi6kuna	34	23	”	"	``
work_izjlueimqneiljcxm4zmi6kuna	34	24	drugs	drug	NNS
work_izjlueimqneiljcxm4zmi6kuna	34	25	even	even	RB
work_izjlueimqneiljcxm4zmi6kuna	34	26	if	if	IN
work_izjlueimqneiljcxm4zmi6kuna	34	27	they	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	34	28	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	34	29	apparently	apparently	RB
work_izjlueimqneiljcxm4zmi6kuna	34	30	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	34	31	do	do	VBP
work_izjlueimqneiljcxm4zmi6kuna	34	32	not	not	RB
work_izjlueimqneiljcxm4zmi6kuna	34	33	add	add	VB
work_izjlueimqneiljcxm4zmi6kuna	34	34	to	to	IN
work_izjlueimqneiljcxm4zmi6kuna	34	35	existing	exist	VBG
work_izjlueimqneiljcxm4zmi6kuna	34	36	therapies2	therapies2	NN
work_izjlueimqneiljcxm4zmi6kuna	34	37	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	35	1	A	a	DT
work_izjlueimqneiljcxm4zmi6kuna	35	2	major	major	JJ
work_izjlueimqneiljcxm4zmi6kuna	35	3	problem	problem	NN
work_izjlueimqneiljcxm4zmi6kuna	35	4	with	with	IN
work_izjlueimqneiljcxm4zmi6kuna	35	5	non	non	JJ
work_izjlueimqneiljcxm4zmi6kuna	35	6	-	-	JJ
work_izjlueimqneiljcxm4zmi6kuna	35	7	innovative	innovative	JJ
work_izjlueimqneiljcxm4zmi6kuna	35	8	drugs	drug	NNS
work_izjlueimqneiljcxm4zmi6kuna	35	9	is	be	VBZ
work_izjlueimqneiljcxm4zmi6kuna	35	10	that	that	IN
work_izjlueimqneiljcxm4zmi6kuna	35	11	pharmaceutical	pharmaceutical	JJ
work_izjlueimqneiljcxm4zmi6kuna	35	12	companies	company	NNS
work_izjlueimqneiljcxm4zmi6kuna	35	13	generally	generally	RB
work_izjlueimqneiljcxm4zmi6kuna	35	14	do	do	VBP
work_izjlueimqneiljcxm4zmi6kuna	35	15	not	not	RB
work_izjlueimqneiljcxm4zmi6kuna	35	16	fairly	fairly	RB
work_izjlueimqneiljcxm4zmi6kuna	35	17	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	35	18	adequately	adequately	RB
work_izjlueimqneiljcxm4zmi6kuna	35	19	inform	inform	VB
work_izjlueimqneiljcxm4zmi6kuna	35	20	doctors	doctor	NNS
work_izjlueimqneiljcxm4zmi6kuna	35	21	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	35	22	consumers	consumer	NNS
work_izjlueimqneiljcxm4zmi6kuna	35	23	about	about	IN
work_izjlueimqneiljcxm4zmi6kuna	35	24	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	35	25	degree	degree	NN
work_izjlueimqneiljcxm4zmi6kuna	35	26	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	35	27	similarity	similarity	NN
work_izjlueimqneiljcxm4zmi6kuna	35	28	be-	be-	XX
work_izjlueimqneiljcxm4zmi6kuna	35	29	tween	tween	NN
work_izjlueimqneiljcxm4zmi6kuna	35	30	new	new	JJ
work_izjlueimqneiljcxm4zmi6kuna	35	31	products	product	NNS
work_izjlueimqneiljcxm4zmi6kuna	35	32	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	35	33	pre	pre	JJ
work_izjlueimqneiljcxm4zmi6kuna	35	34	-	-	JJ
work_izjlueimqneiljcxm4zmi6kuna	35	35	existing	existing	JJ
work_izjlueimqneiljcxm4zmi6kuna	35	36	ones	one	NNS
work_izjlueimqneiljcxm4zmi6kuna	35	37	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	36	1	To	to	TO
work_izjlueimqneiljcxm4zmi6kuna	36	2	boost	boost	VB
work_izjlueimqneiljcxm4zmi6kuna	36	3	sales	sale	NNS
work_izjlueimqneiljcxm4zmi6kuna	36	4	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	36	5	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	36	6	new	new	JJ
work_izjlueimqneiljcxm4zmi6kuna	36	7	drug	drug	NN
work_izjlueimqneiljcxm4zmi6kuna	36	8	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	36	9	companies	company	NNS
work_izjlueimqneiljcxm4zmi6kuna	36	10	almost	almost	RB
work_izjlueimqneiljcxm4zmi6kuna	36	11	invariably	invariably	RB
work_izjlueimqneiljcxm4zmi6kuna	36	12	claim	claim	VBP
work_izjlueimqneiljcxm4zmi6kuna	36	13	that	that	IN
work_izjlueimqneiljcxm4zmi6kuna	36	14	their	-PRON-	PRP$
work_izjlueimqneiljcxm4zmi6kuna	36	15	products	product	NNS
work_izjlueimqneiljcxm4zmi6kuna	36	16	are	be	VBP
work_izjlueimqneiljcxm4zmi6kuna	36	17	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	36	18	some	some	DT
work_izjlueimqneiljcxm4zmi6kuna	36	19	way	way	NN
work_izjlueimqneiljcxm4zmi6kuna	36	20	better	well	JJR
work_izjlueimqneiljcxm4zmi6kuna	36	21	than	than	IN
work_izjlueimqneiljcxm4zmi6kuna	36	22	preceding	precede	VBG
work_izjlueimqneiljcxm4zmi6kuna	36	23	ones	one	NNS
work_izjlueimqneiljcxm4zmi6kuna	36	24	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	36	25	even	even	RB
work_izjlueimqneiljcxm4zmi6kuna	36	26	when	when	WRB
work_izjlueimqneiljcxm4zmi6kuna	36	27	this	this	DT
work_izjlueimqneiljcxm4zmi6kuna	36	28	allegation	allegation	NN
work_izjlueimqneiljcxm4zmi6kuna	36	29	is	be	VBZ
work_izjlueimqneiljcxm4zmi6kuna	36	30	unsupported	unsupporte	VBN
work_izjlueimqneiljcxm4zmi6kuna	36	31	by	by	IN
work_izjlueimqneiljcxm4zmi6kuna	36	32	comparative	comparative	JJ
work_izjlueimqneiljcxm4zmi6kuna	36	33	effec-	effec-	NN
work_izjlueimqneiljcxm4zmi6kuna	36	34	tiveness	tiveness	NN
work_izjlueimqneiljcxm4zmi6kuna	36	35	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	36	36	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	36	37	safety	safety	NN
work_izjlueimqneiljcxm4zmi6kuna	36	38	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	36	39	research	research	NN
work_izjlueimqneiljcxm4zmi6kuna	36	40	data	datum	NNS
work_izjlueimqneiljcxm4zmi6kuna	36	41	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	37	1	A	a	DT
work_izjlueimqneiljcxm4zmi6kuna	37	2	common	common	JJ
work_izjlueimqneiljcxm4zmi6kuna	37	3	allegation	allegation	NN
work_izjlueimqneiljcxm4zmi6kuna	37	4	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	37	5	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	37	6	instance	instance	NN
work_izjlueimqneiljcxm4zmi6kuna	37	7	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	37	8	is	be	VBZ
work_izjlueimqneiljcxm4zmi6kuna	37	9	that	that	IN
work_izjlueimqneiljcxm4zmi6kuna	37	10	it	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	37	11	might	may	MD
work_izjlueimqneiljcxm4zmi6kuna	37	12	be	be	VB
work_izjlueimqneiljcxm4zmi6kuna	37	13	ben-	ben-	RB
work_izjlueimqneiljcxm4zmi6kuna	37	14	eficial	eficial	JJ
work_izjlueimqneiljcxm4zmi6kuna	37	15	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	37	16	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	37	17	subgroup	subgroup	NN
work_izjlueimqneiljcxm4zmi6kuna	37	18	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	37	19	patients	patient	NNS
work_izjlueimqneiljcxm4zmi6kuna	37	20	who	who	WP
work_izjlueimqneiljcxm4zmi6kuna	37	21	do	do	VBP
work_izjlueimqneiljcxm4zmi6kuna	37	22	not	not	RB
work_izjlueimqneiljcxm4zmi6kuna	37	23	re-	re-	RB
work_izjlueimqneiljcxm4zmi6kuna	37	24	spond	spond	VB
work_izjlueimqneiljcxm4zmi6kuna	37	25	satisfactorily	satisfactorily	RB
work_izjlueimqneiljcxm4zmi6kuna	37	26	to	to	IN
work_izjlueimqneiljcxm4zmi6kuna	37	27	similar	similar	JJ
work_izjlueimqneiljcxm4zmi6kuna	37	28	drugs	drug	NNS
work_izjlueimqneiljcxm4zmi6kuna	37	29	already	already	RB
work_izjlueimqneiljcxm4zmi6kuna	37	30	on	on	IN
work_izjlueimqneiljcxm4zmi6kuna	37	31	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	37	32	market	market	NN
work_izjlueimqneiljcxm4zmi6kuna	37	33	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	38	1	In	in	IN
work_izjlueimqneiljcxm4zmi6kuna	38	2	many	many	JJ
work_izjlueimqneiljcxm4zmi6kuna	38	3	cases	case	NNS
work_izjlueimqneiljcxm4zmi6kuna	38	4	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	38	5	however	however	RB
work_izjlueimqneiljcxm4zmi6kuna	38	6	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	38	7	this	this	DT
work_izjlueimqneiljcxm4zmi6kuna	38	8	claim	claim	NN
work_izjlueimqneiljcxm4zmi6kuna	38	9	is	be	VBZ
work_izjlueimqneiljcxm4zmi6kuna	38	10	at	at	IN
work_izjlueimqneiljcxm4zmi6kuna	38	11	best	good	JJS
work_izjlueimqneiljcxm4zmi6kuna	38	12	an	an	DT
work_izjlueimqneiljcxm4zmi6kuna	38	13	untested	untested	JJ
work_izjlueimqneiljcxm4zmi6kuna	38	14	-	-	:
work_izjlueimqneiljcxm4zmi6kuna	38	15	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	38	16	self	self	NN
work_izjlueimqneiljcxm4zmi6kuna	38	17	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	38	18	regarding	regard	VBG
work_izjlueimqneiljcxm4zmi6kuna	38	19	–	–	:
work_izjlueimqneiljcxm4zmi6kuna	38	20	hypoth-	hypoth-	NN
work_izjlueimqneiljcxm4zmi6kuna	38	21	esis2	esis2	NNP
work_izjlueimqneiljcxm4zmi6kuna	38	22	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	39	1	The	the	DT
work_izjlueimqneiljcxm4zmi6kuna	39	2	hypothetical	hypothetical	JJ
work_izjlueimqneiljcxm4zmi6kuna	39	3	subpopulation	subpopulation	NN
work_izjlueimqneiljcxm4zmi6kuna	39	4	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	39	5	patients	patient	NNS
work_izjlueimqneiljcxm4zmi6kuna	39	6	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	39	7	who	who	WP
work_izjlueimqneiljcxm4zmi6kuna	39	8	would	would	MD
work_izjlueimqneiljcxm4zmi6kuna	39	9	respond	respond	VB
work_izjlueimqneiljcxm4zmi6kuna	39	10	differently	differently	RB
work_izjlueimqneiljcxm4zmi6kuna	39	11	to	to	IN
work_izjlueimqneiljcxm4zmi6kuna	39	12	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	39	13	new	new	JJ
work_izjlueimqneiljcxm4zmi6kuna	39	14	drug	drug	NN
work_izjlueimqneiljcxm4zmi6kuna	39	15	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	39	16	is	be	VBZ
work_izjlueimqneiljcxm4zmi6kuna	39	17	seldom	seldom	JJ
work_izjlueimqneiljcxm4zmi6kuna	39	18	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	39	19	if	if	IN
work_izjlueimqneiljcxm4zmi6kuna	39	20	ever	ever	RB
work_izjlueimqneiljcxm4zmi6kuna	39	21	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	39	22	characterized	characterize	VBN
work_izjlueimqneiljcxm4zmi6kuna	39	23	by	by	IN
work_izjlueimqneiljcxm4zmi6kuna	39	24	controlled	control	VBN
work_izjlueimqneiljcxm4zmi6kuna	39	25	clin-	clin-	JJ
work_izjlueimqneiljcxm4zmi6kuna	39	26	ical	ical	JJ
work_izjlueimqneiljcxm4zmi6kuna	39	27	studies	study	NNS
work_izjlueimqneiljcxm4zmi6kuna	39	28	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	40	1	Lenalidomide	lenalidomide	RB
work_izjlueimqneiljcxm4zmi6kuna	40	2	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	40	3	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	40	4	teratogenic	teratogenic	JJ
work_izjlueimqneiljcxm4zmi6kuna	40	5	thalidomide	thalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	40	6	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	40	7	like	like	JJ
work_izjlueimqneiljcxm4zmi6kuna	40	8	drug	drug	NN
work_izjlueimqneiljcxm4zmi6kuna	40	9	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	40	10	Figure	Figure	NNP
work_izjlueimqneiljcxm4zmi6kuna	40	11	1	1	CD
work_izjlueimqneiljcxm4zmi6kuna	40	12	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	40	13	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	40	14	challenged	challenge	VBD
work_izjlueimqneiljcxm4zmi6kuna	40	15	Anvisa	Anvisa	NNP
work_izjlueimqneiljcxm4zmi6kuna	40	16	’s	’s	POS
work_izjlueimqneiljcxm4zmi6kuna	40	17	viewpoint	viewpoint	NN
work_izjlueimqneiljcxm4zmi6kuna	40	18	on	on	IN
work_izjlueimqneiljcxm4zmi6kuna	40	19	“	"	``
work_izjlueimqneiljcxm4zmi6kuna	40	20	me	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	40	21	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	40	22	too	too	RB
work_izjlueimqneiljcxm4zmi6kuna	40	23	”	"	''
work_izjlueimqneiljcxm4zmi6kuna	40	24	products	product	NNS
work_izjlueimqneiljcxm4zmi6kuna	40	25	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	40	26	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	40	27	rekindled	rekindle	VBD
work_izjlueimqneiljcxm4zmi6kuna	40	28	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	40	29	debate	debate	NN
work_izjlueimqneiljcxm4zmi6kuna	40	30	on	on	IN
work_izjlueimqneiljcxm4zmi6kuna	40	31	whether	whether	IN
work_izjlueimqneiljcxm4zmi6kuna	40	32	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	40	33	agency	agency	NN
work_izjlueimqneiljcxm4zmi6kuna	40	34	should	should	MD
work_izjlueimqneiljcxm4zmi6kuna	40	35	require	require	VB
work_izjlueimqneiljcxm4zmi6kuna	40	36	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	40	37	appli-	appli-	NN
work_izjlueimqneiljcxm4zmi6kuna	40	38	ca	can	MD
work_izjlueimqneiljcxm4zmi6kuna	40	39	nt	not	RB
work_izjlueimqneiljcxm4zmi6kuna	40	40	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	40	41	proof	proof	NN
work_izjlueimqneiljcxm4zmi6kuna	40	42	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	40	43	clinical	clinical	JJ
work_izjlueimqneiljcxm4zmi6kuna	40	44	superiority	superiority	NN
work_izjlueimqneiljcxm4zmi6kuna	40	45	over	over	IN
work_izjlueimqneiljcxm4zmi6kuna	40	46	existing	exist	VBG
work_izjlueimqneiljcxm4zmi6kuna	40	47	therapies	therapy	NNS
work_izjlueimqneiljcxm4zmi6kuna	40	48	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	40	49	granting	grant	VBG
work_izjlueimqneiljcxm4zmi6kuna	40	50	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	40	51	marketing	marketing	NN
work_izjlueimqneiljcxm4zmi6kuna	40	52	approval	approval	NN
work_izjlueimqneiljcxm4zmi6kuna	40	53	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	40	54	some	some	DT
work_izjlueimqneiljcxm4zmi6kuna	40	55	drugs	drug	NNS
work_izjlueimqneiljcxm4zmi6kuna	40	56	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	41	1	A	a	DT
work_izjlueimqneiljcxm4zmi6kuna	41	2	demand	demand	NN
work_izjlueimqneiljcxm4zmi6kuna	41	3	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	41	4	comparative	comparative	JJ
work_izjlueimqneiljcxm4zmi6kuna	41	5	effective-	effective-	JJ
work_izjlueimqneiljcxm4zmi6kuna	41	6	ness	ness	NN
work_izjlueimqneiljcxm4zmi6kuna	41	7	research	research	NN
work_izjlueimqneiljcxm4zmi6kuna	41	8	data	datum	NNS
work_izjlueimqneiljcxm4zmi6kuna	41	9	are	be	VBP
work_izjlueimqneiljcxm4zmi6kuna	41	10	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	41	11	utmost	utmost	JJ
work_izjlueimqneiljcxm4zmi6kuna	41	12	importance	importance	NN
work_izjlueimqneiljcxm4zmi6kuna	41	13	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	41	14	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	41	15	instance	instance	NN
work_izjlueimqneiljcxm4zmi6kuna	41	16	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	41	17	if	if	IN
work_izjlueimqneiljcxm4zmi6kuna	41	18	estimated	estimate	VBN
work_izjlueimqneiljcxm4zmi6kuna	41	19	costs	cost	NNS
work_izjlueimqneiljcxm4zmi6kuna	41	20	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	41	21	treatment	treatment	NN
work_izjlueimqneiljcxm4zmi6kuna	41	22	with	with	IN
work_izjlueimqneiljcxm4zmi6kuna	41	23	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	41	24	new	new	JJ
work_izjlueimqneiljcxm4zmi6kuna	41	25	drug	drug	NN
work_izjlueimqneiljcxm4zmi6kuna	41	26	are	be	VBP
work_izjlueimqneiljcxm4zmi6kuna	41	27	much	much	RB
work_izjlueimqneiljcxm4zmi6kuna	41	28	higher	high	JJR
work_izjlueimqneiljcxm4zmi6kuna	41	29	than	than	IN
work_izjlueimqneiljcxm4zmi6kuna	41	30	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	41	31	costs	cost	NNS
work_izjlueimqneiljcxm4zmi6kuna	41	32	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	41	33	ther-	ther-	NN
work_izjlueimqneiljcxm4zmi6kuna	41	34	apies	apie	NNS
work_izjlueimqneiljcxm4zmi6kuna	41	35	with	with	IN
work_izjlueimqneiljcxm4zmi6kuna	41	36	drugs	drug	NNS
work_izjlueimqneiljcxm4zmi6kuna	41	37	already	already	RB
work_izjlueimqneiljcxm4zmi6kuna	41	38	available	available	JJ
work_izjlueimqneiljcxm4zmi6kuna	41	39	on	on	IN
work_izjlueimqneiljcxm4zmi6kuna	41	40	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	41	41	market	market	NN
work_izjlueimqneiljcxm4zmi6kuna	41	42	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	42	1	This	this	DT
work_izjlueimqneiljcxm4zmi6kuna	42	2	article	article	NN
work_izjlueimqneiljcxm4zmi6kuna	42	3	appraises	appraise	VBZ
work_izjlueimqneiljcxm4zmi6kuna	42	4	critically	critically	RB
work_izjlueimqneiljcxm4zmi6kuna	42	5	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	42	6	available	available	JJ
work_izjlueimqneiljcxm4zmi6kuna	42	7	evidence	evidence	NN
work_izjlueimqneiljcxm4zmi6kuna	42	8	on	on	IN
work_izjlueimqneiljcxm4zmi6kuna	42	9	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	42	10	comparative	comparative	JJ
work_izjlueimqneiljcxm4zmi6kuna	42	11	effectiveness	effectiveness	NN
work_izjlueimqneiljcxm4zmi6kuna	42	12	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	42	13	lenalidomide-	lenalidomide-	NN
work_izjlueimqneiljcxm4zmi6kuna	42	14	versus	versus	FW
work_izjlueimqneiljcxm4zmi6kuna	42	15	thalidomide	thalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	42	16	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	42	17	based	base	VBN
work_izjlueimqneiljcxm4zmi6kuna	42	18	thera-	thera-	NN
work_izjlueimqneiljcxm4zmi6kuna	42	19	pies	pie	NNS
work_izjlueimqneiljcxm4zmi6kuna	42	20	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	42	21	MM	MM	NNP
work_izjlueimqneiljcxm4zmi6kuna	42	22	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	42	23	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	42	24	regulatory	regulatory	JJ
work_izjlueimqneiljcxm4zmi6kuna	42	25	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	42	26	cost	cost	NN
work_izjlueimqneiljcxm4zmi6kuna	42	27	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	42	28	effective-	effective-	NN
work_izjlueimqneiljcxm4zmi6kuna	42	29	ness	ness	NN
work_izjlueimqneiljcxm4zmi6kuna	42	30	issues	issue	NNS
work_izjlueimqneiljcxm4zmi6kuna	42	31	behind	behind	IN
work_izjlueimqneiljcxm4zmi6kuna	42	32	lenalidomide	lenalidomide	JJ
work_izjlueimqneiljcxm4zmi6kuna	42	33	authorization	authorization	NN
work_izjlueimqneiljcxm4zmi6kuna	42	34	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	42	35	sales	sale	NNS
work_izjlueimqneiljcxm4zmi6kuna	42	36	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	42	37	Brazil	Brazil	NNP
work_izjlueimqneiljcxm4zmi6kuna	42	38	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	43	1	methods	method	NNS
work_izjlueimqneiljcxm4zmi6kuna	43	2	The	the	DT
work_izjlueimqneiljcxm4zmi6kuna	43	3	approval	approval	NN
work_izjlueimqneiljcxm4zmi6kuna	43	4	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	43	5	lenalidomide	lenalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	43	6	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	43	7	sales	sale	NNS
work_izjlueimqneiljcxm4zmi6kuna	43	8	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	43	9	Brazil	Brazil	NNP
work_izjlueimqneiljcxm4zmi6kuna	43	10	is	be	VBZ
work_izjlueimqneiljcxm4zmi6kuna	43	11	discussed	discuss	VBN
work_izjlueimqneiljcxm4zmi6kuna	43	12	here	here	RB
work_izjlueimqneiljcxm4zmi6kuna	43	13	as	as	IN
work_izjlueimqneiljcxm4zmi6kuna	43	14	an	an	DT
work_izjlueimqneiljcxm4zmi6kuna	43	15	exploratory	exploratory	JJ
work_izjlueimqneiljcxm4zmi6kuna	43	16	case	case	NN
work_izjlueimqneiljcxm4zmi6kuna	43	17	study	study	NN
work_izjlueimqneiljcxm4zmi6kuna	43	18	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	44	1	It	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	44	2	brings	bring	VBZ
work_izjlueimqneiljcxm4zmi6kuna	44	3	us	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	44	4	to	to	TO
work_izjlueimqneiljcxm4zmi6kuna	44	5	question	question	VB
work_izjlueimqneiljcxm4zmi6kuna	44	6	ANVISA	ANVISA	NNP
work_izjlueimqneiljcxm4zmi6kuna	44	7	’s	’s	POS
work_izjlueimqneiljcxm4zmi6kuna	44	8	regulatory	regulatory	JJ
work_izjlueimqneiljcxm4zmi6kuna	44	9	policy	policy	NN
work_izjlueimqneiljcxm4zmi6kuna	44	10	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	44	11	non	non	JJ
work_izjlueimqneiljcxm4zmi6kuna	44	12	-	-	JJ
work_izjlueimqneiljcxm4zmi6kuna	44	13	innovative	innovative	JJ
work_izjlueimqneiljcxm4zmi6kuna	44	14	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	44	15	me	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	44	16	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	44	17	too	too	RB
work_izjlueimqneiljcxm4zmi6kuna	44	18	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	44	19	drugs	drug	NNS
work_izjlueimqneiljcxm4zmi6kuna	44	20	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	44	21	par-	par-	RB
work_izjlueimqneiljcxm4zmi6kuna	44	22	ticularly	ticularly	RB
work_izjlueimqneiljcxm4zmi6kuna	44	23	when	when	WRB
work_izjlueimqneiljcxm4zmi6kuna	44	24	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	44	25	new	new	JJ
work_izjlueimqneiljcxm4zmi6kuna	44	26	product	product	NN
work_izjlueimqneiljcxm4zmi6kuna	44	27	compares	compare	VBZ
work_izjlueimqneiljcxm4zmi6kuna	44	28	un-	un-	RB
work_izjlueimqneiljcxm4zmi6kuna	44	29	favorably	favorably	RB
work_izjlueimqneiljcxm4zmi6kuna	44	30	with	with	IN
work_izjlueimqneiljcxm4zmi6kuna	44	31	its	-PRON-	PRP$
work_izjlueimqneiljcxm4zmi6kuna	44	32	prototype	prototype	NN
work_izjlueimqneiljcxm4zmi6kuna	44	33	medicine	medicine	NN
work_izjlueimqneiljcxm4zmi6kuna	44	34	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	44	35	terms	term	NNS
work_izjlueimqneiljcxm4zmi6kuna	44	36	3	3	CD
work_izjlueimqneiljcxm4zmi6kuna	44	37	7	7	CD
work_izjlueimqneiljcxm4zmi6kuna	44	38	8	8	CD
work_izjlueimqneiljcxm4zmi6kuna	44	39	5	5	CD
work_izjlueimqneiljcxm4zmi6kuna	44	40	C	C	NNP
work_izjlueimqneiljcxm4zmi6kuna	44	41	iên	iên	NN
work_izjlueimqneiljcxm4zmi6kuna	44	42	cia	cia	NNP
work_izjlueimqneiljcxm4zmi6kuna	44	43	&	&	CC
work_izjlueimqneiljcxm4zmi6kuna	44	44	Saú	Saú	NNP
work_izjlueimqneiljcxm4zmi6kuna	44	45	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	44	46	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	44	47	C	C	NNP
work_izjlueimqneiljcxm4zmi6kuna	44	48	o	o	NN
work_izjlueimqneiljcxm4zmi6kuna	44	49	letiva	letiva	NN
work_izjlueimqneiljcxm4zmi6kuna	44	50	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	44	51	2	2	CD
work_izjlueimqneiljcxm4zmi6kuna	44	52	4	4	CD
work_izjlueimqneiljcxm4zmi6kuna	44	53	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	44	54	1	1	CD
work_izjlueimqneiljcxm4zmi6kuna	44	55	0	0	CD
work_izjlueimqneiljcxm4zmi6kuna	44	56	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	44	57	:3	:3	NNP
work_izjlueimqneiljcxm4zmi6kuna	44	58	7	7	CD
work_izjlueimqneiljcxm4zmi6kuna	44	59	8	8	CD
work_izjlueimqneiljcxm4zmi6kuna	44	60	3	3	CD
work_izjlueimqneiljcxm4zmi6kuna	44	61	-3	-3	$
work_izjlueimqneiljcxm4zmi6kuna	44	62	7	7	CD
work_izjlueimqneiljcxm4zmi6kuna	44	63	9	9	CD
work_izjlueimqneiljcxm4zmi6kuna	44	64	2	2	CD
work_izjlueimqneiljcxm4zmi6kuna	44	65	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	44	66	2	2	CD
work_izjlueimqneiljcxm4zmi6kuna	44	67	0	0	CD
work_izjlueimqneiljcxm4zmi6kuna	44	68	1	1	CD
work_izjlueimqneiljcxm4zmi6kuna	44	69	9	9	CD
work_izjlueimqneiljcxm4zmi6kuna	44	70	figure	figure	NN
work_izjlueimqneiljcxm4zmi6kuna	44	71	1	1	CD
work_izjlueimqneiljcxm4zmi6kuna	44	72	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	45	1	Lenalidomide	Lenalidomide	NNP
work_izjlueimqneiljcxm4zmi6kuna	45	2	resulted	result	VBD
work_izjlueimqneiljcxm4zmi6kuna	45	3	from	from	IN
work_izjlueimqneiljcxm4zmi6kuna	45	4	two	two	CD
work_izjlueimqneiljcxm4zmi6kuna	45	5	minor	minor	JJ
work_izjlueimqneiljcxm4zmi6kuna	45	6	alterations	alteration	NNS
work_izjlueimqneiljcxm4zmi6kuna	45	7	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	45	8	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	45	9	phthalimide	phthalimide	NN
work_izjlueimqneiljcxm4zmi6kuna	45	10	ring	ring	NN
work_izjlueimqneiljcxm4zmi6kuna	45	11	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	45	12	thalidomide	thalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	45	13	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	45	14	indicated	indicate	VBN
work_izjlueimqneiljcxm4zmi6kuna	45	15	by	by	IN
work_izjlueimqneiljcxm4zmi6kuna	45	16	circles	circle	NNS
work_izjlueimqneiljcxm4zmi6kuna	45	17	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	45	18	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	46	1	It	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	46	2	is	be	VBZ
work_izjlueimqneiljcxm4zmi6kuna	46	3	more	more	RBR
work_izjlueimqneiljcxm4zmi6kuna	46	4	potent	potent	JJ
work_izjlueimqneiljcxm4zmi6kuna	46	5	than	than	IN
work_izjlueimqneiljcxm4zmi6kuna	46	6	thalidomide	thalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	46	7	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	46	8	therapeutic	therapeutic	JJ
work_izjlueimqneiljcxm4zmi6kuna	46	9	doses	dose	NNS
work_izjlueimqneiljcxm4zmi6kuna	46	10	:	:	:
work_izjlueimqneiljcxm4zmi6kuna	46	11	15	15	CD
work_izjlueimqneiljcxm4zmi6kuna	46	12	-	-	SYM
work_izjlueimqneiljcxm4zmi6kuna	46	13	25	25	CD
work_izjlueimqneiljcxm4zmi6kuna	46	14	mg	mg	NNP
work_izjlueimqneiljcxm4zmi6kuna	46	15	/	/	SYM
work_izjlueimqneiljcxm4zmi6kuna	46	16	day	day	NN
work_izjlueimqneiljcxm4zmi6kuna	46	17	versus	versus	IN
work_izjlueimqneiljcxm4zmi6kuna	46	18	100	100	CD
work_izjlueimqneiljcxm4zmi6kuna	46	19	-	-	SYM
work_izjlueimqneiljcxm4zmi6kuna	46	20	200	200	CD
work_izjlueimqneiljcxm4zmi6kuna	46	21	mg	mg	NN
work_izjlueimqneiljcxm4zmi6kuna	46	22	/	/	SYM
work_izjlueimqneiljcxm4zmi6kuna	46	23	day	day	NN
work_izjlueimqneiljcxm4zmi6kuna	46	24	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	46	25	respectively	respectively	RB
work_izjlueimqneiljcxm4zmi6kuna	46	26	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	46	27	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	47	1	Comparative	comparative	JJ
work_izjlueimqneiljcxm4zmi6kuna	47	2	effectiveness	effectiveness	NN
work_izjlueimqneiljcxm4zmi6kuna	47	3	research	research	NN
work_izjlueimqneiljcxm4zmi6kuna	47	4	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	47	5	however	however	RB
work_izjlueimqneiljcxm4zmi6kuna	47	6	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	47	7	showed	show	VBD
work_izjlueimqneiljcxm4zmi6kuna	47	8	that	that	IN
work_izjlueimqneiljcxm4zmi6kuna	47	9	they	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	47	10	have	have	VBP
work_izjlueimqneiljcxm4zmi6kuna	47	11	nearly	nearly	RB
work_izjlueimqneiljcxm4zmi6kuna	47	12	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	47	13	same	same	JJ
work_izjlueimqneiljcxm4zmi6kuna	47	14	effectiveness	effectiveness	NN
work_izjlueimqneiljcxm4zmi6kuna	47	15	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	47	16	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	47	17	treatment	treatment	NN
work_izjlueimqneiljcxm4zmi6kuna	47	18	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	47	19	multiple	multiple	JJ
work_izjlueimqneiljcxm4zmi6kuna	47	20	myeloma	myeloma	NNS
work_izjlueimqneiljcxm4zmi6kuna	47	21	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	48	1	Nonetheless	nonetheless	RB
work_izjlueimqneiljcxm4zmi6kuna	48	2	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	48	3	lenalidomide	lenalidomide	VB
work_izjlueimqneiljcxm4zmi6kuna	48	4	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	48	5	compared	compare	VBN
work_izjlueimqneiljcxm4zmi6kuna	48	6	with	with	IN
work_izjlueimqneiljcxm4zmi6kuna	48	7	its	-PRON-	PRP$
work_izjlueimqneiljcxm4zmi6kuna	48	8	prototype	prototype	NN
work_izjlueimqneiljcxm4zmi6kuna	48	9	drug	drug	NN
work_izjlueimqneiljcxm4zmi6kuna	48	10	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	48	11	was	be	VBD
work_izjlueimqneiljcxm4zmi6kuna	48	12	associated	associate	VBN
work_izjlueimqneiljcxm4zmi6kuna	48	13	with	with	IN
work_izjlueimqneiljcxm4zmi6kuna	48	14	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	48	15	lower	low	JJR
work_izjlueimqneiljcxm4zmi6kuna	48	16	incidence	incidence	NN
work_izjlueimqneiljcxm4zmi6kuna	48	17	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	48	18	neuropathy	neuropathy	NN
work_izjlueimqneiljcxm4zmi6kuna	48	19	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	48	20	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	48	21	higher	high	JJR
work_izjlueimqneiljcxm4zmi6kuna	48	22	occurrence	occurrence	NN
work_izjlueimqneiljcxm4zmi6kuna	48	23	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	48	24	severe	severe	JJ
work_izjlueimqneiljcxm4zmi6kuna	48	25	hematologic	hematologic	JJ
work_izjlueimqneiljcxm4zmi6kuna	48	26	side	side	NN
work_izjlueimqneiljcxm4zmi6kuna	48	27	effects	effect	NNS
work_izjlueimqneiljcxm4zmi6kuna	48	28	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	49	1	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	49	2	cost	cost	NN
work_izjlueimqneiljcxm4zmi6kuna	49	3	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	49	4	effectiveness	effectiveness	NN
work_izjlueimqneiljcxm4zmi6kuna	49	5	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	50	1	Nonetheless	nonetheless	RB
work_izjlueimqneiljcxm4zmi6kuna	50	2	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	50	3	this	this	DT
work_izjlueimqneiljcxm4zmi6kuna	50	4	case	case	NN
work_izjlueimqneiljcxm4zmi6kuna	50	5	also	also	RB
work_izjlueimqneiljcxm4zmi6kuna	50	6	involves	involve	VBZ
work_izjlueimqneiljcxm4zmi6kuna	50	7	another	another	DT
work_izjlueimqneiljcxm4zmi6kuna	50	8	unique	unique	JJ
work_izjlueimqneiljcxm4zmi6kuna	50	9	regulatory	regulatory	JJ
work_izjlueimqneiljcxm4zmi6kuna	50	10	issue	issue	NN
work_izjlueimqneiljcxm4zmi6kuna	50	11	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	51	1	Owing	owe	VBG
work_izjlueimqneiljcxm4zmi6kuna	51	2	to	to	IN
work_izjlueimqneiljcxm4zmi6kuna	51	3	its	-PRON-	PRP$
work_izjlueimqneiljcxm4zmi6kuna	51	4	teratogenicity	teratogenicity	NN
work_izjlueimqneiljcxm4zmi6kuna	51	5	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	51	6	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	51	7	fact	fact	NN
work_izjlueimqneiljcxm4zmi6kuna	51	8	that	that	IN
work_izjlueimqneiljcxm4zmi6kuna	51	9	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	51	10	coun-	coun-	JJ
work_izjlueimqneiljcxm4zmi6kuna	51	11	try	try	NN
work_izjlueimqneiljcxm4zmi6kuna	51	12	has	have	VBZ
work_izjlueimqneiljcxm4zmi6kuna	51	13	world	world	NN
work_izjlueimqneiljcxm4zmi6kuna	51	14	’s	’s	POS
work_izjlueimqneiljcxm4zmi6kuna	51	15	greatest	great	JJS
work_izjlueimqneiljcxm4zmi6kuna	51	16	number	number	NN
work_izjlueimqneiljcxm4zmi6kuna	51	17	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	51	18	thalidomide	thalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	51	19	victims	victim	NNS
work_izjlueimqneiljcxm4zmi6kuna	51	20	born	bear	VBN
work_izjlueimqneiljcxm4zmi6kuna	51	21	after	after	IN
work_izjlueimqneiljcxm4zmi6kuna	51	22	1965	1965	CD
work_izjlueimqneiljcxm4zmi6kuna	51	23	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	51	24	i.e.	i.e.	FW
work_izjlueimqneiljcxm4zmi6kuna	51	25	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	51	26	“	"	``
work_izjlueimqneiljcxm4zmi6kuna	51	27	avoidable	avoidable	JJ
work_izjlueimqneiljcxm4zmi6kuna	51	28	cases	case	NNS
work_izjlueimqneiljcxm4zmi6kuna	51	29	”	"	''
work_izjlueimqneiljcxm4zmi6kuna	51	30	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	51	31	thalidomide	thalidomide	NNP
work_izjlueimqneiljcxm4zmi6kuna	51	32	birth	birth	NN
work_izjlueimqneiljcxm4zmi6kuna	51	33	defects	defect	NNS
work_izjlueimqneiljcxm4zmi6kuna	51	34	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	51	35	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	51	36	it	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	51	37	is	be	VBZ
work_izjlueimqneiljcxm4zmi6kuna	51	38	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	51	39	only	only	JJ
work_izjlueimqneiljcxm4zmi6kuna	51	40	drug	drug	NN
work_izjlueimqneiljcxm4zmi6kuna	51	41	regulated	regulate	VBN
work_izjlueimqneiljcxm4zmi6kuna	51	42	by	by	IN
work_izjlueimqneiljcxm4zmi6kuna	51	43	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	51	44	specific	specific	JJ
work_izjlueimqneiljcxm4zmi6kuna	51	45	Federal	federal	JJ
work_izjlueimqneiljcxm4zmi6kuna	51	46	law	law	NN
work_izjlueimqneiljcxm4zmi6kuna	51	47	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	51	48	Brazil	Brazil	NNP
work_izjlueimqneiljcxm4zmi6kuna	51	49	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	52	1	The	the	DT
work_izjlueimqneiljcxm4zmi6kuna	52	2	law	law	NN
work_izjlueimqneiljcxm4zmi6kuna	52	3	10.651/2003	10.651/2003	CD
work_izjlueimqneiljcxm4zmi6kuna	52	4	forbids	forbid	NNS
work_izjlueimqneiljcxm4zmi6kuna	52	5	thalidomide	thalidomide	VBP
work_izjlueimqneiljcxm4zmi6kuna	52	6	sales	sale	NNS
work_izjlueimqneiljcxm4zmi6kuna	52	7	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	52	8	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	52	9	further	further	JJ
work_izjlueimqneiljcxm4zmi6kuna	52	10	agency	agency	NN
work_izjlueimqneiljcxm4zmi6kuna	52	11	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	52	12	issued	issue	VBN
work_izjlueimqneiljcxm4zmi6kuna	52	13	regulations	regulation	NNS
work_izjlueimqneiljcxm4zmi6kuna	52	14	impose	impose	VBP
work_izjlueimqneiljcxm4zmi6kuna	52	15	addi-	addi-	JJ
work_izjlueimqneiljcxm4zmi6kuna	52	16	tional	tional	JJ
work_izjlueimqneiljcxm4zmi6kuna	52	17	constraints	constraint	NNS
work_izjlueimqneiljcxm4zmi6kuna	52	18	to	to	IN
work_izjlueimqneiljcxm4zmi6kuna	52	19	prescription	prescription	NN
work_izjlueimqneiljcxm4zmi6kuna	52	20	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	52	21	dispensing	dispense	VBG
work_izjlueimqneiljcxm4zmi6kuna	52	22	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	53	1	Since	since	IN
work_izjlueimqneiljcxm4zmi6kuna	53	2	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	53	3	law	law	NN
work_izjlueimqneiljcxm4zmi6kuna	53	4	makes	make	VBZ
work_izjlueimqneiljcxm4zmi6kuna	53	5	no	no	DT
work_izjlueimqneiljcxm4zmi6kuna	53	6	provision	provision	NN
work_izjlueimqneiljcxm4zmi6kuna	53	7	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	53	8	thalidomide	thalidomide	NNP
work_izjlueimqneiljcxm4zmi6kuna	53	9	analogs	analog	NNS
work_izjlueimqneiljcxm4zmi6kuna	53	10	such	such	JJ
work_izjlueimqneiljcxm4zmi6kuna	53	11	as	as	IN
work_izjlueimqneiljcxm4zmi6kuna	53	12	lenalidomide	lenalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	53	13	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	53	14	Brazil	Brazil	NNP
work_izjlueimqneiljcxm4zmi6kuna	53	15	has	have	VBZ
work_izjlueimqneiljcxm4zmi6kuna	53	16	clearly	clearly	RB
work_izjlueimqneiljcxm4zmi6kuna	53	17	adopted	adopt	VBN
work_izjlueimqneiljcxm4zmi6kuna	53	18	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	53	19	regulatory	regulatory	JJ
work_izjlueimqneiljcxm4zmi6kuna	53	20	double	double	JJ
work_izjlueimqneiljcxm4zmi6kuna	53	21	standard	standard	NN
work_izjlueimqneiljcxm4zmi6kuna	53	22	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	53	23	thalid-	thalid-	NN
work_izjlueimqneiljcxm4zmi6kuna	53	24	omide	omide	NN
work_izjlueimqneiljcxm4zmi6kuna	53	25	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	53	26	thalidomide	thalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	53	27	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	53	28	like	like	JJ
work_izjlueimqneiljcxm4zmi6kuna	53	29	teratogens	teratogen	NNS
work_izjlueimqneiljcxm4zmi6kuna	53	30	marketed	market	VBN
work_izjlueimqneiljcxm4zmi6kuna	53	31	by	by	IN
work_izjlueimqneiljcxm4zmi6kuna	53	32	pharmaceutical	pharmaceutical	JJ
work_izjlueimqneiljcxm4zmi6kuna	53	33	companies	company	NNS
work_izjlueimqneiljcxm4zmi6kuna	53	34	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	54	1	A	a	DT
work_izjlueimqneiljcxm4zmi6kuna	54	2	thorough	thorough	JJ
work_izjlueimqneiljcxm4zmi6kuna	54	3	search	search	NN
work_izjlueimqneiljcxm4zmi6kuna	54	4	was	be	VBD
work_izjlueimqneiljcxm4zmi6kuna	54	5	conducted	conduct	VBN
work_izjlueimqneiljcxm4zmi6kuna	54	6	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	54	7	biomedical	biomedical	JJ
work_izjlueimqneiljcxm4zmi6kuna	54	8	electronic	electronic	JJ
work_izjlueimqneiljcxm4zmi6kuna	54	9	databas-	databas-	NN
work_izjlueimqneiljcxm4zmi6kuna	54	10	es	es	FW
work_izjlueimqneiljcxm4zmi6kuna	54	11	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	54	12	Medline	Medline	NNP
work_izjlueimqneiljcxm4zmi6kuna	54	13	/	/	SYM
work_izjlueimqneiljcxm4zmi6kuna	54	14	Pubmed	Pubmed	NNP
work_izjlueimqneiljcxm4zmi6kuna	54	15	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	54	16	BVS	BVS	NNP
work_izjlueimqneiljcxm4zmi6kuna	54	17	Brazil	Brazil	NNP
work_izjlueimqneiljcxm4zmi6kuna	54	18	/	/	SYM
work_izjlueimqneiljcxm4zmi6kuna	54	19	Bireme	Bireme	NNP
work_izjlueimqneiljcxm4zmi6kuna	54	20	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	54	21	http://	http://	JJ
work_izjlueimqneiljcxm4zmi6kuna	54	22	www.brasil.bvs.br	www.brasil.bvs.br	NNP
work_izjlueimqneiljcxm4zmi6kuna	54	23	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	54	24	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	54	25	to	to	TO
work_izjlueimqneiljcxm4zmi6kuna	54	26	identify	identify	VB
work_izjlueimqneiljcxm4zmi6kuna	54	27	comparative	comparative	JJ
work_izjlueimqneiljcxm4zmi6kuna	54	28	effec-	effec-	NN
work_izjlueimqneiljcxm4zmi6kuna	54	29	tiveness	tiveness	NN
work_izjlueimqneiljcxm4zmi6kuna	54	30	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	54	31	safety	safety	NN
work_izjlueimqneiljcxm4zmi6kuna	54	32	studies	study	NNS
work_izjlueimqneiljcxm4zmi6kuna	54	33	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	54	34	thalidomide	thalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	54	35	versus	versus	IN
work_izjlueimqneiljcxm4zmi6kuna	54	36	lenalidomide	lenalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	54	37	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	54	38	treatment	treatment	NN
work_izjlueimqneiljcxm4zmi6kuna	54	39	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	54	40	multiple	multiple	JJ
work_izjlueimqneiljcxm4zmi6kuna	54	41	myeloma	myeloma	NNS
work_izjlueimqneiljcxm4zmi6kuna	54	42	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	54	43	or	or	CC
work_izjlueimqneiljcxm4zmi6kuna	54	44	myelodysplastic	myelodysplastic	JJ
work_izjlueimqneiljcxm4zmi6kuna	54	45	syndrome	syndrome	NN
work_izjlueimqneiljcxm4zmi6kuna	54	46	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	54	47	MDS	MDS	NNP
work_izjlueimqneiljcxm4zmi6kuna	54	48	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	54	49	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	55	1	A	a	DT
work_izjlueimqneiljcxm4zmi6kuna	55	2	sim-	sim-	JJ
work_izjlueimqneiljcxm4zmi6kuna	55	3	ilar	ilar	JJ
work_izjlueimqneiljcxm4zmi6kuna	55	4	search	search	NN
work_izjlueimqneiljcxm4zmi6kuna	55	5	was	be	VBD
work_izjlueimqneiljcxm4zmi6kuna	55	6	undertaken	undertake	VBN
work_izjlueimqneiljcxm4zmi6kuna	55	7	to	to	TO
work_izjlueimqneiljcxm4zmi6kuna	55	8	find	find	VB
work_izjlueimqneiljcxm4zmi6kuna	55	9	comparative	comparative	JJ
work_izjlueimqneiljcxm4zmi6kuna	55	10	cost	cost	NN
work_izjlueimqneiljcxm4zmi6kuna	55	11	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	55	12	effectiveness	effectiveness	NN
work_izjlueimqneiljcxm4zmi6kuna	55	13	studies	study	NNS
work_izjlueimqneiljcxm4zmi6kuna	55	14	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	55	15	thalidomide	thalidomide	JJ
work_izjlueimqneiljcxm4zmi6kuna	55	16	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	55	17	versus	versus	IN
work_izjlueimqneiljcxm4zmi6kuna	55	18	lenalidomide	lenalidomide	RB
work_izjlueimqneiljcxm4zmi6kuna	55	19	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	55	20	based	base	VBN
work_izjlueimqneiljcxm4zmi6kuna	55	21	therapies	therapy	NNS
work_izjlueimqneiljcxm4zmi6kuna	55	22	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	55	23	MM	MM	NNP
work_izjlueimqneiljcxm4zmi6kuna	55	24	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	55	25	MDS	MDS	NNP
work_izjlueimqneiljcxm4zmi6kuna	55	26	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	56	1	Searches	Searches	NNP
work_izjlueimqneiljcxm4zmi6kuna	56	2	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	56	3	Medline	Medline	NNP
work_izjlueimqneiljcxm4zmi6kuna	56	4	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	56	5	BVS	BVS	NNP
work_izjlueimqneiljcxm4zmi6kuna	56	6	Brazil	Brazil	NNP
work_izjlueimqneiljcxm4zmi6kuna	56	7	/	/	SYM
work_izjlueimqneiljcxm4zmi6kuna	56	8	Bireme	Bireme	NNP
work_izjlueimqneiljcxm4zmi6kuna	56	9	da-	da-	XX
work_izjlueimqneiljcxm4zmi6kuna	56	10	tabases	tabase	NNS
work_izjlueimqneiljcxm4zmi6kuna	56	11	were	be	VBD
work_izjlueimqneiljcxm4zmi6kuna	56	12	conducted	conduct	VBN
work_izjlueimqneiljcxm4zmi6kuna	56	13	using	use	VBG
work_izjlueimqneiljcxm4zmi6kuna	56	14	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	56	15	variety	variety	NN
work_izjlueimqneiljcxm4zmi6kuna	56	16	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	56	17	search-	search-	JJ
work_izjlueimqneiljcxm4zmi6kuna	56	18	ing	ing	NNP
work_izjlueimqneiljcxm4zmi6kuna	56	19	strings	string	NNS
work_izjlueimqneiljcxm4zmi6kuna	56	20	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	56	21	e.g.	e.g.	RB
work_izjlueimqneiljcxm4zmi6kuna	56	22	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	56	23	“	"	``
work_izjlueimqneiljcxm4zmi6kuna	56	24	lenalidomide	lenalidomide	VB
work_izjlueimqneiljcxm4zmi6kuna	56	25	AND	and	CC
work_izjlueimqneiljcxm4zmi6kuna	56	26	thalidomide	thalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	56	27	AND	and	CC
work_izjlueimqneiljcxm4zmi6kuna	56	28	comparative	comparative	JJ
work_izjlueimqneiljcxm4zmi6kuna	56	29	effectiveness	effectiveness	NN
work_izjlueimqneiljcxm4zmi6kuna	56	30	”	"	''
work_izjlueimqneiljcxm4zmi6kuna	56	31	;	;	:
work_izjlueimqneiljcxm4zmi6kuna	56	32	“	"	``
work_izjlueimqneiljcxm4zmi6kuna	56	33	lenalidomide	lenalidomide	VB
work_izjlueimqneiljcxm4zmi6kuna	56	34	AND	and	CC
work_izjlueimqneiljcxm4zmi6kuna	56	35	thalidomide	thalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	56	36	AND	and	CC
work_izjlueimqneiljcxm4zmi6kuna	56	37	multiple	multiple	JJ
work_izjlueimqneiljcxm4zmi6kuna	56	38	myeloma	myeloma	NNS
work_izjlueimqneiljcxm4zmi6kuna	56	39	AND	and	CC
work_izjlueimqneiljcxm4zmi6kuna	56	40	effectiveness	effectiveness	NN
work_izjlueimqneiljcxm4zmi6kuna	56	41	”	"	''
work_izjlueimqneiljcxm4zmi6kuna	56	42	;	;	:
work_izjlueimqneiljcxm4zmi6kuna	56	43	“	"	``
work_izjlueimqneiljcxm4zmi6kuna	56	44	thalidomide	thalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	56	45	AND	and	CC
work_izjlueimqneiljcxm4zmi6kuna	56	46	myeloma	myeloma	NN
work_izjlueimqneiljcxm4zmi6kuna	56	47	AND	and	CC
work_izjlueimqneiljcxm4zmi6kuna	56	48	effectiveness	effectiveness	NN
work_izjlueimqneiljcxm4zmi6kuna	56	49	AND	and	CC
work_izjlueimqneiljcxm4zmi6kuna	56	50	safety	safety	NN
work_izjlueimqneiljcxm4zmi6kuna	56	51	”	"	''
work_izjlueimqneiljcxm4zmi6kuna	56	52	;	;	:
work_izjlueimqneiljcxm4zmi6kuna	56	53	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	56	54	others	other	NNS
work_izjlueimqneiljcxm4zmi6kuna	56	55	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	56	56	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	56	57	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	56	58	cov-	cov-	RB
work_izjlueimqneiljcxm4zmi6kuna	56	59	ered	ere	VBD
work_izjlueimqneiljcxm4zmi6kuna	56	60	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	56	61	time	time	NN
work_izjlueimqneiljcxm4zmi6kuna	56	62	window	window	NN
work_izjlueimqneiljcxm4zmi6kuna	56	63	between	between	IN
work_izjlueimqneiljcxm4zmi6kuna	56	64	database	database	NN
work_izjlueimqneiljcxm4zmi6kuna	56	65	inception	inception	NN
work_izjlueimqneiljcxm4zmi6kuna	56	66	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	56	67	October	October	NNP
work_izjlueimqneiljcxm4zmi6kuna	56	68	31st	31st	NN
work_izjlueimqneiljcxm4zmi6kuna	56	69	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	56	70	2017	2017	CD
work_izjlueimqneiljcxm4zmi6kuna	56	71	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	57	1	Reference	reference	NN
work_izjlueimqneiljcxm4zmi6kuna	57	2	lists	list	NNS
work_izjlueimqneiljcxm4zmi6kuna	57	3	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	57	4	articles	article	NNS
work_izjlueimqneiljcxm4zmi6kuna	57	5	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	57	6	documents	document	NNS
work_izjlueimqneiljcxm4zmi6kuna	57	7	were	be	VBD
work_izjlueimqneiljcxm4zmi6kuna	57	8	examined	examine	VBN
work_izjlueimqneiljcxm4zmi6kuna	57	9	to	to	TO
work_izjlueimqneiljcxm4zmi6kuna	57	10	find	find	VB
work_izjlueimqneiljcxm4zmi6kuna	57	11	any	any	DT
work_izjlueimqneiljcxm4zmi6kuna	57	12	ad-	ad-	JJ
work_izjlueimqneiljcxm4zmi6kuna	57	13	ditional	ditional	JJ
work_izjlueimqneiljcxm4zmi6kuna	57	14	relevant	relevant	JJ
work_izjlueimqneiljcxm4zmi6kuna	57	15	study	study	NN
work_izjlueimqneiljcxm4zmi6kuna	57	16	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	58	1	Furthermore	furthermore	RB
work_izjlueimqneiljcxm4zmi6kuna	58	2	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	58	3	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	58	4	author	author	NN
work_izjlueimqneiljcxm4zmi6kuna	58	5	went	go	VBD
work_izjlueimqneiljcxm4zmi6kuna	58	6	over	over	IN
work_izjlueimqneiljcxm4zmi6kuna	58	7	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	58	8	Virtual	Virtual	NNP
work_izjlueimqneiljcxm4zmi6kuna	58	9	Library	Library	NNP
work_izjlueimqneiljcxm4zmi6kuna	58	10	on	on	IN
work_izjlueimqneiljcxm4zmi6kuna	58	11	Health	Health	NNP
work_izjlueimqneiljcxm4zmi6kuna	58	12	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	58	13	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	58	14	Brazilian	Brazilian	NNP
work_izjlueimqneiljcxm4zmi6kuna	58	15	Ministry	Ministry	NNP
work_izjlueimqneiljcxm4zmi6kuna	58	16	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	58	17	Health	Health	NNP
work_izjlueimqneiljcxm4zmi6kuna	58	18	website	website	NN
work_izjlueimqneiljcxm4zmi6kuna	58	19	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	58	20	BVS	BVS	NNP
work_izjlueimqneiljcxm4zmi6kuna	58	21	MS	MS	NNP
work_izjlueimqneiljcxm4zmi6kuna	58	22	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	58	23	www.bvsms.saude.gov.br/index.php	www.bvsms.saude.gov.br/index.php	NNP
work_izjlueimqneiljcxm4zmi6kuna	58	24	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	58	25	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	58	26	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	58	27	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	58	28	Brazilian	Brazilian	NNP
work_izjlueimqneiljcxm4zmi6kuna	58	29	Sanitary	Sanitary	NNP
work_izjlueimqneiljcxm4zmi6kuna	58	30	Surveillance	Surveillance	NNP
work_izjlueimqneiljcxm4zmi6kuna	58	31	Agency	Agency	NNP
work_izjlueimqneiljcxm4zmi6kuna	58	32	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	58	33	Anvisa	Anvisa	NNP
work_izjlueimqneiljcxm4zmi6kuna	58	34	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	58	35	compilation	compilation	NN
work_izjlueimqneiljcxm4zmi6kuna	58	36	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	58	37	legislation	legislation	NN
work_izjlueimqneiljcxm4zmi6kuna	58	38	on	on	IN
work_izjlueimqneiljcxm4zmi6kuna	58	39	health	health	NN
work_izjlueimqneiljcxm4zmi6kuna	58	40	products	product	NNS
work_izjlueimqneiljcxm4zmi6kuna	58	41	to	to	TO
work_izjlueimqneiljcxm4zmi6kuna	58	42	identify	identify	VB
work_izjlueimqneiljcxm4zmi6kuna	58	43	all	all	DT
work_izjlueimqneiljcxm4zmi6kuna	58	44	regulations	regulation	NNS
work_izjlueimqneiljcxm4zmi6kuna	58	45	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	58	46	laws	law	NNS
work_izjlueimqneiljcxm4zmi6kuna	58	47	potentially	potentially	RB
work_izjlueimqneiljcxm4zmi6kuna	58	48	ap-	ap-	VBP
work_izjlueimqneiljcxm4zmi6kuna	58	49	plicable	plicable	JJ
work_izjlueimqneiljcxm4zmi6kuna	58	50	to	to	IN
work_izjlueimqneiljcxm4zmi6kuna	58	51	this	this	DT
work_izjlueimqneiljcxm4zmi6kuna	58	52	regulatory	regulatory	JJ
work_izjlueimqneiljcxm4zmi6kuna	58	53	drug	drug	NN
work_izjlueimqneiljcxm4zmi6kuna	58	54	topic	topic	NN
work_izjlueimqneiljcxm4zmi6kuna	58	55	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	59	1	Results	result	NNS
work_izjlueimqneiljcxm4zmi6kuna	59	2	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	59	3	Discussion	Discussion	NNP
work_izjlueimqneiljcxm4zmi6kuna	59	4	Brief	brief	JJ
work_izjlueimqneiljcxm4zmi6kuna	59	5	regulatory	regulatory	JJ
work_izjlueimqneiljcxm4zmi6kuna	59	6	history	history	NN
work_izjlueimqneiljcxm4zmi6kuna	59	7	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	59	8	thalidomide	thalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	59	9	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	59	10	lenalidomide	lenalidomide	VB
work_izjlueimqneiljcxm4zmi6kuna	59	11	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	59	12	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	59	13	Us	Us	NNP
work_izjlueimqneiljcxm4zmi6kuna	59	14	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	59	15	Brazil	Brazil	NNP
work_izjlueimqneiljcxm4zmi6kuna	59	16	Owing	Owing	NNP
work_izjlueimqneiljcxm4zmi6kuna	59	17	to	to	IN
work_izjlueimqneiljcxm4zmi6kuna	59	18	its	-PRON-	PRP$
work_izjlueimqneiljcxm4zmi6kuna	59	19	teratogenicity	teratogenicity	NN
work_izjlueimqneiljcxm4zmi6kuna	59	20	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	59	21	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	59	22	because	because	IN
work_izjlueimqneiljcxm4zmi6kuna	59	23	prev-	prev-	XX
work_izjlueimqneiljcxm4zmi6kuna	59	24	alence	alence	NN
work_izjlueimqneiljcxm4zmi6kuna	59	25	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	59	26	Hansen	Hansen	NNP
work_izjlueimqneiljcxm4zmi6kuna	59	27	disease	disease	NN
work_izjlueimqneiljcxm4zmi6kuna	59	28	is	be	VBZ
work_izjlueimqneiljcxm4zmi6kuna	59	29	almost	almost	RB
work_izjlueimqneiljcxm4zmi6kuna	59	30	negligible	negligible	JJ
work_izjlueimqneiljcxm4zmi6kuna	59	31	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	59	32	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	59	33	country	country	NN
work_izjlueimqneiljcxm4zmi6kuna	59	34	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	59	35	thalidomide	thalidomide	NNP
work_izjlueimqneiljcxm4zmi6kuna	59	36	was	be	VBD
work_izjlueimqneiljcxm4zmi6kuna	59	37	not	not	RB
work_izjlueimqneiljcxm4zmi6kuna	59	38	approved	approve	VBN
work_izjlueimqneiljcxm4zmi6kuna	59	39	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	59	40	sale	sale	NN
work_izjlueimqneiljcxm4zmi6kuna	59	41	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	59	42	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	59	43	US	US	NNP
work_izjlueimqneiljcxm4zmi6kuna	59	44	until	until	IN
work_izjlueimqneiljcxm4zmi6kuna	59	45	1998	1998	CD
work_izjlueimqneiljcxm4zmi6kuna	59	46	when	when	WRB
work_izjlueimqneiljcxm4zmi6kuna	59	47	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	59	48	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	59	49	an	an	DT
work_izjlueimqneiljcxm4zmi6kuna	59	50	attempt	attempt	NN
work_izjlueimqneiljcxm4zmi6kuna	59	51	to	to	TO
work_izjlueimqneiljcxm4zmi6kuna	59	52	put	put	VB
work_izjlueimqneiljcxm4zmi6kuna	59	53	an	an	DT
work_izjlueimqneiljcxm4zmi6kuna	59	54	end	end	NN
work_izjlueimqneiljcxm4zmi6kuna	59	55	to	to	IN
work_izjlueimqneiljcxm4zmi6kuna	59	56	smuggling	smuggling	NN
work_izjlueimqneiljcxm4zmi6kuna	59	57	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	59	58	uncontrolled	uncontrolled	JJ
work_izjlueimqneiljcxm4zmi6kuna	59	59	use	use	NN
work_izjlueimqneiljcxm4zmi6kuna	59	60	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	59	61	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	59	62	drug	drug	NN
work_izjlueimqneiljcxm4zmi6kuna	59	63	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	59	64	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	59	65	variety	variety	NN
work_izjlueimqneiljcxm4zmi6kuna	59	66	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	59	67	medical	medical	JJ
work_izjlueimqneiljcxm4zmi6kuna	59	68	conditions	condition	NNS
work_izjlueimqneiljcxm4zmi6kuna	59	69	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	59	70	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	59	71	US	US	NNP
work_izjlueimqneiljcxm4zmi6kuna	59	72	FDA	FDA	NNP
work_izjlueimqneiljcxm4zmi6kuna	59	73	approved	approve	VBD
work_izjlueimqneiljcxm4zmi6kuna	59	74	it	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	59	75	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	60	1	Curiously	Curiously	NNP
work_izjlueimqneiljcxm4zmi6kuna	60	2	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	60	3	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	60	4	first	first	JJ
work_izjlueimqneiljcxm4zmi6kuna	60	5	au-	au-	NN
work_izjlueimqneiljcxm4zmi6kuna	60	6	thorized	thorize	VBN
work_izjlueimqneiljcxm4zmi6kuna	60	7	therapeutic	therapeutic	JJ
work_izjlueimqneiljcxm4zmi6kuna	60	8	indication	indication	NN
work_izjlueimqneiljcxm4zmi6kuna	60	9	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	60	10	thalidomide	thalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	60	11	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	60	12	Thalomid	Thalomid	NNP
work_izjlueimqneiljcxm4zmi6kuna	60	13	®	®	NNPS
work_izjlueimqneiljcxm4zmi6kuna	60	14	made	make	VBN
work_izjlueimqneiljcxm4zmi6kuna	60	15	by	by	IN
work_izjlueimqneiljcxm4zmi6kuna	60	16	Celgene	Celgene	NNP
work_izjlueimqneiljcxm4zmi6kuna	60	17	®	®	.
work_izjlueimqneiljcxm4zmi6kuna	60	18	Co	co	NN
work_izjlueimqneiljcxm4zmi6kuna	60	19	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	60	20	was	be	VBD
work_izjlueimqneiljcxm4zmi6kuna	60	21	erythema	erythema	NNP
work_izjlueimqneiljcxm4zmi6kuna	60	22	nodosum	nodosum	NNP
work_izjlueimqneiljcxm4zmi6kuna	60	23	leprosum	leprosum	NNP
work_izjlueimqneiljcxm4zmi6kuna	60	24	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	60	25	ENL	ENL	NNP
work_izjlueimqneiljcxm4zmi6kuna	60	26	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	60	27	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	60	28	or	or	CC
work_izjlueimqneiljcxm4zmi6kuna	60	29	type-2	type-2	NNP
work_izjlueimqneiljcxm4zmi6kuna	60	30	reaction	reaction	NN
work_izjlueimqneiljcxm4zmi6kuna	60	31	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	60	32	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	60	33	medical	medical	JJ
work_izjlueimqneiljcxm4zmi6kuna	60	34	condition	condition	NN
work_izjlueimqneiljcxm4zmi6kuna	60	35	extremely	extremely	RB
work_izjlueimqneiljcxm4zmi6kuna	60	36	rare	rare	JJ
work_izjlueimqneiljcxm4zmi6kuna	60	37	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	60	38	or	or	CC
work_izjlueimqneiljcxm4zmi6kuna	60	39	even	even	RB
work_izjlueimqneiljcxm4zmi6kuna	60	40	non-	non-	DT
work_izjlueimqneiljcxm4zmi6kuna	60	41	existent	existent	NN
work_izjlueimqneiljcxm4zmi6kuna	60	42	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	60	43	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	60	44	US	US	NNP
work_izjlueimqneiljcxm4zmi6kuna	60	45	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	61	1	Only	only	RB
work_izjlueimqneiljcxm4zmi6kuna	61	2	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	61	3	few	few	JJ
work_izjlueimqneiljcxm4zmi6kuna	61	4	years	year	NNS
work_izjlueimqneiljcxm4zmi6kuna	61	5	later	later	RB
work_izjlueimqneiljcxm4zmi6kuna	61	6	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	61	7	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	61	8	May	May	NNP
work_izjlueimqneiljcxm4zmi6kuna	61	9	2006	2006	CD
work_izjlueimqneiljcxm4zmi6kuna	61	10	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	61	11	FDA	FDA	NNP
work_izjlueimqneiljcxm4zmi6kuna	61	12	granted	grant	VBD
work_izjlueimqneiljcxm4zmi6kuna	61	13	accelerated	accelerated	JJ
work_izjlueimqneiljcxm4zmi6kuna	61	14	approval	approval	NN
work_izjlueimqneiljcxm4zmi6kuna	61	15	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	61	16	tha-	tha-	DT
work_izjlueimqneiljcxm4zmi6kuna	61	17	lidomide	lidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	61	18	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	61	19	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	61	20	combination	combination	NN
work_izjlueimqneiljcxm4zmi6kuna	61	21	with	with	IN
work_izjlueimqneiljcxm4zmi6kuna	61	22	dexamethasone	dexamethasone	NN
work_izjlueimqneiljcxm4zmi6kuna	61	23	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	61	24	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	61	25	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	61	26	treatment	treatment	NN
work_izjlueimqneiljcxm4zmi6kuna	61	27	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	61	28	newly	newly	RB
work_izjlueimqneiljcxm4zmi6kuna	61	29	diagnosed	diagnose	VBN
work_izjlueimqneiljcxm4zmi6kuna	61	30	multiple	multiple	JJ
work_izjlueimqneiljcxm4zmi6kuna	61	31	myeloma	myeloma	NN
work_izjlueimqneiljcxm4zmi6kuna	61	32	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	61	33	MM	MM	NNP
work_izjlueimqneiljcxm4zmi6kuna	61	34	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	61	35	patients	patient	NNS
work_izjlueimqneiljcxm4zmi6kuna	61	36	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	62	1	The	the	DT
work_izjlueimqneiljcxm4zmi6kuna	62	2	German	german	JJ
work_izjlueimqneiljcxm4zmi6kuna	62	3	company	company	NN
work_izjlueimqneiljcxm4zmi6kuna	62	4	Chemie	Chemie	NNP
work_izjlueimqneiljcxm4zmi6kuna	62	5	Grünenthal	Grünenthal	NNP
work_izjlueimqneiljcxm4zmi6kuna	62	6	GmbH	GmbH	NNP
work_izjlueimqneiljcxm4zmi6kuna	62	7	had	have	VBD
work_izjlueimqneiljcxm4zmi6kuna	62	8	launched	launch	VBN
work_izjlueimqneiljcxm4zmi6kuna	62	9	thalid-	thalid-	JJ
work_izjlueimqneiljcxm4zmi6kuna	62	10	omide	omide	NN
work_izjlueimqneiljcxm4zmi6kuna	62	11	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	62	12	1957	1957	CD
work_izjlueimqneiljcxm4zmi6kuna	62	13	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	62	14	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	62	15	thus	thus	RB
work_izjlueimqneiljcxm4zmi6kuna	62	16	it	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	62	17	has	have	VBZ
work_izjlueimqneiljcxm4zmi6kuna	62	18	no	no	RB
work_izjlueimqneiljcxm4zmi6kuna	62	19	longer	long	RBR
work_izjlueimqneiljcxm4zmi6kuna	62	20	patent	patent	NN
work_izjlueimqneiljcxm4zmi6kuna	62	21	protection	protection	NN
work_izjlueimqneiljcxm4zmi6kuna	62	22	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	63	1	Nonetheless	nonetheless	RB
work_izjlueimqneiljcxm4zmi6kuna	63	2	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	63	3	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	63	4	patent	patent	NN
work_izjlueimqneiljcxm4zmi6kuna	63	5	was	be	VBD
work_izjlueimqneiljcxm4zmi6kuna	63	6	granted	grant	VBN
work_izjlueimqneiljcxm4zmi6kuna	63	7	to	to	IN
work_izjlueimqneiljcxm4zmi6kuna	63	8	Celgene	Celgene	NNP
work_izjlueimqneiljcxm4zmi6kuna	63	9	®	®	.
work_izjlueimqneiljcxm4zmi6kuna	63	10	Co	co	NN
work_izjlueimqneiljcxm4zmi6kuna	63	11	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	63	12	its	-PRON-	PRP$
work_izjlueimqneiljcxm4zmi6kuna	63	13	System	system	NN
work_izjlueimqneiljcxm4zmi6kuna	63	14	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	63	15	Thalidomide	Thalidomide	NNP
work_izjlueimqneiljcxm4zmi6kuna	63	16	Edu-	Edu-	NNP
work_izjlueimqneiljcxm4zmi6kuna	63	17	cation	cation	NN
work_izjlueimqneiljcxm4zmi6kuna	63	18	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	63	19	Prescribing	Prescribing	NNP
work_izjlueimqneiljcxm4zmi6kuna	63	20	Safety	Safety	NNP
work_izjlueimqneiljcxm4zmi6kuna	63	21	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	63	22	STEPS	STEPS	NNP
work_izjlueimqneiljcxm4zmi6kuna	63	23	®	®	NNP
work_izjlueimqneiljcxm4zmi6kuna	63	24	Program	Program	NNP
work_izjlueimqneiljcxm4zmi6kuna	63	25	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	63	26	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	63	27	restricted	restricted	JJ
work_izjlueimqneiljcxm4zmi6kuna	63	28	distribution	distribution	NN
work_izjlueimqneiljcxm4zmi6kuna	63	29	system	system	NN
work_izjlueimqneiljcxm4zmi6kuna	63	30	intended	intend	VBN
work_izjlueimqneiljcxm4zmi6kuna	63	31	to	to	TO
work_izjlueimqneiljcxm4zmi6kuna	63	32	pre-	pre-	RB
work_izjlueimqneiljcxm4zmi6kuna	63	33	vent	vent	JJ
work_izjlueimqneiljcxm4zmi6kuna	63	34	thalidomide	thalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	63	35	use	use	NN
work_izjlueimqneiljcxm4zmi6kuna	63	36	by	by	IN
work_izjlueimqneiljcxm4zmi6kuna	63	37	pregnant	pregnant	JJ
work_izjlueimqneiljcxm4zmi6kuna	63	38	women	woman	NNS
work_izjlueimqneiljcxm4zmi6kuna	63	39	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	63	40	what	what	WP
work_izjlueimqneiljcxm4zmi6kuna	63	41	means	mean	VBZ
work_izjlueimqneiljcxm4zmi6kuna	63	42	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	63	43	practice	practice	NN
work_izjlueimqneiljcxm4zmi6kuna	63	44	that	that	WDT
work_izjlueimqneiljcxm4zmi6kuna	63	45	Thalomid	Thalomid	NNP
work_izjlueimqneiljcxm4zmi6kuna	63	46	®	®	NNPS
work_izjlueimqneiljcxm4zmi6kuna	63	47	has	have	VBZ
work_izjlueimqneiljcxm4zmi6kuna	63	48	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	63	49	market-	market-	JJ
work_izjlueimqneiljcxm4zmi6kuna	63	50	ing	ing	NN
work_izjlueimqneiljcxm4zmi6kuna	63	51	exclusivity	exclusivity	NN
work_izjlueimqneiljcxm4zmi6kuna	63	52	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	63	53	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	63	54	US3	US3	NNP
work_izjlueimqneiljcxm4zmi6kuna	63	55	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	64	1	Lenalidomide	Lenalidomide	NNP
work_izjlueimqneiljcxm4zmi6kuna	64	2	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	64	3	Revlimid	Revlimid	NNP
work_izjlueimqneiljcxm4zmi6kuna	64	4	®	®	NNP
work_izjlueimqneiljcxm4zmi6kuna	64	5	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	64	6	was	be	VBD
work_izjlueimqneiljcxm4zmi6kuna	64	7	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	64	8	first	first	JJ
work_izjlueimqneiljcxm4zmi6kuna	64	9	tha-	tha-	DT
work_izjlueimqneiljcxm4zmi6kuna	64	10	lidomide	lidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	64	11	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	64	12	like	like	JJ
work_izjlueimqneiljcxm4zmi6kuna	64	13	drug	drug	NN
work_izjlueimqneiljcxm4zmi6kuna	64	14	obtaining	obtain	VBG
work_izjlueimqneiljcxm4zmi6kuna	64	15	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	64	16	marketing	marketing	NN
work_izjlueimqneiljcxm4zmi6kuna	64	17	autho-	autho-	NN
work_izjlueimqneiljcxm4zmi6kuna	64	18	rization	rization	NN
work_izjlueimqneiljcxm4zmi6kuna	64	19	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	64	20	Figure	figure	NN
work_izjlueimqneiljcxm4zmi6kuna	64	21	1	1	CD
work_izjlueimqneiljcxm4zmi6kuna	64	22	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	64	23	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	65	1	It	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	65	2	was	be	VBD
work_izjlueimqneiljcxm4zmi6kuna	65	3	developed	develop	VBN
work_izjlueimqneiljcxm4zmi6kuna	65	4	by	by	IN
work_izjlueimqneiljcxm4zmi6kuna	65	5	Celgene	Celgene	NNP
work_izjlueimqneiljcxm4zmi6kuna	65	6	®	®	NNPS
work_izjlueimqneiljcxm4zmi6kuna	65	7	Co	co	NN
work_izjlueimqneiljcxm4zmi6kuna	65	8	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	65	9	approved	approve	VBN
work_izjlueimqneiljcxm4zmi6kuna	65	10	by	by	IN
work_izjlueimqneiljcxm4zmi6kuna	65	11	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	65	12	FDA	FDA	NNP
work_izjlueimqneiljcxm4zmi6kuna	65	13	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	65	14	treatment	treatment	NN
work_izjlueimqneiljcxm4zmi6kuna	65	15	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	65	16	myelodysplastic	myelodysplastic	JJ
work_izjlueimqneiljcxm4zmi6kuna	65	17	syndrome	syndrome	NN
work_izjlueimqneiljcxm4zmi6kuna	65	18	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	65	19	MDS	MDS	NNP
work_izjlueimqneiljcxm4zmi6kuna	65	20	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	65	21	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	65	22	multiple	multiple	JJ
work_izjlueimqneiljcxm4zmi6kuna	65	23	myeloma	myeloma	NN
work_izjlueimqneiljcxm4zmi6kuna	65	24	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	65	25	MM	MM	NNP
work_izjlueimqneiljcxm4zmi6kuna	65	26	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	65	27	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	65	28	2005	2005	CD
work_izjlueimqneiljcxm4zmi6kuna	65	29	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	65	30	December	December	NNP
work_izjlueimqneiljcxm4zmi6kuna	65	31	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	65	32	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	65	33	2008	2008	CD
work_izjlueimqneiljcxm4zmi6kuna	65	34	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	65	35	respectively	respectively	RB
work_izjlueimqneiljcxm4zmi6kuna	65	36	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	66	1	The	the	DT
work_izjlueimqneiljcxm4zmi6kuna	66	2	European	European	NNP
work_izjlueimqneiljcxm4zmi6kuna	66	3	Medicines	Medicines	NNP
work_izjlueimqneiljcxm4zmi6kuna	66	4	Agency	Agency	NNP
work_izjlueimqneiljcxm4zmi6kuna	66	5	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	66	6	EMA	EMA	NNP
work_izjlueimqneiljcxm4zmi6kuna	66	7	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	66	8	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	66	9	on	on	IN
work_izjlueimqneiljcxm4zmi6kuna	66	10	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	66	11	other	other	JJ
work_izjlueimqneiljcxm4zmi6kuna	66	12	hand	hand	NN
work_izjlueimqneiljcxm4zmi6kuna	66	13	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	66	14	granted	grant	VBD
work_izjlueimqneiljcxm4zmi6kuna	66	15	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	66	16	marketing	marketing	NN
work_izjlueimqneiljcxm4zmi6kuna	66	17	authorization	authorization	NN
work_izjlueimqneiljcxm4zmi6kuna	66	18	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	66	19	lenalidomide	lenalidomide	JJ
work_izjlueimqneiljcxm4zmi6kuna	66	20	use	use	NN
work_izjlueimqneiljcxm4zmi6kuna	66	21	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	66	22	MM	MM	NNP
work_izjlueimqneiljcxm4zmi6kuna	66	23	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	66	24	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	66	25	combination	combination	NN
work_izjlueimqneiljcxm4zmi6kuna	66	26	with	with	IN
work_izjlueimqneiljcxm4zmi6kuna	66	27	dexamethasone	dexamethasone	NN
work_izjlueimqneiljcxm4zmi6kuna	66	28	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	66	29	patients	patient	NNS
work_izjlueimqneiljcxm4zmi6kuna	66	30	who	who	WP
work_izjlueimqneiljcxm4zmi6kuna	66	31	had	have	VBD
work_izjlueimqneiljcxm4zmi6kuna	66	32	received	receive	VBN
work_izjlueimqneiljcxm4zmi6kuna	66	33	at	at	RB
work_izjlueimqneiljcxm4zmi6kuna	66	34	least	least	RBS
work_izjlueimqneiljcxm4zmi6kuna	66	35	one	one	CD
work_izjlueimqneiljcxm4zmi6kuna	66	36	prior	prior	JJ
work_izjlueimqneiljcxm4zmi6kuna	66	37	therapy	therapy	NN
work_izjlueimqneiljcxm4zmi6kuna	66	38	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	66	39	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	66	40	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	66	41	Thalidomide	Thalidomide	NNP
work_izjlueimqneiljcxm4zmi6kuna	66	42	Lenalidomide	Lenalidomide	NNP
work_izjlueimqneiljcxm4zmi6kuna	66	43	Phthalimide	Phthalimide	NNP
work_izjlueimqneiljcxm4zmi6kuna	66	44	ring	ring	NN
work_izjlueimqneiljcxm4zmi6kuna	66	45	Glutarimide	Glutarimide	NNP
work_izjlueimqneiljcxm4zmi6kuna	66	46	ring	ring	NN
work_izjlueimqneiljcxm4zmi6kuna	66	47	3	3	CD
work_izjlueimqneiljcxm4zmi6kuna	66	48	7	7	CD
work_izjlueimqneiljcxm4zmi6kuna	66	49	8	8	CD
work_izjlueimqneiljcxm4zmi6kuna	66	50	6	6	CD
work_izjlueimqneiljcxm4zmi6kuna	66	51	P	p	NN
work_izjlueimqneiljcxm4zmi6kuna	66	52	au	au	NNP
work_izjlueimqneiljcxm4zmi6kuna	66	53	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	66	54	ga	ga	NNP
work_izjlueimqneiljcxm4zmi6kuna	66	55	rt	rt	NNP
work_izjlueimqneiljcxm4zmi6kuna	66	56	te	te	NNP
work_izjlueimqneiljcxm4zmi6kuna	66	57	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	66	58	F	F	NNP
work_izjlueimqneiljcxm4zmi6kuna	66	59	JR	JR	NNP
work_izjlueimqneiljcxm4zmi6kuna	66	60	2007	2007	CD
work_izjlueimqneiljcxm4zmi6kuna	66	61	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	66	62	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	66	63	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	66	64	use	use	NN
work_izjlueimqneiljcxm4zmi6kuna	66	65	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	66	66	MDS	MDS	NNP
work_izjlueimqneiljcxm4zmi6kuna	66	67	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	66	68	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	66	69	2013	2013	CD
work_izjlueimqneiljcxm4zmi6kuna	66	70	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	67	1	In	in	IN
work_izjlueimqneiljcxm4zmi6kuna	67	2	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	67	3	EU	EU	NNP
work_izjlueimqneiljcxm4zmi6kuna	67	4	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	67	5	US	US	NNP
work_izjlueimqneiljcxm4zmi6kuna	67	6	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	67	7	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	67	8	approved	approve	VBN
work_izjlueimqneiljcxm4zmi6kuna	67	9	indications	indication	NNS
work_izjlueimqneiljcxm4zmi6kuna	67	10	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	67	11	lenalidomide	lenalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	67	12	were	be	VBD
work_izjlueimqneiljcxm4zmi6kuna	67	13	further	further	RB
work_izjlueimqneiljcxm4zmi6kuna	67	14	expanded	expand	VBN
work_izjlueimqneiljcxm4zmi6kuna	67	15	to	to	TO
work_izjlueimqneiljcxm4zmi6kuna	67	16	include	include	VB
work_izjlueimqneiljcxm4zmi6kuna	67	17	previously	previously	RB
work_izjlueimqneiljcxm4zmi6kuna	67	18	un-	un-	RB
work_izjlueimqneiljcxm4zmi6kuna	67	19	treated	treat	VBN
work_izjlueimqneiljcxm4zmi6kuna	67	20	MM	MM	NNP
work_izjlueimqneiljcxm4zmi6kuna	67	21	patients	patient	NNS
work_izjlueimqneiljcxm4zmi6kuna	67	22	who	who	WP
work_izjlueimqneiljcxm4zmi6kuna	67	23	were	be	VBD
work_izjlueimqneiljcxm4zmi6kuna	67	24	not	not	RB
work_izjlueimqneiljcxm4zmi6kuna	67	25	eligible	eligible	JJ
work_izjlueimqneiljcxm4zmi6kuna	67	26	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	67	27	transplants	transplant	NNS
work_izjlueimqneiljcxm4zmi6kuna	67	28	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	67	29	monotherapy	monotherapy	NN
work_izjlueimqneiljcxm4zmi6kuna	67	30	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	67	31	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	67	32	maintenance	maintenance	NN
work_izjlueimqneiljcxm4zmi6kuna	67	33	treatment	treatment	NN
work_izjlueimqneiljcxm4zmi6kuna	67	34	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	67	35	patients	patient	NNS
work_izjlueimqneiljcxm4zmi6kuna	67	36	with	with	IN
work_izjlueimqneiljcxm4zmi6kuna	67	37	newly	newly	RB
work_izjlueimqneiljcxm4zmi6kuna	67	38	diagnosed	diagnose	VBN
work_izjlueimqneiljcxm4zmi6kuna	67	39	MM	MM	NNP
work_izjlueimqneiljcxm4zmi6kuna	67	40	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	67	41	after	after	IN
work_izjlueimqneiljcxm4zmi6kuna	67	42	autologous	autologous	JJ
work_izjlueimqneiljcxm4zmi6kuna	67	43	stem	stem	NN
work_izjlueimqneiljcxm4zmi6kuna	67	44	cell	cell	NN
work_izjlueimqneiljcxm4zmi6kuna	67	45	transplantation	transplantation	NN
work_izjlueimqneiljcxm4zmi6kuna	67	46	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	67	47	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	67	48	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	67	49	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	67	50	therapy	therapy	NN
work_izjlueimqneiljcxm4zmi6kuna	67	51	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	67	52	mantle	mantle	NNP
work_izjlueimqneiljcxm4zmi6kuna	67	53	cell	cell	NN
work_izjlueimqneiljcxm4zmi6kuna	67	54	lymphoma	lymphoma	NN
work_izjlueimqneiljcxm4zmi6kuna	67	55	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	67	56	patients	patient	NNS
work_izjlueimqneiljcxm4zmi6kuna	67	57	whose	whose	WP$
work_izjlueimqneiljcxm4zmi6kuna	67	58	disease	disease	NN
work_izjlueimqneiljcxm4zmi6kuna	67	59	had	have	VBD
work_izjlueimqneiljcxm4zmi6kuna	67	60	relapsed	relapse	VBN
work_izjlueimqneiljcxm4zmi6kuna	67	61	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	67	62	or	or	CC
work_izjlueimqneiljcxm4zmi6kuna	67	63	progressed	progress	VBN
work_izjlueimqneiljcxm4zmi6kuna	67	64	after	after	IN
work_izjlueimqneiljcxm4zmi6kuna	67	65	two	two	CD
work_izjlueimqneiljcxm4zmi6kuna	67	66	prior	prior	JJ
work_izjlueimqneiljcxm4zmi6kuna	67	67	therapies	therapy	NNS
work_izjlueimqneiljcxm4zmi6kuna	67	68	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	68	1	Lenalidomide	lenalidomide	JJ
work_izjlueimqneiljcxm4zmi6kuna	68	2	costs	cost	NNS
work_izjlueimqneiljcxm4zmi6kuna	68	3	near-	near-	VBP
work_izjlueimqneiljcxm4zmi6kuna	68	4	ly	ly	IN
work_izjlueimqneiljcxm4zmi6kuna	68	5	US	US	NNP
work_izjlueimqneiljcxm4zmi6kuna	68	6	$	$	$
work_izjlueimqneiljcxm4zmi6kuna	68	7	163,381	163,381	CD
work_izjlueimqneiljcxm4zmi6kuna	68	8	per	per	IN
work_izjlueimqneiljcxm4zmi6kuna	68	9	year	year	NN
work_izjlueimqneiljcxm4zmi6kuna	68	10	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	68	11	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	68	12	average	average	JJ
work_izjlueimqneiljcxm4zmi6kuna	68	13	patient4	patient4	NN
work_izjlueimqneiljcxm4zmi6kuna	68	14	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	68	15	thus	thus	RB
work_izjlueimqneiljcxm4zmi6kuna	68	16	lenalidomide	lenalidomide	RB
work_izjlueimqneiljcxm4zmi6kuna	68	17	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	68	18	based	base	VBN
work_izjlueimqneiljcxm4zmi6kuna	68	19	therapies	therapy	NNS
work_izjlueimqneiljcxm4zmi6kuna	68	20	are	be	VBP
work_izjlueimqneiljcxm4zmi6kuna	68	21	much	much	RB
work_izjlueimqneiljcxm4zmi6kuna	68	22	costlier	costly	JJR
work_izjlueimqneiljcxm4zmi6kuna	68	23	than	than	IN
work_izjlueimqneiljcxm4zmi6kuna	68	24	thalidomide	thalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	68	25	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	68	26	based	base	VBN
work_izjlueimqneiljcxm4zmi6kuna	68	27	treatments	treatment	NNS
work_izjlueimqneiljcxm4zmi6kuna	68	28	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	68	29	MM	MM	NNP
work_izjlueimqneiljcxm4zmi6kuna	68	30	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	69	1	Both	both	DT
work_izjlueimqneiljcxm4zmi6kuna	69	2	FDA	FDA	NNP
work_izjlueimqneiljcxm4zmi6kuna	69	3	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	69	4	EMA	EMA	NNP
work_izjlueimqneiljcxm4zmi6kuna	69	5	awarded	award	VBD
work_izjlueimqneiljcxm4zmi6kuna	69	6	an	an	DT
work_izjlueimqneiljcxm4zmi6kuna	69	7	orphan	orphan	NN
work_izjlueimqneiljcxm4zmi6kuna	69	8	drug	drug	NN
work_izjlueimqneiljcxm4zmi6kuna	69	9	status	status	NN
work_izjlueimqneiljcxm4zmi6kuna	69	10	/	/	SYM
work_izjlueimqneiljcxm4zmi6kuna	69	11	designation	designation	NN
work_izjlueimqneiljcxm4zmi6kuna	69	12	to	to	TO
work_izjlueimqneiljcxm4zmi6kuna	69	13	lenalidomide	lenalidomide	VB
work_izjlueimqneiljcxm4zmi6kuna	69	14	because	because	IN
work_izjlueimqneiljcxm4zmi6kuna	69	15	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	69	16	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	69	17	rarity	rarity	NN
work_izjlueimqneiljcxm4zmi6kuna	69	18	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	69	19	multiple	multiple	JJ
work_izjlueimqneiljcxm4zmi6kuna	69	20	myeloma	myeloma	NNS
work_izjlueimqneiljcxm4zmi6kuna	69	21	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	70	1	Data	datum	NNS
work_izjlueimqneiljcxm4zmi6kuna	70	2	from	from	IN
work_izjlueimqneiljcxm4zmi6kuna	70	3	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	70	4	National	National	NNP
work_izjlueimqneiljcxm4zmi6kuna	70	5	Cancer	Cancer	NNP
work_izjlueimqneiljcxm4zmi6kuna	70	6	Institute	Institute	NNP
work_izjlueimqneiljcxm4zmi6kuna	70	7	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	70	8	NCI	NCI	NNP
work_izjlueimqneiljcxm4zmi6kuna	70	9	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	70	10	informs	inform	VBZ
work_izjlueimqneiljcxm4zmi6kuna	70	11	that	that	IN
work_izjlueimqneiljcxm4zmi6kuna	70	12	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	70	13	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	70	14	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	70	15	US	US	NNP
work_izjlueimqneiljcxm4zmi6kuna	70	16	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	70	17	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	70	18	incidence	incidence	NN
work_izjlueimqneiljcxm4zmi6kuna	70	19	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	70	20	new	new	JJ
work_izjlueimqneiljcxm4zmi6kuna	70	21	cases	case	NNS
work_izjlueimqneiljcxm4zmi6kuna	70	22	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	70	23	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	70	24	MM	MM	NNP
work_izjlueimqneiljcxm4zmi6kuna	70	25	was	be	VBD
work_izjlueimqneiljcxm4zmi6kuna	70	26	6.6	6.6	CD
work_izjlueimqneiljcxm4zmi6kuna	70	27	per	per	IN
work_izjlueimqneiljcxm4zmi6kuna	70	28	100,000	100,000	CD
work_izjlueimqneiljcxm4zmi6kuna	70	29	men	man	NNS
work_izjlueimqneiljcxm4zmi6kuna	70	30	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	70	31	women	woman	NNS
work_izjlueimqneiljcxm4zmi6kuna	70	32	per	per	IN
work_izjlueimqneiljcxm4zmi6kuna	70	33	year	year	NN
work_izjlueimqneiljcxm4zmi6kuna	70	34	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	70	35	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	70	36	that	that	IN
work_izjlueimqneiljcxm4zmi6kuna	70	37	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	70	38	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	70	39	2014	2014	CD
work_izjlueimqneiljcxm4zmi6kuna	70	40	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	70	41	there	there	EX
work_izjlueimqneiljcxm4zmi6kuna	70	42	were	be	VBD
work_izjlueimqneiljcxm4zmi6kuna	70	43	estimated	estimate	VBN
work_izjlueimqneiljcxm4zmi6kuna	70	44	118,539	118,539	CD
work_izjlueimqneiljcxm4zmi6kuna	70	45	people	people	NNS
work_izjlueimqneiljcxm4zmi6kuna	70	46	liv-	liv-	VBD
work_izjlueimqneiljcxm4zmi6kuna	70	47	ing	ing	NN
work_izjlueimqneiljcxm4zmi6kuna	70	48	with	with	IN
work_izjlueimqneiljcxm4zmi6kuna	70	49	MM	MM	NNP
work_izjlueimqneiljcxm4zmi6kuna	70	50	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	70	51	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	70	52	country5	country5	NN
work_izjlueimqneiljcxm4zmi6kuna	70	53	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	71	1	Notwithstanding	notwithstanding	IN
work_izjlueimqneiljcxm4zmi6kuna	71	2	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	71	3	“	"	``
work_izjlueimqneiljcxm4zmi6kuna	71	4	orphan	orphan	NNP
work_izjlueimqneiljcxm4zmi6kuna	71	5	drug	drug	NN
work_izjlueimqneiljcxm4zmi6kuna	71	6	”	"	''
work_izjlueimqneiljcxm4zmi6kuna	71	7	status	status	NN
work_izjlueimqneiljcxm4zmi6kuna	71	8	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	71	9	lenalidomide	lenalidomide	VB
work_izjlueimqneiljcxm4zmi6kuna	71	10	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	71	11	Revlim-	Revlim-	NNP
work_izjlueimqneiljcxm4zmi6kuna	71	12	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	71	13	d	d	XX
work_izjlueimqneiljcxm4zmi6kuna	71	14	®	®	NNPS
work_izjlueimqneiljcxm4zmi6kuna	71	15	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	71	16	proved	prove	VBD
work_izjlueimqneiljcxm4zmi6kuna	71	17	to	to	TO
work_izjlueimqneiljcxm4zmi6kuna	71	18	be	be	VB
work_izjlueimqneiljcxm4zmi6kuna	71	19	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	71	20	highly	highly	RB
work_izjlueimqneiljcxm4zmi6kuna	71	21	profitable	profitable	JJ
work_izjlueimqneiljcxm4zmi6kuna	71	22	product	product	NN
work_izjlueimqneiljcxm4zmi6kuna	71	23	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	72	1	It	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	72	2	was	be	VBD
work_izjlueimqneiljcxm4zmi6kuna	72	3	Celgene	Celgene	NNP
work_izjlueimqneiljcxm4zmi6kuna	72	4	®	®	NNPS
work_izjlueimqneiljcxm4zmi6kuna	72	5	Co	Co	NNP
work_izjlueimqneiljcxm4zmi6kuna	72	6	’s	’s	POS
work_izjlueimqneiljcxm4zmi6kuna	72	7	blockbuster	blockbuster	JJ
work_izjlueimqneiljcxm4zmi6kuna	72	8	drug	drug	NN
work_izjlueimqneiljcxm4zmi6kuna	72	9	with	with	IN
work_izjlueimqneiljcxm4zmi6kuna	72	10	sales	sale	NNS
work_izjlueimqneiljcxm4zmi6kuna	72	11	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	72	12	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	72	13	first	first	JJ
work_izjlueimqneiljcxm4zmi6kuna	72	14	2017	2017	CD
work_izjlueimqneiljcxm4zmi6kuna	72	15	quarter	quarter	NN
work_izjlueimqneiljcxm4zmi6kuna	72	16	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	72	17	US$	us$	$
work_izjlueimqneiljcxm4zmi6kuna	72	18	1,884	1,884	CD
work_izjlueimqneiljcxm4zmi6kuna	72	19	million	million	CD
work_izjlueimqneiljcxm4zmi6kuna	72	20	against	against	IN
work_izjlueimqneiljcxm4zmi6kuna	72	21	US$	us$	$
work_izjlueimqneiljcxm4zmi6kuna	72	22	26	26	CD
work_izjlueimqneiljcxm4zmi6kuna	72	23	million	million	CD
work_izjlueimqneiljcxm4zmi6kuna	72	24	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	72	25	Thalomid	Thalomid	NNP
work_izjlueimqneiljcxm4zmi6kuna	72	26	®	®	NNPS
work_izjlueimqneiljcxm4zmi6kuna	72	27	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	72	28	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	72	29	same	same	JJ
work_izjlueimqneiljcxm4zmi6kuna	72	30	period6	period6	NN
work_izjlueimqneiljcxm4zmi6kuna	72	31	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	73	1	In	in	IN
work_izjlueimqneiljcxm4zmi6kuna	73	2	2008	2008	CD
work_izjlueimqneiljcxm4zmi6kuna	73	3	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	73	4	Zodiac	Zodiac	NNP
work_izjlueimqneiljcxm4zmi6kuna	73	5	®	®	NNP
work_izjlueimqneiljcxm4zmi6kuna	73	6	Co	co	NN
work_izjlueimqneiljcxm4zmi6kuna	73	7	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	73	8	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	73	9	company	company	NN
work_izjlueimqneiljcxm4zmi6kuna	73	10	licensed	license	VBN
work_izjlueimqneiljcxm4zmi6kuna	73	11	by	by	IN
work_izjlueimqneiljcxm4zmi6kuna	73	12	Celgene	Celgene	NNP
work_izjlueimqneiljcxm4zmi6kuna	73	13	®	®	.
work_izjlueimqneiljcxm4zmi6kuna	73	14	Co	co	VB
work_izjlueimqneiljcxm4zmi6kuna	73	15	to	to	TO
work_izjlueimqneiljcxm4zmi6kuna	73	16	sell	sell	VB
work_izjlueimqneiljcxm4zmi6kuna	73	17	Revlimid	Revlimid	NNP
work_izjlueimqneiljcxm4zmi6kuna	73	18	®	®	NNP
work_izjlueimqneiljcxm4zmi6kuna	73	19	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	73	20	Brazil	Brazil	NNP
work_izjlueimqneiljcxm4zmi6kuna	73	21	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	73	22	filed	file	VBD
work_izjlueimqneiljcxm4zmi6kuna	73	23	an	an	DT
work_izjlueimqneiljcxm4zmi6kuna	73	24	application	application	NN
work_izjlueimqneiljcxm4zmi6kuna	73	25	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	73	26	lenalidomide	lenalidomide	JJ
work_izjlueimqneiljcxm4zmi6kuna	73	27	use	use	NN
work_izjlueimqneiljcxm4zmi6kuna	73	28	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	73	29	MM	MM	NNP
work_izjlueimqneiljcxm4zmi6kuna	73	30	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	73	31	MDS	MDS	NNP
work_izjlueimqneiljcxm4zmi6kuna	73	32	that	that	WDT
work_izjlueimqneiljcxm4zmi6kuna	73	33	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	73	34	Brazilian	brazilian	JJ
work_izjlueimqneiljcxm4zmi6kuna	73	35	agency	agency	NN
work_izjlueimqneiljcxm4zmi6kuna	73	36	ANVISA	ANVISA	NNP
work_izjlueimqneiljcxm4zmi6kuna	73	37	reject-	reject-	JJ
work_izjlueimqneiljcxm4zmi6kuna	73	38	ed	ed	NNP
work_izjlueimqneiljcxm4zmi6kuna	73	39	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	73	40	2010	2010	CD
work_izjlueimqneiljcxm4zmi6kuna	73	41	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	74	1	The	the	DT
work_izjlueimqneiljcxm4zmi6kuna	74	2	rejection	rejection	NN
work_izjlueimqneiljcxm4zmi6kuna	74	3	was	be	VBD
work_izjlueimqneiljcxm4zmi6kuna	74	4	based	base	VBN
work_izjlueimqneiljcxm4zmi6kuna	74	5	on	on	IN
work_izjlueimqneiljcxm4zmi6kuna	74	6	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	74	7	re-	re-	JJ
work_izjlueimqneiljcxm4zmi6kuna	74	8	port	port	NN
work_izjlueimqneiljcxm4zmi6kuna	74	9	by	by	IN
work_izjlueimqneiljcxm4zmi6kuna	74	10	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	74	11	Advisory	Advisory	NNP
work_izjlueimqneiljcxm4zmi6kuna	74	12	Committee	Committee	NNP
work_izjlueimqneiljcxm4zmi6kuna	74	13	on	on	IN
work_izjlueimqneiljcxm4zmi6kuna	74	14	Medicines	Medicines	NNP
work_izjlueimqneiljcxm4zmi6kuna	74	15	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	74	16	CATEME	cateme	NN
work_izjlueimqneiljcxm4zmi6kuna	74	17	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	74	18	whose	whose	WP$
work_izjlueimqneiljcxm4zmi6kuna	74	19	members	member	NNS
work_izjlueimqneiljcxm4zmi6kuna	74	20	pointed	point	VBD
work_izjlueimqneiljcxm4zmi6kuna	74	21	out	out	RP
work_izjlueimqneiljcxm4zmi6kuna	74	22	that	that	IN
work_izjlueimqneiljcxm4zmi6kuna	74	23	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	74	24	applicant	applicant	NN
work_izjlueimqneiljcxm4zmi6kuna	74	25	provided	provide	VBD
work_izjlueimqneiljcxm4zmi6kuna	74	26	no	no	DT
work_izjlueimqneiljcxm4zmi6kuna	74	27	evidence	evidence	NN
work_izjlueimqneiljcxm4zmi6kuna	74	28	that	that	IN
work_izjlueimqneiljcxm4zmi6kuna	74	29	lenalid-	lenalid-	NN
work_izjlueimqneiljcxm4zmi6kuna	74	30	omide	omide	NN
work_izjlueimqneiljcxm4zmi6kuna	74	31	was	be	VBD
work_izjlueimqneiljcxm4zmi6kuna	74	32	more	more	RBR
work_izjlueimqneiljcxm4zmi6kuna	74	33	effective	effective	JJ
work_izjlueimqneiljcxm4zmi6kuna	74	34	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	74	35	or	or	CC
work_izjlueimqneiljcxm4zmi6kuna	74	36	safer	safe	JJR
work_izjlueimqneiljcxm4zmi6kuna	74	37	than	than	IN
work_izjlueimqneiljcxm4zmi6kuna	74	38	tha-	tha-	DT
work_izjlueimqneiljcxm4zmi6kuna	74	39	lidomide	lidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	74	40	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	74	41	both	both	DT
work_izjlueimqneiljcxm4zmi6kuna	74	42	therapeutic	therapeutic	JJ
work_izjlueimqneiljcxm4zmi6kuna	74	43	indications	indication	NNS
work_izjlueimqneiljcxm4zmi6kuna	74	44	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	75	1	On	on	IN
work_izjlueimqneiljcxm4zmi6kuna	75	2	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	75	3	understanding	understanding	NN
work_izjlueimqneiljcxm4zmi6kuna	75	4	that	that	WDT
work_izjlueimqneiljcxm4zmi6kuna	75	5	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	75	6	similarly	similarly	RB
work_izjlueimqneiljcxm4zmi6kuna	75	7	to	to	TO
work_izjlueimqneiljcxm4zmi6kuna	75	8	thalidomide	thalidomide	VB
work_izjlueimqneiljcxm4zmi6kuna	75	9	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	75	10	lenalidomide	lenalidomide	VB
work_izjlueimqneiljcxm4zmi6kuna	75	11	also	also	RB
work_izjlueimqneiljcxm4zmi6kuna	75	12	proved	prove	VBD
work_izjlueimqneiljcxm4zmi6kuna	75	13	to	to	TO
work_izjlueimqneiljcxm4zmi6kuna	75	14	be	be	VB
work_izjlueimqneiljcxm4zmi6kuna	75	15	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	75	16	strong	strong	JJ
work_izjlueimqneiljcxm4zmi6kuna	75	17	teratogen	teratogen	NN
work_izjlueimqneiljcxm4zmi6kuna	75	18	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	75	19	non	non	JJ
work_izjlueimqneiljcxm4zmi6kuna	75	20	-	-	JJ
work_izjlueimqneiljcxm4zmi6kuna	75	21	human	human	JJ
work_izjlueimqneiljcxm4zmi6kuna	75	22	primates	primate	NNS
work_izjlueimqneiljcxm4zmi6kuna	75	23	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	75	24	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	75	25	that	that	IN
work_izjlueimqneiljcxm4zmi6kuna	75	26	it	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	75	27	is	be	VBZ
work_izjlueimqneiljcxm4zmi6kuna	75	28	much	much	RB
work_izjlueimqneiljcxm4zmi6kuna	75	29	more	more	RBR
work_izjlueimqneiljcxm4zmi6kuna	75	30	expensive	expensive	JJ
work_izjlueimqneiljcxm4zmi6kuna	75	31	than	than	IN
work_izjlueimqneiljcxm4zmi6kuna	75	32	its	-PRON-	PRP$
work_izjlueimqneiljcxm4zmi6kuna	75	33	prototype	prototype	NN
work_izjlueimqneiljcxm4zmi6kuna	75	34	drug	drug	NN
work_izjlueimqneiljcxm4zmi6kuna	75	35	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	75	36	CATEME	cateme	NN
work_izjlueimqneiljcxm4zmi6kuna	75	37	rec-	rec-	NNP
work_izjlueimqneiljcxm4zmi6kuna	75	38	ommended	ommende	VBD
work_izjlueimqneiljcxm4zmi6kuna	75	39	that	that	IN
work_izjlueimqneiljcxm4zmi6kuna	75	40	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	75	41	applicant	applicant	NN
work_izjlueimqneiljcxm4zmi6kuna	75	42	should	should	MD
work_izjlueimqneiljcxm4zmi6kuna	75	43	provide	provide	VB
work_izjlueimqneiljcxm4zmi6kuna	75	44	sound	sound	JJ
work_izjlueimqneiljcxm4zmi6kuna	75	45	evidence	evidence	NN
work_izjlueimqneiljcxm4zmi6kuna	75	46	that	that	IN
work_izjlueimqneiljcxm4zmi6kuna	75	47	lenalidomide	lenalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	75	48	is	be	VBZ
work_izjlueimqneiljcxm4zmi6kuna	75	49	clinically	clinically	RB
work_izjlueimqneiljcxm4zmi6kuna	75	50	superior	superior	JJ
work_izjlueimqneiljcxm4zmi6kuna	75	51	to	to	TO
work_izjlueimqneiljcxm4zmi6kuna	75	52	thalidomide	thalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	75	53	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	75	54	to	to	TO
work_izjlueimqneiljcxm4zmi6kuna	75	55	be	be	VB
work_izjlueimqneiljcxm4zmi6kuna	75	56	demonstrated	demonstrate	VBN
work_izjlueimqneiljcxm4zmi6kuna	75	57	by	by	IN
work_izjlueimqneiljcxm4zmi6kuna	75	58	comparative	comparative	JJ
work_izjlueimqneiljcxm4zmi6kuna	75	59	effectiveness	effectiveness	NN
work_izjlueimqneiljcxm4zmi6kuna	75	60	research	research	NNP
work_izjlueimqneiljcxm4zmi6kuna	75	61	data	datum	NNS
work_izjlueimqneiljcxm4zmi6kuna	75	62	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	75	63	before	before	IN
work_izjlueimqneiljcxm4zmi6kuna	75	64	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	75	65	marketing	marketing	NN
work_izjlueimqneiljcxm4zmi6kuna	75	66	authorization	authorization	NN
work_izjlueimqneiljcxm4zmi6kuna	75	67	is	be	VBZ
work_izjlueimqneiljcxm4zmi6kuna	75	68	granted	grant	VBN
work_izjlueimqneiljcxm4zmi6kuna	75	69	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	76	1	The	the	DT
work_izjlueimqneiljcxm4zmi6kuna	76	2	negative	negative	JJ
work_izjlueimqneiljcxm4zmi6kuna	76	3	decision	decision	NN
work_izjlueimqneiljcxm4zmi6kuna	76	4	was	be	VBD
work_izjlueimqneiljcxm4zmi6kuna	76	5	followed	follow	VBN
work_izjlueimqneiljcxm4zmi6kuna	76	6	by	by	IN
work_izjlueimqneiljcxm4zmi6kuna	76	7	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	76	8	powerful	powerful	JJ
work_izjlueimqneiljcxm4zmi6kuna	76	9	lobbying	lobbying	NN
work_izjlueimqneiljcxm4zmi6kuna	76	10	at	at	IN
work_izjlueimqneiljcxm4zmi6kuna	76	11	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	76	12	forefront	forefront	NN
work_izjlueimqneiljcxm4zmi6kuna	76	13	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	76	14	which	which	WDT
work_izjlueimqneiljcxm4zmi6kuna	76	15	were	be	VBD
work_izjlueimqneiljcxm4zmi6kuna	76	16	patient	patient	JJ
work_izjlueimqneiljcxm4zmi6kuna	76	17	organiza-	organiza-	JJ
work_izjlueimqneiljcxm4zmi6kuna	76	18	tions	tion	NNS
work_izjlueimqneiljcxm4zmi6kuna	76	19	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	76	20	medical	medical	JJ
work_izjlueimqneiljcxm4zmi6kuna	76	21	specialty	specialty	NN
work_izjlueimqneiljcxm4zmi6kuna	76	22	societies	society	NNS
work_izjlueimqneiljcxm4zmi6kuna	76	23	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	76	24	politicians	politician	NNS
work_izjlueimqneiljcxm4zmi6kuna	76	25	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	76	26	Congress	Congress	NNP
work_izjlueimqneiljcxm4zmi6kuna	76	27	members	member	NNS
work_izjlueimqneiljcxm4zmi6kuna	76	28	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	77	1	In	in	IN
work_izjlueimqneiljcxm4zmi6kuna	77	2	2012	2012	CD
work_izjlueimqneiljcxm4zmi6kuna	77	3	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	77	4	ANVISA	ANVISA	NNP
work_izjlueimqneiljcxm4zmi6kuna	77	5	’s	’s	POS
work_izjlueimqneiljcxm4zmi6kuna	77	6	board	board	NN
work_izjlueimqneiljcxm4zmi6kuna	77	7	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	77	8	directors	director	NNS
work_izjlueimqneiljcxm4zmi6kuna	77	9	denied	deny	VBD
work_izjlueimqneiljcxm4zmi6kuna	77	10	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	77	11	request	request	NN
work_izjlueimqneiljcxm4zmi6kuna	77	12	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	77	13	reconsideration	reconsideration	NN
work_izjlueimqneiljcxm4zmi6kuna	77	14	filed	file	VBN
work_izjlueimqneiljcxm4zmi6kuna	77	15	by	by	IN
work_izjlueimqneiljcxm4zmi6kuna	77	16	Zodiac	Zodiac	NNP
work_izjlueimqneiljcxm4zmi6kuna	77	17	®	®	NNP
work_izjlueimqneiljcxm4zmi6kuna	77	18	Co	co	VB
work_izjlueimqneiljcxm4zmi6kuna	77	19	thereby	thereby	RB
work_izjlueimqneiljcxm4zmi6kuna	77	20	confirming	confirm	VBG
work_izjlueimqneiljcxm4zmi6kuna	77	21	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	77	22	appli-	appli-	NNP
work_izjlueimqneiljcxm4zmi6kuna	77	23	cation	cation	NNP
work_izjlueimqneiljcxm4zmi6kuna	77	24	rejection	rejection	NN
work_izjlueimqneiljcxm4zmi6kuna	77	25	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	78	1	In	in	IN
work_izjlueimqneiljcxm4zmi6kuna	78	2	April	April	NNP
work_izjlueimqneiljcxm4zmi6kuna	78	3	2017	2017	CD
work_izjlueimqneiljcxm4zmi6kuna	78	4	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	78	5	ANVISA	ANVISA	NNP
work_izjlueimqneiljcxm4zmi6kuna	78	6	ignored	ignore	VBD
work_izjlueimqneiljcxm4zmi6kuna	78	7	all	all	PDT
work_izjlueimqneiljcxm4zmi6kuna	78	8	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	78	9	reasons	reason	NNS
work_izjlueimqneiljcxm4zmi6kuna	78	10	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	78	11	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	78	12	first	first	JJ
work_izjlueimqneiljcxm4zmi6kuna	78	13	application	application	NN
work_izjlueimqneiljcxm4zmi6kuna	78	14	rejection	rejection	NN
work_izjlueimqneiljcxm4zmi6kuna	78	15	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	78	16	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	78	17	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	78	18	an	an	DT
work_izjlueimqneiljcxm4zmi6kuna	78	19	unexplained	unexplained	JJ
work_izjlueimqneiljcxm4zmi6kuna	78	20	retreat	retreat	NN
work_izjlueimqneiljcxm4zmi6kuna	78	21	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	78	22	approved	approve	VBD
work_izjlueimqneiljcxm4zmi6kuna	78	23	lenalid-	lenalid-	NN
work_izjlueimqneiljcxm4zmi6kuna	78	24	omide	omide	NN
work_izjlueimqneiljcxm4zmi6kuna	78	25	registration	registration	NN
work_izjlueimqneiljcxm4zmi6kuna	78	26	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	78	27	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	78	28	country	country	NN
work_izjlueimqneiljcxm4zmi6kuna	78	29	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	79	1	Nonetheless	nonetheless	RB
work_izjlueimqneiljcxm4zmi6kuna	79	2	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	79	3	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	79	4	publication	publication	NN
work_izjlueimqneiljcxm4zmi6kuna	79	5	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	79	6	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	79	7	positive	positive	JJ
work_izjlueimqneiljcxm4zmi6kuna	79	8	decision	decision	NN
work_izjlueimqneiljcxm4zmi6kuna	79	9	on	on	IN
work_izjlueimqneiljcxm4zmi6kuna	79	10	regis-	regis-	NN
work_izjlueimqneiljcxm4zmi6kuna	79	11	tration	tration	NN
work_izjlueimqneiljcxm4zmi6kuna	79	12	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	79	13	that	that	WDT
work_izjlueimqneiljcxm4zmi6kuna	79	14	ultimately	ultimately	RB
work_izjlueimqneiljcxm4zmi6kuna	79	15	enacts	enact	VBZ
work_izjlueimqneiljcxm4zmi6kuna	79	16	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	79	17	authorization	authorization	NN
work_izjlueimqneiljcxm4zmi6kuna	79	18	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	79	19	sales	sale	NNS
work_izjlueimqneiljcxm4zmi6kuna	79	20	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	79	21	still	still	RB
work_izjlueimqneiljcxm4zmi6kuna	79	22	depends	depend	VBZ
work_izjlueimqneiljcxm4zmi6kuna	79	23	on	on	IN
work_izjlueimqneiljcxm4zmi6kuna	79	24	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	79	25	special	special	JJ
work_izjlueimqneiljcxm4zmi6kuna	79	26	regulation	regulation	NN
work_izjlueimqneiljcxm4zmi6kuna	79	27	on	on	IN
work_izjlueimqneiljcxm4zmi6kuna	79	28	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	79	29	control	control	NN
work_izjlueimqneiljcxm4zmi6kuna	79	30	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	79	31	its	-PRON-	PRP$
work_izjlueimqneiljcxm4zmi6kuna	79	32	use	use	NN
work_izjlueimqneiljcxm4zmi6kuna	79	33	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	79	34	dispensing	dispense	VBG
work_izjlueimqneiljcxm4zmi6kuna	79	35	to	to	TO
work_izjlueimqneiljcxm4zmi6kuna	79	36	be	be	VB
work_izjlueimqneiljcxm4zmi6kuna	79	37	issued	issue	VBN
work_izjlueimqneiljcxm4zmi6kuna	79	38	by	by	IN
work_izjlueimqneiljcxm4zmi6kuna	79	39	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	79	40	agency7	agency7	NN
work_izjlueimqneiljcxm4zmi6kuna	79	41	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	80	1	Comparative	comparative	JJ
work_izjlueimqneiljcxm4zmi6kuna	80	2	effectiveness	effectiveness	NN
work_izjlueimqneiljcxm4zmi6kuna	80	3	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	80	4	lenalidomide	lenalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	80	5	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	80	6	thalidomide	thalidomide	VB
work_izjlueimqneiljcxm4zmi6kuna	80	7	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	80	8	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	80	9	treatment	treatment	NN
work_izjlueimqneiljcxm4zmi6kuna	80	10	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	80	11	multiple	multiple	JJ
work_izjlueimqneiljcxm4zmi6kuna	80	12	myeloma	myeloma	NN
work_izjlueimqneiljcxm4zmi6kuna	80	13	Thalidomide	Thalidomide	NNP
work_izjlueimqneiljcxm4zmi6kuna	80	14	The	the	DT
work_izjlueimqneiljcxm4zmi6kuna	80	15	notion	notion	NN
work_izjlueimqneiljcxm4zmi6kuna	80	16	that	that	IN
work_izjlueimqneiljcxm4zmi6kuna	80	17	antiangiogenic	antiangiogenic	JJ
work_izjlueimqneiljcxm4zmi6kuna	80	18	compounds	compound	NNS
work_izjlueimqneiljcxm4zmi6kuna	80	19	could	could	MD
work_izjlueimqneiljcxm4zmi6kuna	80	20	be	be	VB
work_izjlueimqneiljcxm4zmi6kuna	80	21	useful	useful	JJ
work_izjlueimqneiljcxm4zmi6kuna	80	22	to	to	TO
work_izjlueimqneiljcxm4zmi6kuna	80	23	treat	treat	VB
work_izjlueimqneiljcxm4zmi6kuna	80	24	some	some	DT
work_izjlueimqneiljcxm4zmi6kuna	80	25	types	type	NNS
work_izjlueimqneiljcxm4zmi6kuna	80	26	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	80	27	cancer	cancer	NN
work_izjlueimqneiljcxm4zmi6kuna	80	28	stands	stand	VBZ
work_izjlueimqneiljcxm4zmi6kuna	80	29	on	on	IN
work_izjlueimqneiljcxm4zmi6kuna	80	30	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	80	31	observation	observation	NN
work_izjlueimqneiljcxm4zmi6kuna	80	32	that	that	IN
work_izjlueimqneiljcxm4zmi6kuna	80	33	solid	solid	JJ
work_izjlueimqneiljcxm4zmi6kuna	80	34	tumors	tumor	NNS
work_izjlueimqneiljcxm4zmi6kuna	80	35	re-	re-	XX
work_izjlueimqneiljcxm4zmi6kuna	80	36	quired	quire	VBN
work_izjlueimqneiljcxm4zmi6kuna	80	37	neovascularization	neovascularization	NN
work_izjlueimqneiljcxm4zmi6kuna	80	38	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	80	39	angiogenesis	angiogenesis	NN
work_izjlueimqneiljcxm4zmi6kuna	80	40	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	80	41	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	80	42	growth	growth	NN
work_izjlueimqneiljcxm4zmi6kuna	80	43	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	80	44	survival7	survival7	NN
work_izjlueimqneiljcxm4zmi6kuna	80	45	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	81	1	In	in	IN
work_izjlueimqneiljcxm4zmi6kuna	81	2	1994	1994	CD
work_izjlueimqneiljcxm4zmi6kuna	81	3	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	81	4	D’Amato	D’Amato	NNP
work_izjlueimqneiljcxm4zmi6kuna	81	5	et	et	FW
work_izjlueimqneiljcxm4zmi6kuna	81	6	al	al	NNP
work_izjlueimqneiljcxm4zmi6kuna	81	7	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	82	1	reported	report	VBD
work_izjlueimqneiljcxm4zmi6kuna	82	2	that	that	IN
work_izjlueimqneiljcxm4zmi6kuna	82	3	thalidomide	thalidomide	NNP
work_izjlueimqneiljcxm4zmi6kuna	82	4	inhibited	inhibit	VBN
work_izjlueimqneiljcxm4zmi6kuna	82	5	angiogene-	angiogene-	JJ
work_izjlueimqneiljcxm4zmi6kuna	82	6	sis	sis	NN
work_izjlueimqneiljcxm4zmi6kuna	82	7	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	82	8	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	82	9	rabbit	rabbit	NN
work_izjlueimqneiljcxm4zmi6kuna	82	10	cornea	cornea	NN
work_izjlueimqneiljcxm4zmi6kuna	82	11	assay8	assay8	NN
work_izjlueimqneiljcxm4zmi6kuna	82	12	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	83	1	The	the	DT
work_izjlueimqneiljcxm4zmi6kuna	83	2	next	next	JJ
work_izjlueimqneiljcxm4zmi6kuna	83	3	logical	logical	JJ
work_izjlueimqneiljcxm4zmi6kuna	83	4	step	step	NN
work_izjlueimqneiljcxm4zmi6kuna	83	5	was	be	VBD
work_izjlueimqneiljcxm4zmi6kuna	83	6	to	to	TO
work_izjlueimqneiljcxm4zmi6kuna	83	7	test	test	VB
work_izjlueimqneiljcxm4zmi6kuna	83	8	thalidomide	thalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	83	9	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	83	10	patients	patient	NNS
work_izjlueimqneiljcxm4zmi6kuna	83	11	with	with	IN
work_izjlueimqneiljcxm4zmi6kuna	83	12	cancer	cancer	NN
work_izjlueimqneiljcxm4zmi6kuna	83	13	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	84	1	An	an	DT
work_izjlueimqneiljcxm4zmi6kuna	84	2	open	open	JJ
work_izjlueimqneiljcxm4zmi6kuna	84	3	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	84	4	label	label	NN
work_izjlueimqneiljcxm4zmi6kuna	84	5	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	84	6	uncontrolled	uncontrolled	JJ
work_izjlueimqneiljcxm4zmi6kuna	84	7	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	84	8	trial	trial	NN
work_izjlueimqneiljcxm4zmi6kuna	84	9	with	with	IN
work_izjlueimqneiljcxm4zmi6kuna	84	10	relapsed	relapsed	JJ
work_izjlueimqneiljcxm4zmi6kuna	84	11	and/or	and/or	CC
work_izjlueimqneiljcxm4zmi6kuna	84	12	refractory	refractory	NN
work_izjlueimqneiljcxm4zmi6kuna	84	13	MM	mm	NN
work_izjlueimqneiljcxm4zmi6kuna	84	14	patients	patient	NNS
work_izjlueimqneiljcxm4zmi6kuna	84	15	showed	show	VBD
work_izjlueimqneiljcxm4zmi6kuna	84	16	that	that	IN
work_izjlueimqneiljcxm4zmi6kuna	84	17	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	84	18	as	as	IN
work_izjlueimqneiljcxm4zmi6kuna	84	19	anticipated	anticipate	VBN
work_izjlueimqneiljcxm4zmi6kuna	84	20	by	by	IN
work_izjlueimqneiljcxm4zmi6kuna	84	21	Folkman	Folkman	NNP
work_izjlueimqneiljcxm4zmi6kuna	84	22	’s	’s	POS
work_izjlueimqneiljcxm4zmi6kuna	84	23	hypothesis	hypothesis	NN
work_izjlueimqneiljcxm4zmi6kuna	84	24	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	84	25	tha-	tha-	DT
work_izjlueimqneiljcxm4zmi6kuna	84	26	lidomide	lidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	84	27	was	be	VBD
work_izjlueimqneiljcxm4zmi6kuna	84	28	active	active	JJ
work_izjlueimqneiljcxm4zmi6kuna	84	29	against	against	IN
work_izjlueimqneiljcxm4zmi6kuna	84	30	advanced	advanced	JJ
work_izjlueimqneiljcxm4zmi6kuna	84	31	tumors	tumor	NNS
work_izjlueimqneiljcxm4zmi6kuna	84	32	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	84	33	caused	cause	VBD
work_izjlueimqneiljcxm4zmi6kuna	84	34	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	84	35	decline	decline	NN
work_izjlueimqneiljcxm4zmi6kuna	84	36	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	84	37	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	84	38	serum	serum	NN
work_izjlueimqneiljcxm4zmi6kuna	84	39	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	84	40	urine	urine	NN
work_izjlueimqneiljcxm4zmi6kuna	84	41	levels	level	NNS
work_izjlueimqneiljcxm4zmi6kuna	84	42	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	84	43	paraprotein	paraprotein	NNP
work_izjlueimqneiljcxm4zmi6kuna	84	44	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	84	45	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	84	46	primary	primary	JJ
work_izjlueimqneiljcxm4zmi6kuna	84	47	efficacy	efficacy	NN
work_izjlueimqneiljcxm4zmi6kuna	84	48	outcome	outcome	NN
work_izjlueimqneiljcxm4zmi6kuna	84	49	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	84	50	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	84	51	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	84	52	disease	disease	NN
work_izjlueimqneiljcxm4zmi6kuna	84	53	remission	remission	NN
work_izjlueimqneiljcxm4zmi6kuna	84	54	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	84	55	apparently	apparently	RB
work_izjlueimqneiljcxm4zmi6kuna	84	56	an	an	DT
work_izjlueimqneiljcxm4zmi6kuna	84	57	improve-	improve-	JJ
work_izjlueimqneiljcxm4zmi6kuna	84	58	ment	ment	NN
work_izjlueimqneiljcxm4zmi6kuna	84	59	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	84	60	survival9	survival9	NN
work_izjlueimqneiljcxm4zmi6kuna	84	61	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	85	1	Since	since	IN
work_izjlueimqneiljcxm4zmi6kuna	85	2	then	then	RB
work_izjlueimqneiljcxm4zmi6kuna	85	3	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	85	4	evidence	evidence	NN
work_izjlueimqneiljcxm4zmi6kuna	85	5	from	from	IN
work_izjlueimqneiljcxm4zmi6kuna	85	6	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	85	7	set	set	NN
work_izjlueimqneiljcxm4zmi6kuna	85	8	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	85	9	phase	phase	NN
work_izjlueimqneiljcxm4zmi6kuna	85	10	II	II	NNP
work_izjlueimqneiljcxm4zmi6kuna	85	11	studies	study	NNS
work_izjlueimqneiljcxm4zmi6kuna	85	12	confirmed	confirm	VBD
work_izjlueimqneiljcxm4zmi6kuna	85	13	that	that	IN
work_izjlueimqneiljcxm4zmi6kuna	85	14	thalidomide	thalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	85	15	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	85	16	with	with	IN
work_izjlueimqneiljcxm4zmi6kuna	85	17	dexamethasone	dexamethasone	NN
work_izjlueimqneiljcxm4zmi6kuna	85	18	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	85	19	or	or	CC
work_izjlueimqneiljcxm4zmi6kuna	85	20	chemotherapy	chemotherapy	NN
work_izjlueimqneiljcxm4zmi6kuna	85	21	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	85	22	significantly	significantly	RB
work_izjlueimqneiljcxm4zmi6kuna	85	23	improved	improve	VBD
work_izjlueimqneiljcxm4zmi6kuna	85	24	overall	overall	JJ
work_izjlueimqneiljcxm4zmi6kuna	85	25	response	response	NN
work_izjlueimqneiljcxm4zmi6kuna	85	26	rates	rate	NNS
work_izjlueimqneiljcxm4zmi6kuna	85	27	to	to	IN
work_izjlueimqneiljcxm4zmi6kuna	85	28	combined	combine	VBN
work_izjlueimqneiljcxm4zmi6kuna	85	29	therapies	therapy	NNS
work_izjlueimqneiljcxm4zmi6kuna	85	30	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	85	31	relapsed	relapsed	JJ
work_izjlueimqneiljcxm4zmi6kuna	85	32	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	85	33	newly	newly	RB
work_izjlueimqneiljcxm4zmi6kuna	85	34	diag-	diag-	NN
work_izjlueimqneiljcxm4zmi6kuna	85	35	nosed	nosed	JJ
work_izjlueimqneiljcxm4zmi6kuna	85	36	patients10,11	patients10,11	NNP
work_izjlueimqneiljcxm4zmi6kuna	85	37	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	86	1	A	a	DT
work_izjlueimqneiljcxm4zmi6kuna	86	2	further	further	JJ
work_izjlueimqneiljcxm4zmi6kuna	86	3	phase	phase	NN
work_izjlueimqneiljcxm4zmi6kuna	86	4	III	iii	CD
work_izjlueimqneiljcxm4zmi6kuna	86	5	random-	random-	NN
work_izjlueimqneiljcxm4zmi6kuna	86	6	ized	ize	VBN
work_izjlueimqneiljcxm4zmi6kuna	86	7	clinical	clinical	JJ
work_izjlueimqneiljcxm4zmi6kuna	86	8	trial	trial	NN
work_izjlueimqneiljcxm4zmi6kuna	86	9	also	also	RB
work_izjlueimqneiljcxm4zmi6kuna	86	10	showed	show	VBD
work_izjlueimqneiljcxm4zmi6kuna	86	11	that	that	IN
work_izjlueimqneiljcxm4zmi6kuna	86	12	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	86	13	compared	compare	VBN
work_izjlueimqneiljcxm4zmi6kuna	86	14	to	to	IN
work_izjlueimqneiljcxm4zmi6kuna	86	15	“	"	``
work_izjlueimqneiljcxm4zmi6kuna	86	16	dexamethasone	dexamethasone	VB
work_izjlueimqneiljcxm4zmi6kuna	86	17	alone	alone	RB
work_izjlueimqneiljcxm4zmi6kuna	86	18	”	"	''
work_izjlueimqneiljcxm4zmi6kuna	86	19	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	86	20	“	"	``
work_izjlueimqneiljcxm4zmi6kuna	86	21	thalidomide	thalidomide	NNP
work_izjlueimqneiljcxm4zmi6kuna	86	22	plus	plus	CC
work_izjlueimqneiljcxm4zmi6kuna	86	23	dexa-	dexa-	JJ
work_izjlueimqneiljcxm4zmi6kuna	86	24	methasone	methasone	NN
work_izjlueimqneiljcxm4zmi6kuna	86	25	”	"	''
work_izjlueimqneiljcxm4zmi6kuna	86	26	gave	give	VBD
work_izjlueimqneiljcxm4zmi6kuna	86	27	rise	rise	NN
work_izjlueimqneiljcxm4zmi6kuna	86	28	to	to	IN
work_izjlueimqneiljcxm4zmi6kuna	86	29	superior	superior	JJ
work_izjlueimqneiljcxm4zmi6kuna	86	30	responses	response	NNS
work_izjlueimqneiljcxm4zmi6kuna	86	31	rates	rate	NNS
work_izjlueimqneiljcxm4zmi6kuna	86	32	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	86	33	newly	newly	RB
work_izjlueimqneiljcxm4zmi6kuna	86	34	diagnosed	diagnose	VBN
work_izjlueimqneiljcxm4zmi6kuna	86	35	MM	MM	NNP
work_izjlueimqneiljcxm4zmi6kuna	86	36	patients12	patients12	NNP
work_izjlueimqneiljcxm4zmi6kuna	86	37	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	87	1	lenalidomide	lenalidomide	VB
work_izjlueimqneiljcxm4zmi6kuna	87	2	A	a	DT
work_izjlueimqneiljcxm4zmi6kuna	87	3	phase	phase	NN
work_izjlueimqneiljcxm4zmi6kuna	87	4	III	iii	CD
work_izjlueimqneiljcxm4zmi6kuna	87	5	placebo	placebo	NN
work_izjlueimqneiljcxm4zmi6kuna	87	6	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	87	7	controlled	control	VBN
work_izjlueimqneiljcxm4zmi6kuna	87	8	trial	trial	NN
work_izjlueimqneiljcxm4zmi6kuna	87	9	revealed	reveal	VBD
work_izjlueimqneiljcxm4zmi6kuna	87	10	that	that	IN
work_izjlueimqneiljcxm4zmi6kuna	87	11	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	87	12	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	87	13	patients	patient	NNS
work_izjlueimqneiljcxm4zmi6kuna	87	14	with	with	IN
work_izjlueimqneiljcxm4zmi6kuna	87	15	relapsed	relapsed	JJ
work_izjlueimqneiljcxm4zmi6kuna	87	16	or	or	CC
work_izjlueimqneiljcxm4zmi6kuna	87	17	refractory	refractory	NN
work_izjlueimqneiljcxm4zmi6kuna	87	18	MM	mm	NN
work_izjlueimqneiljcxm4zmi6kuna	87	19	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	87	20	lenalidomide	lenalidomide	VB
work_izjlueimqneiljcxm4zmi6kuna	87	21	combined	combine	VBN
work_izjlueimqneiljcxm4zmi6kuna	87	22	with	with	IN
work_izjlueimqneiljcxm4zmi6kuna	87	23	dexamethasone	dexamethasone	NNP
work_izjlueimqneiljcxm4zmi6kuna	87	24	significantly	significantly	RB
work_izjlueimqneiljcxm4zmi6kuna	87	25	prolonged	prolong	VBD
work_izjlueimqneiljcxm4zmi6kuna	87	26	“	"	``
work_izjlueimqneiljcxm4zmi6kuna	87	27	time	time	NN
work_izjlueimqneiljcxm4zmi6kuna	87	28	to	to	IN
work_izjlueimqneiljcxm4zmi6kuna	87	29	progression	progression	NN
work_izjlueimqneiljcxm4zmi6kuna	87	30	”	"	''
work_izjlueimqneiljcxm4zmi6kuna	87	31	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	87	32	11.3	11.3	CD
work_izjlueimqneiljcxm4zmi6kuna	87	33	months	month	NNS
work_izjlueimqneiljcxm4zmi6kuna	87	34	versus	versus	IN
work_izjlueimqneiljcxm4zmi6kuna	87	35	4.3	4.3	CD
work_izjlueimqneiljcxm4zmi6kuna	87	36	months	month	NNS
work_izjlueimqneiljcxm4zmi6kuna	87	37	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	87	38	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	87	39	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	87	40	improved	improve	VBN
work_izjlueimqneiljcxm4zmi6kuna	87	41	overall	overall	JJ
work_izjlueimqneiljcxm4zmi6kuna	87	42	survival13	survival13	NNP
work_izjlueimqneiljcxm4zmi6kuna	87	43	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	88	1	In	in	IN
work_izjlueimqneiljcxm4zmi6kuna	88	2	newly	newly	RB
work_izjlueimqneiljcxm4zmi6kuna	88	3	diagnosed	diagnose	VBN
work_izjlueimqneiljcxm4zmi6kuna	88	4	MM	MM	NNP
work_izjlueimqneiljcxm4zmi6kuna	88	5	pa-	pa-	NN
work_izjlueimqneiljcxm4zmi6kuna	88	6	tients	tient	VBZ
work_izjlueimqneiljcxm4zmi6kuna	88	7	ineligible	ineligible	JJ
work_izjlueimqneiljcxm4zmi6kuna	88	8	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	88	9	bone	bone	NN
work_izjlueimqneiljcxm4zmi6kuna	88	10	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	88	11	marrow	marrow	NN
work_izjlueimqneiljcxm4zmi6kuna	88	12	transplanta-	transplanta-	JJ
work_izjlueimqneiljcxm4zmi6kuna	88	13	tion	tion	NN
work_izjlueimqneiljcxm4zmi6kuna	88	14	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	88	15	maintenance	maintenance	NN
work_izjlueimqneiljcxm4zmi6kuna	88	16	with	with	IN
work_izjlueimqneiljcxm4zmi6kuna	88	17	lenalidomide	lenalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	88	18	after	after	IN
work_izjlueimqneiljcxm4zmi6kuna	88	19	an	an	DT
work_izjlueimqneiljcxm4zmi6kuna	88	20	induction	induction	NN
work_izjlueimqneiljcxm4zmi6kuna	88	21	treatment	treatment	NN
work_izjlueimqneiljcxm4zmi6kuna	88	22	regimen	regimen	NNP
work_izjlueimqneiljcxm4zmi6kuna	88	23	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	88	24	melphalan	melphalan	NNP
work_izjlueimqneiljcxm4zmi6kuna	88	25	+	+	SYM
work_izjlueimqneiljcxm4zmi6kuna	88	26	prednisone	prednisone	NN
work_izjlueimqneiljcxm4zmi6kuna	88	27	+	+	CC
work_izjlueimqneiljcxm4zmi6kuna	88	28	lenalidomide	lenalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	88	29	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	88	30	was	be	VBD
work_izjlueimqneiljcxm4zmi6kuna	88	31	shown	show	VBN
work_izjlueimqneiljcxm4zmi6kuna	88	32	to	to	IN
work_izjlueimqneiljcxm4zmi6kuna	88	33	pro-	pro-	NN
work_izjlueimqneiljcxm4zmi6kuna	88	34	long	long	JJ
work_izjlueimqneiljcxm4zmi6kuna	88	35	“	"	``
work_izjlueimqneiljcxm4zmi6kuna	88	36	progression	progression	NN
work_izjlueimqneiljcxm4zmi6kuna	88	37	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	88	38	free	free	JJ
work_izjlueimqneiljcxm4zmi6kuna	88	39	survival	survival	NN
work_izjlueimqneiljcxm4zmi6kuna	88	40	”	"	''
work_izjlueimqneiljcxm4zmi6kuna	88	41	compared	compare	VBN
work_izjlueimqneiljcxm4zmi6kuna	88	42	with	with	IN
work_izjlueimqneiljcxm4zmi6kuna	88	43	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	88	44	induction	induction	NN
work_izjlueimqneiljcxm4zmi6kuna	88	45	therapy	therapy	NN
work_izjlueimqneiljcxm4zmi6kuna	88	46	followed	follow	VBN
work_izjlueimqneiljcxm4zmi6kuna	88	47	by	by	IN
work_izjlueimqneiljcxm4zmi6kuna	88	48	placebo14	placebo14	NNP
work_izjlueimqneiljcxm4zmi6kuna	88	49	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	89	1	A	a	DT
work_izjlueimqneiljcxm4zmi6kuna	89	2	meta	meta	JJ
work_izjlueimqneiljcxm4zmi6kuna	89	3	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	89	4	analysis	analysis	NN
work_izjlueimqneiljcxm4zmi6kuna	89	5	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	89	6	seven	seven	CD
work_izjlueimqneiljcxm4zmi6kuna	89	7	RCTs	rct	NNS
work_izjlueimqneiljcxm4zmi6kuna	89	8	evaluating	evaluate	VBG
work_izjlueimqneiljcxm4zmi6kuna	89	9	initial	initial	JJ
work_izjlueimqneiljcxm4zmi6kuna	89	10	or	or	CC
work_izjlueimqneiljcxm4zmi6kuna	89	11	maintenance	maintenance	NN
work_izjlueimqneiljcxm4zmi6kuna	89	12	therapeutic	therapeutic	JJ
work_izjlueimqneiljcxm4zmi6kuna	89	13	outcomes	outcome	NNS
work_izjlueimqneiljcxm4zmi6kuna	89	14	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	89	15	such	such	JJ
work_izjlueimqneiljcxm4zmi6kuna	89	16	as	as	IN
work_izjlueimqneiljcxm4zmi6kuna	89	17	response	response	NN
work_izjlueimqneiljcxm4zmi6kuna	89	18	rates	rate	NNS
work_izjlueimqneiljcxm4zmi6kuna	89	19	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	89	20	“	"	``
work_izjlueimqneiljcxm4zmi6kuna	89	21	progression	progression	NN
work_izjlueimqneiljcxm4zmi6kuna	89	22	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	89	23	free	free	JJ
work_izjlueimqneiljcxm4zmi6kuna	89	24	survival	survival	NN
work_izjlueimqneiljcxm4zmi6kuna	89	25	”	"	''
work_izjlueimqneiljcxm4zmi6kuna	89	26	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	89	27	PFS	PFS	NNP
work_izjlueimqneiljcxm4zmi6kuna	89	28	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	89	29	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	89	30	“	"	``
work_izjlueimqneiljcxm4zmi6kuna	89	31	overall	overall	JJ
work_izjlueimqneiljcxm4zmi6kuna	89	32	survival	survival	NN
work_izjlueimqneiljcxm4zmi6kuna	89	33	”	"	''
work_izjlueimqneiljcxm4zmi6kuna	89	34	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	89	35	adverse	adverse	JJ
work_izjlueimqneiljcxm4zmi6kuna	89	36	effects	effect	NNS
work_izjlueimqneiljcxm4zmi6kuna	89	37	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	89	38	concluded	conclude	VBD
work_izjlueimqneiljcxm4zmi6kuna	89	39	3	3	CD
work_izjlueimqneiljcxm4zmi6kuna	89	40	7	7	CD
work_izjlueimqneiljcxm4zmi6kuna	89	41	8	8	CD
work_izjlueimqneiljcxm4zmi6kuna	89	42	7	7	CD
work_izjlueimqneiljcxm4zmi6kuna	89	43	C	C	NNP
work_izjlueimqneiljcxm4zmi6kuna	89	44	iên	iên	NN
work_izjlueimqneiljcxm4zmi6kuna	89	45	cia	cia	NNP
work_izjlueimqneiljcxm4zmi6kuna	89	46	&	&	CC
work_izjlueimqneiljcxm4zmi6kuna	89	47	Saú	Saú	NNP
work_izjlueimqneiljcxm4zmi6kuna	89	48	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	89	49	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	89	50	C	C	NNP
work_izjlueimqneiljcxm4zmi6kuna	89	51	o	o	NN
work_izjlueimqneiljcxm4zmi6kuna	89	52	letiva	letiva	NN
work_izjlueimqneiljcxm4zmi6kuna	89	53	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	89	54	2	2	CD
work_izjlueimqneiljcxm4zmi6kuna	89	55	4	4	CD
work_izjlueimqneiljcxm4zmi6kuna	89	56	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	89	57	1	1	CD
work_izjlueimqneiljcxm4zmi6kuna	89	58	0	0	CD
work_izjlueimqneiljcxm4zmi6kuna	89	59	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	89	60	:3	:3	NNP
work_izjlueimqneiljcxm4zmi6kuna	89	61	7	7	CD
work_izjlueimqneiljcxm4zmi6kuna	89	62	8	8	CD
work_izjlueimqneiljcxm4zmi6kuna	89	63	3	3	CD
work_izjlueimqneiljcxm4zmi6kuna	89	64	-3	-3	$
work_izjlueimqneiljcxm4zmi6kuna	89	65	7	7	CD
work_izjlueimqneiljcxm4zmi6kuna	89	66	9	9	CD
work_izjlueimqneiljcxm4zmi6kuna	89	67	2	2	CD
work_izjlueimqneiljcxm4zmi6kuna	89	68	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	89	69	2	2	CD
work_izjlueimqneiljcxm4zmi6kuna	89	70	0	0	CD
work_izjlueimqneiljcxm4zmi6kuna	89	71	1	1	CD
work_izjlueimqneiljcxm4zmi6kuna	89	72	9	9	CD
work_izjlueimqneiljcxm4zmi6kuna	89	73	that	that	WDT
work_izjlueimqneiljcxm4zmi6kuna	89	74	complete	complete	JJ
work_izjlueimqneiljcxm4zmi6kuna	89	75	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	89	76	very	very	RB
work_izjlueimqneiljcxm4zmi6kuna	89	77	good	good	JJ
work_izjlueimqneiljcxm4zmi6kuna	89	78	partial	partial	JJ
work_izjlueimqneiljcxm4zmi6kuna	89	79	response	response	NN
work_izjlueimqneiljcxm4zmi6kuna	89	80	risk	risk	NN
work_izjlueimqneiljcxm4zmi6kuna	89	81	ratios	ratio	NNS
work_izjlueimqneiljcxm4zmi6kuna	89	82	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	89	83	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	89	84	PFS	PFS	NNP
work_izjlueimqneiljcxm4zmi6kuna	89	85	hazard	hazard	NN
work_izjlueimqneiljcxm4zmi6kuna	89	86	ratios	ratio	VBZ
work_izjlueimqneiljcxm4zmi6kuna	89	87	favored	favor	VBD
work_izjlueimqneiljcxm4zmi6kuna	89	88	lena-	lena-	NN
work_izjlueimqneiljcxm4zmi6kuna	89	89	lidomide	lidomide	VBP
work_izjlueimqneiljcxm4zmi6kuna	89	90	over	over	RP
work_izjlueimqneiljcxm4zmi6kuna	89	91	placebo15	placebo15	NNP
work_izjlueimqneiljcxm4zmi6kuna	89	92	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	90	1	The	the	DT
work_izjlueimqneiljcxm4zmi6kuna	90	2	occurrence	occurrence	NN
work_izjlueimqneiljcxm4zmi6kuna	90	3	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	90	4	ad-	ad-	CC
work_izjlueimqneiljcxm4zmi6kuna	90	5	verse	verse	NN
work_izjlueimqneiljcxm4zmi6kuna	90	6	events	event	NNS
work_izjlueimqneiljcxm4zmi6kuna	90	7	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	90	8	neutropenia	neutropenia	JJ
work_izjlueimqneiljcxm4zmi6kuna	90	9	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	90	10	deep	deep	JJ
work_izjlueimqneiljcxm4zmi6kuna	90	11	vein	vein	NN
work_izjlueimqneiljcxm4zmi6kuna	90	12	thrombosis	thrombosis	NN
work_izjlueimqneiljcxm4zmi6kuna	90	13	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	90	14	infection	infection	NN
work_izjlueimqneiljcxm4zmi6kuna	90	15	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	90	16	hematologic	hematologic	JJ
work_izjlueimqneiljcxm4zmi6kuna	90	17	cancer	cancer	NN
work_izjlueimqneiljcxm4zmi6kuna	90	18	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	90	19	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	90	20	however	however	RB
work_izjlueimqneiljcxm4zmi6kuna	90	21	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	90	22	fa-	fa-	RB
work_izjlueimqneiljcxm4zmi6kuna	90	23	vored	vore	VBD
work_izjlueimqneiljcxm4zmi6kuna	90	24	placebo	placebo	NN
work_izjlueimqneiljcxm4zmi6kuna	90	25	over	over	IN
work_izjlueimqneiljcxm4zmi6kuna	90	26	lenalidomide16	lenalidomide16	NNP
work_izjlueimqneiljcxm4zmi6kuna	90	27	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	91	1	In	in	IN
work_izjlueimqneiljcxm4zmi6kuna	91	2	summary	summary	NN
work_izjlueimqneiljcxm4zmi6kuna	91	3	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	91	4	phase	phase	NN
work_izjlueimqneiljcxm4zmi6kuna	91	5	II	II	NNP
work_izjlueimqneiljcxm4zmi6kuna	91	6	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	91	7	III	iii	CD
work_izjlueimqneiljcxm4zmi6kuna	91	8	clinical	clinical	JJ
work_izjlueimqneiljcxm4zmi6kuna	91	9	studies	study	NNS
work_izjlueimqneiljcxm4zmi6kuna	91	10	showed	show	VBD
work_izjlueimqneiljcxm4zmi6kuna	91	11	that	that	IN
work_izjlueimqneiljcxm4zmi6kuna	91	12	both	both	DT
work_izjlueimqneiljcxm4zmi6kuna	91	13	thalidomide-	thalidomide-	JJ
work_izjlueimqneiljcxm4zmi6kuna	91	14	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	91	15	lenalido-	lenalido-	NNP
work_izjlueimqneiljcxm4zmi6kuna	91	16	mide	mide	NN
work_izjlueimqneiljcxm4zmi6kuna	91	17	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	91	18	based	base	VBN
work_izjlueimqneiljcxm4zmi6kuna	91	19	combination	combination	NN
work_izjlueimqneiljcxm4zmi6kuna	91	20	therapies	therapy	NNS
work_izjlueimqneiljcxm4zmi6kuna	91	21	were	be	VBD
work_izjlueimqneiljcxm4zmi6kuna	91	22	effective	effective	JJ
work_izjlueimqneiljcxm4zmi6kuna	91	23	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	91	24	safe	safe	JJ
work_izjlueimqneiljcxm4zmi6kuna	91	25	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	91	26	that	that	RB
work_izjlueimqneiljcxm4zmi6kuna	91	27	is	is	RB
work_izjlueimqneiljcxm4zmi6kuna	91	28	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	91	29	they	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	91	30	substantially	substantially	RB
work_izjlueimqneiljcxm4zmi6kuna	91	31	improved	improve	VBD
work_izjlueimqneiljcxm4zmi6kuna	91	32	clin-	clin-	JJ
work_izjlueimqneiljcxm4zmi6kuna	91	33	ical	ical	JJ
work_izjlueimqneiljcxm4zmi6kuna	91	34	outcomes	outcome	NNS
work_izjlueimqneiljcxm4zmi6kuna	91	35	such	such	JJ
work_izjlueimqneiljcxm4zmi6kuna	91	36	as	as	IN
work_izjlueimqneiljcxm4zmi6kuna	91	37	“	"	``
work_izjlueimqneiljcxm4zmi6kuna	91	38	progression	progression	NN
work_izjlueimqneiljcxm4zmi6kuna	91	39	free	free	JJ
work_izjlueimqneiljcxm4zmi6kuna	91	40	survival	survival	NN
work_izjlueimqneiljcxm4zmi6kuna	91	41	”	"	''
work_izjlueimqneiljcxm4zmi6kuna	91	42	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	91	43	“	"	``
work_izjlueimqneiljcxm4zmi6kuna	91	44	overall	overall	JJ
work_izjlueimqneiljcxm4zmi6kuna	91	45	survival	survival	NN
work_izjlueimqneiljcxm4zmi6kuna	91	46	”	"	''
work_izjlueimqneiljcxm4zmi6kuna	91	47	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	91	48	patients	patient	NNS
work_izjlueimqneiljcxm4zmi6kuna	91	49	with	with	IN
work_izjlueimqneiljcxm4zmi6kuna	91	50	multiple	multiple	JJ
work_izjlueimqneiljcxm4zmi6kuna	91	51	myeloma	myeloma	NN
work_izjlueimqneiljcxm4zmi6kuna	91	52	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	91	53	MM	MM	NNP
work_izjlueimqneiljcxm4zmi6kuna	91	54	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	91	55	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	92	1	Therapeutic	therapeutic	JJ
work_izjlueimqneiljcxm4zmi6kuna	92	2	regimens	regimen	NNS
work_izjlueimqneiljcxm4zmi6kuna	92	3	based	base	VBN
work_izjlueimqneiljcxm4zmi6kuna	92	4	on	on	IN
work_izjlueimqneiljcxm4zmi6kuna	92	5	thalidomide	thalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	92	6	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	92	7	lenalidomide	lenalidomide	VB
work_izjlueimqneiljcxm4zmi6kuna	92	8	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	92	9	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	92	10	more	more	RBR
work_izjlueimqneiljcxm4zmi6kuna	92	11	recently	recently	RB
work_izjlueimqneiljcxm4zmi6kuna	92	12	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	92	13	on	on	IN
work_izjlueimqneiljcxm4zmi6kuna	92	14	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	92	15	proteasome	proteasome	JJ
work_izjlueimqneiljcxm4zmi6kuna	92	16	inhibitor	inhibitor	NN
work_izjlueimqneiljcxm4zmi6kuna	92	17	drug	drug	NN
work_izjlueimqneiljcxm4zmi6kuna	92	18	bortezomid	bortezomid	NNP
work_izjlueimqneiljcxm4zmi6kuna	92	19	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	92	20	it	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	92	21	diminishes	diminish	VBZ
work_izjlueimqneiljcxm4zmi6kuna	92	22	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	92	23	activity	activity	NN
work_izjlueimqneiljcxm4zmi6kuna	92	24	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	92	25	cell	cell	NN
work_izjlueimqneiljcxm4zmi6kuna	92	26	proteasomes	proteasome	NNS
work_izjlueimqneiljcxm4zmi6kuna	92	27	that	that	WDT
work_izjlueimqneiljcxm4zmi6kuna	92	28	break	break	VBP
work_izjlueimqneiljcxm4zmi6kuna	92	29	down	down	RP
work_izjlueimqneiljcxm4zmi6kuna	92	30	proteins	protein	NNS
work_izjlueimqneiljcxm4zmi6kuna	92	31	including	include	VBG
work_izjlueimqneiljcxm4zmi6kuna	92	32	those	those	DT
work_izjlueimqneiljcxm4zmi6kuna	92	33	that	that	WDT
work_izjlueimqneiljcxm4zmi6kuna	92	34	kill	kill	VBP
work_izjlueimqneiljcxm4zmi6kuna	92	35	ma-	ma-	JJ
work_izjlueimqneiljcxm4zmi6kuna	92	36	lignant	lignant	JJ
work_izjlueimqneiljcxm4zmi6kuna	92	37	cells	cell	NNS
work_izjlueimqneiljcxm4zmi6kuna	92	38	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	92	39	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	92	40	revolutionized	revolutionize	VBD
work_izjlueimqneiljcxm4zmi6kuna	92	41	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	92	42	therapy	therapy	NN
work_izjlueimqneiljcxm4zmi6kuna	92	43	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	92	44	MM	MM	NNP
work_izjlueimqneiljcxm4zmi6kuna	92	45	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	92	46	formerly	formerly	RB
work_izjlueimqneiljcxm4zmi6kuna	92	47	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	92	48	hematologic	hematologic	JJ
work_izjlueimqneiljcxm4zmi6kuna	92	49	cancer	cancer	NN
work_izjlueimqneiljcxm4zmi6kuna	92	50	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	92	51	poor	poor	JJ
work_izjlueimqneiljcxm4zmi6kuna	92	52	progno-	progno-	JJ
work_izjlueimqneiljcxm4zmi6kuna	92	53	sis	sis	NN
work_izjlueimqneiljcxm4zmi6kuna	92	54	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	93	1	MM	MM	NNP
work_izjlueimqneiljcxm4zmi6kuna	93	2	is	be	VBZ
work_izjlueimqneiljcxm4zmi6kuna	93	3	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	93	4	plasma	plasma	NN
work_izjlueimqneiljcxm4zmi6kuna	93	5	cell	cell	NN
work_izjlueimqneiljcxm4zmi6kuna	93	6	proliferative	proliferative	JJ
work_izjlueimqneiljcxm4zmi6kuna	93	7	disorder	disorder	NN
work_izjlueimqneiljcxm4zmi6kuna	93	8	that	that	WDT
work_izjlueimqneiljcxm4zmi6kuna	93	9	leads	lead	VBZ
work_izjlueimqneiljcxm4zmi6kuna	93	10	to	to	IN
work_izjlueimqneiljcxm4zmi6kuna	93	11	an	an	DT
work_izjlueimqneiljcxm4zmi6kuna	93	12	accumulation	accumulation	NN
work_izjlueimqneiljcxm4zmi6kuna	93	13	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	93	14	neoplastic	neoplastic	JJ
work_izjlueimqneiljcxm4zmi6kuna	93	15	cells	cell	NNS
work_izjlueimqneiljcxm4zmi6kuna	93	16	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	93	17	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	93	18	solid	solid	JJ
work_izjlueimqneiljcxm4zmi6kuna	93	19	tumor	tumor	NN
work_izjlueimqneiljcxm4zmi6kuna	93	20	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	93	21	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	93	22	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	93	23	bone	bone	NN
work_izjlueimqneiljcxm4zmi6kuna	93	24	marrow	marrow	NN
work_izjlueimqneiljcxm4zmi6kuna	93	25	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	94	1	The	the	DT
work_izjlueimqneiljcxm4zmi6kuna	94	2	bene-	bene-	JJ
work_izjlueimqneiljcxm4zmi6kuna	94	3	ficial	ficial	JJ
work_izjlueimqneiljcxm4zmi6kuna	94	4	effects	effect	NNS
work_izjlueimqneiljcxm4zmi6kuna	94	5	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	94	6	thalidomide-	thalidomide-	NN
work_izjlueimqneiljcxm4zmi6kuna	94	7	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	94	8	lenalidomide-	lenalidomide-	JJ
work_izjlueimqneiljcxm4zmi6kuna	94	9	combined	combined	JJ
work_izjlueimqneiljcxm4zmi6kuna	94	10	therapies	therapy	NNS
work_izjlueimqneiljcxm4zmi6kuna	94	11	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	94	12	MM	MM	NNP
work_izjlueimqneiljcxm4zmi6kuna	94	13	patients	patient	NNS
work_izjlueimqneiljcxm4zmi6kuna	94	14	apparently	apparently	RB
work_izjlueimqneiljcxm4zmi6kuna	94	15	arise	arise	VBP
work_izjlueimqneiljcxm4zmi6kuna	94	16	from	from	IN
work_izjlueimqneiljcxm4zmi6kuna	94	17	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	94	18	dual	dual	JJ
work_izjlueimqneiljcxm4zmi6kuna	94	19	mechanism	mechanism	NN
work_izjlueimqneiljcxm4zmi6kuna	94	20	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	94	21	action	action	NN
work_izjlueimqneiljcxm4zmi6kuna	94	22	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	94	23	while	while	IN
work_izjlueimqneiljcxm4zmi6kuna	94	24	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	94	25	antiangiogenic	antiangiogenic	JJ
work_izjlueimqneiljcxm4zmi6kuna	94	26	activity	activity	NN
work_izjlueimqneiljcxm4zmi6kuna	94	27	rapidly	rapidly	RB
work_izjlueimqneiljcxm4zmi6kuna	94	28	reduces	reduce	VBZ
work_izjlueimqneiljcxm4zmi6kuna	94	29	MM	MM	NNP
work_izjlueimqneiljcxm4zmi6kuna	94	30	burden	burden	NN
work_izjlueimqneiljcxm4zmi6kuna	94	31	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	94	32	their	-PRON-	PRP$
work_izjlueimqneiljcxm4zmi6kuna	94	33	long	long	JJ
work_izjlueimqneiljcxm4zmi6kuna	94	34	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	94	35	term	term	NN
work_izjlueimqneiljcxm4zmi6kuna	94	36	immunomodulatory	immunomodulatory	JJ
work_izjlueimqneiljcxm4zmi6kuna	94	37	actions	action	NNS
work_izjlueimqneiljcxm4zmi6kuna	94	38	seems	seem	VBZ
work_izjlueimqneiljcxm4zmi6kuna	94	39	to	to	TO
work_izjlueimqneiljcxm4zmi6kuna	94	40	maintain	maintain	VB
work_izjlueimqneiljcxm4zmi6kuna	94	41	tumor	tumor	NN
work_izjlueimqneiljcxm4zmi6kuna	94	42	suppression17	suppression17	NNP
work_izjlueimqneiljcxm4zmi6kuna	94	43	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	95	1	Effective	effective	JJ
work_izjlueimqneiljcxm4zmi6kuna	95	2	therapeutic	therapeutic	NN
work_izjlueimqneiljcxm4zmi6kuna	95	3	regimens	regimen	NNS
work_izjlueimqneiljcxm4zmi6kuna	95	4	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	95	5	MM	MM	NNP
work_izjlueimqneiljcxm4zmi6kuna	95	6	usually	usually	RB
work_izjlueimqneiljcxm4zmi6kuna	95	7	also	also	RB
work_izjlueimqneiljcxm4zmi6kuna	95	8	include	include	VBP
work_izjlueimqneiljcxm4zmi6kuna	95	9	an	an	DT
work_izjlueimqneiljcxm4zmi6kuna	95	10	antimitotic	antimitotic	JJ
work_izjlueimqneiljcxm4zmi6kuna	95	11	drug	drug	NN
work_izjlueimqneiljcxm4zmi6kuna	95	12	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	95	13	e.g.	e.g.	NNP
work_izjlueimqneiljcxm4zmi6kuna	95	14	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	95	15	melphalan	melphalan	NNP
work_izjlueimqneiljcxm4zmi6kuna	95	16	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	95	17	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	95	18	potent	potent	JJ
work_izjlueimqneiljcxm4zmi6kuna	95	19	nitrogen	nitrogen	NN
work_izjlueimqneiljcxm4zmi6kuna	95	20	mustard	mustard	NN
work_izjlueimqneiljcxm4zmi6kuna	95	21	related	related	JJ
work_izjlueimqneiljcxm4zmi6kuna	95	22	alkylating	alkylate	VBG
work_izjlueimqneiljcxm4zmi6kuna	95	23	agent	agent	NN
work_izjlueimqneiljcxm4zmi6kuna	95	24	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	95	25	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	95	26	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	95	27	glucocorticoid	glucocorticoid	NN
work_izjlueimqneiljcxm4zmi6kuna	95	28	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	95	29	e.g.	e.g.	RB
work_izjlueimqneiljcxm4zmi6kuna	95	30	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	95	31	dexamethasone	dexamethasone	NN
work_izjlueimqneiljcxm4zmi6kuna	95	32	or	or	CC
work_izjlueimqneiljcxm4zmi6kuna	95	33	prednisone	prednisone	NN
work_izjlueimqneiljcxm4zmi6kuna	95	34	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	95	35	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	96	1	Comparative	comparative	JJ
work_izjlueimqneiljcxm4zmi6kuna	96	2	effectiveness	effectiveness	NN
work_izjlueimqneiljcxm4zmi6kuna	96	3	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	96	4	thalidomide-	thalidomide-	NN
work_izjlueimqneiljcxm4zmi6kuna	96	5	versus	versus	IN
work_izjlueimqneiljcxm4zmi6kuna	96	6	lenalidomide	lenalidomide	RB
work_izjlueimqneiljcxm4zmi6kuna	96	7	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	96	8	based	base	VBN
work_izjlueimqneiljcxm4zmi6kuna	96	9	therapies	therapy	NNS
work_izjlueimqneiljcxm4zmi6kuna	96	10	Although	although	IN
work_izjlueimqneiljcxm4zmi6kuna	96	11	presenting	present	VBG
work_izjlueimqneiljcxm4zmi6kuna	96	12	similar	similar	JJ
work_izjlueimqneiljcxm4zmi6kuna	96	13	biological	biological	JJ
work_izjlueimqneiljcxm4zmi6kuna	96	14	activ-	activ-	JJ
work_izjlueimqneiljcxm4zmi6kuna	96	15	ities	itie	NNS
work_izjlueimqneiljcxm4zmi6kuna	96	16	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	96	17	lenalidomide	lenalidomide	VB
work_izjlueimqneiljcxm4zmi6kuna	96	18	is	be	VBZ
work_izjlueimqneiljcxm4zmi6kuna	96	19	more	more	RBR
work_izjlueimqneiljcxm4zmi6kuna	96	20	potent	potent	JJ
work_izjlueimqneiljcxm4zmi6kuna	96	21	than	than	IN
work_izjlueimqneiljcxm4zmi6kuna	96	22	thalido-	thalido-	NNP
work_izjlueimqneiljcxm4zmi6kuna	96	23	mide	mide	NNP
work_izjlueimqneiljcxm4zmi6kuna	96	24	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	96	25	i.e.	i.e.	FW
work_izjlueimqneiljcxm4zmi6kuna	96	26	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	96	27	it	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	96	28	achieves	achieve	VBZ
work_izjlueimqneiljcxm4zmi6kuna	96	29	responses	response	NNS
work_izjlueimqneiljcxm4zmi6kuna	96	30	at	at	IN
work_izjlueimqneiljcxm4zmi6kuna	96	31	lower	low	JJR
work_izjlueimqneiljcxm4zmi6kuna	96	32	doses	dose	NNS
work_izjlueimqneiljcxm4zmi6kuna	96	33	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	97	1	Higher	high	JJR
work_izjlueimqneiljcxm4zmi6kuna	97	2	potency	potency	NN
work_izjlueimqneiljcxm4zmi6kuna	97	3	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	97	4	however	however	RB
work_izjlueimqneiljcxm4zmi6kuna	97	5	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	97	6	does	do	VBZ
work_izjlueimqneiljcxm4zmi6kuna	97	7	not	not	RB
work_izjlueimqneiljcxm4zmi6kuna	97	8	imply	imply	VB
work_izjlueimqneiljcxm4zmi6kuna	97	9	greater	great	JJR
work_izjlueimqneiljcxm4zmi6kuna	97	10	clinical	clinical	JJ
work_izjlueimqneiljcxm4zmi6kuna	97	11	efficacy	efficacy	NN
work_izjlueimqneiljcxm4zmi6kuna	97	12	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	97	13	two	two	CD
work_izjlueimqneiljcxm4zmi6kuna	97	14	drugs	drug	NNS
work_izjlueimqneiljcxm4zmi6kuna	97	15	may	may	MD
work_izjlueimqneiljcxm4zmi6kuna	97	16	have	have	VB
work_izjlueimqneiljcxm4zmi6kuna	97	17	different	different	JJ
work_izjlueimqneiljcxm4zmi6kuna	97	18	potencies	potency	NNS
work_izjlueimqneiljcxm4zmi6kuna	97	19	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	97	20	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	97	21	same	same	JJ
work_izjlueimqneiljcxm4zmi6kuna	97	22	efficacy	efficacy	NN
work_izjlueimqneiljcxm4zmi6kuna	97	23	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	98	1	To	to	IN
work_izjlueimqneiljcxm4zmi6kuna	98	2	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	98	3	best	good	JJS
work_izjlueimqneiljcxm4zmi6kuna	98	4	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	98	5	our	-PRON-	PRP$
work_izjlueimqneiljcxm4zmi6kuna	98	6	knowledge	knowledge	NN
work_izjlueimqneiljcxm4zmi6kuna	98	7	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	98	8	only	only	RB
work_izjlueimqneiljcxm4zmi6kuna	98	9	two	two	CD
work_izjlueimqneiljcxm4zmi6kuna	98	10	ran-	ran-	NN
work_izjlueimqneiljcxm4zmi6kuna	98	11	domized	domize	VBN
work_izjlueimqneiljcxm4zmi6kuna	98	12	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	98	13	phase	phase	NN
work_izjlueimqneiljcxm4zmi6kuna	98	14	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	98	15	III	iii	NN
work_izjlueimqneiljcxm4zmi6kuna	98	16	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	98	17	trials	trial	NNS
work_izjlueimqneiljcxm4zmi6kuna	98	18	have	have	VBP
work_izjlueimqneiljcxm4zmi6kuna	98	19	compared	compare	VBN
work_izjlueimqneiljcxm4zmi6kuna	98	20	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	98	21	ef-	ef-	JJ
work_izjlueimqneiljcxm4zmi6kuna	98	22	fectiveness	fectiveness	NN
work_izjlueimqneiljcxm4zmi6kuna	98	23	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	98	24	thalidomide	thalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	98	25	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	98	26	based	base	VBN
work_izjlueimqneiljcxm4zmi6kuna	98	27	versus	versus	IN
work_izjlueimqneiljcxm4zmi6kuna	98	28	lenalid-	lenalid-	NNP
work_izjlueimqneiljcxm4zmi6kuna	98	29	omide	omide	NN
work_izjlueimqneiljcxm4zmi6kuna	98	30	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	98	31	based	base	VBN
work_izjlueimqneiljcxm4zmi6kuna	98	32	therapeutic	therapeutic	NN
work_izjlueimqneiljcxm4zmi6kuna	98	33	regimens	regimen	NNS
work_izjlueimqneiljcxm4zmi6kuna	98	34	so	so	RB
work_izjlueimqneiljcxm4zmi6kuna	98	35	far	far	RB
work_izjlueimqneiljcxm4zmi6kuna	98	36	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	98	37	Table	table	NN
work_izjlueimqneiljcxm4zmi6kuna	98	38	1	1	CD
work_izjlueimqneiljcxm4zmi6kuna	98	39	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	98	40	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	99	1	Stewart	Stewart	NNP
work_izjlueimqneiljcxm4zmi6kuna	99	2	et	et	NNP
work_izjlueimqneiljcxm4zmi6kuna	99	3	al.18	al.18	NNP
work_izjlueimqneiljcxm4zmi6kuna	99	4	conducted	conduct	VBD
work_izjlueimqneiljcxm4zmi6kuna	99	5	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	99	6	phase	phase	NN
work_izjlueimqneiljcxm4zmi6kuna	99	7	III	iii	CD
work_izjlueimqneiljcxm4zmi6kuna	99	8	RTC	RTC	NNP
work_izjlueimqneiljcxm4zmi6kuna	99	9	to	to	TO
work_izjlueimqneiljcxm4zmi6kuna	99	10	compare	compare	VB
work_izjlueimqneiljcxm4zmi6kuna	99	11	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	99	12	with	with	IN
work_izjlueimqneiljcxm4zmi6kuna	99	13	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	99	14	non	non	JJ
work_izjlueimqneiljcxm4zmi6kuna	99	15	-	-	JJ
work_izjlueimqneiljcxm4zmi6kuna	99	16	inferiority	inferiority	JJ
work_izjlueimqneiljcxm4zmi6kuna	99	17	design	design	NN
work_izjlueimqneiljcxm4zmi6kuna	99	18	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	99	19	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	99	20	“	"	``
work_izjlueimqneiljcxm4zmi6kuna	99	21	mel-	mel-	NNP
work_izjlueimqneiljcxm4zmi6kuna	99	22	phalan	phalan	NN
work_izjlueimqneiljcxm4zmi6kuna	99	23	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	99	24	prednisone	prednisone	NN
work_izjlueimqneiljcxm4zmi6kuna	99	25	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	99	26	thalidomide	thalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	99	27	”	"	''
work_izjlueimqneiljcxm4zmi6kuna	99	28	induction	induction	NN
work_izjlueimqneiljcxm4zmi6kuna	99	29	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	99	30	maintenance	maintenance	NN
work_izjlueimqneiljcxm4zmi6kuna	99	31	with	with	IN
work_izjlueimqneiljcxm4zmi6kuna	99	32	thalidomide	thalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	99	33	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	99	34	MPT	MPT	NNP
work_izjlueimqneiljcxm4zmi6kuna	99	35	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	99	36	T	T	NNP
work_izjlueimqneiljcxm4zmi6kuna	99	37	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	99	38	with	with	IN
work_izjlueimqneiljcxm4zmi6kuna	99	39	“	"	``
work_izjlueimqneiljcxm4zmi6kuna	99	40	melphalan	melphalan	NNP
work_izjlueimqneiljcxm4zmi6kuna	99	41	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	99	42	prednisone	prednisone	NN
work_izjlueimqneiljcxm4zmi6kuna	99	43	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	99	44	lenalidomide	lenalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	99	45	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	99	46	Revlim-	Revlim-	NNP
work_izjlueimqneiljcxm4zmi6kuna	99	47	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	99	48	d	d	XX
work_izjlueimqneiljcxm4zmi6kuna	99	49	®	®	NNPS
work_izjlueimqneiljcxm4zmi6kuna	99	50	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	99	51	”	"	''
work_izjlueimqneiljcxm4zmi6kuna	99	52	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	99	53	maintenance	maintenance	VB
work_izjlueimqneiljcxm4zmi6kuna	99	54	with	with	IN
work_izjlueimqneiljcxm4zmi6kuna	99	55	lenalidomide	lenalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	99	56	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	99	57	MPR	MPR	NNP
work_izjlueimqneiljcxm4zmi6kuna	99	58	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	99	59	R	R	NNP
work_izjlueimqneiljcxm4zmi6kuna	99	60	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	99	61	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	99	62	elderly	elderly	JJ
work_izjlueimqneiljcxm4zmi6kuna	99	63	patients	patient	NNS
work_izjlueimqneiljcxm4zmi6kuna	99	64	with	with	IN
work_izjlueimqneiljcxm4zmi6kuna	99	65	untreated	untreated	JJ
work_izjlueimqneiljcxm4zmi6kuna	99	66	MM	mm	NN
work_izjlueimqneiljcxm4zmi6kuna	99	67	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	100	1	Results	result	NNS
work_izjlueimqneiljcxm4zmi6kuna	100	2	showed	show	VBD
work_izjlueimqneiljcxm4zmi6kuna	100	3	that	that	IN
work_izjlueimqneiljcxm4zmi6kuna	100	4	there	there	EX
work_izjlueimqneiljcxm4zmi6kuna	100	5	was	be	VBD
work_izjlueimqneiljcxm4zmi6kuna	100	6	no	no	DT
work_izjlueimqneiljcxm4zmi6kuna	100	7	difference	difference	NN
work_izjlueimqneiljcxm4zmi6kuna	100	8	be-	be-	XX
work_izjlueimqneiljcxm4zmi6kuna	100	9	tween	tween	NN
work_izjlueimqneiljcxm4zmi6kuna	100	10	MPT	MPT	NNP
work_izjlueimqneiljcxm4zmi6kuna	100	11	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	100	12	T	T	NNP
work_izjlueimqneiljcxm4zmi6kuna	100	13	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	100	14	MPR	MPR	NNP
work_izjlueimqneiljcxm4zmi6kuna	100	15	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	100	16	R	R	NNP
work_izjlueimqneiljcxm4zmi6kuna	100	17	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	100	18	response	response	NN
work_izjlueimqneiljcxm4zmi6kuna	100	19	rates	rate	NNS
work_izjlueimqneiljcxm4zmi6kuna	100	20	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	100	21	pro-	pro-	NN
work_izjlueimqneiljcxm4zmi6kuna	100	22	gression	gression	NN
work_izjlueimqneiljcxm4zmi6kuna	100	23	free	free	JJ
work_izjlueimqneiljcxm4zmi6kuna	100	24	survival	survival	NN
work_izjlueimqneiljcxm4zmi6kuna	100	25	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	100	26	PFS	PFS	NNP
work_izjlueimqneiljcxm4zmi6kuna	100	27	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	100	28	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	100	29	overall	overall	JJ
work_izjlueimqneiljcxm4zmi6kuna	100	30	survival	survival	NN
work_izjlueimqneiljcxm4zmi6kuna	100	31	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	101	1	MPR	MPR	NNP
work_izjlueimqneiljcxm4zmi6kuna	101	2	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	101	3	R	R	NNP
work_izjlueimqneiljcxm4zmi6kuna	101	4	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	101	5	however	however	RB
work_izjlueimqneiljcxm4zmi6kuna	101	6	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	101	7	presented	present	VBD
work_izjlueimqneiljcxm4zmi6kuna	101	8	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	101	9	lower	low	JJR
work_izjlueimqneiljcxm4zmi6kuna	101	10	occurrence	occurrence	NN
work_izjlueimqneiljcxm4zmi6kuna	101	11	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	101	12	peripheral	peripheral	JJ
work_izjlueimqneiljcxm4zmi6kuna	101	13	neuropathy	neuropathy	JJ
work_izjlueimqneiljcxm4zmi6kuna	101	14	side	side	NN
work_izjlueimqneiljcxm4zmi6kuna	101	15	effects	effect	NNS
work_izjlueimqneiljcxm4zmi6kuna	101	16	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	101	17	Table	table	NN
work_izjlueimqneiljcxm4zmi6kuna	101	18	1	1	CD
work_izjlueimqneiljcxm4zmi6kuna	101	19	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	101	20	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	102	1	A	a	DT
work_izjlueimqneiljcxm4zmi6kuna	102	2	similarly	similarly	RB
work_izjlueimqneiljcxm4zmi6kuna	102	3	designed	design	VBN
work_izjlueimqneiljcxm4zmi6kuna	102	4	multicenter	multicenter	NN
work_izjlueimqneiljcxm4zmi6kuna	102	5	open	open	JJ
work_izjlueimqneiljcxm4zmi6kuna	102	6	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	102	7	label	label	NN
work_izjlueimqneiljcxm4zmi6kuna	102	8	RCT	RCT	NNP
work_izjlueimqneiljcxm4zmi6kuna	102	9	by	by	IN
work_izjlueimqneiljcxm4zmi6kuna	102	10	Zweegman	Zweegman	NNP
work_izjlueimqneiljcxm4zmi6kuna	102	11	et	et	NNP
work_izjlueimqneiljcxm4zmi6kuna	102	12	al.19	al.19	NNP
work_izjlueimqneiljcxm4zmi6kuna	102	13	compared	compare	VBD
work_izjlueimqneiljcxm4zmi6kuna	102	14	MPT	MPT	NNP
work_izjlueimqneiljcxm4zmi6kuna	102	15	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	102	16	T	T	NNP
work_izjlueimqneiljcxm4zmi6kuna	102	17	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	102	18	MPR	MPR	NNP
work_izjlueimqneiljcxm4zmi6kuna	102	19	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	102	20	R	R	NNP
work_izjlueimqneiljcxm4zmi6kuna	102	21	regimens	regimen	NNS
work_izjlueimqneiljcxm4zmi6kuna	102	22	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	102	23	newly	newly	RB
work_izjlueimqneiljcxm4zmi6kuna	102	24	diagnosed	diagnose	VBN
work_izjlueimqneiljcxm4zmi6kuna	102	25	MM	MM	NNP
work_izjlueimqneiljcxm4zmi6kuna	102	26	pa-	pa-	NN
work_izjlueimqneiljcxm4zmi6kuna	102	27	tients	tient	NNS
work_izjlueimqneiljcxm4zmi6kuna	102	28	who	who	WP
work_izjlueimqneiljcxm4zmi6kuna	102	29	were	be	VBD
work_izjlueimqneiljcxm4zmi6kuna	102	30	ineligible	ineligible	JJ
work_izjlueimqneiljcxm4zmi6kuna	102	31	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	102	32	stem	stem	NN
work_izjlueimqneiljcxm4zmi6kuna	102	33	cell	cell	NN
work_izjlueimqneiljcxm4zmi6kuna	102	34	transplan-	transplan-	NN
work_izjlueimqneiljcxm4zmi6kuna	102	35	tation	tation	NN
work_izjlueimqneiljcxm4zmi6kuna	102	36	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	103	1	Again	again	RB
work_izjlueimqneiljcxm4zmi6kuna	103	2	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	103	3	this	this	DT
work_izjlueimqneiljcxm4zmi6kuna	103	4	second	second	JJ
work_izjlueimqneiljcxm4zmi6kuna	103	5	study	study	NN
work_izjlueimqneiljcxm4zmi6kuna	103	6	showed	show	VBD
work_izjlueimqneiljcxm4zmi6kuna	103	7	no	no	DT
work_izjlueimqneiljcxm4zmi6kuna	103	8	supe-	supe-	JJ
work_izjlueimqneiljcxm4zmi6kuna	103	9	riority	riority	NN
work_izjlueimqneiljcxm4zmi6kuna	103	10	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	103	11	MPR	MPR	NNP
work_izjlueimqneiljcxm4zmi6kuna	103	12	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	103	13	R	R	NNP
work_izjlueimqneiljcxm4zmi6kuna	103	14	over	over	IN
work_izjlueimqneiljcxm4zmi6kuna	103	15	MPT	MPT	NNP
work_izjlueimqneiljcxm4zmi6kuna	103	16	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	103	17	T	T	NNP
work_izjlueimqneiljcxm4zmi6kuna	103	18	regarding	regard	VBG
work_izjlueimqneiljcxm4zmi6kuna	103	19	clinical	clinical	JJ
work_izjlueimqneiljcxm4zmi6kuna	103	20	efficacy	efficacy	NN
work_izjlueimqneiljcxm4zmi6kuna	103	21	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	103	22	PFS	PFS	NNP
work_izjlueimqneiljcxm4zmi6kuna	103	23	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	103	24	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	104	1	The	the	DT
work_izjlueimqneiljcxm4zmi6kuna	104	2	trial	trial	NN
work_izjlueimqneiljcxm4zmi6kuna	104	3	found	find	VBD
work_izjlueimqneiljcxm4zmi6kuna	104	4	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	104	5	however	however	RB
work_izjlueimqneiljcxm4zmi6kuna	104	6	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	104	7	an	an	DT
work_izjlueimqneiljcxm4zmi6kuna	104	8	in-	in-	JJ
work_izjlueimqneiljcxm4zmi6kuna	104	9	creased	crease	VBN
work_izjlueimqneiljcxm4zmi6kuna	104	10	occurrence	occurrence	NN
work_izjlueimqneiljcxm4zmi6kuna	104	11	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	104	12	neuropathy	neuropathy	JJ
work_izjlueimqneiljcxm4zmi6kuna	104	13	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	104	14	MPT	MPT	NNP
work_izjlueimqneiljcxm4zmi6kuna	104	15	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	104	16	T	T	NNP
work_izjlueimqneiljcxm4zmi6kuna	104	17	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	104	18	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	104	19	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	104	20	hematologic	hematologic	JJ
work_izjlueimqneiljcxm4zmi6kuna	104	21	toxicity	toxicity	NN
work_izjlueimqneiljcxm4zmi6kuna	104	22	requiring	require	VBG
work_izjlueimqneiljcxm4zmi6kuna	104	23	growth	growth	NN
work_izjlueimqneiljcxm4zmi6kuna	104	24	factor	factor	NN
work_izjlueimqneiljcxm4zmi6kuna	104	25	support	support	NN
work_izjlueimqneiljcxm4zmi6kuna	104	26	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	104	27	MPR	MPR	NNP
work_izjlueimqneiljcxm4zmi6kuna	104	28	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	104	29	R	R	NNP
work_izjlueimqneiljcxm4zmi6kuna	104	30	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	104	31	Table	table	NN
work_izjlueimqneiljcxm4zmi6kuna	104	32	1	1	CD
work_izjlueimqneiljcxm4zmi6kuna	104	33	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	104	34	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	105	1	In	in	IN
work_izjlueimqneiljcxm4zmi6kuna	105	2	addition	addition	NN
work_izjlueimqneiljcxm4zmi6kuna	105	3	to	to	IN
work_izjlueimqneiljcxm4zmi6kuna	105	4	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	105	5	foregoing	foregoing	JJ
work_izjlueimqneiljcxm4zmi6kuna	105	6	RCTs	RCTs	NNP
work_izjlueimqneiljcxm4zmi6kuna	105	7	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	105	8	three	three	CD
work_izjlueimqneiljcxm4zmi6kuna	105	9	non	non	JJ
work_izjlueimqneiljcxm4zmi6kuna	105	10	-	-	JJ
work_izjlueimqneiljcxm4zmi6kuna	105	11	interventional	interventional	JJ
work_izjlueimqneiljcxm4zmi6kuna	105	12	studies	study	NNS
work_izjlueimqneiljcxm4zmi6kuna	105	13	also	also	RB
work_izjlueimqneiljcxm4zmi6kuna	105	14	addressed	address	VBD
work_izjlueimqneiljcxm4zmi6kuna	105	15	com-	com-	NN
work_izjlueimqneiljcxm4zmi6kuna	105	16	parative	parative	JJ
work_izjlueimqneiljcxm4zmi6kuna	105	17	effectiveness	effectiveness	NN
work_izjlueimqneiljcxm4zmi6kuna	105	18	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	105	19	thalidomide-	thalidomide-	NN
work_izjlueimqneiljcxm4zmi6kuna	105	20	versus	versus	IN
work_izjlueimqneiljcxm4zmi6kuna	105	21	lenalidomide	lenalidomide	RB
work_izjlueimqneiljcxm4zmi6kuna	105	22	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	105	23	based	base	VBN
work_izjlueimqneiljcxm4zmi6kuna	105	24	combination	combination	NN
work_izjlueimqneiljcxm4zmi6kuna	105	25	regimens	regimen	NNS
work_izjlueimqneiljcxm4zmi6kuna	105	26	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	105	27	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	105	28	therapy	therapy	NN
work_izjlueimqneiljcxm4zmi6kuna	105	29	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	105	30	MM	MM	NNP
work_izjlueimqneiljcxm4zmi6kuna	105	31	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	105	32	Table	table	NN
work_izjlueimqneiljcxm4zmi6kuna	105	33	1	1	CD
work_izjlueimqneiljcxm4zmi6kuna	105	34	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	105	35	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	106	1	A	a	DT
work_izjlueimqneiljcxm4zmi6kuna	106	2	retrospective	retrospective	JJ
work_izjlueimqneiljcxm4zmi6kuna	106	3	case	case	NN
work_izjlueimqneiljcxm4zmi6kuna	106	4	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	106	5	control	control	NN
work_izjlueimqneiljcxm4zmi6kuna	106	6	study	study	NN
work_izjlueimqneiljcxm4zmi6kuna	106	7	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	106	8	matched	match	VBN
work_izjlueimqneiljcxm4zmi6kuna	106	9	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	106	10	pair	pair	NN
work_izjlueimqneiljcxm4zmi6kuna	106	11	analysis	analysis	NN
work_izjlueimqneiljcxm4zmi6kuna	106	12	ad-	ad-	CC
work_izjlueimqneiljcxm4zmi6kuna	106	13	justed	juste	VBN
work_izjlueimqneiljcxm4zmi6kuna	106	14	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	106	15	age	age	NN
work_izjlueimqneiljcxm4zmi6kuna	106	16	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	106	17	sex	sex	NN
work_izjlueimqneiljcxm4zmi6kuna	106	18	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	106	19	transplantation	transplantation	NN
work_izjlueimqneiljcxm4zmi6kuna	106	20	status	status	NN
work_izjlueimqneiljcxm4zmi6kuna	106	21	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	106	22	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	106	23	dexamethasone	dexamethasone	NN
work_izjlueimqneiljcxm4zmi6kuna	106	24	dose	dose	VB
work_izjlueimqneiljcxm4zmi6kuna	106	25	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	106	26	by	by	IN
work_izjlueimqneiljcxm4zmi6kuna	106	27	Gay	Gay	NNP
work_izjlueimqneiljcxm4zmi6kuna	106	28	et	et	NNP
work_izjlueimqneiljcxm4zmi6kuna	106	29	al.20	al.20	NNP
work_izjlueimqneiljcxm4zmi6kuna	106	30	compared	compare	VBD
work_izjlueimqneiljcxm4zmi6kuna	106	31	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	106	32	efficacy	efficacy	NN
work_izjlueimqneiljcxm4zmi6kuna	106	33	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	106	34	safety	safety	NN
work_izjlueimqneiljcxm4zmi6kuna	106	35	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	106	36	“	"	``
work_izjlueimqneiljcxm4zmi6kuna	106	37	thalidomide	thalidomide	NNP
work_izjlueimqneiljcxm4zmi6kuna	106	38	plus	plus	CC
work_izjlueimqneiljcxm4zmi6kuna	106	39	dexamethasone	dexamethasone	NN
work_izjlueimqneiljcxm4zmi6kuna	106	40	”	"	''
work_izjlueimqneiljcxm4zmi6kuna	106	41	versus	versus	IN
work_izjlueimqneiljcxm4zmi6kuna	106	42	“	"	``
work_izjlueimqneiljcxm4zmi6kuna	106	43	lenalidomide	lenalidomide	NNP
work_izjlueimqneiljcxm4zmi6kuna	106	44	plus	plus	CC
work_izjlueimqneiljcxm4zmi6kuna	106	45	dexa-	dexa-	JJ
work_izjlueimqneiljcxm4zmi6kuna	106	46	methasone	methasone	NN
work_izjlueimqneiljcxm4zmi6kuna	106	47	”	"	''
work_izjlueimqneiljcxm4zmi6kuna	106	48	as	as	IN
work_izjlueimqneiljcxm4zmi6kuna	106	49	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	106	50	initial	initial	JJ
work_izjlueimqneiljcxm4zmi6kuna	106	51	therapy	therapy	NN
work_izjlueimqneiljcxm4zmi6kuna	106	52	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	106	53	newly	newly	RB
work_izjlueimqneiljcxm4zmi6kuna	106	54	di-	di-	XX
work_izjlueimqneiljcxm4zmi6kuna	106	55	agnosed	agnose	VBN
work_izjlueimqneiljcxm4zmi6kuna	106	56	MM	MM	NNP
work_izjlueimqneiljcxm4zmi6kuna	106	57	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	107	1	The	the	DT
work_izjlueimqneiljcxm4zmi6kuna	107	2	authors	author	NNS
work_izjlueimqneiljcxm4zmi6kuna	107	3	concluded	conclude	VBD
work_izjlueimqneiljcxm4zmi6kuna	107	4	that	that	IN
work_izjlueimqneiljcxm4zmi6kuna	107	5	lena-	lena-	NN
work_izjlueimqneiljcxm4zmi6kuna	107	6	lidomide	lidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	107	7	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	107	8	dexamethasone	dexamethasone	NNP
work_izjlueimqneiljcxm4zmi6kuna	107	9	was	be	VBD
work_izjlueimqneiljcxm4zmi6kuna	107	10	well	well	RB
work_izjlueimqneiljcxm4zmi6kuna	107	11	tolerated	tolerate	VBN
work_izjlueimqneiljcxm4zmi6kuna	107	12	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	107	13	more	more	RBR
work_izjlueimqneiljcxm4zmi6kuna	107	14	effective	effective	JJ
work_izjlueimqneiljcxm4zmi6kuna	107	15	than	than	IN
work_izjlueimqneiljcxm4zmi6kuna	107	16	thalidomide	thalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	107	17	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	107	18	dexamethasone	dexamethasone	JJ
work_izjlueimqneiljcxm4zmi6kuna	107	19	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	108	1	This	this	DT
work_izjlueimqneiljcxm4zmi6kuna	108	2	retrospective	retrospective	JJ
work_izjlueimqneiljcxm4zmi6kuna	108	3	study	study	NN
work_izjlueimqneiljcxm4zmi6kuna	108	4	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	108	5	however	however	RB
work_izjlueimqneiljcxm4zmi6kuna	108	6	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	108	7	has	have	VBZ
work_izjlueimqneiljcxm4zmi6kuna	108	8	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	108	9	number	number	NN
work_izjlueimqneiljcxm4zmi6kuna	108	10	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	108	11	important	important	JJ
work_izjlueimqneiljcxm4zmi6kuna	108	12	methodological	methodological	JJ
work_izjlueimqneiljcxm4zmi6kuna	108	13	limitations	limitation	NNS
work_izjlueimqneiljcxm4zmi6kuna	108	14	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	108	15	includ-	includ-	NNP
work_izjlueimqneiljcxm4zmi6kuna	108	16	ing	e	VBG
work_izjlueimqneiljcxm4zmi6kuna	108	17	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	108	18	fact	fact	NN
work_izjlueimqneiljcxm4zmi6kuna	108	19	that	that	IN
work_izjlueimqneiljcxm4zmi6kuna	108	20	patients	patient	NNS
work_izjlueimqneiljcxm4zmi6kuna	108	21	treated	treat	VBN
work_izjlueimqneiljcxm4zmi6kuna	108	22	with	with	IN
work_izjlueimqneiljcxm4zmi6kuna	108	23	thalido-	thalido-	NNP
work_izjlueimqneiljcxm4zmi6kuna	108	24	mide	mide	NNP
work_izjlueimqneiljcxm4zmi6kuna	108	25	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	108	26	dexamethasone	dexamethasone	NNP
work_izjlueimqneiljcxm4zmi6kuna	108	27	received	receive	VBD
work_izjlueimqneiljcxm4zmi6kuna	108	28	different	different	JJ
work_izjlueimqneiljcxm4zmi6kuna	108	29	doses	dose	NNS
work_izjlueimqneiljcxm4zmi6kuna	108	30	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	108	31	thalidomide	thalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	108	32	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	109	1	It	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	109	2	is	be	VBZ
work_izjlueimqneiljcxm4zmi6kuna	109	3	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	109	4	note	note	NN
work_izjlueimqneiljcxm4zmi6kuna	109	5	that	that	IN
work_izjlueimqneiljcxm4zmi6kuna	109	6	nearly	nearly	RB
work_izjlueimqneiljcxm4zmi6kuna	109	7	all	all	DT
work_izjlueimqneiljcxm4zmi6kuna	109	8	authors	author	NNS
work_izjlueimqneiljcxm4zmi6kuna	109	9	informed	inform	VBN
work_izjlueimqneiljcxm4zmi6kuna	109	10	having	have	VBG
work_izjlueimqneiljcxm4zmi6kuna	109	11	received	receive	VBN
work_izjlueimqneiljcxm4zmi6kuna	109	12	honoraria	honorarium	NNS
work_izjlueimqneiljcxm4zmi6kuna	109	13	from	from	IN
work_izjlueimqneiljcxm4zmi6kuna	109	14	Cel-	Cel-	NNP
work_izjlueimqneiljcxm4zmi6kuna	109	15	gene	gene	NN
work_izjlueimqneiljcxm4zmi6kuna	109	16	®	®	.
work_izjlueimqneiljcxm4zmi6kuna	109	17	Co	co	NN
work_izjlueimqneiljcxm4zmi6kuna	109	18	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	109	19	their	-PRON-	PRP$
work_izjlueimqneiljcxm4zmi6kuna	109	20	conflict	conflict	NN
work_izjlueimqneiljcxm4zmi6kuna	109	21	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	109	22	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	109	23	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	109	24	interest	interest	NN
work_izjlueimqneiljcxm4zmi6kuna	109	25	disclosure	disclosure	NN
work_izjlueimqneiljcxm4zmi6kuna	109	26	statement	statement	NN
work_izjlueimqneiljcxm4zmi6kuna	109	27	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	110	1	An	an	DT
work_izjlueimqneiljcxm4zmi6kuna	110	2	observational	observational	JJ
work_izjlueimqneiljcxm4zmi6kuna	110	3	retrospective	retrospective	JJ
work_izjlueimqneiljcxm4zmi6kuna	110	4	study	study	NN
work_izjlueimqneiljcxm4zmi6kuna	110	5	conducted	conduct	VBN
work_izjlueimqneiljcxm4zmi6kuna	110	6	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	110	7	India	India	NNP
work_izjlueimqneiljcxm4zmi6kuna	110	8	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	110	9	analysis	analysis	NN
work_izjlueimqneiljcxm4zmi6kuna	110	10	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	110	11	medical	medical	JJ
work_izjlueimqneiljcxm4zmi6kuna	110	12	record	record	NN
work_izjlueimqneiljcxm4zmi6kuna	110	13	files	file	NNS
work_izjlueimqneiljcxm4zmi6kuna	110	14	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	110	15	compared	compare	VBD
work_izjlueimqneiljcxm4zmi6kuna	110	16	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	110	17	efficacy	efficacy	NN
work_izjlueimqneiljcxm4zmi6kuna	110	18	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	110	19	occurrence	occurrence	NN
work_izjlueimqneiljcxm4zmi6kuna	110	20	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	110	21	adverse	adverse	JJ
work_izjlueimqneiljcxm4zmi6kuna	110	22	events	event	NNS
work_izjlueimqneiljcxm4zmi6kuna	110	23	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	110	24	17	17	CD
work_izjlueimqneiljcxm4zmi6kuna	110	25	patients	patient	NNS
work_izjlueimqneiljcxm4zmi6kuna	110	26	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	110	27	newly	newly	RB
work_izjlueimqneiljcxm4zmi6kuna	110	28	diagnosed	diagnose	VBN
work_izjlueimqneiljcxm4zmi6kuna	110	29	MM	MM	NNP
work_izjlueimqneiljcxm4zmi6kuna	110	30	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	110	31	that	that	WDT
work_izjlueimqneiljcxm4zmi6kuna	110	32	had	have	VBD
work_izjlueimqneiljcxm4zmi6kuna	110	33	received	receive	VBN
work_izjlueimqneiljcxm4zmi6kuna	110	34	thalidomide	thalidomide	RB
work_izjlueimqneiljcxm4zmi6kuna	110	35	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	110	36	dexameth-	dexameth-	JJ
work_izjlueimqneiljcxm4zmi6kuna	110	37	asone	asone	NN
work_izjlueimqneiljcxm4zmi6kuna	110	38	with	with	IN
work_izjlueimqneiljcxm4zmi6kuna	110	39	19	19	CD
work_izjlueimqneiljcxm4zmi6kuna	110	40	patients	patient	NNS
work_izjlueimqneiljcxm4zmi6kuna	110	41	treated	treat	VBN
work_izjlueimqneiljcxm4zmi6kuna	110	42	with	with	IN
work_izjlueimqneiljcxm4zmi6kuna	110	43	lenalido-	lenalido-	JJ
work_izjlueimqneiljcxm4zmi6kuna	110	44	mide	mide	NN
work_izjlueimqneiljcxm4zmi6kuna	110	45	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	110	46	dexamethasone18	dexamethasone18	JJ
work_izjlueimqneiljcxm4zmi6kuna	110	47	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	111	1	The	the	DT
work_izjlueimqneiljcxm4zmi6kuna	111	2	authors	author	NNS
work_izjlueimqneiljcxm4zmi6kuna	111	3	found	find	VBD
work_izjlueimqneiljcxm4zmi6kuna	111	4	no	no	DT
work_izjlueimqneiljcxm4zmi6kuna	111	5	difference	difference	NN
work_izjlueimqneiljcxm4zmi6kuna	111	6	between	between	IN
work_izjlueimqneiljcxm4zmi6kuna	111	7	thalidomide-	thalidomide-	NN
work_izjlueimqneiljcxm4zmi6kuna	111	8	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	111	9	lenalido-	lenalido-	NNP
work_izjlueimqneiljcxm4zmi6kuna	111	10	mide	mide	NN
work_izjlueimqneiljcxm4zmi6kuna	111	11	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	111	12	based	base	VBN
work_izjlueimqneiljcxm4zmi6kuna	111	13	therapies	therapy	NNS
work_izjlueimqneiljcxm4zmi6kuna	111	14	with	with	IN
work_izjlueimqneiljcxm4zmi6kuna	111	15	respect	respect	NN
work_izjlueimqneiljcxm4zmi6kuna	111	16	to	to	IN
work_izjlueimqneiljcxm4zmi6kuna	111	17	efficacy	efficacy	NN
work_izjlueimqneiljcxm4zmi6kuna	111	18	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	111	19	safety21	safety21	NN
work_izjlueimqneiljcxm4zmi6kuna	111	20	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	112	1	A	a	DT
work_izjlueimqneiljcxm4zmi6kuna	112	2	recent	recent	JJ
work_izjlueimqneiljcxm4zmi6kuna	112	3	population	population	NN
work_izjlueimqneiljcxm4zmi6kuna	112	4	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	112	5	based	base	VBN
work_izjlueimqneiljcxm4zmi6kuna	112	6	cohort	cohort	NN
work_izjlueimqneiljcxm4zmi6kuna	112	7	study	study	NN
work_izjlueimqneiljcxm4zmi6kuna	112	8	by	by	IN
work_izjlueimqneiljcxm4zmi6kuna	112	9	Luo	Luo	NNP
work_izjlueimqneiljcxm4zmi6kuna	112	10	et	et	NNP
work_izjlueimqneiljcxm4zmi6kuna	112	11	al.22	al.22	CD
work_izjlueimqneiljcxm4zmi6kuna	112	12	compared	compare	VBN
work_izjlueimqneiljcxm4zmi6kuna	112	13	survival	survival	NN
work_izjlueimqneiljcxm4zmi6kuna	112	14	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	112	15	rates	rate	NNS
work_izjlueimqneiljcxm4zmi6kuna	112	16	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	112	17	pe-	pe-	CD
work_izjlueimqneiljcxm4zmi6kuna	112	18	ripheral	ripheral	JJ
work_izjlueimqneiljcxm4zmi6kuna	112	19	neuropathy	neuropathy	NN
work_izjlueimqneiljcxm4zmi6kuna	112	20	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	112	21	MM	MM	NNP
work_izjlueimqneiljcxm4zmi6kuna	112	22	patients	patient	NNS
work_izjlueimqneiljcxm4zmi6kuna	112	23	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	112	24	n	n	IN
work_izjlueimqneiljcxm4zmi6kuna	112	25	=	=	SYM
work_izjlueimqneiljcxm4zmi6kuna	112	26	1264	1264	CD
work_izjlueimqneiljcxm4zmi6kuna	112	27	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	112	28	receiving	receive	VBG
work_izjlueimqneiljcxm4zmi6kuna	112	29	either	either	CC
work_izjlueimqneiljcxm4zmi6kuna	112	30	thalidomide	thalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	112	31	or	or	CC
work_izjlueimqneiljcxm4zmi6kuna	112	32	lenalidomide	lenalidomide	VB
work_izjlueimqneiljcxm4zmi6kuna	112	33	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	112	34	routine	routine	JJ
work_izjlueimqneiljcxm4zmi6kuna	112	35	care	care	NN
work_izjlueimqneiljcxm4zmi6kuna	112	36	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	112	37	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	112	38	US	US	NNP
work_izjlueimqneiljcxm4zmi6kuna	112	39	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	113	1	The	the	DT
work_izjlueimqneiljcxm4zmi6kuna	113	2	study	study	NN
work_izjlueimqneiljcxm4zmi6kuna	113	3	found	find	VBD
work_izjlueimqneiljcxm4zmi6kuna	113	4	no	no	DT
work_izjlueimqneiljcxm4zmi6kuna	113	5	dif-	dif-	RB
work_izjlueimqneiljcxm4zmi6kuna	113	6	ference	ference	NN
work_izjlueimqneiljcxm4zmi6kuna	113	7	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	113	8	rates	rate	NNS
work_izjlueimqneiljcxm4zmi6kuna	113	9	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	113	10	death	death	NN
work_izjlueimqneiljcxm4zmi6kuna	113	11	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	113	12	hazard	hazard	NN
work_izjlueimqneiljcxm4zmi6kuna	113	13	ratio	ratio	NN
work_izjlueimqneiljcxm4zmi6kuna	113	14	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	113	15	95	95	CD
work_izjlueimqneiljcxm4zmi6kuna	113	16	%	%	NN
work_izjlueimqneiljcxm4zmi6kuna	113	17	CI	CI	NNP
work_izjlueimqneiljcxm4zmi6kuna	113	18	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	113	19	1.00	1.00	CD
work_izjlueimqneiljcxm4zmi6kuna	113	20	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	113	21	0.71	0.71	CD
work_izjlueimqneiljcxm4zmi6kuna	113	22	-	-	SYM
work_izjlueimqneiljcxm4zmi6kuna	113	23	1.41	1.41	CD
work_izjlueimqneiljcxm4zmi6kuna	113	24	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	113	25	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	113	26	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	113	27	lower	low	JJR
work_izjlueimqneiljcxm4zmi6kuna	113	28	risk	risk	NN
work_izjlueimqneiljcxm4zmi6kuna	113	29	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	113	30	peripheral	peripheral	JJ
work_izjlueimqneiljcxm4zmi6kuna	113	31	neuropathy	neuropathy	NN
work_izjlueimqneiljcxm4zmi6kuna	113	32	associated	associate	VBN
work_izjlueimqneiljcxm4zmi6kuna	113	33	with	with	IN
work_izjlueimqneiljcxm4zmi6kuna	113	34	lenalidomide	lenalidomide	JJ
work_izjlueimqneiljcxm4zmi6kuna	113	35	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	113	36	0.71	0.71	CD
work_izjlueimqneiljcxm4zmi6kuna	113	37	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	113	38	0.56	0.56	CD
work_izjlueimqneiljcxm4zmi6kuna	113	39	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	113	40	0.92	0.92	CD
work_izjlueimqneiljcxm4zmi6kuna	113	41	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	113	42	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	114	1	Overall	overall	RB
work_izjlueimqneiljcxm4zmi6kuna	114	2	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	114	3	available	available	JJ
work_izjlueimqneiljcxm4zmi6kuna	114	4	comparative	comparative	JJ
work_izjlueimqneiljcxm4zmi6kuna	114	5	effectiveness	effectiveness	NN
work_izjlueimqneiljcxm4zmi6kuna	114	6	studies	study	NNS
work_izjlueimqneiljcxm4zmi6kuna	114	7	showed	show	VBD
work_izjlueimqneiljcxm4zmi6kuna	114	8	no	no	DT
work_izjlueimqneiljcxm4zmi6kuna	114	9	difference	difference	NN
work_izjlueimqneiljcxm4zmi6kuna	114	10	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	114	11	efficacy	efficacy	NN
work_izjlueimqneiljcxm4zmi6kuna	114	12	between	between	IN
work_izjlueimqneiljcxm4zmi6kuna	114	13	lenalidomide-	lenalidomide-	NN
work_izjlueimqneiljcxm4zmi6kuna	114	14	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	114	15	thalidomide	thalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	114	16	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	114	17	based	base	VBN
work_izjlueimqneiljcxm4zmi6kuna	114	18	therapies	therapy	NNS
work_izjlueimqneiljcxm4zmi6kuna	114	19	3	3	CD
work_izjlueimqneiljcxm4zmi6kuna	114	20	7	7	CD
work_izjlueimqneiljcxm4zmi6kuna	114	21	8	8	CD
work_izjlueimqneiljcxm4zmi6kuna	114	22	8	8	CD
work_izjlueimqneiljcxm4zmi6kuna	114	23	P	p	NN
work_izjlueimqneiljcxm4zmi6kuna	114	24	au	au	NNP
work_izjlueimqneiljcxm4zmi6kuna	114	25	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	114	26	ga	ga	NNP
work_izjlueimqneiljcxm4zmi6kuna	114	27	rt	rt	NNP
work_izjlueimqneiljcxm4zmi6kuna	114	28	te	te	NNP
work_izjlueimqneiljcxm4zmi6kuna	114	29	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	114	30	F	F	NNP
work_izjlueimqneiljcxm4zmi6kuna	114	31	JR	JR	NNP
work_izjlueimqneiljcxm4zmi6kuna	114	32	T	T	NNP
work_izjlueimqneiljcxm4zmi6kuna	114	33	ab	ab	NNP
work_izjlueimqneiljcxm4zmi6kuna	114	34	le	le	NNP
work_izjlueimqneiljcxm4zmi6kuna	114	35	1	1	CD
work_izjlueimqneiljcxm4zmi6kuna	114	36	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	115	1	S	S	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	2	tu	tu	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	3	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	4	ie	ie	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	5	s	s	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	6	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	7	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	8	t	t	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	9	h	h	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	10	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	11	co	co	NN
work_izjlueimqneiljcxm4zmi6kuna	115	12	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	13	p	p	NN
work_izjlueimqneiljcxm4zmi6kuna	115	14	ar	ar	NN
work_izjlueimqneiljcxm4zmi6kuna	115	15	at	at	IN
work_izjlueimqneiljcxm4zmi6kuna	115	16	iv	iv	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	17	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	18	ef	ef	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	19	fe	fe	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	20	ct	ct	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	21	iv	iv	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	22	en	en	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	23	es	es	FW
work_izjlueimqneiljcxm4zmi6kuna	115	24	s	s	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	25	an	an	DT
work_izjlueimqneiljcxm4zmi6kuna	115	26	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	27	s	s	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	28	af	af	FW
work_izjlueimqneiljcxm4zmi6kuna	115	29	et	et	NN
work_izjlueimqneiljcxm4zmi6kuna	115	30	y	y	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	31	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	32	f	f	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	33	th	th	XX
work_izjlueimqneiljcxm4zmi6kuna	115	34	al	al	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	35	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	115	36	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	37	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	38	m	m	NN
work_izjlueimqneiljcxm4zmi6kuna	115	39	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	115	40	d	d	NN
work_izjlueimqneiljcxm4zmi6kuna	115	41	e-	e-	XX
work_izjlueimqneiljcxm4zmi6kuna	115	42	b	b	NN
work_izjlueimqneiljcxm4zmi6kuna	115	43	as	as	IN
work_izjlueimqneiljcxm4zmi6kuna	115	44	ed	ed	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	45	v	v	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	46	er	er	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	47	su	su	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	48	s	s	POS
work_izjlueimqneiljcxm4zmi6kuna	115	49	le	le	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	50	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	51	al	al	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	52	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	115	53	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	54	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	55	m	m	NN
work_izjlueimqneiljcxm4zmi6kuna	115	56	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	115	57	d	d	NN
work_izjlueimqneiljcxm4zmi6kuna	115	58	e-	e-	XX
work_izjlueimqneiljcxm4zmi6kuna	115	59	b	b	NN
work_izjlueimqneiljcxm4zmi6kuna	115	60	as	as	IN
work_izjlueimqneiljcxm4zmi6kuna	115	61	ed	ed	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	62	t	t	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	63	h	h	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	64	er	er	UH
work_izjlueimqneiljcxm4zmi6kuna	115	65	ap	ap	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	66	ie	ie	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	67	s	s	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	68	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	115	69	t	t	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	70	h	h	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	71	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	72	tr	tr	IN
work_izjlueimqneiljcxm4zmi6kuna	115	73	ea	ea	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	74	tm	tm	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	75	en	en	IN
work_izjlueimqneiljcxm4zmi6kuna	115	76	t	t	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	77	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	78	f	f	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	79	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	80	u	u	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	81	lt	lt	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	82	ip	ip	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	83	le	le	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	84	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	85	ye	ye	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	86	lo	lo	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	87	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	88	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	115	89	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	115	90	M	M	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	91	M	M	NNP
work_izjlueimqneiljcxm4zmi6kuna	115	92	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	115	93	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	116	1	A	a	DT
work_izjlueimqneiljcxm4zmi6kuna	116	2	u	u	NN
work_izjlueimqneiljcxm4zmi6kuna	116	3	th	th	NN
work_izjlueimqneiljcxm4zmi6kuna	116	4	o	o	NN
work_izjlueimqneiljcxm4zmi6kuna	116	5	rs	rs	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	6	/	/	SYM
work_izjlueimqneiljcxm4zmi6kuna	116	7	ye	ye	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	8	ar	ar	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	9	s	s	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	10	tu	tu	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	11	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	12	y	y	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	13	ty	ty	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	14	p	p	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	15	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	16	s	s	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	17	tu	tu	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	18	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	19	y	y	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	20	p	p	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	21	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	22	p	p	NN
work_izjlueimqneiljcxm4zmi6kuna	116	23	u	u	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	24	la	la	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	25	ti	ti	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	26	o	o	NN
work_izjlueimqneiljcxm4zmi6kuna	116	27	n	n	NN
work_izjlueimqneiljcxm4zmi6kuna	116	28	C	C	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	29	o	o	NN
work_izjlueimqneiljcxm4zmi6kuna	116	30	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	31	p	p	NN
work_izjlueimqneiljcxm4zmi6kuna	116	32	ar	ar	NN
work_izjlueimqneiljcxm4zmi6kuna	116	33	ed	ed	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	34	t	t	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	35	h	h	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	36	er	er	UH
work_izjlueimqneiljcxm4zmi6kuna	116	37	ap	ap	UH
work_izjlueimqneiljcxm4zmi6kuna	116	38	ie	ie	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	39	s	s	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	40	C	C	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	41	li	li	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	42	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	43	ic	ic	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	44	al	al	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	45	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	46	u	u	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	47	tc	tc	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	48	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	49	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	50	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	51	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	52	ffi	ffi	NN
work_izjlueimqneiljcxm4zmi6kuna	116	53	ca	ca	MD
work_izjlueimqneiljcxm4zmi6kuna	116	54	cy	cy	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	55	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	56	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	57	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	58	p	p	NN
work_izjlueimqneiljcxm4zmi6kuna	116	59	o	o	NN
work_izjlueimqneiljcxm4zmi6kuna	116	60	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	116	61	ts	ts	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	62	s	s	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	63	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	116	64	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	65	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	66	ef	ef	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	67	fe	fe	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	68	ct	ct	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	69	s	s	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	70	St	St	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	71	ew	ew	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	72	ar	ar	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	73	t	t	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	74	et	et	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	75	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	116	76	l.	l.	NN
work_izjlueimqneiljcxm4zmi6kuna	116	77	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	116	78	2	2	CD
work_izjlueimqneiljcxm4zmi6kuna	116	79	0	0	CD
work_izjlueimqneiljcxm4zmi6kuna	116	80	1	1	CD
work_izjlueimqneiljcxm4zmi6kuna	116	81	5	5	CD
work_izjlueimqneiljcxm4zmi6kuna	116	82	1	1	CD
work_izjlueimqneiljcxm4zmi6kuna	116	83	8	8	CD
work_izjlueimqneiljcxm4zmi6kuna	116	84	P	p	NN
work_izjlueimqneiljcxm4zmi6kuna	116	85	h	h	NN
work_izjlueimqneiljcxm4zmi6kuna	116	86	as	as	IN
work_izjlueimqneiljcxm4zmi6kuna	116	87	e	e	NN
work_izjlueimqneiljcxm4zmi6kuna	116	88	II	II	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	89	I	i	NN
work_izjlueimqneiljcxm4zmi6kuna	116	90	R	r	NN
work_izjlueimqneiljcxm4zmi6kuna	116	91	an	an	DT
work_izjlueimqneiljcxm4zmi6kuna	116	92	d	d	NN
work_izjlueimqneiljcxm4zmi6kuna	116	93	o	o	NN
work_izjlueimqneiljcxm4zmi6kuna	116	94	m	m	NN
work_izjlueimqneiljcxm4zmi6kuna	116	95	iz	iz	NN
work_izjlueimqneiljcxm4zmi6kuna	116	96	ed	ed	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	97	C	C	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	98	o	o	NN
work_izjlueimqneiljcxm4zmi6kuna	116	99	n	n	CC
work_izjlueimqneiljcxm4zmi6kuna	116	100	tr	tr	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	101	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	102	ll	will	NN
work_izjlueimqneiljcxm4zmi6kuna	116	103	ed	ed	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	104	T	T	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	105	ri	ri	FW
work_izjlueimqneiljcxm4zmi6kuna	116	106	al	al	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	107	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	116	108	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	109	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	110	n	n	NN
work_izjlueimqneiljcxm4zmi6kuna	116	111	-i	-i	:
work_izjlueimqneiljcxm4zmi6kuna	116	112	n	n	LS
work_izjlueimqneiljcxm4zmi6kuna	116	113	fe	fe	FW
work_izjlueimqneiljcxm4zmi6kuna	116	114	ri	ri	FW
work_izjlueimqneiljcxm4zmi6kuna	116	115	o	o	FW
work_izjlueimqneiljcxm4zmi6kuna	116	116	ri	ri	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	117	ty	ty	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	118	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	119	es	es	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	120	ig	ig	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	121	n	n	JJ
work_izjlueimqneiljcxm4zmi6kuna	116	122	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	116	123	E	e	NN
work_izjlueimqneiljcxm4zmi6kuna	116	124	ld	ld	UH
work_izjlueimqneiljcxm4zmi6kuna	116	125	er	er	UH
work_izjlueimqneiljcxm4zmi6kuna	116	126	ly	ly	XX
work_izjlueimqneiljcxm4zmi6kuna	116	127	p	p	NN
work_izjlueimqneiljcxm4zmi6kuna	116	128	at	at	IN
work_izjlueimqneiljcxm4zmi6kuna	116	129	ie	ie	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	130	n	n	CC
work_izjlueimqneiljcxm4zmi6kuna	116	131	ts	ts	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	132	w	w	NN
work_izjlueimqneiljcxm4zmi6kuna	116	133	it	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	116	134	h	h	VBZ
work_izjlueimqneiljcxm4zmi6kuna	116	135	u	u	CC
work_izjlueimqneiljcxm4zmi6kuna	116	136	n	n	CC
work_izjlueimqneiljcxm4zmi6kuna	116	137	tr	tr	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	138	ea	ea	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	139	te	te	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	140	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	141	M	m	NN
work_izjlueimqneiljcxm4zmi6kuna	116	142	M	m	NN
work_izjlueimqneiljcxm4zmi6kuna	116	143	M	M	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	144	P	p	NN
work_izjlueimqneiljcxm4zmi6kuna	116	145	T	t	NN
work_izjlueimqneiljcxm4zmi6kuna	116	146	-T	-T	:
work_izjlueimqneiljcxm4zmi6kuna	116	147	v	v	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	148	er	er	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	149	su	su	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	150	s	s	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	151	M	M	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	152	P	P	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	153	R	r	NN
work_izjlueimqneiljcxm4zmi6kuna	116	154	-R	-r	NN
work_izjlueimqneiljcxm4zmi6kuna	116	155	N	n	NN
work_izjlueimqneiljcxm4zmi6kuna	116	156	o	o	NN
work_izjlueimqneiljcxm4zmi6kuna	116	157	d	d	NN
work_izjlueimqneiljcxm4zmi6kuna	116	158	if	if	IN
work_izjlueimqneiljcxm4zmi6kuna	116	159	fe	fe	FW
work_izjlueimqneiljcxm4zmi6kuna	116	160	re	re	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	161	n	n	CC
work_izjlueimqneiljcxm4zmi6kuna	116	162	ce	ce	XX
work_izjlueimqneiljcxm4zmi6kuna	116	163	i	i	PRP
work_izjlueimqneiljcxm4zmi6kuna	116	164	n	n	CC
work_izjlueimqneiljcxm4zmi6kuna	116	165	R	r	NN
work_izjlueimqneiljcxm4zmi6kuna	116	166	R	r	NN
work_izjlueimqneiljcxm4zmi6kuna	116	167	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	116	168	P	P	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	169	F	F	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	170	S	S	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	171	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	116	172	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	116	173	n	n	NN
work_izjlueimqneiljcxm4zmi6kuna	116	174	d	d	NN
work_izjlueimqneiljcxm4zmi6kuna	116	175	O	o	NN
work_izjlueimqneiljcxm4zmi6kuna	116	176	S	s	NN
work_izjlueimqneiljcxm4zmi6kuna	116	177	M	m	NN
work_izjlueimqneiljcxm4zmi6kuna	116	178	P	p	NN
work_izjlueimqneiljcxm4zmi6kuna	116	179	R	r	NN
work_izjlueimqneiljcxm4zmi6kuna	116	180	-R	-R	:
work_izjlueimqneiljcxm4zmi6kuna	116	181	:	:	:
work_izjlueimqneiljcxm4zmi6kuna	116	182	l	l	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	183	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	184	w	w	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	185	er	er	UH
work_izjlueimqneiljcxm4zmi6kuna	116	186	i	i	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	187	n	n	CC
work_izjlueimqneiljcxm4zmi6kuna	116	188	ci	ci	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	189	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	190	en	en	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	191	ce	ce	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	192	o	o	XX
work_izjlueimqneiljcxm4zmi6kuna	116	193	f	f	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	194	p	p	NN
work_izjlueimqneiljcxm4zmi6kuna	116	195	er	er	UH
work_izjlueimqneiljcxm4zmi6kuna	116	196	ip	ip	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	197	h	h	UH
work_izjlueimqneiljcxm4zmi6kuna	116	198	er	er	UH
work_izjlueimqneiljcxm4zmi6kuna	116	199	al	al	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	200	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	201	eu	eu	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	202	ro	ro	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	203	p	p	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	204	at	at	IN
work_izjlueimqneiljcxm4zmi6kuna	116	205	h	h	NNP
work_izjlueimqneiljcxm4zmi6kuna	116	206	y.	y.	NN
work_izjlueimqneiljcxm4zmi6kuna	117	1	Z	Z	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	2	w	w	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	3	ee	ee	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	4	gm	gm	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	5	an	an	DT
work_izjlueimqneiljcxm4zmi6kuna	117	6	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	7	t	t	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	8	al	al	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	9	.	.	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	10	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	117	11	2	2	CD
work_izjlueimqneiljcxm4zmi6kuna	117	12	0	0	CD
work_izjlueimqneiljcxm4zmi6kuna	117	13	1	1	CD
work_izjlueimqneiljcxm4zmi6kuna	117	14	6	6	CD
work_izjlueimqneiljcxm4zmi6kuna	117	15	1	1	CD
work_izjlueimqneiljcxm4zmi6kuna	117	16	9	9	CD
work_izjlueimqneiljcxm4zmi6kuna	117	17	P	p	NN
work_izjlueimqneiljcxm4zmi6kuna	117	18	h	h	NN
work_izjlueimqneiljcxm4zmi6kuna	117	19	as	as	IN
work_izjlueimqneiljcxm4zmi6kuna	117	20	e	e	NN
work_izjlueimqneiljcxm4zmi6kuna	117	21	II	II	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	22	I	i	NN
work_izjlueimqneiljcxm4zmi6kuna	117	23	M	M	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	24	u	u	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	25	lt	lt	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	26	ic	ic	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	27	en	en	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	28	te	te	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	29	r	r	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	30	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	31	p	p	NN
work_izjlueimqneiljcxm4zmi6kuna	117	32	en	en	FW
work_izjlueimqneiljcxm4zmi6kuna	117	33	-l	-l	FW
work_izjlueimqneiljcxm4zmi6kuna	117	34	ab	ab	FW
work_izjlueimqneiljcxm4zmi6kuna	117	35	el	el	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	36	R	R	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	37	C	C	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	38	T	T	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	39	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	117	40	s	s	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	41	tu	tu	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	42	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	43	y	y	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	44	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	45	es	es	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	46	ig	ig	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	47	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	48	s	s	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	49	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	117	50	m	be	VBP
work_izjlueimqneiljcxm4zmi6kuna	117	51	il	il	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	52	ar	ar	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	53	t	t	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	54	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	55	t	t	NN
work_izjlueimqneiljcxm4zmi6kuna	117	56	h	h	NN
work_izjlueimqneiljcxm4zmi6kuna	117	57	at	at	IN
work_izjlueimqneiljcxm4zmi6kuna	117	58	o	o	NN
work_izjlueimqneiljcxm4zmi6kuna	117	59	f	f	NN
work_izjlueimqneiljcxm4zmi6kuna	117	60	St	St	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	61	ew	ew	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	62	ar	ar	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	63	t	t	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	64	et	et	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	65	a	a	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	66	l.	l.	NN
work_izjlueimqneiljcxm4zmi6kuna	117	67	’	'	''
work_izjlueimqneiljcxm4zmi6kuna	117	68	s	s	VBZ
work_izjlueimqneiljcxm4zmi6kuna	117	69	tr	tr	UH
work_izjlueimqneiljcxm4zmi6kuna	117	70	ia	ia	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	71	l	l	NN
work_izjlueimqneiljcxm4zmi6kuna	117	72	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	117	73	N	n	NN
work_izjlueimqneiljcxm4zmi6kuna	117	74	ew	ew	UH
work_izjlueimqneiljcxm4zmi6kuna	117	75	ly	ly	XX
work_izjlueimqneiljcxm4zmi6kuna	117	76	-d	-d	:
work_izjlueimqneiljcxm4zmi6kuna	117	77	ia	ia	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	78	gn	gn	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	79	o	o	FW
work_izjlueimqneiljcxm4zmi6kuna	117	80	se	se	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	81	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	82	M	M	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	83	M	M	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	84	w	w	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	85	h	h	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	86	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	87	w	w	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	88	er	er	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	89	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	90	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	117	91	el	el	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	92	ig	ig	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	93	ib	ib	FW
work_izjlueimqneiljcxm4zmi6kuna	117	94	le	le	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	95	t	t	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	96	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	97	st	st	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	98	em	-PRON-	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	99	c	c	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	100	el	el	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	101	l	l	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	102	tr	tr	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	103	an	an	DT
work_izjlueimqneiljcxm4zmi6kuna	117	104	sp	sp	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	105	la	la	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	106	n	n	CC
work_izjlueimqneiljcxm4zmi6kuna	117	107	t	t	NN
work_izjlueimqneiljcxm4zmi6kuna	117	108	M	M	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	109	P	P	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	110	T	T	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	111	-T	-T	:
work_izjlueimqneiljcxm4zmi6kuna	117	112	v	v	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	113	er	er	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	114	su	su	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	115	s	s	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	116	M	M	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	117	P	P	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	118	R	r	NN
work_izjlueimqneiljcxm4zmi6kuna	117	119	-R	-r	NN
work_izjlueimqneiljcxm4zmi6kuna	117	120	N	n	NN
work_izjlueimqneiljcxm4zmi6kuna	117	121	o	o	NN
work_izjlueimqneiljcxm4zmi6kuna	117	122	d	d	NN
work_izjlueimqneiljcxm4zmi6kuna	117	123	if	if	IN
work_izjlueimqneiljcxm4zmi6kuna	117	124	fe	fe	FW
work_izjlueimqneiljcxm4zmi6kuna	117	125	re	re	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	126	n	n	CC
work_izjlueimqneiljcxm4zmi6kuna	117	127	ce	ce	XX
work_izjlueimqneiljcxm4zmi6kuna	117	128	i	i	PRP
work_izjlueimqneiljcxm4zmi6kuna	117	129	n	n	CC
work_izjlueimqneiljcxm4zmi6kuna	117	130	P	p	NN
work_izjlueimqneiljcxm4zmi6kuna	117	131	F	F	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	132	S	S	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	133	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	117	134	p	p	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	135	ri	ri	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	136	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	137	ar	ar	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	138	y	y	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	139	ef	ef	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	140	fi	fi	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	141	ca	ca	MD
work_izjlueimqneiljcxm4zmi6kuna	117	142	cy	cy	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	143	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	144	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	145	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	146	p	p	NN
work_izjlueimqneiljcxm4zmi6kuna	117	147	o	o	NN
work_izjlueimqneiljcxm4zmi6kuna	117	148	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	117	149	t	t	NN
work_izjlueimqneiljcxm4zmi6kuna	117	150	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	117	151	M	M	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	152	P	p	NN
work_izjlueimqneiljcxm4zmi6kuna	117	153	T	T	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	154	-T	-T	:
work_izjlueimqneiljcxm4zmi6kuna	117	155	:	:	:
work_izjlueimqneiljcxm4zmi6kuna	117	156	i	i	PRP
work_izjlueimqneiljcxm4zmi6kuna	117	157	n	n	CC
work_izjlueimqneiljcxm4zmi6kuna	117	158	cr	cr	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	159	ea	ea	FW
work_izjlueimqneiljcxm4zmi6kuna	117	160	se	se	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	161	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	162	i	i	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	163	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	164	ci	ci	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	165	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	166	en	en	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	167	ce	ce	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	168	o	o	XX
work_izjlueimqneiljcxm4zmi6kuna	117	169	f	f	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	170	p	p	NN
work_izjlueimqneiljcxm4zmi6kuna	117	171	er	er	UH
work_izjlueimqneiljcxm4zmi6kuna	117	172	ip	ip	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	173	h	h	UH
work_izjlueimqneiljcxm4zmi6kuna	117	174	er	er	UH
work_izjlueimqneiljcxm4zmi6kuna	117	175	al	al	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	176	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	177	eu	eu	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	178	ro	ro	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	179	p	p	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	180	at	at	IN
work_izjlueimqneiljcxm4zmi6kuna	117	181	h	h	NN
work_izjlueimqneiljcxm4zmi6kuna	117	182	y	y	NN
work_izjlueimqneiljcxm4zmi6kuna	117	183	M	m	NN
work_izjlueimqneiljcxm4zmi6kuna	117	184	P	p	NN
work_izjlueimqneiljcxm4zmi6kuna	117	185	R	r	NN
work_izjlueimqneiljcxm4zmi6kuna	117	186	-R	-R	:
work_izjlueimqneiljcxm4zmi6kuna	117	187	:	:	:
work_izjlueimqneiljcxm4zmi6kuna	117	188	i	i	PRP
work_izjlueimqneiljcxm4zmi6kuna	117	189	n	n	CC
work_izjlueimqneiljcxm4zmi6kuna	117	190	cr	cr	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	191	ea	ea	FW
work_izjlueimqneiljcxm4zmi6kuna	117	192	se	se	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	193	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	194	i	i	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	195	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	196	ci	ci	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	197	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	198	en	en	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	199	ce	ce	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	200	o	o	XX
work_izjlueimqneiljcxm4zmi6kuna	117	201	f	f	NN
work_izjlueimqneiljcxm4zmi6kuna	117	202	h	h	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	203	em	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	117	204	at	at	IN
work_izjlueimqneiljcxm4zmi6kuna	117	205	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	206	lo	lo	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	207	gi	gi	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	208	c	c	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	209	to	to	IN
work_izjlueimqneiljcxm4zmi6kuna	117	210	xi	xi	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	211	ci	ci	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	212	ty	ty	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	213	r	r	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	214	eq	eq	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	215	u	u	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	216	ir	ir	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	217	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	117	218	g	g	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	219	gr	gr	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	220	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	221	w	w	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	222	th	th	XX
work_izjlueimqneiljcxm4zmi6kuna	117	223	f	f	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	224	ac	ac	NN
work_izjlueimqneiljcxm4zmi6kuna	117	225	to	to	IN
work_izjlueimqneiljcxm4zmi6kuna	117	226	r	r	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	227	su	su	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	228	p	p	NNP
work_izjlueimqneiljcxm4zmi6kuna	117	229	p	p	NN
work_izjlueimqneiljcxm4zmi6kuna	117	230	o	o	NN
work_izjlueimqneiljcxm4zmi6kuna	117	231	rt	rt	NN
work_izjlueimqneiljcxm4zmi6kuna	117	232	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	118	1	G	G	NNP
work_izjlueimqneiljcxm4zmi6kuna	118	2	ay	ay	IN
work_izjlueimqneiljcxm4zmi6kuna	118	3	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	118	4	t	t	NNP
work_izjlueimqneiljcxm4zmi6kuna	118	5	al	al	NNP
work_izjlueimqneiljcxm4zmi6kuna	118	6	.	.	NNP
work_izjlueimqneiljcxm4zmi6kuna	118	7	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	118	8	2	2	CD
work_izjlueimqneiljcxm4zmi6kuna	118	9	0	0	CD
work_izjlueimqneiljcxm4zmi6kuna	118	10	1	1	CD
work_izjlueimqneiljcxm4zmi6kuna	118	11	0	0	CD
work_izjlueimqneiljcxm4zmi6kuna	118	12	2	2	CD
work_izjlueimqneiljcxm4zmi6kuna	118	13	0	0	CD
work_izjlueimqneiljcxm4zmi6kuna	118	14	O	o	NN
work_izjlueimqneiljcxm4zmi6kuna	118	15	b	b	NN
work_izjlueimqneiljcxm4zmi6kuna	118	16	se	se	NN
work_izjlueimqneiljcxm4zmi6kuna	118	17	rv	rv	NNP
work_izjlueimqneiljcxm4zmi6kuna	118	18	at	at	IN
work_izjlueimqneiljcxm4zmi6kuna	118	19	io	io	NNP
work_izjlueimqneiljcxm4zmi6kuna	118	20	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	118	21	al	al	NNP
work_izjlueimqneiljcxm4zmi6kuna	118	22	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	118	23	ca	ca	MD
work_izjlueimqneiljcxm4zmi6kuna	118	24	se	se	NNP
work_izjlueimqneiljcxm4zmi6kuna	118	25	-c	-c	FW
work_izjlueimqneiljcxm4zmi6kuna	118	26	o	o	NN
work_izjlueimqneiljcxm4zmi6kuna	118	27	n	n	NN
work_izjlueimqneiljcxm4zmi6kuna	118	28	tr	tr	NN
work_izjlueimqneiljcxm4zmi6kuna	118	29	o	o	NN
work_izjlueimqneiljcxm4zmi6kuna	118	30	l	l	NN
work_izjlueimqneiljcxm4zmi6kuna	118	31	d	d	NN
work_izjlueimqneiljcxm4zmi6kuna	118	32	es	es	NN
work_izjlueimqneiljcxm4zmi6kuna	118	33	ig	ig	NNP
work_izjlueimqneiljcxm4zmi6kuna	118	34	n	n	CC
work_izjlueimqneiljcxm4zmi6kuna	118	35	ed	ed	NN
work_izjlueimqneiljcxm4zmi6kuna	118	36	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	118	37	re	re	VB
work_izjlueimqneiljcxm4zmi6kuna	118	38	tr	tr	IN
work_izjlueimqneiljcxm4zmi6kuna	118	39	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	118	40	sp	sp	NNP
work_izjlueimqneiljcxm4zmi6kuna	118	41	ec	ec	NNP
work_izjlueimqneiljcxm4zmi6kuna	118	42	ti	ti	NNP
work_izjlueimqneiljcxm4zmi6kuna	118	43	ve	ve	NNP
work_izjlueimqneiljcxm4zmi6kuna	118	44	s	s	NNPS
work_izjlueimqneiljcxm4zmi6kuna	118	45	tu	tu	NNP
work_izjlueimqneiljcxm4zmi6kuna	118	46	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	118	47	y.	y.	NNP
work_izjlueimqneiljcxm4zmi6kuna	118	48	M	M	NNP
work_izjlueimqneiljcxm4zmi6kuna	118	49	at	at	IN
work_izjlueimqneiljcxm4zmi6kuna	118	50	ch	ch	NNP
work_izjlueimqneiljcxm4zmi6kuna	118	51	ed	ed	NNP
work_izjlueimqneiljcxm4zmi6kuna	118	52	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	118	53	p	p	NNP
work_izjlueimqneiljcxm4zmi6kuna	118	54	ai	ai	NNP
work_izjlueimqneiljcxm4zmi6kuna	118	55	r	r	NN
work_izjlueimqneiljcxm4zmi6kuna	118	56	an	an	DT
work_izjlueimqneiljcxm4zmi6kuna	118	57	al	al	NNP
work_izjlueimqneiljcxm4zmi6kuna	118	58	ys	ys	NNP
work_izjlueimqneiljcxm4zmi6kuna	118	59	is	be	VBZ
work_izjlueimqneiljcxm4zmi6kuna	118	60	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	118	61	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	118	62	ju	ju	NNP
work_izjlueimqneiljcxm4zmi6kuna	118	63	st	st	NNP
work_izjlueimqneiljcxm4zmi6kuna	118	64	ed	ed	NNP
work_izjlueimqneiljcxm4zmi6kuna	118	65	f	f	NNP
work_izjlueimqneiljcxm4zmi6kuna	118	66	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	118	67	r	r	NNP
work_izjlueimqneiljcxm4zmi6kuna	118	68	ag	ag	NNP
work_izjlueimqneiljcxm4zmi6kuna	118	69	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	118	70	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	118	71	s	s	POS
work_izjlueimqneiljcxm4zmi6kuna	118	72	ex	ex	NNP
work_izjlueimqneiljcxm4zmi6kuna	118	73	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	118	74	tr	tr	IN
work_izjlueimqneiljcxm4zmi6kuna	118	75	an	an	DT
work_izjlueimqneiljcxm4zmi6kuna	118	76	sp	sp	NNP
work_izjlueimqneiljcxm4zmi6kuna	118	77	la	la	NNP
work_izjlueimqneiljcxm4zmi6kuna	118	78	n	n	CC
work_izjlueimqneiljcxm4zmi6kuna	118	79	ta	ta	NNP
work_izjlueimqneiljcxm4zmi6kuna	118	80	ti	ti	NNP
work_izjlueimqneiljcxm4zmi6kuna	118	81	o	o	XX
work_izjlueimqneiljcxm4zmi6kuna	118	82	n	n	NN
work_izjlueimqneiljcxm4zmi6kuna	118	83	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	118	84	D	D	NNP
work_izjlueimqneiljcxm4zmi6kuna	118	85	X	x	NN
work_izjlueimqneiljcxm4zmi6kuna	118	86	M	m	NN
work_izjlueimqneiljcxm4zmi6kuna	118	87	d	d	NN
work_izjlueimqneiljcxm4zmi6kuna	118	88	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	118	89	se	se	NN
work_izjlueimqneiljcxm4zmi6kuna	118	90	+	+	NNP
work_izjlueimqneiljcxm4zmi6kuna	118	91	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	119	1	N	n	CC
work_izjlueimqneiljcxm4zmi6kuna	119	2	ew	ew	UH
work_izjlueimqneiljcxm4zmi6kuna	119	3	ly	ly	XX
work_izjlueimqneiljcxm4zmi6kuna	119	4	d	d	XX
work_izjlueimqneiljcxm4zmi6kuna	119	5	ia	ia	NNP
work_izjlueimqneiljcxm4zmi6kuna	119	6	gn	gn	NNP
work_izjlueimqneiljcxm4zmi6kuna	119	7	o	o	FW
work_izjlueimqneiljcxm4zmi6kuna	119	8	se	se	NNP
work_izjlueimqneiljcxm4zmi6kuna	119	9	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	119	10	M	M	NNP
work_izjlueimqneiljcxm4zmi6kuna	119	11	M	M	NNP
work_izjlueimqneiljcxm4zmi6kuna	119	12	p	p	NN
work_izjlueimqneiljcxm4zmi6kuna	119	13	at	at	IN
work_izjlueimqneiljcxm4zmi6kuna	119	14	ie	ie	NNP
work_izjlueimqneiljcxm4zmi6kuna	119	15	n	n	NN
work_izjlueimqneiljcxm4zmi6kuna	119	16	ts	ts	NNP
work_izjlueimqneiljcxm4zmi6kuna	119	17	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	119	18	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	119	19	it	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	119	20	ia	ia	UH
work_izjlueimqneiljcxm4zmi6kuna	119	21	l	l	NN
work_izjlueimqneiljcxm4zmi6kuna	119	22	th	th	XX
work_izjlueimqneiljcxm4zmi6kuna	119	23	er	er	UH
work_izjlueimqneiljcxm4zmi6kuna	119	24	ap	ap	NNP
work_izjlueimqneiljcxm4zmi6kuna	119	25	y	y	NNP
work_izjlueimqneiljcxm4zmi6kuna	119	26	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	119	27	L	L	NNP
work_izjlueimqneiljcxm4zmi6kuna	119	28	en	en	FW
work_izjlueimqneiljcxm4zmi6kuna	119	29	al	al	NNP
work_izjlueimqneiljcxm4zmi6kuna	119	30	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	119	31	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	119	32	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	119	33	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	119	34	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	119	35	d	d	NN
work_izjlueimqneiljcxm4zmi6kuna	119	36	e	e	NN
work_izjlueimqneiljcxm4zmi6kuna	119	37	+	+	NN
work_izjlueimqneiljcxm4zmi6kuna	119	38	D	d	NN
work_izjlueimqneiljcxm4zmi6kuna	119	39	X	x	NN
work_izjlueimqneiljcxm4zmi6kuna	119	40	M	m	NN
work_izjlueimqneiljcxm4zmi6kuna	119	41	v	v	NN
work_izjlueimqneiljcxm4zmi6kuna	119	42	er	er	UH
work_izjlueimqneiljcxm4zmi6kuna	119	43	su	su	NNP
work_izjlueimqneiljcxm4zmi6kuna	119	44	s	s	NNP
work_izjlueimqneiljcxm4zmi6kuna	119	45	T	T	NNP
work_izjlueimqneiljcxm4zmi6kuna	119	46	h	h	NN
work_izjlueimqneiljcxm4zmi6kuna	119	47	al	al	NNP
work_izjlueimqneiljcxm4zmi6kuna	119	48	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	119	49	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	119	50	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	119	51	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	119	52	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	119	53	d	d	NN
work_izjlueimqneiljcxm4zmi6kuna	119	54	e	e	NN
work_izjlueimqneiljcxm4zmi6kuna	119	55	+	+	NN
work_izjlueimqneiljcxm4zmi6kuna	119	56	D	d	NN
work_izjlueimqneiljcxm4zmi6kuna	119	57	X	x	NN
work_izjlueimqneiljcxm4zmi6kuna	119	58	M	m	NN
work_izjlueimqneiljcxm4zmi6kuna	119	59	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	120	1	L	L	NNP
work_izjlueimqneiljcxm4zmi6kuna	120	2	en	en	FW
work_izjlueimqneiljcxm4zmi6kuna	120	3	al	al	NNP
work_izjlueimqneiljcxm4zmi6kuna	120	4	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	120	5	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	120	6	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	120	7	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	120	8	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	120	9	d	d	NN
work_izjlueimqneiljcxm4zmi6kuna	120	10	e	e	NN
work_izjlueimqneiljcxm4zmi6kuna	120	11	+	+	NN
work_izjlueimqneiljcxm4zmi6kuna	120	12	D	D	NNP
work_izjlueimqneiljcxm4zmi6kuna	120	13	M	M	NNP
work_izjlueimqneiljcxm4zmi6kuna	120	14	X	x	NN
work_izjlueimqneiljcxm4zmi6kuna	120	15	:	:	:
work_izjlueimqneiljcxm4zmi6kuna	120	16	l	l	NNP
work_izjlueimqneiljcxm4zmi6kuna	120	17	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	120	18	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	120	19	ge	ge	NNP
work_izjlueimqneiljcxm4zmi6kuna	120	20	r	r	NNP
work_izjlueimqneiljcxm4zmi6kuna	120	21	T	t	NN
work_izjlueimqneiljcxm4zmi6kuna	120	22	T	t	NN
work_izjlueimqneiljcxm4zmi6kuna	120	23	P	p	NN
work_izjlueimqneiljcxm4zmi6kuna	120	24	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	120	25	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	120	26	ed	ed	NNP
work_izjlueimqneiljcxm4zmi6kuna	120	27	ia	ia	NNP
work_izjlueimqneiljcxm4zmi6kuna	120	28	n	n	CC
work_izjlueimqneiljcxm4zmi6kuna	120	29	2	2	CD
work_izjlueimqneiljcxm4zmi6kuna	120	30	7	7	CD
work_izjlueimqneiljcxm4zmi6kuna	120	31	.4	.4	CD
work_izjlueimqneiljcxm4zmi6kuna	120	32	v	v	NNP
work_izjlueimqneiljcxm4zmi6kuna	120	33	er	er	NNP
work_izjlueimqneiljcxm4zmi6kuna	120	34	su	su	NNP
work_izjlueimqneiljcxm4zmi6kuna	120	35	s	s	NNP
work_izjlueimqneiljcxm4zmi6kuna	120	36	1	1	CD
work_izjlueimqneiljcxm4zmi6kuna	120	37	7	7	CD
work_izjlueimqneiljcxm4zmi6kuna	120	38	.2	.2	CD
work_izjlueimqneiljcxm4zmi6kuna	120	39	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	120	40	o	o	NN
work_izjlueimqneiljcxm4zmi6kuna	120	41	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	120	42	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	120	43	P	p	NN
work_izjlueimqneiljcxm4zmi6kuna	120	44	F	F	NNP
work_izjlueimqneiljcxm4zmi6kuna	120	45	S	s	NN
work_izjlueimqneiljcxm4zmi6kuna	120	46	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	120	47	2	2	CD
work_izjlueimqneiljcxm4zmi6kuna	120	48	6	6	CD
work_izjlueimqneiljcxm4zmi6kuna	120	49	.7	.7	NN
work_izjlueimqneiljcxm4zmi6kuna	120	50	v	v	NNP
work_izjlueimqneiljcxm4zmi6kuna	120	51	er	er	NNP
work_izjlueimqneiljcxm4zmi6kuna	120	52	su	su	NNP
work_izjlueimqneiljcxm4zmi6kuna	120	53	s	s	NNP
work_izjlueimqneiljcxm4zmi6kuna	120	54	1	1	CD
work_izjlueimqneiljcxm4zmi6kuna	120	55	7	7	CD
work_izjlueimqneiljcxm4zmi6kuna	120	56	.1	.1	CD
work_izjlueimqneiljcxm4zmi6kuna	120	57	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	120	58	o	o	NN
work_izjlueimqneiljcxm4zmi6kuna	120	59	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	120	60	;	;	:
work_izjlueimqneiljcxm4zmi6kuna	120	61	O	o	UH
work_izjlueimqneiljcxm4zmi6kuna	120	62	S	s	NN
work_izjlueimqneiljcxm4zmi6kuna	120	63	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	120	64	n	n	NN
work_izjlueimqneiljcxm4zmi6kuna	120	65	o	o	NN
work_izjlueimqneiljcxm4zmi6kuna	120	66	t	t	NN
work_izjlueimqneiljcxm4zmi6kuna	120	67	re	re	NN
work_izjlueimqneiljcxm4zmi6kuna	120	68	ac	ac	IN
work_izjlueimqneiljcxm4zmi6kuna	120	69	h	h	NN
work_izjlueimqneiljcxm4zmi6kuna	120	70	ed	ed	NNP
work_izjlueimqneiljcxm4zmi6kuna	120	71	v	v	NNP
work_izjlueimqneiljcxm4zmi6kuna	120	72	er	er	NNP
work_izjlueimqneiljcxm4zmi6kuna	120	73	su	su	NNP
work_izjlueimqneiljcxm4zmi6kuna	120	74	s	s	NNP
work_izjlueimqneiljcxm4zmi6kuna	120	75	5	5	CD
work_izjlueimqneiljcxm4zmi6kuna	120	76	7	7	CD
work_izjlueimqneiljcxm4zmi6kuna	120	77	.2	.2	CD
work_izjlueimqneiljcxm4zmi6kuna	120	78	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	120	79	o	o	NN
work_izjlueimqneiljcxm4zmi6kuna	120	80	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	120	81	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	121	1	Si	Si	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	2	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	3	il	il	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	4	ar	ar	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	5	p	p	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	6	ro	ro	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	7	p	p	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	8	o	o	XX
work_izjlueimqneiljcxm4zmi6kuna	121	9	rt	rt	VBP
work_izjlueimqneiljcxm4zmi6kuna	121	10	io	io	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	11	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	12	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	13	f	f	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	14	p	p	NN
work_izjlueimqneiljcxm4zmi6kuna	121	15	at	at	IN
work_izjlueimqneiljcxm4zmi6kuna	121	16	ie	ie	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	17	n	n	CC
work_izjlueimqneiljcxm4zmi6kuna	121	18	ts	ts	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	19	i	i	NN
work_izjlueimqneiljcxm4zmi6kuna	121	20	n	n	CC
work_izjlueimqneiljcxm4zmi6kuna	121	21	t	t	NN
work_izjlueimqneiljcxm4zmi6kuna	121	22	h	h	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	23	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	24	2	2	CD
work_izjlueimqneiljcxm4zmi6kuna	121	25	g	g	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	26	ro	ro	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	27	u	u	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	28	p	p	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	29	s	s	FW
work_izjlueimqneiljcxm4zmi6kuna	121	30	ex	ex	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	31	p	p	NN
work_izjlueimqneiljcxm4zmi6kuna	121	32	er	er	UH
work_izjlueimqneiljcxm4zmi6kuna	121	33	ie	ie	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	34	n	n	CC
work_izjlueimqneiljcxm4zmi6kuna	121	35	ce	ce	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	36	d	d	NN
work_izjlueimqneiljcxm4zmi6kuna	121	37	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	121	38	t	t	NN
work_izjlueimqneiljcxm4zmi6kuna	121	39	le	le	NN
work_izjlueimqneiljcxm4zmi6kuna	121	40	as	as	IN
work_izjlueimqneiljcxm4zmi6kuna	121	41	t	t	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	42	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	43	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	44	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	45	gr	gr	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	46	ad	ad	NN
work_izjlueimqneiljcxm4zmi6kuna	121	47	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	48	3	3	CD
work_izjlueimqneiljcxm4zmi6kuna	121	49	o	o	NN
work_izjlueimqneiljcxm4zmi6kuna	121	50	r	r	NN
work_izjlueimqneiljcxm4zmi6kuna	121	51	4	4	CD
work_izjlueimqneiljcxm4zmi6kuna	121	52	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	121	53	d	d	NN
work_izjlueimqneiljcxm4zmi6kuna	121	54	ve	ve	NN
work_izjlueimqneiljcxm4zmi6kuna	121	55	rs	rs	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	56	e	e	XX
work_izjlueimqneiljcxm4zmi6kuna	121	57	ev	ev	XX
work_izjlueimqneiljcxm4zmi6kuna	121	58	en	en	IN
work_izjlueimqneiljcxm4zmi6kuna	121	59	t	t	NN
work_izjlueimqneiljcxm4zmi6kuna	121	60	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	121	61	t	t	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	62	h	h	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	63	al	al	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	64	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	121	65	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	66	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	67	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	68	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	121	69	d	d	NN
work_izjlueimqneiljcxm4zmi6kuna	121	70	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	71	ve	ve	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	72	rs	rs	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	73	u	u	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	74	s	s	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	75	le	le	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	76	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	77	al	al	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	78	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	121	79	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	80	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	81	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	82	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	121	83	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	84	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	85	:	:	:
work_izjlueimqneiljcxm4zmi6kuna	121	86	5	5	CD
work_izjlueimqneiljcxm4zmi6kuna	121	87	4	4	CD
work_izjlueimqneiljcxm4zmi6kuna	121	88	.6	.6	CD
work_izjlueimqneiljcxm4zmi6kuna	121	89	%	%	NN
work_izjlueimqneiljcxm4zmi6kuna	121	90	v	v	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	91	er	er	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	92	su	su	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	93	s	s	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	94	5	5	CD
work_izjlueimqneiljcxm4zmi6kuna	121	95	7	7	CD
work_izjlueimqneiljcxm4zmi6kuna	121	96	.5	.5	.
work_izjlueimqneiljcxm4zmi6kuna	121	97	%	%	NN
work_izjlueimqneiljcxm4zmi6kuna	121	98	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	121	99	#	#	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	100	S	S	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	101	as	as	IN
work_izjlueimqneiljcxm4zmi6kuna	121	102	h	h	NN
work_izjlueimqneiljcxm4zmi6kuna	121	103	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	121	104	d	d	NN
work_izjlueimqneiljcxm4zmi6kuna	121	105	h	h	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	106	ar	ar	NN
work_izjlueimqneiljcxm4zmi6kuna	121	107	an	an	DT
work_izjlueimqneiljcxm4zmi6kuna	121	108	et	et	FW
work_izjlueimqneiljcxm4zmi6kuna	121	109	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	121	110	l.	l.	NN
work_izjlueimqneiljcxm4zmi6kuna	121	111	2	2	CD
work_izjlueimqneiljcxm4zmi6kuna	121	112	0	0	CD
work_izjlueimqneiljcxm4zmi6kuna	121	113	1	1	CD
work_izjlueimqneiljcxm4zmi6kuna	121	114	5	5	CD
work_izjlueimqneiljcxm4zmi6kuna	121	115	2	2	CD
work_izjlueimqneiljcxm4zmi6kuna	121	116	1	1	CD
work_izjlueimqneiljcxm4zmi6kuna	121	117	O	o	NN
work_izjlueimqneiljcxm4zmi6kuna	121	118	b	b	NN
work_izjlueimqneiljcxm4zmi6kuna	121	119	se	se	NN
work_izjlueimqneiljcxm4zmi6kuna	121	120	rv	rv	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	121	at	at	IN
work_izjlueimqneiljcxm4zmi6kuna	121	122	io	io	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	123	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	124	al	al	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	125	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	121	126	an	an	DT
work_izjlueimqneiljcxm4zmi6kuna	121	127	al	al	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	128	ys	ys	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	129	is	be	VBZ
work_izjlueimqneiljcxm4zmi6kuna	121	130	o	o	XX
work_izjlueimqneiljcxm4zmi6kuna	121	131	f	f	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	132	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	133	ed	ed	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	134	ic	ic	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	135	al	al	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	136	re	re	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	137	co	co	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	138	rd	rd	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	139	fi	fi	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	140	le	le	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	141	s	s	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	142	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	121	143	r	r	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	144	et	et	FW
work_izjlueimqneiljcxm4zmi6kuna	121	145	ro	ro	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	146	sp	sp	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	147	ec	ec	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	148	ti	ti	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	149	ve	ve	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	150	s	s	NNPS
work_izjlueimqneiljcxm4zmi6kuna	121	151	tu	tu	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	152	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	153	y.	y.	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	154	N	N	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	155	ew	ew	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	156	ly	ly	XX
work_izjlueimqneiljcxm4zmi6kuna	121	157	d	d	XX
work_izjlueimqneiljcxm4zmi6kuna	121	158	ia	ia	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	159	gn	gn	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	160	o	o	FW
work_izjlueimqneiljcxm4zmi6kuna	121	161	se	se	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	162	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	163	M	M	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	164	M	M	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	165	p	p	NN
work_izjlueimqneiljcxm4zmi6kuna	121	166	at	at	IN
work_izjlueimqneiljcxm4zmi6kuna	121	167	ie	ie	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	168	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	169	ts	ts	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	170	w	w	NN
work_izjlueimqneiljcxm4zmi6kuna	121	171	h	h	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	172	o	o	NN
work_izjlueimqneiljcxm4zmi6kuna	121	173	a	a	FW
work_izjlueimqneiljcxm4zmi6kuna	121	174	tt	tt	FW
work_izjlueimqneiljcxm4zmi6kuna	121	175	en	en	NN
work_izjlueimqneiljcxm4zmi6kuna	121	176	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	177	ed	ed	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	178	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	179	ed	ed	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	180	ic	ic	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	181	al	al	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	182	c	c	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	183	ar	ar	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	184	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	185	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	121	186	t	t	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	187	er	er	UH
work_izjlueimqneiljcxm4zmi6kuna	121	188	ti	ti	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	189	ar	ar	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	190	y	y	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	191	h	h	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	192	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	193	sp	sp	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	194	it	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	121	195	al	al	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	196	s	s	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	197	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	121	198	I	I	NNP
work_izjlueimqneiljcxm4zmi6kuna	121	199	n	n	CC
work_izjlueimqneiljcxm4zmi6kuna	121	200	d	d	XX
work_izjlueimqneiljcxm4zmi6kuna	121	201	ia	ia	XX
work_izjlueimqneiljcxm4zmi6kuna	121	202	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	122	1	T	T	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	2	h	h	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	3	al	al	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	4	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	122	5	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	6	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	7	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	8	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	122	9	d	d	NN
work_izjlueimqneiljcxm4zmi6kuna	122	10	e	e	NN
work_izjlueimqneiljcxm4zmi6kuna	122	11	+	+	NN
work_izjlueimqneiljcxm4zmi6kuna	122	12	D	d	NN
work_izjlueimqneiljcxm4zmi6kuna	122	13	X	x	NN
work_izjlueimqneiljcxm4zmi6kuna	122	14	M	m	NN
work_izjlueimqneiljcxm4zmi6kuna	122	15	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	122	16	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	17	=	=	SYM
work_izjlueimqneiljcxm4zmi6kuna	122	18	1	1	CD
work_izjlueimqneiljcxm4zmi6kuna	122	19	7	7	CD
work_izjlueimqneiljcxm4zmi6kuna	122	20	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	122	21	ve	ve	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	22	rs	rs	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	23	u	u	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	24	s	s	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	25	le	le	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	26	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	27	al	al	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	28	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	122	29	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	30	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	31	m	m	NN
work_izjlueimqneiljcxm4zmi6kuna	122	32	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	122	33	d	d	NN
work_izjlueimqneiljcxm4zmi6kuna	122	34	e+	e+	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	35	D	d	NN
work_izjlueimqneiljcxm4zmi6kuna	122	36	X	x	NN
work_izjlueimqneiljcxm4zmi6kuna	122	37	M	m	NN
work_izjlueimqneiljcxm4zmi6kuna	122	38	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	122	39	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	40	=	=	SYM
work_izjlueimqneiljcxm4zmi6kuna	122	41	1	1	CD
work_izjlueimqneiljcxm4zmi6kuna	122	42	9	9	CD
work_izjlueimqneiljcxm4zmi6kuna	122	43	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	122	44	P	p	NN
work_izjlueimqneiljcxm4zmi6kuna	122	45	ro	ro	NN
work_izjlueimqneiljcxm4zmi6kuna	122	46	p	p	NN
work_izjlueimqneiljcxm4zmi6kuna	122	47	o	o	XX
work_izjlueimqneiljcxm4zmi6kuna	122	48	rt	rt	VBP
work_izjlueimqneiljcxm4zmi6kuna	122	49	io	io	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	50	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	51	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	52	f	f	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	53	p	p	NN
work_izjlueimqneiljcxm4zmi6kuna	122	54	at	at	IN
work_izjlueimqneiljcxm4zmi6kuna	122	55	ie	ie	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	56	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	57	ts	ts	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	58	s	s	NN
work_izjlueimqneiljcxm4zmi6kuna	122	59	h	h	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	60	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	61	w	w	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	62	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	122	63	g	g	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	64	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	65	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	122	66	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	122	67	m	be	VBP
work_izjlueimqneiljcxm4zmi6kuna	122	68	al	al	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	69	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	122	70	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	71	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	72	p	p	NN
work_izjlueimqneiljcxm4zmi6kuna	122	73	ar	ar	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	74	ti	ti	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	75	al	al	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	76	c	c	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	77	li	li	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	78	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	79	ic	ic	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	80	al	al	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	81	re	re	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	82	sp	sp	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	83	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	84	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	85	se	se	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	86	t	t	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	87	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	88	t	t	NN
work_izjlueimqneiljcxm4zmi6kuna	122	89	re	re	NN
work_izjlueimqneiljcxm4zmi6kuna	122	90	at	at	IN
work_izjlueimqneiljcxm4zmi6kuna	122	91	m	m	NN
work_izjlueimqneiljcxm4zmi6kuna	122	92	en	en	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	93	t	t	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	94	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	122	95	s	s	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	96	er	er	UH
work_izjlueimqneiljcxm4zmi6kuna	122	97	u	u	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	98	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	99	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	122	100	m	be	VBP
work_izjlueimqneiljcxm4zmi6kuna	122	101	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	102	u	u	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	103	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	104	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	105	gl	gl	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	106	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	107	b	b	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	108	u	u	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	109	li	li	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	110	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	111	l	l	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	112	ev	ev	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	113	el	el	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	114	s	s	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	115	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	122	116	b	b	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	117	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	118	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	119	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	120	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	121	ar	ar	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	122	ro	ro	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	123	w	w	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	124	b	b	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	125	io	io	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	126	p	p	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	127	sy	sy	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	128	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	122	129	P	p	NN
work_izjlueimqneiljcxm4zmi6kuna	122	130	ro	ro	NN
work_izjlueimqneiljcxm4zmi6kuna	122	131	p	p	NN
work_izjlueimqneiljcxm4zmi6kuna	122	132	o	o	XX
work_izjlueimqneiljcxm4zmi6kuna	122	133	rt	rt	VBP
work_izjlueimqneiljcxm4zmi6kuna	122	134	io	io	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	135	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	136	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	137	f	f	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	138	ad	ad	NN
work_izjlueimqneiljcxm4zmi6kuna	122	139	ve	ve	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	140	rs	rs	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	141	e	e	XX
work_izjlueimqneiljcxm4zmi6kuna	122	142	ev	ev	XX
work_izjlueimqneiljcxm4zmi6kuna	122	143	en	en	FW
work_izjlueimqneiljcxm4zmi6kuna	122	144	ts	ts	DT
work_izjlueimqneiljcxm4zmi6kuna	122	145	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	146	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	122	147	d	d	NN
work_izjlueimqneiljcxm4zmi6kuna	122	148	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	149	o	o	NN
work_izjlueimqneiljcxm4zmi6kuna	122	150	t	t	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	151	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	152	if	if	IN
work_izjlueimqneiljcxm4zmi6kuna	122	153	fe	fe	FW
work_izjlueimqneiljcxm4zmi6kuna	122	154	r.	r.	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	155	Y	Y	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	156	et	et	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	157	n	n	NN
work_izjlueimqneiljcxm4zmi6kuna	122	158	o	o	NN
work_izjlueimqneiljcxm4zmi6kuna	122	159	t	t	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	160	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	161	if	if	IN
work_izjlueimqneiljcxm4zmi6kuna	122	162	fe	fe	FW
work_izjlueimqneiljcxm4zmi6kuna	122	163	ri	ri	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	164	n	n	CC
work_izjlueimqneiljcxm4zmi6kuna	122	165	g	g	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	166	st	st	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	167	at	at	IN
work_izjlueimqneiljcxm4zmi6kuna	122	168	is	be	VBZ
work_izjlueimqneiljcxm4zmi6kuna	122	169	ti	ti	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	170	ca	ca	NN
work_izjlueimqneiljcxm4zmi6kuna	122	171	ll	will	IN
work_izjlueimqneiljcxm4zmi6kuna	122	172	y	y	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	173	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	122	174	0	0	CD
work_izjlueimqneiljcxm4zmi6kuna	122	175	4	4	CD
work_izjlueimqneiljcxm4zmi6kuna	122	176	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	122	177	2	2	CD
work_izjlueimqneiljcxm4zmi6kuna	122	178	3	3	CD
work_izjlueimqneiljcxm4zmi6kuna	122	179	.5	.5	.
work_izjlueimqneiljcxm4zmi6kuna	122	180	%	%	NN
work_izjlueimqneiljcxm4zmi6kuna	122	181	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	122	182	p	p	NN
work_izjlueimqneiljcxm4zmi6kuna	122	183	at	at	IN
work_izjlueimqneiljcxm4zmi6kuna	122	184	ie	ie	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	185	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	186	ts	ts	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	187	t	t	NN
work_izjlueimqneiljcxm4zmi6kuna	122	188	re	re	NN
work_izjlueimqneiljcxm4zmi6kuna	122	189	at	at	IN
work_izjlueimqneiljcxm4zmi6kuna	122	190	ed	ed	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	191	w	w	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	192	it	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	122	193	h	h	VBZ
work_izjlueimqneiljcxm4zmi6kuna	122	194	t	t	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	195	h	h	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	196	al	al	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	197	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	122	198	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	199	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	200	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	201	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	122	202	d	d	NN
work_izjlueimqneiljcxm4zmi6kuna	122	203	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	204	p	p	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	205	re	re	NN
work_izjlueimqneiljcxm4zmi6kuna	122	206	se	se	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	207	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	208	te	te	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	209	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	210	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	211	eu	eu	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	212	ro	ro	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	213	p	p	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	214	at	at	IN
work_izjlueimqneiljcxm4zmi6kuna	122	215	h	h	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	216	y	y	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	217	ag	ag	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	218	ai	ai	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	219	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	220	st	st	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	221	0	0	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	222	1	1	CD
work_izjlueimqneiljcxm4zmi6kuna	122	223	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	122	224	5	5	CD
work_izjlueimqneiljcxm4zmi6kuna	122	225	.3	.3	CD
work_izjlueimqneiljcxm4zmi6kuna	122	226	%	%	NN
work_izjlueimqneiljcxm4zmi6kuna	122	227	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	122	228	th	th	XX
work_izjlueimqneiljcxm4zmi6kuna	122	229	at	at	IN
work_izjlueimqneiljcxm4zmi6kuna	122	230	r	r	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	231	ec	ec	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	232	ei	ei	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	233	ve	ve	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	234	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	235	le	le	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	236	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	237	al	al	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	238	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	122	239	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	240	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	241	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	242	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	122	243	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	244	e.	e.	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	245	L	L	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	246	u	u	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	247	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	248	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	249	t	t	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	250	al	al	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	251	.	.	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	252	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	122	253	2	2	CD
work_izjlueimqneiljcxm4zmi6kuna	122	254	0	0	CD
work_izjlueimqneiljcxm4zmi6kuna	122	255	1	1	CD
work_izjlueimqneiljcxm4zmi6kuna	122	256	7	7	CD
work_izjlueimqneiljcxm4zmi6kuna	122	257	2	2	CD
work_izjlueimqneiljcxm4zmi6kuna	122	258	2	2	CD
work_izjlueimqneiljcxm4zmi6kuna	122	259	O	o	NN
work_izjlueimqneiljcxm4zmi6kuna	122	260	b	b	NN
work_izjlueimqneiljcxm4zmi6kuna	122	261	se	se	NN
work_izjlueimqneiljcxm4zmi6kuna	122	262	rv	rv	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	263	at	at	IN
work_izjlueimqneiljcxm4zmi6kuna	122	264	io	io	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	265	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	266	al	al	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	267	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	122	268	p	p	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	269	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	270	p	p	NN
work_izjlueimqneiljcxm4zmi6kuna	122	271	u	u	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	272	la	la	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	273	ti	ti	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	274	o	o	XX
work_izjlueimqneiljcxm4zmi6kuna	122	275	n	n	XX
work_izjlueimqneiljcxm4zmi6kuna	122	276	-b	-b	:
work_izjlueimqneiljcxm4zmi6kuna	122	277	as	as	IN
work_izjlueimqneiljcxm4zmi6kuna	122	278	ed	ed	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	279	co	co	NN
work_izjlueimqneiljcxm4zmi6kuna	122	280	h	h	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	281	o	o	XX
work_izjlueimqneiljcxm4zmi6kuna	122	282	rt	rt	NNP
work_izjlueimqneiljcxm4zmi6kuna	122	283	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	122	284	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	123	1	P	p	NN
work_izjlueimqneiljcxm4zmi6kuna	123	2	at	at	IN
work_izjlueimqneiljcxm4zmi6kuna	123	3	ie	ie	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	4	n	n	CC
work_izjlueimqneiljcxm4zmi6kuna	123	5	ts	ts	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	6	w	w	NN
work_izjlueimqneiljcxm4zmi6kuna	123	7	it	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	123	8	h	h	VBZ
work_izjlueimqneiljcxm4zmi6kuna	123	9	M	M	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	10	M	M	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	11	re	re	NN
work_izjlueimqneiljcxm4zmi6kuna	123	12	ce	ce	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	13	iv	iv	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	14	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	123	15	g	g	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	16	th	th	XX
work_izjlueimqneiljcxm4zmi6kuna	123	17	al	al	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	18	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	123	19	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	20	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	21	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	22	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	123	23	d	d	NN
work_izjlueimqneiljcxm4zmi6kuna	123	24	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	25	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	26	r	r	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	27	le	le	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	28	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	29	al	al	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	30	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	123	31	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	32	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	33	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	34	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	123	35	d	d	NN
work_izjlueimqneiljcxm4zmi6kuna	123	36	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	37	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	123	38	r	r	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	39	o	o	NN
work_izjlueimqneiljcxm4zmi6kuna	123	40	u	u	NN
work_izjlueimqneiljcxm4zmi6kuna	123	41	ti	ti	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	42	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	43	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	44	ca	ca	MD
work_izjlueimqneiljcxm4zmi6kuna	123	45	re	re	VB
work_izjlueimqneiljcxm4zmi6kuna	123	46	i	i	PRP
work_izjlueimqneiljcxm4zmi6kuna	123	47	n	n	CC
work_izjlueimqneiljcxm4zmi6kuna	123	48	t	t	NN
work_izjlueimqneiljcxm4zmi6kuna	123	49	h	h	NN
work_izjlueimqneiljcxm4zmi6kuna	123	50	e	e	NN
work_izjlueimqneiljcxm4zmi6kuna	123	51	U	U	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	52	S.	S.	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	53	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	123	54	N	N	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	55	=	=	SYM
work_izjlueimqneiljcxm4zmi6kuna	123	56	1	1	CD
work_izjlueimqneiljcxm4zmi6kuna	123	57	2	2	CD
work_izjlueimqneiljcxm4zmi6kuna	123	58	6	6	CD
work_izjlueimqneiljcxm4zmi6kuna	123	59	4	4	CD
work_izjlueimqneiljcxm4zmi6kuna	123	60	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	123	61	T	t	NN
work_izjlueimqneiljcxm4zmi6kuna	123	62	h	h	NN
work_izjlueimqneiljcxm4zmi6kuna	123	63	al	al	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	64	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	123	65	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	66	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	67	m	m	NN
work_izjlueimqneiljcxm4zmi6kuna	123	68	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	123	69	d	d	NN
work_izjlueimqneiljcxm4zmi6kuna	123	70	e-	e-	XX
work_izjlueimqneiljcxm4zmi6kuna	123	71	b	b	NN
work_izjlueimqneiljcxm4zmi6kuna	123	72	as	as	IN
work_izjlueimqneiljcxm4zmi6kuna	123	73	ed	ed	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	74	ve	ve	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	75	rs	rs	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	76	u	u	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	77	s	s	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	78	le	le	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	79	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	80	al	al	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	81	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	123	82	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	83	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	84	m	m	NN
work_izjlueimqneiljcxm4zmi6kuna	123	85	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	123	86	d	d	NN
work_izjlueimqneiljcxm4zmi6kuna	123	87	e-	e-	XX
work_izjlueimqneiljcxm4zmi6kuna	123	88	b	b	NN
work_izjlueimqneiljcxm4zmi6kuna	123	89	as	as	IN
work_izjlueimqneiljcxm4zmi6kuna	123	90	ed	ed	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	91	t	t	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	92	h	h	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	93	er	er	UH
work_izjlueimqneiljcxm4zmi6kuna	123	94	ap	ap	UH
work_izjlueimqneiljcxm4zmi6kuna	123	95	ie	ie	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	96	s	s	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	97	N	n	NN
work_izjlueimqneiljcxm4zmi6kuna	123	98	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	99	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	100	if	if	IN
work_izjlueimqneiljcxm4zmi6kuna	123	101	fe	fe	FW
work_izjlueimqneiljcxm4zmi6kuna	123	102	re	re	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	103	n	n	CC
work_izjlueimqneiljcxm4zmi6kuna	123	104	ce	ce	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	105	i	i	PRP
work_izjlueimqneiljcxm4zmi6kuna	123	106	n	n	CC
work_izjlueimqneiljcxm4zmi6kuna	123	107	r	r	NN
work_izjlueimqneiljcxm4zmi6kuna	123	108	at	at	IN
work_izjlueimqneiljcxm4zmi6kuna	123	109	es	es	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	110	o	o	XX
work_izjlueimqneiljcxm4zmi6kuna	123	111	f	f	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	112	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	113	ea	ea	NN
work_izjlueimqneiljcxm4zmi6kuna	123	114	th	th	XX
work_izjlueimqneiljcxm4zmi6kuna	123	115	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	123	116	H	h	NN
work_izjlueimqneiljcxm4zmi6kuna	123	117	R	r	NN
work_izjlueimqneiljcxm4zmi6kuna	123	118	:	:	:
work_izjlueimqneiljcxm4zmi6kuna	123	119	9	9	CD
work_izjlueimqneiljcxm4zmi6kuna	123	120	5	5	CD
work_izjlueimqneiljcxm4zmi6kuna	123	121	%	%	NN
work_izjlueimqneiljcxm4zmi6kuna	123	122	C	c	NN
work_izjlueimqneiljcxm4zmi6kuna	123	123	I	i	CD
work_izjlueimqneiljcxm4zmi6kuna	123	124	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	123	125	1	1	CD
work_izjlueimqneiljcxm4zmi6kuna	123	126	.0	.0	CD
work_izjlueimqneiljcxm4zmi6kuna	123	127	0	0	CD
work_izjlueimqneiljcxm4zmi6kuna	123	128	:	:	SYM
work_izjlueimqneiljcxm4zmi6kuna	123	129	0	0	CD
work_izjlueimqneiljcxm4zmi6kuna	123	130	.7	.7	NN
work_izjlueimqneiljcxm4zmi6kuna	123	131	1	1	CD
work_izjlueimqneiljcxm4zmi6kuna	123	132	-1	-1	NN
work_izjlueimqneiljcxm4zmi6kuna	123	133	.4	.4	NN
work_izjlueimqneiljcxm4zmi6kuna	123	134	1	1	LS
work_izjlueimqneiljcxm4zmi6kuna	123	135	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	123	136	L	L	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	137	en	en	FW
work_izjlueimqneiljcxm4zmi6kuna	123	138	al	al	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	139	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	123	140	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	141	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	142	m	m	NN
work_izjlueimqneiljcxm4zmi6kuna	123	143	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	123	144	d	d	NN
work_izjlueimqneiljcxm4zmi6kuna	123	145	e-	e-	XX
work_izjlueimqneiljcxm4zmi6kuna	123	146	b	b	NN
work_izjlueimqneiljcxm4zmi6kuna	123	147	as	as	IN
work_izjlueimqneiljcxm4zmi6kuna	123	148	ed	ed	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	149	t	t	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	150	h	h	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	151	er	er	UH
work_izjlueimqneiljcxm4zmi6kuna	123	152	ap	ap	UH
work_izjlueimqneiljcxm4zmi6kuna	123	153	ie	ie	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	154	s	s	POS
work_izjlueimqneiljcxm4zmi6kuna	123	155	:	:	:
work_izjlueimqneiljcxm4zmi6kuna	123	156	l	l	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	157	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	158	w	w	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	159	er	er	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	160	r	r	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	161	is	be	VBZ
work_izjlueimqneiljcxm4zmi6kuna	123	162	k	k	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	163	o	o	XX
work_izjlueimqneiljcxm4zmi6kuna	123	164	f	f	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	165	p	p	NN
work_izjlueimqneiljcxm4zmi6kuna	123	166	er	er	UH
work_izjlueimqneiljcxm4zmi6kuna	123	167	ip	ip	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	168	h	h	UH
work_izjlueimqneiljcxm4zmi6kuna	123	169	er	er	UH
work_izjlueimqneiljcxm4zmi6kuna	123	170	al	al	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	171	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	172	eu	eu	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	173	ro	ro	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	174	p	p	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	175	at	at	IN
work_izjlueimqneiljcxm4zmi6kuna	123	176	h	h	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	177	y	y	NNP
work_izjlueimqneiljcxm4zmi6kuna	123	178	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	123	179	H	h	NN
work_izjlueimqneiljcxm4zmi6kuna	123	180	R	r	NN
work_izjlueimqneiljcxm4zmi6kuna	123	181	:	:	:
work_izjlueimqneiljcxm4zmi6kuna	123	182	9	9	CD
work_izjlueimqneiljcxm4zmi6kuna	123	183	5	5	CD
work_izjlueimqneiljcxm4zmi6kuna	123	184	%	%	NN
work_izjlueimqneiljcxm4zmi6kuna	123	185	C	c	NN
work_izjlueimqneiljcxm4zmi6kuna	123	186	I	i	NN
work_izjlueimqneiljcxm4zmi6kuna	123	187	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	123	188	0	0	CD
work_izjlueimqneiljcxm4zmi6kuna	123	189	.7	.7	NN
work_izjlueimqneiljcxm4zmi6kuna	123	190	1	1	CD
work_izjlueimqneiljcxm4zmi6kuna	123	191	:	:	SYM
work_izjlueimqneiljcxm4zmi6kuna	123	192	0	0	CD
work_izjlueimqneiljcxm4zmi6kuna	123	193	.5	.5	NN
work_izjlueimqneiljcxm4zmi6kuna	123	194	6	6	CD
work_izjlueimqneiljcxm4zmi6kuna	123	195	-0	-0	NN
work_izjlueimqneiljcxm4zmi6kuna	123	196	.9	.9	CD
work_izjlueimqneiljcxm4zmi6kuna	123	197	2	2	CD
work_izjlueimqneiljcxm4zmi6kuna	123	198	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	123	199	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	124	1	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	2	P	p	NN
work_izjlueimqneiljcxm4zmi6kuna	124	3	T	T	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	4	-T	-T	:
work_izjlueimqneiljcxm4zmi6kuna	124	5	:	:	:
work_izjlueimqneiljcxm4zmi6kuna	124	6	I	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	124	7	n	n	CC
work_izjlueimqneiljcxm4zmi6kuna	124	8	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	9	u	u	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	10	ct	ct	XX
work_izjlueimqneiljcxm4zmi6kuna	124	11	io	io	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	12	n	n	CC
work_izjlueimqneiljcxm4zmi6kuna	124	13	w	w	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	14	it	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	124	15	h	h	VBZ
work_izjlueimqneiljcxm4zmi6kuna	124	16	“	"	``
work_izjlueimqneiljcxm4zmi6kuna	124	17	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	18	el	el	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	19	p	p	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	20	h	h	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	21	al	al	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	22	an	an	DT
work_izjlueimqneiljcxm4zmi6kuna	124	23	/p	/p	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	24	re	re	IN
work_izjlueimqneiljcxm4zmi6kuna	124	25	d	d	NN
work_izjlueimqneiljcxm4zmi6kuna	124	26	n	n	CC
work_izjlueimqneiljcxm4zmi6kuna	124	27	is	be	VBZ
work_izjlueimqneiljcxm4zmi6kuna	124	28	o	o	XX
work_izjlueimqneiljcxm4zmi6kuna	124	29	n	n	CC
work_izjlueimqneiljcxm4zmi6kuna	124	30	e/	e/	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	31	th	th	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	32	al	al	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	33	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	124	34	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	35	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	36	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	37	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	124	38	d	d	NN
work_izjlueimqneiljcxm4zmi6kuna	124	39	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	40	”	"	''
work_izjlueimqneiljcxm4zmi6kuna	124	41	a	a	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	42	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	43	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	44	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	45	ai	ai	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	46	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	47	te	te	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	48	n	n	CC
work_izjlueimqneiljcxm4zmi6kuna	124	49	an	an	DT
work_izjlueimqneiljcxm4zmi6kuna	124	50	ce	ce	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	51	w	w	NN
work_izjlueimqneiljcxm4zmi6kuna	124	52	it	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	124	53	h	h	VBZ
work_izjlueimqneiljcxm4zmi6kuna	124	54	t	t	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	55	h	h	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	56	al	al	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	57	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	124	58	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	59	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	60	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	61	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	124	62	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	63	e.	e.	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	64	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	65	P	P	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	66	R	R	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	67	-R	-R	:
work_izjlueimqneiljcxm4zmi6kuna	124	68	:	:	:
work_izjlueimqneiljcxm4zmi6kuna	124	69	I	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	124	70	n	n	CC
work_izjlueimqneiljcxm4zmi6kuna	124	71	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	72	u	u	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	73	ct	ct	XX
work_izjlueimqneiljcxm4zmi6kuna	124	74	io	io	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	75	n	n	CC
work_izjlueimqneiljcxm4zmi6kuna	124	76	w	w	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	77	it	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	124	78	h	h	VBZ
work_izjlueimqneiljcxm4zmi6kuna	124	79	“	"	``
work_izjlueimqneiljcxm4zmi6kuna	124	80	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	81	el	el	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	82	p	p	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	83	h	h	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	84	al	al	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	85	an	an	DT
work_izjlueimqneiljcxm4zmi6kuna	124	86	/p	/p	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	87	re	re	IN
work_izjlueimqneiljcxm4zmi6kuna	124	88	d	d	NN
work_izjlueimqneiljcxm4zmi6kuna	124	89	n	n	CC
work_izjlueimqneiljcxm4zmi6kuna	124	90	is	be	VBZ
work_izjlueimqneiljcxm4zmi6kuna	124	91	o	o	XX
work_izjlueimqneiljcxm4zmi6kuna	124	92	n	n	CC
work_izjlueimqneiljcxm4zmi6kuna	124	93	e/	e/	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	94	le	le	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	95	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	96	al	al	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	97	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	124	98	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	99	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	100	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	101	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	124	102	d	d	NN
work_izjlueimqneiljcxm4zmi6kuna	124	103	e	e	NN
work_izjlueimqneiljcxm4zmi6kuna	124	104	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	124	105	R	r	NN
work_izjlueimqneiljcxm4zmi6kuna	124	106	ev	ev	IN
work_izjlueimqneiljcxm4zmi6kuna	124	107	il	il	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	108	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	124	109	m	be	VBP
work_izjlueimqneiljcxm4zmi6kuna	124	110	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	124	111	d	d	XX
work_izjlueimqneiljcxm4zmi6kuna	124	112	®	®	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	113	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	124	114	”	"	''
work_izjlueimqneiljcxm4zmi6kuna	124	115	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	124	116	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	117	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	118	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	119	ai	ai	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	120	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	121	te	te	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	122	n	n	CC
work_izjlueimqneiljcxm4zmi6kuna	124	123	an	an	DT
work_izjlueimqneiljcxm4zmi6kuna	124	124	ce	ce	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	125	w	w	NN
work_izjlueimqneiljcxm4zmi6kuna	124	126	it	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	124	127	h	h	VBZ
work_izjlueimqneiljcxm4zmi6kuna	124	128	l	l	NN
work_izjlueimqneiljcxm4zmi6kuna	124	129	en	en	FW
work_izjlueimqneiljcxm4zmi6kuna	124	130	al	al	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	131	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	124	132	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	133	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	134	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	135	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	124	136	d	d	XX
work_izjlueimqneiljcxm4zmi6kuna	124	137	e.	e.	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	138	D	D	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	139	X	x	NN
work_izjlueimqneiljcxm4zmi6kuna	124	140	M	m	NN
work_izjlueimqneiljcxm4zmi6kuna	124	141	:	:	:
work_izjlueimqneiljcxm4zmi6kuna	124	142	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	143	ex	ex	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	144	am	am	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	145	et	et	NN
work_izjlueimqneiljcxm4zmi6kuna	124	146	h	h	NN
work_izjlueimqneiljcxm4zmi6kuna	124	147	as	as	IN
work_izjlueimqneiljcxm4zmi6kuna	124	148	o	o	NN
work_izjlueimqneiljcxm4zmi6kuna	124	149	n	n	NN
work_izjlueimqneiljcxm4zmi6kuna	124	150	e.	e.	NN
work_izjlueimqneiljcxm4zmi6kuna	124	151	+	+	CC
work_izjlueimqneiljcxm4zmi6kuna	124	152	P	p	NN
work_izjlueimqneiljcxm4zmi6kuna	124	153	at	at	IN
work_izjlueimqneiljcxm4zmi6kuna	124	154	ie	ie	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	155	n	n	NN
work_izjlueimqneiljcxm4zmi6kuna	124	156	ts	ts	NN
work_izjlueimqneiljcxm4zmi6kuna	124	157	t	t	NN
work_izjlueimqneiljcxm4zmi6kuna	124	158	re	re	NN
work_izjlueimqneiljcxm4zmi6kuna	124	159	at	at	IN
work_izjlueimqneiljcxm4zmi6kuna	124	160	ed	ed	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	161	w	w	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	162	it	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	124	163	h	h	VBZ
work_izjlueimqneiljcxm4zmi6kuna	124	164	t	t	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	165	h	h	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	166	al	al	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	167	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	124	168	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	169	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	170	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	171	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	124	172	d	d	NN
work_izjlueimqneiljcxm4zmi6kuna	124	173	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	174	an	an	DT
work_izjlueimqneiljcxm4zmi6kuna	124	175	d	d	NN
work_izjlueimqneiljcxm4zmi6kuna	124	176	D	d	NN
work_izjlueimqneiljcxm4zmi6kuna	124	177	X	x	NN
work_izjlueimqneiljcxm4zmi6kuna	124	178	M	M	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	179	r	r	NN
work_izjlueimqneiljcxm4zmi6kuna	124	180	ec	ec	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	181	ei	ei	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	182	ve	ve	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	183	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	184	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	185	if	if	IN
work_izjlueimqneiljcxm4zmi6kuna	124	186	fe	fe	FW
work_izjlueimqneiljcxm4zmi6kuna	124	187	re	re	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	188	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	189	t	t	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	190	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	191	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	192	se	se	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	193	s	s	NNP
work_izjlueimqneiljcxm4zmi6kuna	124	194	o	o	NN
work_izjlueimqneiljcxm4zmi6kuna	124	195	f	f	NN
work_izjlueimqneiljcxm4zmi6kuna	124	196	D	d	NN
work_izjlueimqneiljcxm4zmi6kuna	124	197	X	x	NN
work_izjlueimqneiljcxm4zmi6kuna	124	198	M	m	NN
work_izjlueimqneiljcxm4zmi6kuna	124	199	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	125	1	A	a	DT
work_izjlueimqneiljcxm4zmi6kuna	125	2	d	d	NN
work_izjlueimqneiljcxm4zmi6kuna	125	3	ve	ve	NN
work_izjlueimqneiljcxm4zmi6kuna	125	4	rs	rs	NN
work_izjlueimqneiljcxm4zmi6kuna	125	5	e	e	XX
work_izjlueimqneiljcxm4zmi6kuna	125	6	ev	ev	XX
work_izjlueimqneiljcxm4zmi6kuna	125	7	en	en	FW
work_izjlueimqneiljcxm4zmi6kuna	125	8	ts	ts	NNP
work_izjlueimqneiljcxm4zmi6kuna	125	9	w	w	NN
work_izjlueimqneiljcxm4zmi6kuna	125	10	er	er	UH
work_izjlueimqneiljcxm4zmi6kuna	125	11	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	125	12	gr	gr	NNP
work_izjlueimqneiljcxm4zmi6kuna	125	13	ad	ad	NNP
work_izjlueimqneiljcxm4zmi6kuna	125	14	ed	ed	NNP
work_izjlueimqneiljcxm4zmi6kuna	125	15	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	125	16	cc	cc	NNP
work_izjlueimqneiljcxm4zmi6kuna	125	17	o	o	NN
work_izjlueimqneiljcxm4zmi6kuna	125	18	rd	rd	NNP
work_izjlueimqneiljcxm4zmi6kuna	125	19	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	125	20	g	g	NNP
work_izjlueimqneiljcxm4zmi6kuna	125	21	to	to	IN
work_izjlueimqneiljcxm4zmi6kuna	125	22	t	t	NN
work_izjlueimqneiljcxm4zmi6kuna	125	23	h	h	NN
work_izjlueimqneiljcxm4zmi6kuna	125	24	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	125	25	U	U	NNP
work_izjlueimqneiljcxm4zmi6kuna	125	26	S	S	NNP
work_izjlueimqneiljcxm4zmi6kuna	125	27	N	N	NNP
work_izjlueimqneiljcxm4zmi6kuna	125	28	at	at	IN
work_izjlueimqneiljcxm4zmi6kuna	125	29	io	io	NNP
work_izjlueimqneiljcxm4zmi6kuna	125	30	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	125	31	al	al	NNP
work_izjlueimqneiljcxm4zmi6kuna	125	32	C	C	NNP
work_izjlueimqneiljcxm4zmi6kuna	125	33	an	an	DT
work_izjlueimqneiljcxm4zmi6kuna	125	34	ce	ce	NNP
work_izjlueimqneiljcxm4zmi6kuna	125	35	r	r	NN
work_izjlueimqneiljcxm4zmi6kuna	125	36	In	in	IN
work_izjlueimqneiljcxm4zmi6kuna	125	37	st	st	NNP
work_izjlueimqneiljcxm4zmi6kuna	125	38	it	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	125	39	u	u	NNP
work_izjlueimqneiljcxm4zmi6kuna	125	40	te	te	NNP
work_izjlueimqneiljcxm4zmi6kuna	125	41	C	C	NNP
work_izjlueimqneiljcxm4zmi6kuna	125	42	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	125	43	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	125	44	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	125	45	o	o	NN
work_izjlueimqneiljcxm4zmi6kuna	125	46	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	125	47	T	t	NN
work_izjlueimqneiljcxm4zmi6kuna	125	48	er	er	UH
work_izjlueimqneiljcxm4zmi6kuna	125	49	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	125	50	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	125	51	o	o	NN
work_izjlueimqneiljcxm4zmi6kuna	125	52	lo	lo	NNP
work_izjlueimqneiljcxm4zmi6kuna	125	53	gy	gy	NNP
work_izjlueimqneiljcxm4zmi6kuna	125	54	C	C	NNP
work_izjlueimqneiljcxm4zmi6kuna	125	55	ri	ri	NNP
work_izjlueimqneiljcxm4zmi6kuna	125	56	te	te	NNP
work_izjlueimqneiljcxm4zmi6kuna	125	57	ri	ri	FW
work_izjlueimqneiljcxm4zmi6kuna	125	58	a.	a.	NN
work_izjlueimqneiljcxm4zmi6kuna	125	59	H	h	NN
work_izjlueimqneiljcxm4zmi6kuna	125	60	R	r	NN
work_izjlueimqneiljcxm4zmi6kuna	125	61	:	:	:
work_izjlueimqneiljcxm4zmi6kuna	125	62	h	h	NN
work_izjlueimqneiljcxm4zmi6kuna	125	63	az	az	NNP
work_izjlueimqneiljcxm4zmi6kuna	125	64	ar	ar	NNP
work_izjlueimqneiljcxm4zmi6kuna	125	65	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	125	66	r	r	NNP
work_izjlueimqneiljcxm4zmi6kuna	125	67	at	at	IN
work_izjlueimqneiljcxm4zmi6kuna	125	68	io	io	NNP
work_izjlueimqneiljcxm4zmi6kuna	125	69	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	126	1	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	126	2	o	o	XX
work_izjlueimqneiljcxm4zmi6kuna	126	3	:	:	:
work_izjlueimqneiljcxm4zmi6kuna	126	4	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	126	5	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	126	6	n	n	NN
work_izjlueimqneiljcxm4zmi6kuna	126	7	th	th	XX
work_izjlueimqneiljcxm4zmi6kuna	126	8	s.	s.	NN
work_izjlueimqneiljcxm4zmi6kuna	126	9	R	R	NNP
work_izjlueimqneiljcxm4zmi6kuna	126	10	R	R	NNP
work_izjlueimqneiljcxm4zmi6kuna	126	11	:	:	:
work_izjlueimqneiljcxm4zmi6kuna	126	12	r	r	NN
work_izjlueimqneiljcxm4zmi6kuna	126	13	es	es	NNP
work_izjlueimqneiljcxm4zmi6kuna	126	14	p	p	NNP
work_izjlueimqneiljcxm4zmi6kuna	126	15	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	126	16	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	126	17	se	se	NNP
work_izjlueimqneiljcxm4zmi6kuna	126	18	r	r	NN
work_izjlueimqneiljcxm4zmi6kuna	126	19	at	at	IN
work_izjlueimqneiljcxm4zmi6kuna	126	20	es	es	NNP
work_izjlueimqneiljcxm4zmi6kuna	126	21	P	P	NNP
work_izjlueimqneiljcxm4zmi6kuna	126	22	F	f	NN
work_izjlueimqneiljcxm4zmi6kuna	126	23	S	s	NN
work_izjlueimqneiljcxm4zmi6kuna	126	24	:	:	:
work_izjlueimqneiljcxm4zmi6kuna	126	25	P	p	NN
work_izjlueimqneiljcxm4zmi6kuna	126	26	ro	ro	NNP
work_izjlueimqneiljcxm4zmi6kuna	126	27	gr	gr	FW
work_izjlueimqneiljcxm4zmi6kuna	126	28	es	es	XX
work_izjlueimqneiljcxm4zmi6kuna	126	29	si	si	NNP
work_izjlueimqneiljcxm4zmi6kuna	126	30	o	o	NNP
work_izjlueimqneiljcxm4zmi6kuna	126	31	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	126	32	f	f	NNP
work_izjlueimqneiljcxm4zmi6kuna	126	33	re	re	NN
work_izjlueimqneiljcxm4zmi6kuna	126	34	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	126	35	su	su	NNP
work_izjlueimqneiljcxm4zmi6kuna	126	36	rv	rv	NNP
work_izjlueimqneiljcxm4zmi6kuna	126	37	iv	iv	NNP
work_izjlueimqneiljcxm4zmi6kuna	126	38	al	al	NNP
work_izjlueimqneiljcxm4zmi6kuna	126	39	;	;	:
work_izjlueimqneiljcxm4zmi6kuna	126	40	T	T	NNP
work_izjlueimqneiljcxm4zmi6kuna	126	41	T	T	NNP
work_izjlueimqneiljcxm4zmi6kuna	126	42	P	p	NN
work_izjlueimqneiljcxm4zmi6kuna	126	43	:	:	:
work_izjlueimqneiljcxm4zmi6kuna	126	44	t	t	NNP
work_izjlueimqneiljcxm4zmi6kuna	126	45	i	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	126	46	m	be	VBP
work_izjlueimqneiljcxm4zmi6kuna	126	47	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	126	48	to	to	IN
work_izjlueimqneiljcxm4zmi6kuna	126	49	p	p	NN
work_izjlueimqneiljcxm4zmi6kuna	126	50	ro	ro	FW
work_izjlueimqneiljcxm4zmi6kuna	126	51	gr	gr	FW
work_izjlueimqneiljcxm4zmi6kuna	126	52	es	es	XX
work_izjlueimqneiljcxm4zmi6kuna	126	53	si	si	NNP
work_izjlueimqneiljcxm4zmi6kuna	126	54	o	o	NN
work_izjlueimqneiljcxm4zmi6kuna	126	55	n	n	XX
work_izjlueimqneiljcxm4zmi6kuna	126	56	;	;	:
work_izjlueimqneiljcxm4zmi6kuna	126	57	O	o	UH
work_izjlueimqneiljcxm4zmi6kuna	126	58	S	s	NN
work_izjlueimqneiljcxm4zmi6kuna	126	59	:	:	:
work_izjlueimqneiljcxm4zmi6kuna	126	60	o	o	XX
work_izjlueimqneiljcxm4zmi6kuna	126	61	ve	ve	NNP
work_izjlueimqneiljcxm4zmi6kuna	126	62	ra	ra	NNP
work_izjlueimqneiljcxm4zmi6kuna	126	63	ll	will	NNP
work_izjlueimqneiljcxm4zmi6kuna	126	64	s	s	NNP
work_izjlueimqneiljcxm4zmi6kuna	126	65	u	u	NNP
work_izjlueimqneiljcxm4zmi6kuna	126	66	rv	rv	NNP
work_izjlueimqneiljcxm4zmi6kuna	126	67	iv	iv	NNP
work_izjlueimqneiljcxm4zmi6kuna	126	68	al	al	NNP
work_izjlueimqneiljcxm4zmi6kuna	126	69	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	127	1	3	3	CD
work_izjlueimqneiljcxm4zmi6kuna	127	2	7	7	CD
work_izjlueimqneiljcxm4zmi6kuna	127	3	8	8	CD
work_izjlueimqneiljcxm4zmi6kuna	127	4	9	9	CD
work_izjlueimqneiljcxm4zmi6kuna	127	5	C	C	NNP
work_izjlueimqneiljcxm4zmi6kuna	127	6	iên	iên	NN
work_izjlueimqneiljcxm4zmi6kuna	127	7	cia	cia	NNP
work_izjlueimqneiljcxm4zmi6kuna	127	8	&	&	CC
work_izjlueimqneiljcxm4zmi6kuna	127	9	Saú	Saú	NNP
work_izjlueimqneiljcxm4zmi6kuna	127	10	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	127	11	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	127	12	C	C	NNP
work_izjlueimqneiljcxm4zmi6kuna	127	13	o	o	NN
work_izjlueimqneiljcxm4zmi6kuna	127	14	letiva	letiva	NN
work_izjlueimqneiljcxm4zmi6kuna	127	15	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	127	16	2	2	CD
work_izjlueimqneiljcxm4zmi6kuna	127	17	4	4	CD
work_izjlueimqneiljcxm4zmi6kuna	127	18	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	127	19	1	1	CD
work_izjlueimqneiljcxm4zmi6kuna	127	20	0	0	CD
work_izjlueimqneiljcxm4zmi6kuna	127	21	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	127	22	:3	:3	NNP
work_izjlueimqneiljcxm4zmi6kuna	127	23	7	7	CD
work_izjlueimqneiljcxm4zmi6kuna	127	24	8	8	CD
work_izjlueimqneiljcxm4zmi6kuna	127	25	3	3	CD
work_izjlueimqneiljcxm4zmi6kuna	127	26	-3	-3	$
work_izjlueimqneiljcxm4zmi6kuna	127	27	7	7	CD
work_izjlueimqneiljcxm4zmi6kuna	127	28	9	9	CD
work_izjlueimqneiljcxm4zmi6kuna	127	29	2	2	CD
work_izjlueimqneiljcxm4zmi6kuna	127	30	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	127	31	2	2	CD
work_izjlueimqneiljcxm4zmi6kuna	127	32	0	0	CD
work_izjlueimqneiljcxm4zmi6kuna	127	33	1	1	CD
work_izjlueimqneiljcxm4zmi6kuna	127	34	9	9	CD
work_izjlueimqneiljcxm4zmi6kuna	127	35	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	127	36	MM	mm	NN
work_izjlueimqneiljcxm4zmi6kuna	127	37	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	128	1	Nonetheless	nonetheless	RB
work_izjlueimqneiljcxm4zmi6kuna	128	2	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	128	3	studies	study	NNS
work_izjlueimqneiljcxm4zmi6kuna	128	4	suggest	suggest	VBP
work_izjlueimqneiljcxm4zmi6kuna	128	5	that	that	IN
work_izjlueimqneiljcxm4zmi6kuna	128	6	lena-	lena-	NN
work_izjlueimqneiljcxm4zmi6kuna	128	7	lidomide	lidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	128	8	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	128	9	based	base	VBN
work_izjlueimqneiljcxm4zmi6kuna	128	10	regimens	regimen	NNS
work_izjlueimqneiljcxm4zmi6kuna	128	11	are	be	VBP
work_izjlueimqneiljcxm4zmi6kuna	128	12	associated	associate	VBN
work_izjlueimqneiljcxm4zmi6kuna	128	13	with	with	IN
work_izjlueimqneiljcxm4zmi6kuna	128	14	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	128	15	lower	low	JJR
work_izjlueimqneiljcxm4zmi6kuna	128	16	risk	risk	NN
work_izjlueimqneiljcxm4zmi6kuna	128	17	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	128	18	peripheral	peripheral	JJ
work_izjlueimqneiljcxm4zmi6kuna	128	19	neuropathy	neuropathy	NN
work_izjlueimqneiljcxm4zmi6kuna	128	20	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	128	21	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	128	22	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	128	23	higher	high	JJR
work_izjlueimqneiljcxm4zmi6kuna	128	24	risk	risk	NN
work_izjlueimqneiljcxm4zmi6kuna	128	25	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	128	26	hematologic	hematologic	JJ
work_izjlueimqneiljcxm4zmi6kuna	128	27	adverse	adverse	JJ
work_izjlueimqneiljcxm4zmi6kuna	128	28	effects	effect	NNS
work_izjlueimqneiljcxm4zmi6kuna	128	29	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	128	30	Table	table	NN
work_izjlueimqneiljcxm4zmi6kuna	128	31	1	1	CD
work_izjlueimqneiljcxm4zmi6kuna	128	32	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	128	33	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	129	1	Concluding	conclude	VBG
work_izjlueimqneiljcxm4zmi6kuna	129	2	remarks	remark	NNS
work_izjlueimqneiljcxm4zmi6kuna	129	3	Lenalidomide	lenalidomide	JJ
work_izjlueimqneiljcxm4zmi6kuna	129	4	approval	approval	NN
work_izjlueimqneiljcxm4zmi6kuna	129	5	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	129	6	marketing	marketing	NN
work_izjlueimqneiljcxm4zmi6kuna	129	7	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	129	8	Brazil	Brazil	NNP
work_izjlueimqneiljcxm4zmi6kuna	129	9	is	be	VBZ
work_izjlueimqneiljcxm4zmi6kuna	129	10	an	an	DT
work_izjlueimqneiljcxm4zmi6kuna	129	11	unquestionable	unquestionable	JJ
work_izjlueimqneiljcxm4zmi6kuna	129	12	triumph	triumph	NN
work_izjlueimqneiljcxm4zmi6kuna	129	13	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	129	14	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	129	15	lobbying	lobbying	NN
work_izjlueimqneiljcxm4zmi6kuna	129	16	involv-	involv-	VBD
work_izjlueimqneiljcxm4zmi6kuna	129	17	ing	ing	NNP
work_izjlueimqneiljcxm4zmi6kuna	129	18	Congress	Congress	NNP
work_izjlueimqneiljcxm4zmi6kuna	129	19	members	member	NNS
work_izjlueimqneiljcxm4zmi6kuna	129	20	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	129	21	patient	patient	JJ
work_izjlueimqneiljcxm4zmi6kuna	129	22	organizations	organization	NNS
work_izjlueimqneiljcxm4zmi6kuna	129	23	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	129	24	most	most	JJS
work_izjlueimqneiljcxm4zmi6kuna	129	25	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	129	26	which	which	WDT
work_izjlueimqneiljcxm4zmi6kuna	129	27	supported	support	VBN
work_izjlueimqneiljcxm4zmi6kuna	129	28	by	by	IN
work_izjlueimqneiljcxm4zmi6kuna	129	29	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	129	30	pharmaceutical	pharmaceutical	JJ
work_izjlueimqneiljcxm4zmi6kuna	129	31	company	company	NN
work_izjlueimqneiljcxm4zmi6kuna	129	32	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	129	33	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	129	34	medical	medical	JJ
work_izjlueimqneiljcxm4zmi6kuna	129	35	specialty	specialty	NN
work_izjlueimqneiljcxm4zmi6kuna	129	36	associations	association	NNS
work_izjlueimqneiljcxm4zmi6kuna	129	37	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	130	1	As	as	IN
work_izjlueimqneiljcxm4zmi6kuna	130	2	always	always	RB
work_izjlueimqneiljcxm4zmi6kuna	130	3	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	130	4	lobbying	lobby	VBG
work_izjlueimqneiljcxm4zmi6kuna	130	5	campaign	campaign	NN
work_izjlueimqneiljcxm4zmi6kuna	130	6	blurred	blur	VBD
work_izjlueimqneiljcxm4zmi6kuna	130	7	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	130	8	scientific	scientific	JJ
work_izjlueimqneiljcxm4zmi6kuna	130	9	evidence	evidence	NN
work_izjlueimqneiljcxm4zmi6kuna	130	10	behind	behind	IN
work_izjlueimqneiljcxm4zmi6kuna	130	11	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	130	12	arguments	argument	NNS
work_izjlueimqneiljcxm4zmi6kuna	130	13	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	130	14	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	130	15	against	against	IN
work_izjlueimqneiljcxm4zmi6kuna	130	16	an	an	DT
work_izjlueimqneiljcxm4zmi6kuna	130	17	approval	approval	NN
work_izjlueimqneiljcxm4zmi6kuna	130	18	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	130	19	marketing	marketing	NN
work_izjlueimqneiljcxm4zmi6kuna	130	20	decision	decision	NN
work_izjlueimqneiljcxm4zmi6kuna	130	21	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	131	1	Lenalidomide	lenalidomide	JJ
work_izjlueimqneiljcxm4zmi6kuna	131	2	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	131	3	thalidomide	thalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	131	4	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	131	5	proteasome	proteasome	JJ
work_izjlueimqneiljcxm4zmi6kuna	131	6	inhibitors	inhibitor	NNS
work_izjlueimqneiljcxm4zmi6kuna	131	7	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	131	8	bortezomid	bortezomid	NNP
work_izjlueimqneiljcxm4zmi6kuna	131	9	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	131	10	are	be	VBP
work_izjlueimqneiljcxm4zmi6kuna	131	11	effective	effective	JJ
work_izjlueimqneiljcxm4zmi6kuna	131	12	drugs	drug	NNS
work_izjlueimqneiljcxm4zmi6kuna	131	13	that	that	WDT
work_izjlueimqneiljcxm4zmi6kuna	131	14	have	have	VBP
work_izjlueimqneiljcxm4zmi6kuna	131	15	revolutionized	revolutionize	VBN
work_izjlueimqneiljcxm4zmi6kuna	131	16	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	131	17	treatment	treatment	NN
work_izjlueimqneiljcxm4zmi6kuna	131	18	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	131	19	MM	MM	NNP
work_izjlueimqneiljcxm4zmi6kuna	131	20	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	132	1	Com-	Com-	NNP
work_izjlueimqneiljcxm4zmi6kuna	132	2	parative	parative	JJ
work_izjlueimqneiljcxm4zmi6kuna	132	3	effectiveness	effectiveness	NN
work_izjlueimqneiljcxm4zmi6kuna	132	4	research	research	NN
work_izjlueimqneiljcxm4zmi6kuna	132	5	failed	fail	VBD
work_izjlueimqneiljcxm4zmi6kuna	132	6	to	to	IN
work_izjlueimqneiljcxm4zmi6kuna	132	7	demon-	demon-	NNP
work_izjlueimqneiljcxm4zmi6kuna	132	8	strate	strate	VB
work_izjlueimqneiljcxm4zmi6kuna	132	9	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	132	10	greater	great	JJR
work_izjlueimqneiljcxm4zmi6kuna	132	11	efficacy	efficacy	NN
work_izjlueimqneiljcxm4zmi6kuna	132	12	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	132	13	lenalidomide	lenalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	132	14	over	over	IN
work_izjlueimqneiljcxm4zmi6kuna	132	15	thalidomide	thalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	132	16	or	or	CC
work_izjlueimqneiljcxm4zmi6kuna	132	17	bortezomid	bortezomid	VB
work_izjlueimqneiljcxm4zmi6kuna	132	18	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	132	19	patients	patient	NNS
work_izjlueimqneiljcxm4zmi6kuna	132	20	with	with	IN
work_izjlueimqneiljcxm4zmi6kuna	132	21	MM18	MM18	NNP
work_izjlueimqneiljcxm4zmi6kuna	132	22	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	132	23	21,23	21,23	CD
work_izjlueimqneiljcxm4zmi6kuna	132	24	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	133	1	All	all	PDT
work_izjlueimqneiljcxm4zmi6kuna	133	2	these	these	DT
work_izjlueimqneiljcxm4zmi6kuna	133	3	drugs	drug	NNS
work_izjlueimqneiljcxm4zmi6kuna	133	4	can	can	MD
work_izjlueimqneiljcxm4zmi6kuna	133	5	cause	cause	VB
work_izjlueimqneiljcxm4zmi6kuna	133	6	potentially	potentially	RB
work_izjlueimqneiljcxm4zmi6kuna	133	7	severe	severe	JJ
work_izjlueimqneiljcxm4zmi6kuna	133	8	adverse	adverse	JJ
work_izjlueimqneiljcxm4zmi6kuna	133	9	effects	effect	NNS
work_izjlueimqneiljcxm4zmi6kuna	133	10	but	but	CC
work_izjlueimqneiljcxm4zmi6kuna	133	11	their	-PRON-	PRP$
work_izjlueimqneiljcxm4zmi6kuna	133	12	toxicity	toxicity	NN
work_izjlueimqneiljcxm4zmi6kuna	133	13	profiles	profile	NNS
work_izjlueimqneiljcxm4zmi6kuna	133	14	are	be	VBP
work_izjlueimqneiljcxm4zmi6kuna	133	15	somewhat	somewhat	RB
work_izjlueimqneiljcxm4zmi6kuna	133	16	different	different	JJ
work_izjlueimqneiljcxm4zmi6kuna	133	17	from	from	IN
work_izjlueimqneiljcxm4zmi6kuna	133	18	each	each	DT
work_izjlueimqneiljcxm4zmi6kuna	133	19	other	other	JJ
work_izjlueimqneiljcxm4zmi6kuna	133	20	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	134	1	For	for	IN
work_izjlueimqneiljcxm4zmi6kuna	134	2	in-	in-	JJ
work_izjlueimqneiljcxm4zmi6kuna	134	3	stance	stance	NN
work_izjlueimqneiljcxm4zmi6kuna	134	4	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	134	5	lenalidomide	lenalidomide	VB
work_izjlueimqneiljcxm4zmi6kuna	134	6	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	134	7	compared	compare	VBN
work_izjlueimqneiljcxm4zmi6kuna	134	8	to	to	IN
work_izjlueimqneiljcxm4zmi6kuna	134	9	thalidomide	thalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	134	10	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	134	11	apparently	apparently	RB
work_izjlueimqneiljcxm4zmi6kuna	134	12	causes	cause	VBZ
work_izjlueimqneiljcxm4zmi6kuna	134	13	less	less	RBR
work_izjlueimqneiljcxm4zmi6kuna	134	14	peripheral	peripheral	JJ
work_izjlueimqneiljcxm4zmi6kuna	134	15	neuropathy	neuropathy	NN
work_izjlueimqneiljcxm4zmi6kuna	134	16	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	134	17	more	more	RBR
work_izjlueimqneiljcxm4zmi6kuna	134	18	severe	severe	JJ
work_izjlueimqneiljcxm4zmi6kuna	134	19	hematologic	hematologic	JJ
work_izjlueimqneiljcxm4zmi6kuna	134	20	toxicity	toxicity	NN
work_izjlueimqneiljcxm4zmi6kuna	134	21	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	135	1	If	if	IN
work_izjlueimqneiljcxm4zmi6kuna	135	2	comparative	comparative	JJ
work_izjlueimqneiljcxm4zmi6kuna	135	3	effectiveness	effectiveness	NN
work_izjlueimqneiljcxm4zmi6kuna	135	4	research	research	NN
work_izjlueimqneiljcxm4zmi6kuna	135	5	do	do	VBP
work_izjlueimqneiljcxm4zmi6kuna	135	6	not	not	RB
work_izjlueimqneiljcxm4zmi6kuna	135	7	reveal	reveal	VB
work_izjlueimqneiljcxm4zmi6kuna	135	8	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	135	9	clinical	clinical	JJ
work_izjlueimqneiljcxm4zmi6kuna	135	10	superiority	superiority	NN
work_izjlueimqneiljcxm4zmi6kuna	135	11	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	135	12	lenalidomide	lenalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	135	13	over	over	IN
work_izjlueimqneiljcxm4zmi6kuna	135	14	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	135	15	other	other	JJ
work_izjlueimqneiljcxm4zmi6kuna	135	16	drugs	drug	NNS
work_izjlueimqneiljcxm4zmi6kuna	135	17	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	135	18	cost	cost	NN
work_izjlueimqneiljcxm4zmi6kuna	135	19	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	135	20	effectiveness	effectiveness	NN
work_izjlueimqneiljcxm4zmi6kuna	135	21	seems	seem	VBZ
work_izjlueimqneiljcxm4zmi6kuna	135	22	to	to	TO
work_izjlueimqneiljcxm4zmi6kuna	135	23	be	be	VB
work_izjlueimqneiljcxm4zmi6kuna	135	24	different	different	JJ
work_izjlueimqneiljcxm4zmi6kuna	135	25	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	136	1	Thalidomide	Thalidomide	NNP
work_izjlueimqneiljcxm4zmi6kuna	136	2	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	136	3	based	base	VBN
work_izjlueimqneiljcxm4zmi6kuna	136	4	treatments	treatment	NNS
work_izjlueimqneiljcxm4zmi6kuna	136	5	are	be	VBP
work_izjlueimqneiljcxm4zmi6kuna	136	6	cost	cost	NN
work_izjlueimqneiljcxm4zmi6kuna	136	7	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	136	8	effective	effective	JJ
work_izjlueimqneiljcxm4zmi6kuna	136	9	compared	compare	VBN
work_izjlueimqneiljcxm4zmi6kuna	136	10	with	with	IN
work_izjlueimqneiljcxm4zmi6kuna	136	11	those	those	DT
work_izjlueimqneiljcxm4zmi6kuna	136	12	based	base	VBN
work_izjlueimqneiljcxm4zmi6kuna	136	13	on	on	IN
work_izjlueimqneiljcxm4zmi6kuna	136	14	lenalidomide	lenalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	136	15	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	137	1	This	this	DT
work_izjlueimqneiljcxm4zmi6kuna	137	2	was	be	VBD
work_izjlueimqneiljcxm4zmi6kuna	137	3	shown	show	VBN
work_izjlueimqneiljcxm4zmi6kuna	137	4	by	by	IN
work_izjlueimqneiljcxm4zmi6kuna	137	5	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	137	6	study	study	NN
work_izjlueimqneiljcxm4zmi6kuna	137	7	com-	com-	NN
work_izjlueimqneiljcxm4zmi6kuna	137	8	paring	pare	VBG
work_izjlueimqneiljcxm4zmi6kuna	137	9	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	137	10	cost	cost	NN
work_izjlueimqneiljcxm4zmi6kuna	137	11	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	137	12	effectiveness	effectiveness	NN
work_izjlueimqneiljcxm4zmi6kuna	137	13	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	137	14	initial	initial	JJ
work_izjlueimqneiljcxm4zmi6kuna	137	15	treatment	treatment	NN
work_izjlueimqneiljcxm4zmi6kuna	137	16	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	137	17	MM	MM	NNP
work_izjlueimqneiljcxm4zmi6kuna	137	18	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	137	19	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	137	20	US	US	NNP
work_izjlueimqneiljcxm4zmi6kuna	137	21	with	with	IN
work_izjlueimqneiljcxm4zmi6kuna	137	22	“	"	``
work_izjlueimqneiljcxm4zmi6kuna	137	23	bortezomid	bortezomid	NNP
work_izjlueimqneiljcxm4zmi6kuna	137	24	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	137	25	Velcade	Velcade	NNP
work_izjlueimqneiljcxm4zmi6kuna	137	26	®	®	NNPS
work_izjlueimqneiljcxm4zmi6kuna	137	27	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	137	28	+	+	SYM
work_izjlueimqneiljcxm4zmi6kuna	137	29	melphalan	melphalan	NN
work_izjlueimqneiljcxm4zmi6kuna	137	30	+	+	SYM
work_izjlueimqneiljcxm4zmi6kuna	137	31	prednisone	prednisone	NN
work_izjlueimqneiljcxm4zmi6kuna	137	32	”	"	''
work_izjlueimqneiljcxm4zmi6kuna	137	33	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	137	34	VMP	VMP	NNP
work_izjlueimqneiljcxm4zmi6kuna	137	35	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	137	36	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	137	37	versus	versus	IN
work_izjlueimqneiljcxm4zmi6kuna	137	38	“	"	``
work_izjlueimqneiljcxm4zmi6kuna	137	39	tha-	tha-	NN
work_izjlueimqneiljcxm4zmi6kuna	137	40	lidomide	lidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	137	41	+	+	SYM
work_izjlueimqneiljcxm4zmi6kuna	137	42	melphalan	melphalan	NN
work_izjlueimqneiljcxm4zmi6kuna	137	43	+	+	SYM
work_izjlueimqneiljcxm4zmi6kuna	137	44	prednisone	prednisone	NN
work_izjlueimqneiljcxm4zmi6kuna	137	45	”	"	''
work_izjlueimqneiljcxm4zmi6kuna	137	46	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	137	47	MPT	MPT	NNP
work_izjlueimqneiljcxm4zmi6kuna	137	48	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	137	49	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	137	50	versus	versus	IN
work_izjlueimqneiljcxm4zmi6kuna	137	51	“	"	``
work_izjlueimqneiljcxm4zmi6kuna	137	52	lenalidomide	lenalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	137	53	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	137	54	Revlimid	Revlimid	NNP
work_izjlueimqneiljcxm4zmi6kuna	137	55	®	®	NNP
work_izjlueimqneiljcxm4zmi6kuna	137	56	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	137	57	+	+	SYM
work_izjlueimqneiljcxm4zmi6kuna	137	58	melphalan	melphalan	NN
work_izjlueimqneiljcxm4zmi6kuna	137	59	+	+	CC
work_izjlueimqneiljcxm4zmi6kuna	137	60	prednisone	prednisone	NN
work_izjlueimqneiljcxm4zmi6kuna	137	61	plus	plus	CC
work_izjlueimqneiljcxm4zmi6kuna	137	62	lenalidomide	lenalidomide	JJ
work_izjlueimqneiljcxm4zmi6kuna	137	63	maintenance	maintenance	NN
work_izjlueimqneiljcxm4zmi6kuna	137	64	”	"	''
work_izjlueimqneiljcxm4zmi6kuna	137	65	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	137	66	MPR	MPR	NNP
work_izjlueimqneiljcxm4zmi6kuna	137	67	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	137	68	R	R	NNP
work_izjlueimqneiljcxm4zmi6kuna	137	69	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	137	70	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	137	71	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	137	72	found	find	VBD
work_izjlueimqneiljcxm4zmi6kuna	137	73	that	that	IN
work_izjlueimqneiljcxm4zmi6kuna	137	74	VMP	vmp	NN
work_izjlueimqneiljcxm4zmi6kuna	137	75	cost	cost	VBD
work_izjlueimqneiljcxm4zmi6kuna	137	76	$	$	$
work_izjlueimqneiljcxm4zmi6kuna	137	77	119,102	119,102	CD
work_izjlueimqneiljcxm4zmi6kuna	137	78	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	137	79	MPT	MPT	NNP
work_izjlueimqneiljcxm4zmi6kuna	137	80	$	$	$
work_izjlueimqneiljcxm4zmi6kuna	137	81	142,452	142,452	CD
work_izjlueimqneiljcxm4zmi6kuna	137	82	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	137	83	MPR	MPR	NNP
work_izjlueimqneiljcxm4zmi6kuna	137	84	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	137	85	R	R	NNP
work_izjlueimqneiljcxm4zmi6kuna	137	86	$	$	$
work_izjlueimqneiljcxm4zmi6kuna	137	87	248,35824	248,35824	CD
work_izjlueimqneiljcxm4zmi6kuna	137	88	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	138	1	Thalid-	Thalid-	NNP
work_izjlueimqneiljcxm4zmi6kuna	138	2	omide	omide	NN
work_izjlueimqneiljcxm4zmi6kuna	138	3	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	138	4	based	base	VBN
work_izjlueimqneiljcxm4zmi6kuna	138	5	therapies	therapy	NNS
work_izjlueimqneiljcxm4zmi6kuna	138	6	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	138	7	however	however	RB
work_izjlueimqneiljcxm4zmi6kuna	138	8	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	138	9	are	be	VBP
work_izjlueimqneiljcxm4zmi6kuna	138	10	certain-	certain-	VBG
work_izjlueimqneiljcxm4zmi6kuna	138	11	ly	ly	XX
work_izjlueimqneiljcxm4zmi6kuna	138	12	much	much	RB
work_izjlueimqneiljcxm4zmi6kuna	138	13	cheaper	cheap	JJR
work_izjlueimqneiljcxm4zmi6kuna	138	14	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	138	15	Brazil	Brazil	NNP
work_izjlueimqneiljcxm4zmi6kuna	138	16	where	where	WRB
work_izjlueimqneiljcxm4zmi6kuna	138	17	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	138	18	state	state	NN
work_izjlueimqneiljcxm4zmi6kuna	138	19	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	138	20	owned	own	VBN
work_izjlueimqneiljcxm4zmi6kuna	138	21	pharmaceutical	pharmaceutical	NN
work_izjlueimqneiljcxm4zmi6kuna	138	22	industry	industry	NN
work_izjlueimqneiljcxm4zmi6kuna	138	23	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	138	24	FUNED	FUNED	NNP
work_izjlueimqneiljcxm4zmi6kuna	138	25	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	138	26	MG	MG	NNP
work_izjlueimqneiljcxm4zmi6kuna	138	27	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	138	28	produc-	produc-	FW
work_izjlueimqneiljcxm4zmi6kuna	138	29	es	es	XX
work_izjlueimqneiljcxm4zmi6kuna	138	30	–	–	:
work_izjlueimqneiljcxm4zmi6kuna	138	31	at	at	IN
work_izjlueimqneiljcxm4zmi6kuna	138	32	very	very	RB
work_izjlueimqneiljcxm4zmi6kuna	138	33	low	low	JJ
work_izjlueimqneiljcxm4zmi6kuna	138	34	manufacturing	manufacturing	NN
work_izjlueimqneiljcxm4zmi6kuna	138	35	costs	cost	NNS
work_izjlueimqneiljcxm4zmi6kuna	138	36	-	-	:
work_izjlueimqneiljcxm4zmi6kuna	138	37	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	138	38	thalid-	thalid-	NN
work_izjlueimqneiljcxm4zmi6kuna	138	39	omide	omide	NN
work_izjlueimqneiljcxm4zmi6kuna	138	40	used	use	VBN
work_izjlueimqneiljcxm4zmi6kuna	138	41	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	138	42	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	138	43	country	country	NN
work_izjlueimqneiljcxm4zmi6kuna	138	44	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	139	1	It	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	139	2	was	be	VBD
work_izjlueimqneiljcxm4zmi6kuna	139	3	estimated	estimate	VBN
work_izjlueimqneiljcxm4zmi6kuna	139	4	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	139	5	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	139	6	instance	instance	NN
work_izjlueimqneiljcxm4zmi6kuna	139	7	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	139	8	that	that	IN
work_izjlueimqneiljcxm4zmi6kuna	139	9	US	US	NNP
work_izjlueimqneiljcxm4zmi6kuna	139	10	brand	brand	NN
work_izjlueimqneiljcxm4zmi6kuna	139	11	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	139	12	name	name	NN
work_izjlueimqneiljcxm4zmi6kuna	139	13	thalidomide	thalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	139	14	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	139	15	Tha-	tha-	NN
work_izjlueimqneiljcxm4zmi6kuna	139	16	lomid	lomid	NN
work_izjlueimqneiljcxm4zmi6kuna	139	17	®	®	.
work_izjlueimqneiljcxm4zmi6kuna	139	18	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	139	19	costs	cost	VBZ
work_izjlueimqneiljcxm4zmi6kuna	139	20	approximately	approximately	RB
work_izjlueimqneiljcxm4zmi6kuna	139	21	122-fold	122-fold	CD
work_izjlueimqneiljcxm4zmi6kuna	139	22	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	139	23	thalid-	thalid-	JJ
work_izjlueimqneiljcxm4zmi6kuna	139	24	omide	omide	NN
work_izjlueimqneiljcxm4zmi6kuna	139	25	made	make	VBN
work_izjlueimqneiljcxm4zmi6kuna	139	26	by	by	IN
work_izjlueimqneiljcxm4zmi6kuna	139	27	Brazilian	brazilian	JJ
work_izjlueimqneiljcxm4zmi6kuna	139	28	FUNED2	funed2	NN
work_izjlueimqneiljcxm4zmi6kuna	139	29	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	140	1	Therefore	therefore	RB
work_izjlueimqneiljcxm4zmi6kuna	140	2	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	140	3	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	140	4	eventual	eventual	JJ
work_izjlueimqneiljcxm4zmi6kuna	140	5	substitution	substitution	NN
work_izjlueimqneiljcxm4zmi6kuna	140	6	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	140	7	thalidomide	thalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	140	8	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	140	9	based	base	VBN
work_izjlueimqneiljcxm4zmi6kuna	140	10	therapies	therapy	NNS
work_izjlueimqneiljcxm4zmi6kuna	140	11	by	by	IN
work_izjlueimqneiljcxm4zmi6kuna	140	12	those	those	DT
work_izjlueimqneiljcxm4zmi6kuna	140	13	based	base	VBN
work_izjlueimqneiljcxm4zmi6kuna	140	14	on	on	IN
work_izjlueimqneiljcxm4zmi6kuna	140	15	lenalidomide	lenalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	140	16	is	be	VBZ
work_izjlueimqneiljcxm4zmi6kuna	140	17	like-	like-	VBN
work_izjlueimqneiljcxm4zmi6kuna	140	18	ly	ly	XX
work_izjlueimqneiljcxm4zmi6kuna	140	19	to	to	TO
work_izjlueimqneiljcxm4zmi6kuna	140	20	raise	raise	VB
work_izjlueimqneiljcxm4zmi6kuna	140	21	substantially	substantially	RB
work_izjlueimqneiljcxm4zmi6kuna	140	22	healthcare	healthcare	NN
work_izjlueimqneiljcxm4zmi6kuna	140	23	costs	cost	NNS
work_izjlueimqneiljcxm4zmi6kuna	140	24	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	140	25	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	140	26	country	country	NN
work_izjlueimqneiljcxm4zmi6kuna	140	27	without	without	IN
work_izjlueimqneiljcxm4zmi6kuna	140	28	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	140	29	significant	significant	JJ
work_izjlueimqneiljcxm4zmi6kuna	140	30	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	140	31	if	if	IN
work_izjlueimqneiljcxm4zmi6kuna	140	32	any	any	DT
work_izjlueimqneiljcxm4zmi6kuna	140	33	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	140	34	improve-	improve-	NN
work_izjlueimqneiljcxm4zmi6kuna	140	35	ment	ment	NN
work_izjlueimqneiljcxm4zmi6kuna	140	36	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	140	37	treatment	treatment	NN
work_izjlueimqneiljcxm4zmi6kuna	140	38	effectiveness	effectiveness	NN
work_izjlueimqneiljcxm4zmi6kuna	140	39	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	141	1	Another	another	DT
work_izjlueimqneiljcxm4zmi6kuna	141	2	major	major	JJ
work_izjlueimqneiljcxm4zmi6kuna	141	3	problem	problem	NN
work_izjlueimqneiljcxm4zmi6kuna	141	4	with	with	IN
work_izjlueimqneiljcxm4zmi6kuna	141	5	lenalidomide	lenalidomide	JJ
work_izjlueimqneiljcxm4zmi6kuna	141	6	approval	approval	NN
work_izjlueimqneiljcxm4zmi6kuna	141	7	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	141	8	Brazil	Brazil	NNP
work_izjlueimqneiljcxm4zmi6kuna	141	9	is	be	VBZ
work_izjlueimqneiljcxm4zmi6kuna	141	10	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	141	11	establishment	establishment	NN
work_izjlueimqneiljcxm4zmi6kuna	141	12	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	141	13	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	141	14	reg-	reg-	RB
work_izjlueimqneiljcxm4zmi6kuna	141	15	ulatory	ulatory	JJ
work_izjlueimqneiljcxm4zmi6kuna	141	16	double	double	JJ
work_izjlueimqneiljcxm4zmi6kuna	141	17	standard	standard	NN
work_izjlueimqneiljcxm4zmi6kuna	141	18	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	141	19	analogous	analogous	JJ
work_izjlueimqneiljcxm4zmi6kuna	141	20	drugs	drug	NNS
work_izjlueimqneiljcxm4zmi6kuna	141	21	having	have	VBG
work_izjlueimqneiljcxm4zmi6kuna	141	22	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	141	23	common	common	JJ
work_izjlueimqneiljcxm4zmi6kuna	141	24	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	141	25	high	high	JJ
work_izjlueimqneiljcxm4zmi6kuna	141	26	teratogenic	teratogenic	JJ
work_izjlueimqneiljcxm4zmi6kuna	141	27	risk	risk	NN
work_izjlueimqneiljcxm4zmi6kuna	141	28	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	141	29	Table	table	NN
work_izjlueimqneiljcxm4zmi6kuna	141	30	2	2	CD
work_izjlueimqneiljcxm4zmi6kuna	141	31	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	141	32	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	142	1	Owing	owe	VBG
work_izjlueimqneiljcxm4zmi6kuna	142	2	to	to	IN
work_izjlueimqneiljcxm4zmi6kuna	142	3	risk	risk	NN
work_izjlueimqneiljcxm4zmi6kuna	142	4	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	142	5	harm	harm	NN
work_izjlueimqneiljcxm4zmi6kuna	142	6	to	to	IN
work_izjlueimqneiljcxm4zmi6kuna	142	7	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	142	8	unborn	unborn	JJ
work_izjlueimqneiljcxm4zmi6kuna	142	9	child	child	NN
work_izjlueimqneiljcxm4zmi6kuna	142	10	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	142	11	thalidomide	thalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	142	12	is	be	VBZ
work_izjlueimqneiljcxm4zmi6kuna	142	13	regulated	regulate	VBN
work_izjlueimqneiljcxm4zmi6kuna	142	14	by	by	IN
work_izjlueimqneiljcxm4zmi6kuna	142	15	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	142	16	specific	specific	JJ
work_izjlueimqneiljcxm4zmi6kuna	142	17	Federal	federal	JJ
work_izjlueimqneiljcxm4zmi6kuna	142	18	law	law	NN
work_izjlueimqneiljcxm4zmi6kuna	142	19	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	142	20	Law	Law	NNP
work_izjlueimqneiljcxm4zmi6kuna	142	21	No.10.651/2003	No.10.651/2003	NNP
work_izjlueimqneiljcxm4zmi6kuna	142	22	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	142	23	that	that	WDT
work_izjlueimqneiljcxm4zmi6kuna	142	24	prohibits	prohibit	VBZ
work_izjlueimqneiljcxm4zmi6kuna	142	25	its	-PRON-	PRP$
work_izjlueimqneiljcxm4zmi6kuna	142	26	sale	sale	NN
work_izjlueimqneiljcxm4zmi6kuna	142	27	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	142	28	or	or	CC
work_izjlueimqneiljcxm4zmi6kuna	142	29	dispensing	dispense	VBG
work_izjlueimqneiljcxm4zmi6kuna	142	30	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	142	31	commercial	commercial	JJ
work_izjlueimqneiljcxm4zmi6kuna	142	32	pharmacies	pharmacy	NNS
work_izjlueimqneiljcxm4zmi6kuna	142	33	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	143	1	It	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	143	2	also	also	RB
work_izjlueimqneiljcxm4zmi6kuna	143	3	states	state	VBZ
work_izjlueimqneiljcxm4zmi6kuna	143	4	that	that	IN
work_izjlueimqneiljcxm4zmi6kuna	143	5	thalidomide	thalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	143	6	shall	shall	MD
work_izjlueimqneiljcxm4zmi6kuna	143	7	be	be	VB
work_izjlueimqneiljcxm4zmi6kuna	143	8	distributed	distribute	VBN
work_izjlueimqneiljcxm4zmi6kuna	143	9	exclusively	exclusively	RB
work_izjlueimqneiljcxm4zmi6kuna	143	10	to	to	IN
work_izjlueimqneiljcxm4zmi6kuna	143	11	public	public	JJ
work_izjlueimqneiljcxm4zmi6kuna	143	12	health	health	NN
work_izjlueimqneiljcxm4zmi6kuna	143	13	units	unit	NNS
work_izjlueimqneiljcxm4zmi6kuna	143	14	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	143	15	hospitals	hospital	NNS
work_izjlueimqneiljcxm4zmi6kuna	143	16	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	144	1	There	there	EX
work_izjlueimqneiljcxm4zmi6kuna	144	2	are	be	VBP
work_izjlueimqneiljcxm4zmi6kuna	144	3	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	144	4	number	number	NN
work_izjlueimqneiljcxm4zmi6kuna	144	5	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	144	6	additional	additional	JJ
work_izjlueimqneiljcxm4zmi6kuna	144	7	rules	rule	NNS
work_izjlueimqneiljcxm4zmi6kuna	144	8	issued	issue	VBN
work_izjlueimqneiljcxm4zmi6kuna	144	9	by	by	IN
work_izjlueimqneiljcxm4zmi6kuna	144	10	ANVISA	ANVISA	NNP
work_izjlueimqneiljcxm4zmi6kuna	144	11	that	that	WDT
work_izjlueimqneiljcxm4zmi6kuna	144	12	impose	impose	VBP
work_izjlueimqneiljcxm4zmi6kuna	144	13	strict	strict	JJ
work_izjlueimqneiljcxm4zmi6kuna	144	14	conditions	condition	NNS
work_izjlueimqneiljcxm4zmi6kuna	144	15	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	144	16	prescribing	prescribe	VBG
work_izjlueimqneiljcxm4zmi6kuna	144	17	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	144	18	dispensing	dispense	VBG
work_izjlueimqneiljcxm4zmi6kuna	144	19	thalidomide	thalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	144	20	to	to	IN
work_izjlueimqneiljcxm4zmi6kuna	144	21	ap-	ap-	NNP
work_izjlueimqneiljcxm4zmi6kuna	144	22	proved	proved	JJ
work_izjlueimqneiljcxm4zmi6kuna	144	23	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	144	24	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	144	25	off	off	IN
work_izjlueimqneiljcxm4zmi6kuna	144	26	label	label	NNP
work_izjlueimqneiljcxm4zmi6kuna	144	27	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	144	28	therapeutic	therapeutic	JJ
work_izjlueimqneiljcxm4zmi6kuna	144	29	indications	indication	NNS
work_izjlueimqneiljcxm4zmi6kuna	144	30	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	145	1	The	the	DT
work_izjlueimqneiljcxm4zmi6kuna	145	2	law	law	NN
work_izjlueimqneiljcxm4zmi6kuna	145	3	10.651/2003	10.651/2003	CD
work_izjlueimqneiljcxm4zmi6kuna	145	4	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	145	5	however	however	RB
work_izjlueimqneiljcxm4zmi6kuna	145	6	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	145	7	makes	make	VBZ
work_izjlueimqneiljcxm4zmi6kuna	145	8	no	no	DT
work_izjlueimqneiljcxm4zmi6kuna	145	9	pro-	pro-	NN
work_izjlueimqneiljcxm4zmi6kuna	145	10	vision	vision	NN
work_izjlueimqneiljcxm4zmi6kuna	145	11	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	145	12	lenalidomide	lenalidomide	JJ
work_izjlueimqneiljcxm4zmi6kuna	145	13	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	145	14	other	other	JJ
work_izjlueimqneiljcxm4zmi6kuna	145	15	teratogenic	teratogenic	JJ
work_izjlueimqneiljcxm4zmi6kuna	145	16	analogues	analogue	NNS
work_izjlueimqneiljcxm4zmi6kuna	145	17	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	145	18	thalidomide	thalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	145	19	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	146	1	Unless	unless	IN
work_izjlueimqneiljcxm4zmi6kuna	146	2	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	146	3	Brazilian	brazilian	JJ
work_izjlueimqneiljcxm4zmi6kuna	146	4	Congress	Congress	NNP
work_izjlueimqneiljcxm4zmi6kuna	146	5	amends	amend	VBZ
work_izjlueimqneiljcxm4zmi6kuna	146	6	law	law	NN
work_izjlueimqneiljcxm4zmi6kuna	146	7	10.651/2003	10.651/2003	CD
work_izjlueimqneiljcxm4zmi6kuna	146	8	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	146	9	lenalidomide	lenalidomide	JJ
work_izjlueimqneiljcxm4zmi6kuna	146	10	sale	sale	NN
work_izjlueimqneiljcxm4zmi6kuna	146	11	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	146	12	prescribing	prescribing	NN
work_izjlueimqneiljcxm4zmi6kuna	146	13	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	146	14	dispensing	dispensing	NN
work_izjlueimqneiljcxm4zmi6kuna	146	15	will	will	MD
work_izjlueimqneiljcxm4zmi6kuna	146	16	be	be	VB
work_izjlueimqneiljcxm4zmi6kuna	146	17	regulat-	regulat-	JJ
work_izjlueimqneiljcxm4zmi6kuna	146	18	ed	ed	NN
work_izjlueimqneiljcxm4zmi6kuna	146	19	exclusively	exclusively	RB
work_izjlueimqneiljcxm4zmi6kuna	146	20	by	by	IN
work_izjlueimqneiljcxm4zmi6kuna	146	21	ANVISA	ANVISA	NNP
work_izjlueimqneiljcxm4zmi6kuna	146	22	rules	rule	NNS
work_izjlueimqneiljcxm4zmi6kuna	146	23	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	146	24	i.e.	i.e.	FW
work_izjlueimqneiljcxm4zmi6kuna	146	25	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	146	26	by	by	IN
work_izjlueimqneiljcxm4zmi6kuna	146	27	agency	agency	NN
work_izjlueimqneiljcxm4zmi6kuna	146	28	resolutions	resolution	NNS
work_izjlueimqneiljcxm4zmi6kuna	146	29	that	that	WDT
work_izjlueimqneiljcxm4zmi6kuna	146	30	do	do	VBP
work_izjlueimqneiljcxm4zmi6kuna	146	31	not	not	RB
work_izjlueimqneiljcxm4zmi6kuna	146	32	have	have	VB
work_izjlueimqneiljcxm4zmi6kuna	146	33	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	146	34	force	force	NN
work_izjlueimqneiljcxm4zmi6kuna	146	35	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	146	36	law	law	NN
work_izjlueimqneiljcxm4zmi6kuna	146	37	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	147	1	Re-	re-	UH
work_izjlueimqneiljcxm4zmi6kuna	147	2	cently	cently	RB
work_izjlueimqneiljcxm4zmi6kuna	147	3	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	147	4	ANVISA	ANVISA	NNP
work_izjlueimqneiljcxm4zmi6kuna	147	5	conducted	conduct	VBD
work_izjlueimqneiljcxm4zmi6kuna	147	6	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	147	7	public	public	JJ
work_izjlueimqneiljcxm4zmi6kuna	147	8	consultation	consultation	NN
work_izjlueimqneiljcxm4zmi6kuna	147	9	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	147	10	CP	CP	NNP
work_izjlueimqneiljcxm4zmi6kuna	147	11	No	no	UH
work_izjlueimqneiljcxm4zmi6kuna	147	12	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	148	1	393/2017	393/2017	LS
work_izjlueimqneiljcxm4zmi6kuna	148	2	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	148	3	on	on	IN
work_izjlueimqneiljcxm4zmi6kuna	148	4	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	148	5	Regulatory	Regulatory	NNP
work_izjlueimqneiljcxm4zmi6kuna	148	6	Act	Act	NNP
work_izjlueimqneiljcxm4zmi6kuna	148	7	on	on	IN
work_izjlueimqneiljcxm4zmi6kuna	148	8	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	148	9	control	control	NN
work_izjlueimqneiljcxm4zmi6kuna	148	10	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	148	11	lenalidomide	lenalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	148	12	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	149	1	A	a	DT
work_izjlueimqneiljcxm4zmi6kuna	149	2	key	key	JJ
work_izjlueimqneiljcxm4zmi6kuna	149	3	difference	difference	NN
work_izjlueimqneiljcxm4zmi6kuna	149	4	regard-	regard-	VBD
work_izjlueimqneiljcxm4zmi6kuna	149	5	ing	e	VBG
work_izjlueimqneiljcxm4zmi6kuna	149	6	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	149	7	current	current	JJ
work_izjlueimqneiljcxm4zmi6kuna	149	8	thalidomide	thalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	149	9	control	control	NN
work_izjlueimqneiljcxm4zmi6kuna	149	10	regulation	regulation	NN
work_izjlueimqneiljcxm4zmi6kuna	149	11	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	149	12	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	149	13	country	country	NN
work_izjlueimqneiljcxm4zmi6kuna	149	14	is	be	VBZ
work_izjlueimqneiljcxm4zmi6kuna	149	15	that	that	IN
work_izjlueimqneiljcxm4zmi6kuna	149	16	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	149	17	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	149	18	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	149	19	case	case	NN
work_izjlueimqneiljcxm4zmi6kuna	149	20	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	149	21	lenalidomide	lenalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	149	22	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	149	23	it	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	149	24	is	be	VBZ
work_izjlueimqneiljcxm4zmi6kuna	149	25	up	up	IN
work_izjlueimqneiljcxm4zmi6kuna	149	26	to	to	IN
work_izjlueimqneiljcxm4zmi6kuna	149	27	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	149	28	drug	drug	NN
work_izjlueimqneiljcxm4zmi6kuna	149	29	manufacturing	manufacture	VBG
work_izjlueimqneiljcxm4zmi6kuna	149	30	company	company	NN
work_izjlueimqneiljcxm4zmi6kuna	149	31	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	149	32	implementation	implementation	NN
work_izjlueimqneiljcxm4zmi6kuna	149	33	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	149	34	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	149	35	detailed	detailed	JJ
work_izjlueimqneiljcxm4zmi6kuna	149	36	plan	plan	NN
work_izjlueimqneiljcxm4zmi6kuna	149	37	on	on	IN
work_izjlueimqneiljcxm4zmi6kuna	149	38	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	149	39	sales	sale	NNS
work_izjlueimqneiljcxm4zmi6kuna	149	40	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	149	41	distribution	distribution	NN
work_izjlueimqneiljcxm4zmi6kuna	149	42	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	149	43	dispensing	dispensing	NN
work_izjlueimqneiljcxm4zmi6kuna	149	44	that	that	WDT
work_izjlueimqneiljcxm4zmi6kuna	149	45	must	must	MD
work_izjlueimqneiljcxm4zmi6kuna	149	46	comply	comply	VB
work_izjlueimqneiljcxm4zmi6kuna	149	47	with	with	IN
work_izjlueimqneiljcxm4zmi6kuna	149	48	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	149	49	Pregnancy	Pregnancy	NNP
work_izjlueimqneiljcxm4zmi6kuna	149	50	Prevention	Prevention	NNP
work_izjlueimqneiljcxm4zmi6kuna	149	51	Plan	Plan	NNP
work_izjlueimqneiljcxm4zmi6kuna	149	52	approved	approve	VBN
work_izjlueimqneiljcxm4zmi6kuna	149	53	by	by	IN
work_izjlueimqneiljcxm4zmi6kuna	149	54	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	149	55	agency	agency	NN
work_izjlueimqneiljcxm4zmi6kuna	149	56	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	149	57	Table	table	NN
work_izjlueimqneiljcxm4zmi6kuna	149	58	2	2	CD
work_izjlueimqneiljcxm4zmi6kuna	149	59	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	149	60	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	150	1	Finally	finally	RB
work_izjlueimqneiljcxm4zmi6kuna	150	2	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	150	3	there	there	EX
work_izjlueimqneiljcxm4zmi6kuna	150	4	is	be	VBZ
work_izjlueimqneiljcxm4zmi6kuna	150	5	no	no	DT
work_izjlueimqneiljcxm4zmi6kuna	150	6	reason	reason	NN
work_izjlueimqneiljcxm4zmi6kuna	150	7	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	150	8	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	150	9	regulatory	regulatory	JJ
work_izjlueimqneiljcxm4zmi6kuna	150	10	double	double	JJ
work_izjlueimqneiljcxm4zmi6kuna	150	11	standard	standard	NN
work_izjlueimqneiljcxm4zmi6kuna	150	12	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	150	13	lenalidomide	lenalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	150	14	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	150	15	thalido-	thalido-	NN
work_izjlueimqneiljcxm4zmi6kuna	150	16	mide	mide	NNP
work_izjlueimqneiljcxm4zmi6kuna	150	17	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	150	18	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	150	19	therefore	therefore	RB
work_izjlueimqneiljcxm4zmi6kuna	150	20	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	150	21	law	law	NN
work_izjlueimqneiljcxm4zmi6kuna	150	22	10.651/2003	10.651/2003	CD
work_izjlueimqneiljcxm4zmi6kuna	150	23	should	should	MD
work_izjlueimqneiljcxm4zmi6kuna	150	24	be	be	VB
work_izjlueimqneiljcxm4zmi6kuna	150	25	amended	amend	VBN
work_izjlueimqneiljcxm4zmi6kuna	150	26	to	to	TO
work_izjlueimqneiljcxm4zmi6kuna	150	27	include	include	VB
work_izjlueimqneiljcxm4zmi6kuna	150	28	lenalidomide	lenalidomide	RB
work_izjlueimqneiljcxm4zmi6kuna	150	29	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	150	30	any	any	DT
work_izjlueimqneiljcxm4zmi6kuna	150	31	other	other	JJ
work_izjlueimqneiljcxm4zmi6kuna	150	32	thalidomide	thalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	150	33	analogue	analogue	NN
work_izjlueimqneiljcxm4zmi6kuna	150	34	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	151	1	The	the	DT
work_izjlueimqneiljcxm4zmi6kuna	151	2	rules	rule	NNS
work_izjlueimqneiljcxm4zmi6kuna	151	3	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	151	4	prescription	prescription	NN
work_izjlueimqneiljcxm4zmi6kuna	151	5	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	151	6	dispensing	dispensing	NN
work_izjlueimqneiljcxm4zmi6kuna	151	7	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	151	8	lenalidomide	lenalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	151	9	should	should	MD
work_izjlueimqneiljcxm4zmi6kuna	151	10	be	be	VB
work_izjlueimqneiljcxm4zmi6kuna	151	11	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	151	12	same	same	JJ
work_izjlueimqneiljcxm4zmi6kuna	151	13	prevailing	prevailing	NN
work_izjlueimqneiljcxm4zmi6kuna	151	14	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	151	15	thalidomide	thalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	151	16	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	151	17	thus	thus	RB
work_izjlueimqneiljcxm4zmi6kuna	151	18	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	151	19	pro-	pro-	NN
work_izjlueimqneiljcxm4zmi6kuna	151	20	motion	motion	NN
work_izjlueimqneiljcxm4zmi6kuna	151	21	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	151	22	lenalidomide	lenalidomide	JJ
work_izjlueimqneiljcxm4zmi6kuna	151	23	prescription	prescription	NN
work_izjlueimqneiljcxm4zmi6kuna	151	24	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	151	25	adver-	adver-	NN
work_izjlueimqneiljcxm4zmi6kuna	151	26	tisement	tisement	NN
work_izjlueimqneiljcxm4zmi6kuna	151	27	by	by	IN
work_izjlueimqneiljcxm4zmi6kuna	151	28	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	151	29	pharmaceutical	pharmaceutical	JJ
work_izjlueimqneiljcxm4zmi6kuna	151	30	company	company	NN
work_izjlueimqneiljcxm4zmi6kuna	151	31	should	should	MD
work_izjlueimqneiljcxm4zmi6kuna	151	32	be	be	VB
work_izjlueimqneiljcxm4zmi6kuna	151	33	forbidden	forbid	VBN
work_izjlueimqneiljcxm4zmi6kuna	151	34	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	152	1	The	the	DT
work_izjlueimqneiljcxm4zmi6kuna	152	2	use	use	NN
work_izjlueimqneiljcxm4zmi6kuna	152	3	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	152	4	lenalidomide	lenalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	152	5	should	should	MD
work_izjlueimqneiljcxm4zmi6kuna	152	6	be	be	VB
work_izjlueimqneiljcxm4zmi6kuna	152	7	controlled	control	VBN
work_izjlueimqneiljcxm4zmi6kuna	152	8	by	by	IN
work_izjlueimqneiljcxm4zmi6kuna	152	9	health	health	NN
work_izjlueimqneiljcxm4zmi6kuna	152	10	authorities	authority	NNS
work_izjlueimqneiljcxm4zmi6kuna	152	11	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	152	12	restricted	restrict	VBD
work_izjlueimqneiljcxm4zmi6kuna	152	13	to	to	IN
work_izjlueimqneiljcxm4zmi6kuna	152	14	those	those	DT
work_izjlueimqneiljcxm4zmi6kuna	152	15	patients	patient	NNS
work_izjlueimqneiljcxm4zmi6kuna	152	16	who	who	WP
work_izjlueimqneiljcxm4zmi6kuna	152	17	can	can	MD
work_izjlueimqneiljcxm4zmi6kuna	152	18	not	not	RB
work_izjlueimqneiljcxm4zmi6kuna	152	19	otherwise	otherwise	RB
work_izjlueimqneiljcxm4zmi6kuna	152	20	be	be	VB
work_izjlueimqneiljcxm4zmi6kuna	152	21	treated	treat	VBN
work_izjlueimqneiljcxm4zmi6kuna	152	22	with	with	IN
work_izjlueimqneiljcxm4zmi6kuna	152	23	more	more	JJR
work_izjlueimqneiljcxm4zmi6kuna	152	24	cost	cost	NN
work_izjlueimqneiljcxm4zmi6kuna	152	25	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	152	26	effective	effective	JJ
work_izjlueimqneiljcxm4zmi6kuna	152	27	alternatives	alternative	NNS
work_izjlueimqneiljcxm4zmi6kuna	152	28	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	152	29	e.g.	e.g.	RB
work_izjlueimqneiljcxm4zmi6kuna	152	30	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	152	31	be-	be-	XX
work_izjlueimqneiljcxm4zmi6kuna	152	32	cause	cause	NN
work_izjlueimqneiljcxm4zmi6kuna	152	33	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	152	34	peripheral	peripheral	JJ
work_izjlueimqneiljcxm4zmi6kuna	152	35	neuropathy	neuropathy	JJ
work_izjlueimqneiljcxm4zmi6kuna	152	36	side	side	NN
work_izjlueimqneiljcxm4zmi6kuna	152	37	effects	effect	NNS
work_izjlueimqneiljcxm4zmi6kuna	152	38	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	152	39	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	153	1	3	3	CD
work_izjlueimqneiljcxm4zmi6kuna	153	2	7	7	CD
work_izjlueimqneiljcxm4zmi6kuna	153	3	9	9	CD
work_izjlueimqneiljcxm4zmi6kuna	153	4	0	0	CD
work_izjlueimqneiljcxm4zmi6kuna	153	5	P	p	NN
work_izjlueimqneiljcxm4zmi6kuna	153	6	au	au	NNP
work_izjlueimqneiljcxm4zmi6kuna	153	7	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	153	8	ga	ga	NNP
work_izjlueimqneiljcxm4zmi6kuna	153	9	rt	rt	NNP
work_izjlueimqneiljcxm4zmi6kuna	153	10	te	te	NNP
work_izjlueimqneiljcxm4zmi6kuna	153	11	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	153	12	F	F	NNP
work_izjlueimqneiljcxm4zmi6kuna	153	13	JR	JR	NNP
work_izjlueimqneiljcxm4zmi6kuna	153	14	Table	Table	NNP
work_izjlueimqneiljcxm4zmi6kuna	153	15	2	2	CD
work_izjlueimqneiljcxm4zmi6kuna	153	16	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	154	1	Brazilian	brazilian	JJ
work_izjlueimqneiljcxm4zmi6kuna	154	2	asymmetric	asymmetric	JJ
work_izjlueimqneiljcxm4zmi6kuna	154	3	regulatory	regulatory	JJ
work_izjlueimqneiljcxm4zmi6kuna	154	4	standards	standard	NNS
work_izjlueimqneiljcxm4zmi6kuna	154	5	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	154	6	thalidomide	thalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	154	7	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	154	8	its	-PRON-	PRP$
work_izjlueimqneiljcxm4zmi6kuna	154	9	teratogenic	teratogenic	JJ
work_izjlueimqneiljcxm4zmi6kuna	154	10	analogue	analogue	NN
work_izjlueimqneiljcxm4zmi6kuna	154	11	lenalidomide	lenalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	154	12	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	155	1	Thalidomide	thalidomide	LS
work_izjlueimqneiljcxm4zmi6kuna	155	2	lenalidomide	lenalidomide	VB
work_izjlueimqneiljcxm4zmi6kuna	155	3	Brand	brand	NN
work_izjlueimqneiljcxm4zmi6kuna	155	4	name	name	NN
work_izjlueimqneiljcxm4zmi6kuna	155	5	Generic	Generic	NNP
work_izjlueimqneiljcxm4zmi6kuna	155	6	name	name	NN
work_izjlueimqneiljcxm4zmi6kuna	155	7	Revilimid	Revilimid	NNP
work_izjlueimqneiljcxm4zmi6kuna	155	8	®	®	NNP
work_izjlueimqneiljcxm4zmi6kuna	155	9	Manufacturer	Manufacturer	NNP
work_izjlueimqneiljcxm4zmi6kuna	155	10	State	State	NNP
work_izjlueimqneiljcxm4zmi6kuna	155	11	owned	own	VBD
work_izjlueimqneiljcxm4zmi6kuna	155	12	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	155	13	public	public	JJ
work_izjlueimqneiljcxm4zmi6kuna	155	14	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	155	15	industry	industry	NN
work_izjlueimqneiljcxm4zmi6kuna	155	16	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	155	17	FUNED	FUNED	NNP
work_izjlueimqneiljcxm4zmi6kuna	155	18	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	155	19	MG	MG	NNP
work_izjlueimqneiljcxm4zmi6kuna	155	20	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	155	21	Pharmaceutical	pharmaceutical	NN
work_izjlueimqneiljcxm4zmi6kuna	155	22	company	company	NN
work_izjlueimqneiljcxm4zmi6kuna	155	23	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	155	24	Celgene	Celgene	NNP
work_izjlueimqneiljcxm4zmi6kuna	155	25	®	®	NNPS
work_izjlueimqneiljcxm4zmi6kuna	155	26	Co	co	NN
work_izjlueimqneiljcxm4zmi6kuna	155	27	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	155	28	Potential	potential	NN
work_izjlueimqneiljcxm4zmi6kuna	155	29	to	to	TO
work_izjlueimqneiljcxm4zmi6kuna	155	30	cause	cause	VB
work_izjlueimqneiljcxm4zmi6kuna	155	31	birth	birth	NN
work_izjlueimqneiljcxm4zmi6kuna	155	32	defects	defect	NNS
work_izjlueimqneiljcxm4zmi6kuna	155	33	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	155	34	teratogenicity	teratogenicity	NN
work_izjlueimqneiljcxm4zmi6kuna	155	35	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	155	36	Proven	prove	VBN
work_izjlueimqneiljcxm4zmi6kuna	155	37	to	to	IN
work_izjlueimqneiljcxm4zmi6kuna	155	38	humans	human	NNS
work_izjlueimqneiljcxm4zmi6kuna	155	39	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	155	40	non	non	JJ
work_izjlueimqneiljcxm4zmi6kuna	155	41	-	-	JJ
work_izjlueimqneiljcxm4zmi6kuna	155	42	human	human	JJ
work_izjlueimqneiljcxm4zmi6kuna	155	43	primates	primate	NNS
work_izjlueimqneiljcxm4zmi6kuna	155	44	Proven	prove	VBN
work_izjlueimqneiljcxm4zmi6kuna	155	45	to	to	IN
work_izjlueimqneiljcxm4zmi6kuna	155	46	non	non	JJ
work_izjlueimqneiljcxm4zmi6kuna	155	47	-	-	JJ
work_izjlueimqneiljcxm4zmi6kuna	155	48	human	human	JJ
work_izjlueimqneiljcxm4zmi6kuna	155	49	primates	primate	NNS
work_izjlueimqneiljcxm4zmi6kuna	155	50	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	155	51	likely	likely	RB
work_izjlueimqneiljcxm4zmi6kuna	155	52	human	human	JJ
work_izjlueimqneiljcxm4zmi6kuna	155	53	teratogen	teratogen	NN
work_izjlueimqneiljcxm4zmi6kuna	155	54	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	155	55	Regulation	Regulation	NNP
work_izjlueimqneiljcxm4zmi6kuna	155	56	Federal	Federal	NNP
work_izjlueimqneiljcxm4zmi6kuna	155	57	Law	Law	NNP
work_izjlueimqneiljcxm4zmi6kuna	155	58	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	155	59	10.651/2003	10.651/2003	CD
work_izjlueimqneiljcxm4zmi6kuna	155	60	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	155	61	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	155	62	additional	additional	JJ
work_izjlueimqneiljcxm4zmi6kuna	155	63	rules	rule	NNS
work_izjlueimqneiljcxm4zmi6kuna	155	64	issued	issue	VBN
work_izjlueimqneiljcxm4zmi6kuna	155	65	by	by	IN
work_izjlueimqneiljcxm4zmi6kuna	155	66	ANVISA	ANVISA	NNP
work_izjlueimqneiljcxm4zmi6kuna	155	67	Regulation	Regulation	NNP
work_izjlueimqneiljcxm4zmi6kuna	155	68	to	to	TO
work_izjlueimqneiljcxm4zmi6kuna	155	69	be	be	VB
work_izjlueimqneiljcxm4zmi6kuna	155	70	issued	issue	VBN
work_izjlueimqneiljcxm4zmi6kuna	155	71	by	by	IN
work_izjlueimqneiljcxm4zmi6kuna	155	72	ANVISA	ANVISA	NNP
work_izjlueimqneiljcxm4zmi6kuna	155	73	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	155	74	Public	Public	NNP
work_izjlueimqneiljcxm4zmi6kuna	155	75	Consultation	Consultation	NNP
work_izjlueimqneiljcxm4zmi6kuna	155	76	No	no	UH
work_izjlueimqneiljcxm4zmi6kuna	155	77	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	156	1	393/2017	393/2017	LS
work_izjlueimqneiljcxm4zmi6kuna	156	2	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	156	3	Sales	sale	NNS
work_izjlueimqneiljcxm4zmi6kuna	156	4	Prohibited	prohibit	VBD
work_izjlueimqneiljcxm4zmi6kuna	156	5	No	no	DT
work_izjlueimqneiljcxm4zmi6kuna	156	6	restriction	restriction	NN
work_izjlueimqneiljcxm4zmi6kuna	156	7	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	157	1	Costs	cost	NNS
work_izjlueimqneiljcxm4zmi6kuna	157	2	Low	low	JJ
work_izjlueimqneiljcxm4zmi6kuna	157	3	cost	cost	NN
work_izjlueimqneiljcxm4zmi6kuna	157	4	medicine	medicine	NN
work_izjlueimqneiljcxm4zmi6kuna	157	5	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	157	6	very	very	RB
work_izjlueimqneiljcxm4zmi6kuna	157	7	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	157	8	High	high	JJ
work_izjlueimqneiljcxm4zmi6kuna	157	9	cost	cost	NN
work_izjlueimqneiljcxm4zmi6kuna	157	10	medicine	medicine	NN
work_izjlueimqneiljcxm4zmi6kuna	157	11	Promotion	Promotion	NNP
work_izjlueimqneiljcxm4zmi6kuna	157	12	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	157	13	Prescription	Prescription	NNP
work_izjlueimqneiljcxm4zmi6kuna	157	14	&	&	CC
work_izjlueimqneiljcxm4zmi6kuna	157	15	Advertisement	Advertisement	NNP
work_izjlueimqneiljcxm4zmi6kuna	157	16	Prohibited	Prohibited	NNP
work_izjlueimqneiljcxm4zmi6kuna	157	17	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	157	18	nonexistent	nonexistent	JJ
work_izjlueimqneiljcxm4zmi6kuna	157	19	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	157	20	Allowed	allow	VBN
work_izjlueimqneiljcxm4zmi6kuna	157	21	if	if	IN
work_izjlueimqneiljcxm4zmi6kuna	157	22	directed	direct	VBN
work_izjlueimqneiljcxm4zmi6kuna	157	23	to	to	IN
work_izjlueimqneiljcxm4zmi6kuna	157	24	prescribers	prescriber	NNS
work_izjlueimqneiljcxm4zmi6kuna	157	25	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	157	26	as	as	IN
work_izjlueimqneiljcxm4zmi6kuna	157	27	any	any	DT
work_izjlueimqneiljcxm4zmi6kuna	157	28	other	other	JJ
work_izjlueimqneiljcxm4zmi6kuna	157	29	prescription	prescription	NN
work_izjlueimqneiljcxm4zmi6kuna	157	30	drug)+	drug)+	NNP
work_izjlueimqneiljcxm4zmi6kuna	157	31	Use	Use	NNP
work_izjlueimqneiljcxm4zmi6kuna	157	32	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	157	33	off	off	JJ
work_izjlueimqneiljcxm4zmi6kuna	157	34	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	157	35	label	label	NN
work_izjlueimqneiljcxm4zmi6kuna	157	36	therapeutic	therapeutic	NN
work_izjlueimqneiljcxm4zmi6kuna	157	37	indications	indication	NNS
work_izjlueimqneiljcxm4zmi6kuna	157	38	Strictly	strictly	RB
work_izjlueimqneiljcxm4zmi6kuna	157	39	controlled	control	VBN
work_izjlueimqneiljcxm4zmi6kuna	157	40	by	by	IN
work_izjlueimqneiljcxm4zmi6kuna	157	41	ANVISA	ANVISA	NNP
work_izjlueimqneiljcxm4zmi6kuna	157	42	Uncontrolled	uncontrolle	VBN
work_izjlueimqneiljcxm4zmi6kuna	157	43	by	by	IN
work_izjlueimqneiljcxm4zmi6kuna	157	44	ANVISA	ANVISA	NNP
work_izjlueimqneiljcxm4zmi6kuna	157	45	Drug	Drug	NNP
work_izjlueimqneiljcxm4zmi6kuna	157	46	distribution	distribution	NN
work_izjlueimqneiljcxm4zmi6kuna	157	47	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	157	48	dispensing	dispense	VBG
work_izjlueimqneiljcxm4zmi6kuna	157	49	Exclusively	exclusively	RB
work_izjlueimqneiljcxm4zmi6kuna	157	50	to	to	IN
work_izjlueimqneiljcxm4zmi6kuna	157	51	public	public	JJ
work_izjlueimqneiljcxm4zmi6kuna	157	52	health	health	NN
work_izjlueimqneiljcxm4zmi6kuna	157	53	units	unit	NNS
work_izjlueimqneiljcxm4zmi6kuna	157	54	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	157	55	hospitals	hospital	NNS
work_izjlueimqneiljcxm4zmi6kuna	157	56	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	157	57	controlled	control	VBN
work_izjlueimqneiljcxm4zmi6kuna	157	58	by	by	IN
work_izjlueimqneiljcxm4zmi6kuna	157	59	health	health	NN
work_izjlueimqneiljcxm4zmi6kuna	157	60	authorities	authority	NNS
work_izjlueimqneiljcxm4zmi6kuna	157	61	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	157	62	Distribution	distribution	NN
work_izjlueimqneiljcxm4zmi6kuna	157	63	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	157	64	dispensing	dispensing	NN
work_izjlueimqneiljcxm4zmi6kuna	157	65	controlled	control	VBN
work_izjlueimqneiljcxm4zmi6kuna	157	66	by	by	IN
work_izjlueimqneiljcxm4zmi6kuna	157	67	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	157	68	company	company	NN
work_izjlueimqneiljcxm4zmi6kuna	157	69	Authorized	authorize	VBN
work_izjlueimqneiljcxm4zmi6kuna	157	70	prescribers	prescriber	NNS
work_izjlueimqneiljcxm4zmi6kuna	157	71	/	/	SYM
work_izjlueimqneiljcxm4zmi6kuna	157	72	pharmacists	pharmacist	NNS
work_izjlueimqneiljcxm4zmi6kuna	157	73	Registered	register	VBN
work_izjlueimqneiljcxm4zmi6kuna	157	74	by	by	IN
work_izjlueimqneiljcxm4zmi6kuna	157	75	local	local	JJ
work_izjlueimqneiljcxm4zmi6kuna	157	76	health	health	NN
work_izjlueimqneiljcxm4zmi6kuna	157	77	authority	authority	NN
work_izjlueimqneiljcxm4zmi6kuna	157	78	Qualified	qualified	JJ
work_izjlueimqneiljcxm4zmi6kuna	157	79	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	157	80	registered	register	VBN
work_izjlueimqneiljcxm4zmi6kuna	157	81	by	by	IN
work_izjlueimqneiljcxm4zmi6kuna	157	82	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	157	83	company	company	NN
work_izjlueimqneiljcxm4zmi6kuna	157	84	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	158	1	+	+	NFP
work_izjlueimqneiljcxm4zmi6kuna	158	2	According	accord	VBG
work_izjlueimqneiljcxm4zmi6kuna	158	3	to	to	IN
work_izjlueimqneiljcxm4zmi6kuna	158	4	PC	PC	NNP
work_izjlueimqneiljcxm4zmi6kuna	158	5	393/2017	393/2017	NNP
work_izjlueimqneiljcxm4zmi6kuna	158	6	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	158	7	Art,45	Art,45	NNP
work_izjlueimqneiljcxm4zmi6kuna	158	8	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	158	9	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	158	10	“	"	``
work_izjlueimqneiljcxm4zmi6kuna	158	11	any	any	DT
work_izjlueimqneiljcxm4zmi6kuna	158	12	”	"	''
work_izjlueimqneiljcxm4zmi6kuna	158	13	advertisement	advertisement	NN
work_izjlueimqneiljcxm4zmi6kuna	158	14	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	158	15	lenalidomide	lenalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	158	16	is	be	VBZ
work_izjlueimqneiljcxm4zmi6kuna	158	17	forbidden	forbid	VBN
work_izjlueimqneiljcxm4zmi6kuna	158	18	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	159	1	However	however	RB
work_izjlueimqneiljcxm4zmi6kuna	159	2	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	159	3	Art.45	art.45	CD
work_izjlueimqneiljcxm4zmi6kuna	159	4	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	159	5	paragraph	paragraph	NN
work_izjlueimqneiljcxm4zmi6kuna	159	6	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	159	7	makes	make	VBZ
work_izjlueimqneiljcxm4zmi6kuna	159	8	an	an	DT
work_izjlueimqneiljcxm4zmi6kuna	159	9	exemption	exemption	NN
work_izjlueimqneiljcxm4zmi6kuna	159	10	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	159	11	advertising	advertising	NN
work_izjlueimqneiljcxm4zmi6kuna	159	12	lenalidomide	lenalidomide	RB
work_izjlueimqneiljcxm4zmi6kuna	159	13	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	159	14	based	base	VBN
work_izjlueimqneiljcxm4zmi6kuna	159	15	medicines	medicine	NNS
work_izjlueimqneiljcxm4zmi6kuna	159	16	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	159	17	publications	publication	NNS
work_izjlueimqneiljcxm4zmi6kuna	159	18	intended	intend	VBN
work_izjlueimqneiljcxm4zmi6kuna	159	19	to	to	IN
work_izjlueimqneiljcxm4zmi6kuna	159	20	medical	medical	JJ
work_izjlueimqneiljcxm4zmi6kuna	159	21	or	or	CC
work_izjlueimqneiljcxm4zmi6kuna	159	22	scientific	scientific	JJ
work_izjlueimqneiljcxm4zmi6kuna	159	23	purposes	purpose	NNS
work_izjlueimqneiljcxm4zmi6kuna	159	24	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	160	1	In	in	IN
work_izjlueimqneiljcxm4zmi6kuna	160	2	practice	practice	NN
work_izjlueimqneiljcxm4zmi6kuna	160	3	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	160	4	there	there	EX
work_izjlueimqneiljcxm4zmi6kuna	160	5	is	be	VBZ
work_izjlueimqneiljcxm4zmi6kuna	160	6	no	no	DT
work_izjlueimqneiljcxm4zmi6kuna	160	7	restriction	restriction	NN
work_izjlueimqneiljcxm4zmi6kuna	160	8	to	to	IN
work_izjlueimqneiljcxm4zmi6kuna	160	9	propaganda	propaganda	NN
work_izjlueimqneiljcxm4zmi6kuna	160	10	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	160	11	because	because	IN
work_izjlueimqneiljcxm4zmi6kuna	160	12	this	this	DT
work_izjlueimqneiljcxm4zmi6kuna	160	13	is	be	VBZ
work_izjlueimqneiljcxm4zmi6kuna	160	14	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	160	15	usual	usual	JJ
work_izjlueimqneiljcxm4zmi6kuna	160	16	way	way	NN
work_izjlueimqneiljcxm4zmi6kuna	160	17	by	by	IN
work_izjlueimqneiljcxm4zmi6kuna	160	18	which	which	WDT
work_izjlueimqneiljcxm4zmi6kuna	160	19	pharmaceutical	pharmaceutical	NN
work_izjlueimqneiljcxm4zmi6kuna	160	20	companies	company	NNS
work_izjlueimqneiljcxm4zmi6kuna	160	21	promote	promote	VBP
work_izjlueimqneiljcxm4zmi6kuna	160	22	prescription	prescription	NN
work_izjlueimqneiljcxm4zmi6kuna	160	23	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	160	24	“	"	``
work_izjlueimqneiljcxm4zmi6kuna	160	25	prescription	prescription	NN
work_izjlueimqneiljcxm4zmi6kuna	160	26	-	-	,
work_izjlueimqneiljcxm4zmi6kuna	160	27	only	only	RB
work_izjlueimqneiljcxm4zmi6kuna	160	28	”	"	''
work_izjlueimqneiljcxm4zmi6kuna	160	29	drugs	drug	NNS
work_izjlueimqneiljcxm4zmi6kuna	160	30	among	among	IN
work_izjlueimqneiljcxm4zmi6kuna	160	31	physicians	physician	NNS
work_izjlueimqneiljcxm4zmi6kuna	160	32	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	161	1	3	3	CD
work_izjlueimqneiljcxm4zmi6kuna	161	2	7	7	CD
work_izjlueimqneiljcxm4zmi6kuna	161	3	9	9	CD
work_izjlueimqneiljcxm4zmi6kuna	161	4	1	1	CD
work_izjlueimqneiljcxm4zmi6kuna	161	5	C	C	NNP
work_izjlueimqneiljcxm4zmi6kuna	161	6	iên	iên	NNP
work_izjlueimqneiljcxm4zmi6kuna	161	7	cia	cia	NNP
work_izjlueimqneiljcxm4zmi6kuna	161	8	&	&	CC
work_izjlueimqneiljcxm4zmi6kuna	161	9	Saú	Saú	NNP
work_izjlueimqneiljcxm4zmi6kuna	161	10	d	d	NNP
work_izjlueimqneiljcxm4zmi6kuna	161	11	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	161	12	C	C	NNP
work_izjlueimqneiljcxm4zmi6kuna	161	13	o	o	NN
work_izjlueimqneiljcxm4zmi6kuna	161	14	letiva	letiva	NN
work_izjlueimqneiljcxm4zmi6kuna	161	15	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	161	16	2	2	CD
work_izjlueimqneiljcxm4zmi6kuna	161	17	4	4	CD
work_izjlueimqneiljcxm4zmi6kuna	161	18	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	161	19	1	1	CD
work_izjlueimqneiljcxm4zmi6kuna	161	20	0	0	CD
work_izjlueimqneiljcxm4zmi6kuna	161	21	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	161	22	:3	:3	NNP
work_izjlueimqneiljcxm4zmi6kuna	161	23	7	7	CD
work_izjlueimqneiljcxm4zmi6kuna	161	24	8	8	CD
work_izjlueimqneiljcxm4zmi6kuna	161	25	3	3	CD
work_izjlueimqneiljcxm4zmi6kuna	161	26	-3	-3	$
work_izjlueimqneiljcxm4zmi6kuna	161	27	7	7	CD
work_izjlueimqneiljcxm4zmi6kuna	161	28	9	9	CD
work_izjlueimqneiljcxm4zmi6kuna	161	29	2	2	CD
work_izjlueimqneiljcxm4zmi6kuna	161	30	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	161	31	2	2	CD
work_izjlueimqneiljcxm4zmi6kuna	161	32	0	0	CD
work_izjlueimqneiljcxm4zmi6kuna	161	33	1	1	CD
work_izjlueimqneiljcxm4zmi6kuna	161	34	9	9	CD
work_izjlueimqneiljcxm4zmi6kuna	161	35	References	reference	NNS
work_izjlueimqneiljcxm4zmi6kuna	161	36	1	1	CD
work_izjlueimqneiljcxm4zmi6kuna	161	37	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	162	1	DiMasi	DiMasi	NNP
work_izjlueimqneiljcxm4zmi6kuna	162	2	JA	JA	NNP
work_izjlueimqneiljcxm4zmi6kuna	162	3	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	162	4	Faden	Faden	NNP
work_izjlueimqneiljcxm4zmi6kuna	162	5	LB	LB	NNP
work_izjlueimqneiljcxm4zmi6kuna	162	6	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	163	1	Competitiveness	competitiveness	NN
work_izjlueimqneiljcxm4zmi6kuna	163	2	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	163	3	follow	follow	VB
work_izjlueimqneiljcxm4zmi6kuna	163	4	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	163	5	on	on	RP
work_izjlueimqneiljcxm4zmi6kuna	163	6	drug	drug	NN
work_izjlueimqneiljcxm4zmi6kuna	163	7	R&D	r&d	NN
work_izjlueimqneiljcxm4zmi6kuna	163	8	:	:	:
work_izjlueimqneiljcxm4zmi6kuna	163	9	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	163	10	race	race	NN
work_izjlueimqneiljcxm4zmi6kuna	163	11	or	or	CC
work_izjlueimqneiljcxm4zmi6kuna	163	12	imitation	imitation	NN
work_izjlueimqneiljcxm4zmi6kuna	163	13	?	?	.
work_izjlueimqneiljcxm4zmi6kuna	164	1	Nat	Nat	NNP
work_izjlueimqneiljcxm4zmi6kuna	164	2	Rev	Rev	NNP
work_izjlueimqneiljcxm4zmi6kuna	164	3	Drug	Drug	NNP
work_izjlueimqneiljcxm4zmi6kuna	164	4	Discov	Discov	NNP
work_izjlueimqneiljcxm4zmi6kuna	164	5	2011	2011	CD
work_izjlueimqneiljcxm4zmi6kuna	164	6	;	;	:
work_izjlueimqneiljcxm4zmi6kuna	164	7	10(1):23	10(1):23	NNP
work_izjlueimqneiljcxm4zmi6kuna	164	8	-	-	:
work_izjlueimqneiljcxm4zmi6kuna	164	9	27	27	CD
work_izjlueimqneiljcxm4zmi6kuna	164	10	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	165	1	2	2	LS
work_izjlueimqneiljcxm4zmi6kuna	165	2	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	166	1	Paumgartten	Paumgartten	NNP
work_izjlueimqneiljcxm4zmi6kuna	166	2	FJ	FJ	NNP
work_izjlueimqneiljcxm4zmi6kuna	166	3	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	167	1	Novel	novel	JJ
work_izjlueimqneiljcxm4zmi6kuna	167	2	thalidomide	thalidomide	JJ
work_izjlueimqneiljcxm4zmi6kuna	167	3	analogues	analogue	NNS
work_izjlueimqneiljcxm4zmi6kuna	167	4	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	167	5	“	"	``
work_izjlueimqneiljcxm4zmi6kuna	167	6	me	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	167	7	too	too	RB
work_izjlueimqneiljcxm4zmi6kuna	167	8	”	"	''
work_izjlueimqneiljcxm4zmi6kuna	167	9	drugs	drug	NNS
work_izjlueimqneiljcxm4zmi6kuna	167	10	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	167	11	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	167	12	Brazilian	brazilian	JJ
work_izjlueimqneiljcxm4zmi6kuna	167	13	law	law	NN
work_izjlueimqneiljcxm4zmi6kuna	167	14	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	168	1	Visa	Visa	NNP
work_izjlueimqneiljcxm4zmi6kuna	168	2	em	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	168	3	Debate	debate	NN
work_izjlueimqneiljcxm4zmi6kuna	168	4	2013	2013	CD
work_izjlueimqneiljcxm4zmi6kuna	168	5	;	;	:
work_izjlueimqneiljcxm4zmi6kuna	168	6	1:2	1:2	CD
work_izjlueimqneiljcxm4zmi6kuna	168	7	-	-	SYM
work_izjlueimqneiljcxm4zmi6kuna	168	8	10	10	CD
work_izjlueimqneiljcxm4zmi6kuna	168	9	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	169	1	3	3	LS
work_izjlueimqneiljcxm4zmi6kuna	169	2	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	170	1	Sarpatwari	Sarpatwari	NNP
work_izjlueimqneiljcxm4zmi6kuna	170	2	A	A	NNP
work_izjlueimqneiljcxm4zmi6kuna	170	3	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	170	4	Avorn	Avorn	NNP
work_izjlueimqneiljcxm4zmi6kuna	170	5	J	J	NNP
work_izjlueimqneiljcxm4zmi6kuna	170	6	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	170	7	Kesselheim	Kesselheim	NNP
work_izjlueimqneiljcxm4zmi6kuna	170	8	AS	as	IN
work_izjlueimqneiljcxm4zmi6kuna	170	9	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	171	1	Using	use	VBG
work_izjlueimqneiljcxm4zmi6kuna	171	2	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	171	3	drug	drug	NN
work_izjlueimqneiljcxm4zmi6kuna	171	4	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	171	5	safety	safety	NN
work_izjlueimqneiljcxm4zmi6kuna	171	6	tool	tool	NN
work_izjlueimqneiljcxm4zmi6kuna	171	7	to	to	TO
work_izjlueimqneiljcxm4zmi6kuna	171	8	prevent	prevent	VB
work_izjlueimqneiljcxm4zmi6kuna	171	9	competition	competition	NN
work_izjlueimqneiljcxm4zmi6kuna	171	10	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	172	1	N	N	NNP
work_izjlueimqneiljcxm4zmi6kuna	172	2	Engl	engl	NN
work_izjlueimqneiljcxm4zmi6kuna	172	3	J	j	NN
work_izjlueimqneiljcxm4zmi6kuna	172	4	Med	Med	NNP
work_izjlueimqneiljcxm4zmi6kuna	172	5	2014	2014	CD
work_izjlueimqneiljcxm4zmi6kuna	172	6	;	;	:
work_izjlueimqneiljcxm4zmi6kuna	172	7	370(16):1476	370(16):1476	CD
work_izjlueimqneiljcxm4zmi6kuna	172	8	-	-	SYM
work_izjlueimqneiljcxm4zmi6kuna	172	9	1478	1478	CD
work_izjlueimqneiljcxm4zmi6kuna	172	10	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	173	1	4	4	LS
work_izjlueimqneiljcxm4zmi6kuna	173	2	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	174	1	Badros	Badros	NNP
work_izjlueimqneiljcxm4zmi6kuna	174	2	AZ	AZ	NNP
work_izjlueimqneiljcxm4zmi6kuna	174	3	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	175	1	Lenalidomide	lenalidomide	JJ
work_izjlueimqneiljcxm4zmi6kuna	175	2	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	175	3	myeloma	myeloma	NNP
work_izjlueimqneiljcxm4zmi6kuna	175	4	--	--	:
work_izjlueimqneiljcxm4zmi6kuna	175	5	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	175	6	high	high	JJ
work_izjlueimqneiljcxm4zmi6kuna	175	7	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	175	8	main-	main-	NN
work_izjlueimqneiljcxm4zmi6kuna	175	9	tenance	tenance	NN
work_izjlueimqneiljcxm4zmi6kuna	175	10	friend	friend	NN
work_izjlueimqneiljcxm4zmi6kuna	175	11	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	176	1	N	N	NNP
work_izjlueimqneiljcxm4zmi6kuna	176	2	Engl	Engl	NNP
work_izjlueimqneiljcxm4zmi6kuna	176	3	J	J	NNP
work_izjlueimqneiljcxm4zmi6kuna	176	4	Med	Med	NNP
work_izjlueimqneiljcxm4zmi6kuna	176	5	2012	2012	CD
work_izjlueimqneiljcxm4zmi6kuna	176	6	;	;	:
work_izjlueimqneiljcxm4zmi6kuna	176	7	366(19):1836-	366(19):1836-	CD
work_izjlueimqneiljcxm4zmi6kuna	176	8	1838	1838	CD
work_izjlueimqneiljcxm4zmi6kuna	176	9	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	177	1	5	5	CD
work_izjlueimqneiljcxm4zmi6kuna	177	2	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	178	1	National	National	NNP
work_izjlueimqneiljcxm4zmi6kuna	178	2	Cancer	Cancer	NNP
work_izjlueimqneiljcxm4zmi6kuna	178	3	Institute	Institute	NNP
work_izjlueimqneiljcxm4zmi6kuna	178	4	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	178	5	NCI	NCI	NNP
work_izjlueimqneiljcxm4zmi6kuna	178	6	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	178	7	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	179	1	Surveillance	surveillance	NN
work_izjlueimqneiljcxm4zmi6kuna	179	2	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	179	3	Epide-	Epide-	NNP
work_izjlueimqneiljcxm4zmi6kuna	179	4	miology	miology	NN
work_izjlueimqneiljcxm4zmi6kuna	179	5	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	179	6	End	End	NNP
work_izjlueimqneiljcxm4zmi6kuna	179	7	Results	Results	NNP
work_izjlueimqneiljcxm4zmi6kuna	179	8	program	program	NN
work_izjlueimqneiljcxm4zmi6kuna	179	9	[	[	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	179	10	Internet	internet	NN
work_izjlueimqneiljcxm4zmi6kuna	179	11	]	]	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	179	12	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	180	1	Cancer	Cancer	NNP
work_izjlueimqneiljcxm4zmi6kuna	180	2	Stat	stat	JJ
work_izjlueimqneiljcxm4zmi6kuna	180	3	facts	fact	NNS
work_izjlueimqneiljcxm4zmi6kuna	180	4	:	:	:
work_izjlueimqneiljcxm4zmi6kuna	180	5	Myeloma	Myeloma	NNP
work_izjlueimqneiljcxm4zmi6kuna	180	6	[	[	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	180	7	cited	cite	VBD
work_izjlueimqneiljcxm4zmi6kuna	180	8	2017	2017	CD
work_izjlueimqneiljcxm4zmi6kuna	180	9	Nov	Nov	NNP
work_izjlueimqneiljcxm4zmi6kuna	180	10	10	10	CD
work_izjlueimqneiljcxm4zmi6kuna	180	11	]	]	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	180	12	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	181	1	Available	available	JJ
work_izjlueimqneiljcxm4zmi6kuna	181	2	at	at	IN
work_izjlueimqneiljcxm4zmi6kuna	181	3	:	:	:
work_izjlueimqneiljcxm4zmi6kuna	181	4	https://seer.cancer.gov/statfacts/html/mulmy.html	https://seer.cancer.gov/statfacts/html/mulmy.html	ADD
work_izjlueimqneiljcxm4zmi6kuna	181	5	6	6	CD
work_izjlueimqneiljcxm4zmi6kuna	181	6	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	182	1	Celgene	celgene	NN
work_izjlueimqneiljcxm4zmi6kuna	182	2	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	183	1	Celgene	celgene	NN
work_izjlueimqneiljcxm4zmi6kuna	183	2	Reports	report	VBZ
work_izjlueimqneiljcxm4zmi6kuna	183	3	First	First	NNP
work_izjlueimqneiljcxm4zmi6kuna	183	4	Quarter	Quarter	NNP
work_izjlueimqneiljcxm4zmi6kuna	183	5	2017	2017	CD
work_izjlueimqneiljcxm4zmi6kuna	183	6	Operating	operate	VBG
work_izjlueimqneiljcxm4zmi6kuna	183	7	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	183	8	Financial	financial	JJ
work_izjlueimqneiljcxm4zmi6kuna	183	9	results	result	NNS
work_izjlueimqneiljcxm4zmi6kuna	183	10	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	184	1	[	[	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	184	2	cited	cite	VBD
work_izjlueimqneiljcxm4zmi6kuna	184	3	2017	2017	CD
work_izjlueimqneiljcxm4zmi6kuna	184	4	Nov	Nov	NNP
work_izjlueimqneiljcxm4zmi6kuna	184	5	12	12	CD
work_izjlueimqneiljcxm4zmi6kuna	184	6	]	]	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	184	7	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	185	1	Available	available	JJ
work_izjlueimqneiljcxm4zmi6kuna	185	2	at	at	IN
work_izjlueimqneiljcxm4zmi6kuna	185	3	:	:	:
work_izjlueimqneiljcxm4zmi6kuna	185	4	http://ir.celgene.com/releasedetail.cfm?releaseid=	http://ir.celgene.com/releasedetail.cfm?releaseid=	CD
work_izjlueimqneiljcxm4zmi6kuna	185	5	1023223	1023223	CD
work_izjlueimqneiljcxm4zmi6kuna	185	6	7	7	CD
work_izjlueimqneiljcxm4zmi6kuna	185	7	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	186	1	Brasil	Brasil	NNP
work_izjlueimqneiljcxm4zmi6kuna	186	2	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	187	1	Ministério	Ministério	NNP
work_izjlueimqneiljcxm4zmi6kuna	187	2	da	da	NNP
work_izjlueimqneiljcxm4zmi6kuna	187	3	Saúde	Saúde	NNP
work_izjlueimqneiljcxm4zmi6kuna	187	4	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	187	5	MS	MS	NNP
work_izjlueimqneiljcxm4zmi6kuna	187	6	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	187	7	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	188	1	Agência	Agência	NNP
work_izjlueimqneiljcxm4zmi6kuna	188	2	Nacional	Nacional	NNP
work_izjlueimqneiljcxm4zmi6kuna	188	3	de	de	NNP
work_izjlueimqneiljcxm4zmi6kuna	188	4	Vigilância	Vigilância	NNP
work_izjlueimqneiljcxm4zmi6kuna	188	5	Sanitária	Sanitária	NNP
work_izjlueimqneiljcxm4zmi6kuna	188	6	–	–	:
work_izjlueimqneiljcxm4zmi6kuna	188	7	Anvisa	Anvisa	NNP
work_izjlueimqneiljcxm4zmi6kuna	188	8	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	189	1	CP	CP	NNP
work_izjlueimqneiljcxm4zmi6kuna	189	2	393	393	CD
work_izjlueimqneiljcxm4zmi6kuna	189	3	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	189	4	12	12	CD
work_izjlueimqneiljcxm4zmi6kuna	189	5	Septem-	Septem-	NNP
work_izjlueimqneiljcxm4zmi6kuna	189	6	ber	ber	NNP
work_izjlueimqneiljcxm4zmi6kuna	189	7	2017	2017	CD
work_izjlueimqneiljcxm4zmi6kuna	189	8	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	190	1	Proposta	Proposta	NNP
work_izjlueimqneiljcxm4zmi6kuna	190	2	sobre	sobre	NNP
work_izjlueimqneiljcxm4zmi6kuna	190	3	controle	controle	NNP
work_izjlueimqneiljcxm4zmi6kuna	190	4	da	da	NNP
work_izjlueimqneiljcxm4zmi6kuna	190	5	substância	substância	NNP
work_izjlueimqneiljcxm4zmi6kuna	190	6	lenalid-	lenalid-	NNP
work_izjlueimqneiljcxm4zmi6kuna	190	7	omida	omida	NNP
work_izjlueimqneiljcxm4zmi6kuna	190	8	e	e	NNP
work_izjlueimqneiljcxm4zmi6kuna	190	9	do	do	VB
work_izjlueimqneiljcxm4zmi6kuna	190	10	medicamento	medicamento	NNP
work_izjlueimqneiljcxm4zmi6kuna	190	11	que	que	NNP
work_izjlueimqneiljcxm4zmi6kuna	190	12	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	190	13	contenha	contenha	NNS
work_izjlueimqneiljcxm4zmi6kuna	190	14	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	191	1	[	[	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	191	2	cited	cite	VBD
work_izjlueimqneiljcxm4zmi6kuna	191	3	2017	2017	CD
work_izjlueimqneiljcxm4zmi6kuna	191	4	Oct	Oct	NNP
work_izjlueimqneiljcxm4zmi6kuna	191	5	31	31	CD
work_izjlueimqneiljcxm4zmi6kuna	191	6	]	]	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	191	7	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	192	1	Available	available	JJ
work_izjlueimqneiljcxm4zmi6kuna	192	2	at	at	IN
work_izjlueimqneiljcxm4zmi6kuna	192	3	:	:	:
work_izjlueimqneiljcxm4zmi6kuna	192	4	http://portal.anvisa.gov.br/rss/	http://portal.anvisa.gov.br/rss/	ADD
work_izjlueimqneiljcxm4zmi6kuna	192	5	asset_publisher	asset_publisher	NNP
work_izjlueimqneiljcxm4zmi6kuna	192	6	/	/	SYM
work_izjlueimqneiljcxm4zmi6kuna	192	7	Zk4q6UQCj9Pn	Zk4q6UQCj9Pn	NNP
work_izjlueimqneiljcxm4zmi6kuna	192	8	/	/	SYM
work_izjlueimqneiljcxm4zmi6kuna	192	9	content	content	NN
work_izjlueimqneiljcxm4zmi6kuna	192	10	/	/	SYM
work_izjlueimqneiljcxm4zmi6kuna	192	11	id/3605796	id/3605796	$
work_izjlueimqneiljcxm4zmi6kuna	192	12	8	8	CD
work_izjlueimqneiljcxm4zmi6kuna	192	13	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	193	1	D’Amato	D’Amato	NNP
work_izjlueimqneiljcxm4zmi6kuna	193	2	RJ	RJ	NNP
work_izjlueimqneiljcxm4zmi6kuna	193	3	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	193	4	Loughnan	Loughnan	NNP
work_izjlueimqneiljcxm4zmi6kuna	193	5	MS	MS	NNP
work_izjlueimqneiljcxm4zmi6kuna	193	6	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	193	7	Flynn	Flynn	NNP
work_izjlueimqneiljcxm4zmi6kuna	193	8	E	E	NNP
work_izjlueimqneiljcxm4zmi6kuna	193	9	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	193	10	Folkman	Folkman	NNP
work_izjlueimqneiljcxm4zmi6kuna	193	11	J.	J.	NNP
work_izjlueimqneiljcxm4zmi6kuna	193	12	Tha-	Tha-	NNP
work_izjlueimqneiljcxm4zmi6kuna	193	13	lidomide	lidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	193	14	is	be	VBZ
work_izjlueimqneiljcxm4zmi6kuna	193	15	an	an	DT
work_izjlueimqneiljcxm4zmi6kuna	193	16	inhibitor	inhibitor	NN
work_izjlueimqneiljcxm4zmi6kuna	193	17	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	193	18	angiogenesis	angiogenesis	NN
work_izjlueimqneiljcxm4zmi6kuna	193	19	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	194	1	Proc	Proc	NNP
work_izjlueimqneiljcxm4zmi6kuna	194	2	Natl	Natl	NNP
work_izjlueimqneiljcxm4zmi6kuna	194	3	Acad	Acad	NNP
work_izjlueimqneiljcxm4zmi6kuna	194	4	Sci	Sci	NNP
work_izjlueimqneiljcxm4zmi6kuna	194	5	USA	USA	NNP
work_izjlueimqneiljcxm4zmi6kuna	194	6	1994	1994	CD
work_izjlueimqneiljcxm4zmi6kuna	194	7	;	;	:
work_izjlueimqneiljcxm4zmi6kuna	194	8	91(9):4082	91(9):4082	CD
work_izjlueimqneiljcxm4zmi6kuna	194	9	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	194	10	4085	4085	CD
work_izjlueimqneiljcxm4zmi6kuna	194	11	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	195	1	9	9	CD
work_izjlueimqneiljcxm4zmi6kuna	195	2	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	196	1	Folkman	Folkman	NNP
work_izjlueimqneiljcxm4zmi6kuna	196	2	J.	J.	NNP
work_izjlueimqneiljcxm4zmi6kuna	196	3	Tumor	Tumor	NNP
work_izjlueimqneiljcxm4zmi6kuna	196	4	angiogenesis	angiogenesis	NN
work_izjlueimqneiljcxm4zmi6kuna	196	5	:	:	:
work_izjlueimqneiljcxm4zmi6kuna	196	6	therapeutic	therapeutic	JJ
work_izjlueimqneiljcxm4zmi6kuna	196	7	implica-	implica-	JJ
work_izjlueimqneiljcxm4zmi6kuna	196	8	tions	tion	NNS
work_izjlueimqneiljcxm4zmi6kuna	196	9	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	197	1	N	N	NNP
work_izjlueimqneiljcxm4zmi6kuna	197	2	Engl	Engl	NNP
work_izjlueimqneiljcxm4zmi6kuna	197	3	J	j	NN
work_izjlueimqneiljcxm4zmi6kuna	197	4	Med	Med	NNP
work_izjlueimqneiljcxm4zmi6kuna	197	5	1971	1971	CD
work_izjlueimqneiljcxm4zmi6kuna	197	6	;	;	:
work_izjlueimqneiljcxm4zmi6kuna	197	7	285(21):1182	285(21):1182	CD
work_izjlueimqneiljcxm4zmi6kuna	197	8	-	-	SYM
work_izjlueimqneiljcxm4zmi6kuna	197	9	1186	1186	CD
work_izjlueimqneiljcxm4zmi6kuna	197	10	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	198	1	10	10	CD
work_izjlueimqneiljcxm4zmi6kuna	198	2	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	198	3	von	von	NNP
work_izjlueimqneiljcxm4zmi6kuna	198	4	Lilienfeld	Lilienfeld	NNP
work_izjlueimqneiljcxm4zmi6kuna	198	5	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	198	6	Toal	Toal	NNP
work_izjlueimqneiljcxm4zmi6kuna	198	7	M	M	NNP
work_izjlueimqneiljcxm4zmi6kuna	198	8	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	198	9	Hahn	Hahn	NNP
work_izjlueimqneiljcxm4zmi6kuna	198	10	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	198	11	Ast	Ast	NNP
work_izjlueimqneiljcxm4zmi6kuna	198	12	C	C	NNP
work_izjlueimqneiljcxm4zmi6kuna	198	13	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	198	14	Furkert	Furkert	NNP
work_izjlueimqneiljcxm4zmi6kuna	198	15	K	K	NNP
work_izjlueimqneiljcxm4zmi6kuna	198	16	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	198	17	Hoff-	Hoff-	NNP
work_izjlueimqneiljcxm4zmi6kuna	198	18	mann	mann	NNP
work_izjlueimqneiljcxm4zmi6kuna	198	19	F	F	NNP
work_izjlueimqneiljcxm4zmi6kuna	198	20	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	198	21	Naumann	Naumann	NNP
work_izjlueimqneiljcxm4zmi6kuna	198	22	R	R	NNP
work_izjlueimqneiljcxm4zmi6kuna	198	23	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	198	24	Bargou	Bargou	NNP
work_izjlueimqneiljcxm4zmi6kuna	198	25	R	R	NNP
work_izjlueimqneiljcxm4zmi6kuna	198	26	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	198	27	Cook	Cook	NNP
work_izjlueimqneiljcxm4zmi6kuna	198	28	G	G	NNP
work_izjlueimqneiljcxm4zmi6kuna	198	29	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	198	30	Glasmacher	Glasmacher	NNP
work_izjlueimqneiljcxm4zmi6kuna	198	31	A.	A.	NNP
work_izjlueimqneiljcxm4zmi6kuna	199	1	A	a	DT
work_izjlueimqneiljcxm4zmi6kuna	199	2	systematic	systematic	JJ
work_izjlueimqneiljcxm4zmi6kuna	199	3	review	review	NN
work_izjlueimqneiljcxm4zmi6kuna	199	4	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	199	5	phase	phase	NN
work_izjlueimqneiljcxm4zmi6kuna	199	6	II	ii	CD
work_izjlueimqneiljcxm4zmi6kuna	199	7	trials	trial	NNS
work_izjlueimqneiljcxm4zmi6kuna	199	8	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	199	9	thalido-	thalido-	NNP
work_izjlueimqneiljcxm4zmi6kuna	199	10	mide	mide	NNP
work_izjlueimqneiljcxm4zmi6kuna	199	11	/	/	SYM
work_izjlueimqneiljcxm4zmi6kuna	199	12	dexamethasone	dexamethasone	VBN
work_izjlueimqneiljcxm4zmi6kuna	199	13	combination	combination	NN
work_izjlueimqneiljcxm4zmi6kuna	199	14	therapy	therapy	NN
work_izjlueimqneiljcxm4zmi6kuna	199	15	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	199	16	pa-	pa-	JJ
work_izjlueimqneiljcxm4zmi6kuna	199	17	tients	tient	NNS
work_izjlueimqneiljcxm4zmi6kuna	199	18	with	with	IN
work_izjlueimqneiljcxm4zmi6kuna	199	19	relapsed	relapsed	JJ
work_izjlueimqneiljcxm4zmi6kuna	199	20	or	or	CC
work_izjlueimqneiljcxm4zmi6kuna	199	21	refractory	refractory	JJ
work_izjlueimqneiljcxm4zmi6kuna	199	22	multiple	multiple	JJ
work_izjlueimqneiljcxm4zmi6kuna	199	23	myeloma	myeloma	NNS
work_izjlueimqneiljcxm4zmi6kuna	199	24	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	200	1	Eur	Eur	NNP
work_izjlueimqneiljcxm4zmi6kuna	200	2	J	J	NNP
work_izjlueimqneiljcxm4zmi6kuna	200	3	Haematol	Haematol	NNP
work_izjlueimqneiljcxm4zmi6kuna	200	4	2008	2008	CD
work_izjlueimqneiljcxm4zmi6kuna	200	5	;	;	:
work_izjlueimqneiljcxm4zmi6kuna	200	6	81(4):247	81(4):247	CD
work_izjlueimqneiljcxm4zmi6kuna	200	7	-	-	SYM
work_izjlueimqneiljcxm4zmi6kuna	200	8	252	252	CD
work_izjlueimqneiljcxm4zmi6kuna	200	9	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	201	1	11	11	CD
work_izjlueimqneiljcxm4zmi6kuna	201	2	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	202	1	Singhal	Singhal	NNP
work_izjlueimqneiljcxm4zmi6kuna	202	2	S	S	NNP
work_izjlueimqneiljcxm4zmi6kuna	202	3	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	202	4	Mehta	Mehta	NNP
work_izjlueimqneiljcxm4zmi6kuna	202	5	J	J	NNP
work_izjlueimqneiljcxm4zmi6kuna	202	6	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	202	7	Desikan	Desikan	NNP
work_izjlueimqneiljcxm4zmi6kuna	202	8	R	R	NNP
work_izjlueimqneiljcxm4zmi6kuna	202	9	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	202	10	Ayers	Ayers	NNP
work_izjlueimqneiljcxm4zmi6kuna	202	11	D	D	NNP
work_izjlueimqneiljcxm4zmi6kuna	202	12	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	202	13	Roberson	Roberson	NNP
work_izjlueimqneiljcxm4zmi6kuna	202	14	P	P	NNP
work_izjlueimqneiljcxm4zmi6kuna	202	15	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	202	16	Eddlemon	Eddlemon	NNP
work_izjlueimqneiljcxm4zmi6kuna	202	17	P	P	NNP
work_izjlueimqneiljcxm4zmi6kuna	202	18	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	202	19	Munshi	Munshi	NNP
work_izjlueimqneiljcxm4zmi6kuna	202	20	N	N	NNP
work_izjlueimqneiljcxm4zmi6kuna	202	21	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	202	22	Anaissie	Anaissie	NNP
work_izjlueimqneiljcxm4zmi6kuna	202	23	E	E	NNP
work_izjlueimqneiljcxm4zmi6kuna	202	24	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	202	25	Wilson	Wilson	NNP
work_izjlueimqneiljcxm4zmi6kuna	202	26	C	C	NNP
work_izjlueimqneiljcxm4zmi6kuna	202	27	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	202	28	Dhodapkar	Dhodapkar	NNP
work_izjlueimqneiljcxm4zmi6kuna	202	29	M	M	NNP
work_izjlueimqneiljcxm4zmi6kuna	202	30	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	202	31	Zeddis	Zeddis	NNP
work_izjlueimqneiljcxm4zmi6kuna	202	32	J	J	NNP
work_izjlueimqneiljcxm4zmi6kuna	202	33	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	202	34	Barlogie	Barlogie	NNP
work_izjlueimqneiljcxm4zmi6kuna	202	35	B.	B.	NNP
work_izjlueimqneiljcxm4zmi6kuna	202	36	Antitumor	Antitumor	NNP
work_izjlueimqneiljcxm4zmi6kuna	202	37	activ-	activ-	VBD
work_izjlueimqneiljcxm4zmi6kuna	202	38	ity	ity	NN
work_izjlueimqneiljcxm4zmi6kuna	202	39	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	202	40	thalidomide	thalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	202	41	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	202	42	refractory	refractory	JJ
work_izjlueimqneiljcxm4zmi6kuna	202	43	multiple	multiple	JJ
work_izjlueimqneiljcxm4zmi6kuna	202	44	myeloma	myeloma	NNS
work_izjlueimqneiljcxm4zmi6kuna	202	45	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	203	1	N	N	NNP
work_izjlueimqneiljcxm4zmi6kuna	203	2	Engl	Engl	NNP
work_izjlueimqneiljcxm4zmi6kuna	203	3	J	J	NNP
work_izjlueimqneiljcxm4zmi6kuna	203	4	Med	Med	NNP
work_izjlueimqneiljcxm4zmi6kuna	203	5	1999	1999	CD
work_izjlueimqneiljcxm4zmi6kuna	203	6	;	;	:
work_izjlueimqneiljcxm4zmi6kuna	203	7	341(21):1565	341(21):1565	CD
work_izjlueimqneiljcxm4zmi6kuna	203	8	-	-	SYM
work_izjlueimqneiljcxm4zmi6kuna	203	9	1571	1571	CD
work_izjlueimqneiljcxm4zmi6kuna	203	10	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	204	1	12	12	CD
work_izjlueimqneiljcxm4zmi6kuna	204	2	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	205	1	Moehler	Moehler	NNP
work_izjlueimqneiljcxm4zmi6kuna	205	2	TM	TM	NNP
work_izjlueimqneiljcxm4zmi6kuna	205	3	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	205	4	Hillengass	Hillengass	NNP
work_izjlueimqneiljcxm4zmi6kuna	205	5	J	J	NNP
work_izjlueimqneiljcxm4zmi6kuna	205	6	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	205	7	Glasmacher	Glasmacher	NNP
work_izjlueimqneiljcxm4zmi6kuna	205	8	A	A	NNP
work_izjlueimqneiljcxm4zmi6kuna	205	9	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	205	10	Gold-	Gold-	NNP
work_izjlueimqneiljcxm4zmi6kuna	205	11	schmidt	schmidt	NN
work_izjlueimqneiljcxm4zmi6kuna	205	12	H.	H.	NNP
work_izjlueimqneiljcxm4zmi6kuna	205	13	Thalidomide	Thalidomide	NNP
work_izjlueimqneiljcxm4zmi6kuna	205	14	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	205	15	multiple	multiple	JJ
work_izjlueimqneiljcxm4zmi6kuna	205	16	myeloma	myeloma	NN
work_izjlueimqneiljcxm4zmi6kuna	205	17	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	206	1	Curr	Curr	NNP
work_izjlueimqneiljcxm4zmi6kuna	206	2	Pharm	Pharm	NNP
work_izjlueimqneiljcxm4zmi6kuna	206	3	Biotechnol	Biotechnol	NNP
work_izjlueimqneiljcxm4zmi6kuna	206	4	2006	2006	CD
work_izjlueimqneiljcxm4zmi6kuna	206	5	;	;	:
work_izjlueimqneiljcxm4zmi6kuna	206	6	7(6):431	7(6):431	CD
work_izjlueimqneiljcxm4zmi6kuna	206	7	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	206	8	440	440	CD
work_izjlueimqneiljcxm4zmi6kuna	206	9	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	207	1	13	13	CD
work_izjlueimqneiljcxm4zmi6kuna	207	2	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	208	1	SV	SV	NNP
work_izjlueimqneiljcxm4zmi6kuna	208	2	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	208	3	Blood	blood	NN
work_izjlueimqneiljcxm4zmi6kuna	208	4	E	E	NNS
work_izjlueimqneiljcxm4zmi6kuna	208	5	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	208	6	Vesole	Vesole	NNP
work_izjlueimqneiljcxm4zmi6kuna	208	7	D	D	NNP
work_izjlueimqneiljcxm4zmi6kuna	208	8	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	208	9	Fonseca	Fonseca	NNP
work_izjlueimqneiljcxm4zmi6kuna	208	10	R	R	NNP
work_izjlueimqneiljcxm4zmi6kuna	208	11	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	208	12	Greipp	Greipp	NNP
work_izjlueimqneiljcxm4zmi6kuna	208	13	PR	PR	NNP
work_izjlueimqneiljcxm4zmi6kuna	208	14	;	;	:
work_izjlueimqneiljcxm4zmi6kuna	208	15	Eastern	Eastern	NNP
work_izjlueimqneiljcxm4zmi6kuna	208	16	Cooperative	Cooperative	NNP
work_izjlueimqneiljcxm4zmi6kuna	208	17	Oncology	Oncology	NNP
work_izjlueimqneiljcxm4zmi6kuna	208	18	Group	Group	NNP
work_izjlueimqneiljcxm4zmi6kuna	208	19	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	209	1	Phase	phase	NN
work_izjlueimqneiljcxm4zmi6kuna	209	2	III	iii	CD
work_izjlueimqneiljcxm4zmi6kuna	209	3	clinical	clinical	JJ
work_izjlueimqneiljcxm4zmi6kuna	209	4	trial	trial	NN
work_izjlueimqneiljcxm4zmi6kuna	209	5	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	209	6	thalidomide	thalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	209	7	plus	plus	CC
work_izjlueimqneiljcxm4zmi6kuna	209	8	dexamethasone	dexamethasone	NN
work_izjlueimqneiljcxm4zmi6kuna	209	9	compared	compare	VBN
work_izjlueimqneiljcxm4zmi6kuna	209	10	with	with	IN
work_izjlueimqneiljcxm4zmi6kuna	209	11	dexamethasone	dexamethasone	NN
work_izjlueimqneiljcxm4zmi6kuna	209	12	alone	alone	RB
work_izjlueimqneiljcxm4zmi6kuna	209	13	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	209	14	newly	newly	RB
work_izjlueimqneiljcxm4zmi6kuna	209	15	diagnosed	diagnose	VBN
work_izjlueimqneiljcxm4zmi6kuna	209	16	multiple	multiple	JJ
work_izjlueimqneiljcxm4zmi6kuna	209	17	myeloma	myeloma	NN
work_izjlueimqneiljcxm4zmi6kuna	209	18	:	:	:
work_izjlueimqneiljcxm4zmi6kuna	209	19	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	209	20	clinical	clinical	JJ
work_izjlueimqneiljcxm4zmi6kuna	209	21	trial	trial	NN
work_izjlueimqneiljcxm4zmi6kuna	209	22	coordinated	coordinate	VBN
work_izjlueimqneiljcxm4zmi6kuna	209	23	by	by	IN
work_izjlueimqneiljcxm4zmi6kuna	209	24	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	209	25	Eastern	Eastern	NNP
work_izjlueimqneiljcxm4zmi6kuna	209	26	Cooperative	Cooperative	NNP
work_izjlueimqneiljcxm4zmi6kuna	209	27	Oncology	Oncology	NNP
work_izjlueimqneiljcxm4zmi6kuna	209	28	Group	Group	NNP
work_izjlueimqneiljcxm4zmi6kuna	209	29	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	210	1	J	J	NNP
work_izjlueimqneiljcxm4zmi6kuna	210	2	Clin	Clin	NNP
work_izjlueimqneiljcxm4zmi6kuna	210	3	Oncol	Oncol	NNP
work_izjlueimqneiljcxm4zmi6kuna	210	4	2006	2006	CD
work_izjlueimqneiljcxm4zmi6kuna	210	5	;	;	:
work_izjlueimqneiljcxm4zmi6kuna	210	6	24(3):431	24(3):431	NNP
work_izjlueimqneiljcxm4zmi6kuna	210	7	-	-	SYM
work_izjlueimqneiljcxm4zmi6kuna	210	8	436	436	CD
work_izjlueimqneiljcxm4zmi6kuna	210	9	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	211	1	14	14	CD
work_izjlueimqneiljcxm4zmi6kuna	211	2	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	212	1	Dimopoulos	Dimopoulos	NNP
work_izjlueimqneiljcxm4zmi6kuna	212	2	M	M	NNP
work_izjlueimqneiljcxm4zmi6kuna	212	3	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	212	4	Spencer	Spencer	NNP
work_izjlueimqneiljcxm4zmi6kuna	212	5	A	A	NNP
work_izjlueimqneiljcxm4zmi6kuna	212	6	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	212	7	Attal	Attal	NNP
work_izjlueimqneiljcxm4zmi6kuna	212	8	M	M	NNP
work_izjlueimqneiljcxm4zmi6kuna	212	9	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	212	10	Prince	Prince	NNP
work_izjlueimqneiljcxm4zmi6kuna	212	11	HM	HM	NNP
work_izjlueimqneiljcxm4zmi6kuna	212	12	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	212	13	Harousseau	Harousseau	NNP
work_izjlueimqneiljcxm4zmi6kuna	212	14	JL	JL	NNP
work_izjlueimqneiljcxm4zmi6kuna	212	15	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	212	16	Dmoszynska	Dmoszynska	NNP
work_izjlueimqneiljcxm4zmi6kuna	212	17	A	A	NNP
work_izjlueimqneiljcxm4zmi6kuna	212	18	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	212	19	San	San	NNP
work_izjlueimqneiljcxm4zmi6kuna	212	20	Miguel	Miguel	NNP
work_izjlueimqneiljcxm4zmi6kuna	212	21	J	J	NNP
work_izjlueimqneiljcxm4zmi6kuna	212	22	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	212	23	Hell-	Hell-	NNP
work_izjlueimqneiljcxm4zmi6kuna	212	24	mann	mann	NNP
work_izjlueimqneiljcxm4zmi6kuna	212	25	A	A	NNP
work_izjlueimqneiljcxm4zmi6kuna	212	26	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	212	27	Facon	Facon	NNP
work_izjlueimqneiljcxm4zmi6kuna	212	28	T	T	NNP
work_izjlueimqneiljcxm4zmi6kuna	212	29	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	212	30	Foà	Foà	NNP
work_izjlueimqneiljcxm4zmi6kuna	212	31	R	R	NNP
work_izjlueimqneiljcxm4zmi6kuna	212	32	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	212	33	Corso	Corso	NNP
work_izjlueimqneiljcxm4zmi6kuna	212	34	A	A	NNP
work_izjlueimqneiljcxm4zmi6kuna	212	35	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	212	36	Masliak	Masliak	NNP
work_izjlueimqneiljcxm4zmi6kuna	212	37	Z	Z	NNP
work_izjlueimqneiljcxm4zmi6kuna	212	38	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	212	39	Olesny-	Olesny-	NNP
work_izjlueimqneiljcxm4zmi6kuna	212	40	ckyj	ckyj	NN
work_izjlueimqneiljcxm4zmi6kuna	212	41	M	M	NNP
work_izjlueimqneiljcxm4zmi6kuna	212	42	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	212	43	Yu	Yu	NNP
work_izjlueimqneiljcxm4zmi6kuna	212	44	Z	Z	NNP
work_izjlueimqneiljcxm4zmi6kuna	212	45	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	212	46	Patin	Patin	NNP
work_izjlueimqneiljcxm4zmi6kuna	212	47	J	J	NNP
work_izjlueimqneiljcxm4zmi6kuna	212	48	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	212	49	Zeldis	Zeldis	NNP
work_izjlueimqneiljcxm4zmi6kuna	212	50	JB	JB	NNP
work_izjlueimqneiljcxm4zmi6kuna	212	51	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	212	52	Knight	Knight	NNP
work_izjlueimqneiljcxm4zmi6kuna	212	53	RD	RD	NNP
work_izjlueimqneiljcxm4zmi6kuna	212	54	;	;	:
work_izjlueimqneiljcxm4zmi6kuna	212	55	Multiple	Multiple	NNP
work_izjlueimqneiljcxm4zmi6kuna	212	56	Myeloma	Myeloma	NNP
work_izjlueimqneiljcxm4zmi6kuna	212	57	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	212	58	010	010	CD
work_izjlueimqneiljcxm4zmi6kuna	212	59	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	212	60	Study	Study	NNP
work_izjlueimqneiljcxm4zmi6kuna	212	61	Investigators	Investigators	NNPS
work_izjlueimqneiljcxm4zmi6kuna	212	62	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	213	1	Lenalidomide	lenalidomide	JJ
work_izjlueimqneiljcxm4zmi6kuna	213	2	plus	plus	CC
work_izjlueimqneiljcxm4zmi6kuna	213	3	dexamethasone	dexamethasone	NN
work_izjlueimqneiljcxm4zmi6kuna	213	4	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	213	5	relapsed	relapsed	JJ
work_izjlueimqneiljcxm4zmi6kuna	213	6	or	or	CC
work_izjlueimqneiljcxm4zmi6kuna	213	7	refractory	refractory	NN
work_izjlueimqneiljcxm4zmi6kuna	213	8	multi-	multi-	FW
work_izjlueimqneiljcxm4zmi6kuna	213	9	ple	ple	NNP
work_izjlueimqneiljcxm4zmi6kuna	213	10	myeloma	myeloma	NNP
work_izjlueimqneiljcxm4zmi6kuna	213	11	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	214	1	N	N	NNP
work_izjlueimqneiljcxm4zmi6kuna	214	2	Engl	engl	NN
work_izjlueimqneiljcxm4zmi6kuna	214	3	J	j	NN
work_izjlueimqneiljcxm4zmi6kuna	214	4	Med	Med	NNP
work_izjlueimqneiljcxm4zmi6kuna	214	5	2007	2007	CD
work_izjlueimqneiljcxm4zmi6kuna	214	6	;	;	:
work_izjlueimqneiljcxm4zmi6kuna	214	7	357(21):2123	357(21):2123	CD
work_izjlueimqneiljcxm4zmi6kuna	214	8	-	-	SYM
work_izjlueimqneiljcxm4zmi6kuna	214	9	2132	2132	CD
work_izjlueimqneiljcxm4zmi6kuna	214	10	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	215	1	15	15	CD
work_izjlueimqneiljcxm4zmi6kuna	215	2	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	216	1	Palumbo	Palumbo	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	2	A	A	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	3	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	216	4	Hajek	Hajek	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	5	R	R	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	6	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	216	7	Delforge	Delforge	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	8	M	M	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	9	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	216	10	Kropff	Kropff	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	11	M	M	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	12	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	216	13	Petrucci	Petrucci	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	14	MT	MT	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	15	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	216	16	Catalano	Catalano	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	17	J	J	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	18	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	216	19	Gisslinger	Gisslinger	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	20	H	H	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	21	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	216	22	Wiktor	Wiktor	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	23	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	216	24	Jędrzejczak	Jędrzejczak	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	25	W	W	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	26	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	216	27	Zodelava	Zodelava	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	28	M	M	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	29	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	216	30	Weisel	Weisel	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	31	K	K	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	32	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	216	33	Cascavilla	Cascavilla	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	34	N	N	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	35	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	216	36	Iosava	Iosava	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	37	G	G	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	38	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	216	39	Cavo	Cavo	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	40	M	M	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	41	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	216	42	Kloczko	Kloczko	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	43	J	J	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	44	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	216	45	Bladé	Bladé	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	46	J	J	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	47	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	216	48	Beksac	Beksac	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	49	M	M	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	50	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	216	51	Spicka	Spicka	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	52	I	I	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	53	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	216	54	Plesner	plesner	NN
work_izjlueimqneiljcxm4zmi6kuna	216	55	T	T	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	56	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	216	57	Radke	Radke	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	58	J	J	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	59	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	216	60	Langer	Langer	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	61	C	C	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	62	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	216	63	Ben	Ben	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	64	Yehuda	Yehuda	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	65	D	D	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	66	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	216	67	Corso	Corso	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	68	A	A	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	69	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	216	70	Herbein	Herbein	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	71	L	L	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	72	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	216	73	Yu	Yu	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	74	Z	Z	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	75	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	216	76	Mei	Mei	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	77	J	J	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	78	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	216	79	Jacques	Jacques	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	80	C	C	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	81	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	216	82	Dimopoulos	Dimopoulos	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	83	MA	MA	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	84	;	;	:
work_izjlueimqneiljcxm4zmi6kuna	216	85	MM-015	MM-015	NNP
work_izjlueimqneiljcxm4zmi6kuna	216	86	Investigators	Investigators	NNPS
work_izjlueimqneiljcxm4zmi6kuna	216	87	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	217	1	Continuous	continuous	JJ
work_izjlueimqneiljcxm4zmi6kuna	217	2	lenalidomide	lenalidomide	JJ
work_izjlueimqneiljcxm4zmi6kuna	217	3	treatment	treatment	NN
work_izjlueimqneiljcxm4zmi6kuna	217	4	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	217	5	newly	newly	RB
work_izjlueimqneiljcxm4zmi6kuna	217	6	diagnosed	diagnose	VBN
work_izjlueimqneiljcxm4zmi6kuna	217	7	multiple	multiple	JJ
work_izjlueimqneiljcxm4zmi6kuna	217	8	myeloma	myeloma	NNS
work_izjlueimqneiljcxm4zmi6kuna	217	9	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	218	1	N	N	NNP
work_izjlueimqneiljcxm4zmi6kuna	218	2	Engl	Engl	NNP
work_izjlueimqneiljcxm4zmi6kuna	218	3	J	J	NNP
work_izjlueimqneiljcxm4zmi6kuna	218	4	Med	Med	NNP
work_izjlueimqneiljcxm4zmi6kuna	218	5	2012	2012	CD
work_izjlueimqneiljcxm4zmi6kuna	218	6	;	;	:
work_izjlueimqneiljcxm4zmi6kuna	218	7	366(19):1759	366(19):1759	CD
work_izjlueimqneiljcxm4zmi6kuna	218	8	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	218	9	1769	1769	CD
work_izjlueimqneiljcxm4zmi6kuna	218	10	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	219	1	16	16	CD
work_izjlueimqneiljcxm4zmi6kuna	219	2	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	220	1	Yang	Yang	NNP
work_izjlueimqneiljcxm4zmi6kuna	220	2	B	B	NNP
work_izjlueimqneiljcxm4zmi6kuna	220	3	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	220	4	Yu	Yu	NNP
work_izjlueimqneiljcxm4zmi6kuna	220	5	RL	RL	NNP
work_izjlueimqneiljcxm4zmi6kuna	220	6	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	220	7	Chi	Chi	NNP
work_izjlueimqneiljcxm4zmi6kuna	220	8	XH	xh	NN
work_izjlueimqneiljcxm4zmi6kuna	220	9	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	220	10	Lu	Lu	NNP
work_izjlueimqneiljcxm4zmi6kuna	220	11	XC	XC	NNP
work_izjlueimqneiljcxm4zmi6kuna	220	12	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	221	1	Lenalidomide	lenalidomide	VB
work_izjlueimqneiljcxm4zmi6kuna	221	2	treat-	treat-	JJ
work_izjlueimqneiljcxm4zmi6kuna	221	3	ment	ment	NN
work_izjlueimqneiljcxm4zmi6kuna	221	4	for	for	IN
work_izjlueimqneiljcxm4zmi6kuna	221	5	multiple	multiple	JJ
work_izjlueimqneiljcxm4zmi6kuna	221	6	myeloma	myeloma	NN
work_izjlueimqneiljcxm4zmi6kuna	221	7	:	:	:
work_izjlueimqneiljcxm4zmi6kuna	221	8	systematic	systematic	JJ
work_izjlueimqneiljcxm4zmi6kuna	221	9	review	review	NN
work_izjlueimqneiljcxm4zmi6kuna	221	10	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	221	11	meta	meta	JJ
work_izjlueimqneiljcxm4zmi6kuna	221	12	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	221	13	analysis	analysis	NN
work_izjlueimqneiljcxm4zmi6kuna	221	14	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	221	15	randomized	randomized	JJ
work_izjlueimqneiljcxm4zmi6kuna	221	16	controlled	controlled	JJ
work_izjlueimqneiljcxm4zmi6kuna	221	17	trials	trial	NNS
work_izjlueimqneiljcxm4zmi6kuna	221	18	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	222	1	PLoS	plos	ADD
work_izjlueimqneiljcxm4zmi6kuna	222	2	One	one	CD
work_izjlueimqneiljcxm4zmi6kuna	222	3	2013	2013	CD
work_izjlueimqneiljcxm4zmi6kuna	222	4	;	;	:
work_izjlueimqneiljcxm4zmi6kuna	222	5	8(5):e64354	8(5):e64354	CD
work_izjlueimqneiljcxm4zmi6kuna	222	6	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	223	1	17	17	CD
work_izjlueimqneiljcxm4zmi6kuna	223	2	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	224	1	Morgan	Morgan	NNP
work_izjlueimqneiljcxm4zmi6kuna	224	2	G.	G.	NNP
work_izjlueimqneiljcxm4zmi6kuna	224	3	Future	Future	NNP
work_izjlueimqneiljcxm4zmi6kuna	224	4	drug	drug	NN
work_izjlueimqneiljcxm4zmi6kuna	224	5	developments	development	NNS
work_izjlueimqneiljcxm4zmi6kuna	224	6	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	224	7	multiple	multiple	JJ
work_izjlueimqneiljcxm4zmi6kuna	224	8	myeloma	myeloma	NN
work_izjlueimqneiljcxm4zmi6kuna	224	9	:	:	:
work_izjlueimqneiljcxm4zmi6kuna	224	10	an	an	DT
work_izjlueimqneiljcxm4zmi6kuna	224	11	overview	overview	NN
work_izjlueimqneiljcxm4zmi6kuna	224	12	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	224	13	novel	novel	JJ
work_izjlueimqneiljcxm4zmi6kuna	224	14	lenalidomide	lenalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	224	15	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	224	16	based	base	VBN
work_izjlueimqneiljcxm4zmi6kuna	224	17	combination	combination	NN
work_izjlueimqneiljcxm4zmi6kuna	224	18	therapies	therapy	NNS
work_izjlueimqneiljcxm4zmi6kuna	224	19	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	225	1	Blood	blood	NN
work_izjlueimqneiljcxm4zmi6kuna	225	2	Rev	Rev	NNP
work_izjlueimqneiljcxm4zmi6kuna	225	3	2010	2010	CD
work_izjlueimqneiljcxm4zmi6kuna	225	4	;	;	:
work_izjlueimqneiljcxm4zmi6kuna	225	5	24(Supl	24(supl	CD
work_izjlueimqneiljcxm4zmi6kuna	225	6	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	226	1	1):S27-S32	1):s27-s32	LS
work_izjlueimqneiljcxm4zmi6kuna	226	2	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	227	1	18	18	CD
work_izjlueimqneiljcxm4zmi6kuna	227	2	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	228	1	Stewart	Stewart	NNP
work_izjlueimqneiljcxm4zmi6kuna	228	2	AK	AK	NNP
work_izjlueimqneiljcxm4zmi6kuna	228	3	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	228	4	Jacobus	Jacobus	NNP
work_izjlueimqneiljcxm4zmi6kuna	228	5	S	S	NNP
work_izjlueimqneiljcxm4zmi6kuna	228	6	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	228	7	Fonseca	Fonseca	NNP
work_izjlueimqneiljcxm4zmi6kuna	228	8	R	R	NNP
work_izjlueimqneiljcxm4zmi6kuna	228	9	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	228	10	Weiss	Weiss	NNP
work_izjlueimqneiljcxm4zmi6kuna	228	11	M	M	NNP
work_izjlueimqneiljcxm4zmi6kuna	228	12	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	228	13	Calland-	Calland-	NNP
work_izjlueimqneiljcxm4zmi6kuna	228	14	er	er	UH
work_izjlueimqneiljcxm4zmi6kuna	228	15	NS	NS	NNP
work_izjlueimqneiljcxm4zmi6kuna	228	16	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	228	17	Chanan	Chanan	NNP
work_izjlueimqneiljcxm4zmi6kuna	228	18	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	228	19	Khan	Khan	NNP
work_izjlueimqneiljcxm4zmi6kuna	228	20	AA	AA	NNP
work_izjlueimqneiljcxm4zmi6kuna	228	21	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	228	22	Rajkumar	Rajkumar	NNP
work_izjlueimqneiljcxm4zmi6kuna	228	23	SV	SV	NNP
work_izjlueimqneiljcxm4zmi6kuna	228	24	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	229	1	Melphalan	Melphalan	NNP
work_izjlueimqneiljcxm4zmi6kuna	229	2	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	229	3	prednisone	prednisone	NN
work_izjlueimqneiljcxm4zmi6kuna	229	4	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	229	5	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	229	6	thalidomide	thalidomide	NNP
work_izjlueimqneiljcxm4zmi6kuna	229	7	vs	vs	IN
work_izjlueimqneiljcxm4zmi6kuna	229	8	melphalan	melphalan	NNP
work_izjlueimqneiljcxm4zmi6kuna	229	9	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	229	10	predni-	predni-	NNP
work_izjlueimqneiljcxm4zmi6kuna	229	11	sone	sone	NNP
work_izjlueimqneiljcxm4zmi6kuna	229	12	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	229	13	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	229	14	lenalidomide	lenalidomide	VB
work_izjlueimqneiljcxm4zmi6kuna	229	15	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	229	16	ECOG	ECOG	NNP
work_izjlueimqneiljcxm4zmi6kuna	229	17	E1A06	E1A06	NNP
work_izjlueimqneiljcxm4zmi6kuna	229	18	)	)	-RRB-
work_izjlueimqneiljcxm4zmi6kuna	229	19	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	229	20	untreated	untreated	JJ
work_izjlueimqneiljcxm4zmi6kuna	229	21	multiple	multiple	JJ
work_izjlueimqneiljcxm4zmi6kuna	229	22	myeloma	myeloma	NNS
work_izjlueimqneiljcxm4zmi6kuna	229	23	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	230	1	Blood	blood	NN
work_izjlueimqneiljcxm4zmi6kuna	230	2	2015	2015	CD
work_izjlueimqneiljcxm4zmi6kuna	230	3	;	;	:
work_izjlueimqneiljcxm4zmi6kuna	230	4	126(11):1294	126(11):1294	CD
work_izjlueimqneiljcxm4zmi6kuna	230	5	-	-	SYM
work_izjlueimqneiljcxm4zmi6kuna	230	6	1301	1301	CD
work_izjlueimqneiljcxm4zmi6kuna	230	7	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	231	1	19	19	CD
work_izjlueimqneiljcxm4zmi6kuna	231	2	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	232	1	Zweegman	Zweegman	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	2	S	S	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	3	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	232	4	van	van	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	5	der	der	IN
work_izjlueimqneiljcxm4zmi6kuna	232	6	Holt	Holt	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	7	B	B	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	8	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	232	9	Mellqvist	Mellqvist	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	10	UH	UH	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	11	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	232	12	Salomo	Salomo	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	13	M	M	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	14	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	232	15	Bos	Bos	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	16	GM	GM	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	17	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	232	18	Levin	Levin	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	19	MD	MD	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	20	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	232	21	Visser	Visser	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	22	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	232	23	Wisselaar	Wisselaar	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	24	H	H	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	25	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	232	26	Hansson	Hansson	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	27	M	M	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	28	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	232	29	van	van	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	30	der	der	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	31	Velden	Velden	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	32	AW	AW	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	33	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	232	34	Deenik	Deenik	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	35	W	W	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	36	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	232	37	Gruber	Gruber	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	38	A	A	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	39	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	232	40	Coenen	Coenen	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	41	JL	JL	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	42	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	232	43	Plesner	Plesner	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	44	T	T	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	45	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	232	46	Klein	Klein	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	47	SK	SK	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	48	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	232	49	Tanis	Tanis	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	50	BC	BC	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	51	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	232	52	Szatkowski	Szatkowski	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	53	DL	DL	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	54	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	232	55	Brouwer	Brouwer	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	56	RE	RE	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	57	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	232	58	Westerman	Westerman	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	59	M	M	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	60	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	232	61	Leys	Leys	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	62	MR	MR	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	63	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	232	64	Sinnige	Sinnige	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	65	HA	HA	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	66	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	232	67	Haukås	Haukås	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	68	E	E	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	69	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	232	70	van	van	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	71	der	der	NN
work_izjlueimqneiljcxm4zmi6kuna	232	72	Hem	Hem	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	73	KG	KG	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	74	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	232	75	Durian	Durian	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	76	MF	MF	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	77	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	232	78	Mattijssen	Mattijssen	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	79	EV	EV	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	80	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	232	81	van	van	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	82	de	de	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	83	Donk	Donk	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	84	NW	NW	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	85	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	232	86	Stevens	Stevens	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	87	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	232	88	Kroef	Kroef	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	89	MJ	MJ	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	90	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	232	91	Sonneveld	Sonneveld	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	92	P	P	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	93	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	232	94	Waage	Waage	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	95	A.	a.	NN
work_izjlueimqneiljcxm4zmi6kuna	232	96	Melphalan	Melphalan	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	97	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	232	98	prednisone	prednisone	NN
work_izjlueimqneiljcxm4zmi6kuna	232	99	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	232	100	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	232	101	lenalido-	lenalido-	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	102	mide	mide	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	103	versus	versus	IN
work_izjlueimqneiljcxm4zmi6kuna	232	104	melphalan	melphalan	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	105	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	232	106	prednisone	prednisone	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	107	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	232	108	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	232	109	thalido-	thalido-	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	110	mide	mide	NNP
work_izjlueimqneiljcxm4zmi6kuna	232	111	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	232	112	untreated	untreated	JJ
work_izjlueimqneiljcxm4zmi6kuna	232	113	multiple	multiple	JJ
work_izjlueimqneiljcxm4zmi6kuna	232	114	myeloma	myeloma	NNS
work_izjlueimqneiljcxm4zmi6kuna	232	115	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	233	1	Blood	blood	NN
work_izjlueimqneiljcxm4zmi6kuna	233	2	2016	2016	CD
work_izjlueimqneiljcxm4zmi6kuna	233	3	;	;	:
work_izjlueimqneiljcxm4zmi6kuna	233	4	127(9):1109	127(9):1109	NNP
work_izjlueimqneiljcxm4zmi6kuna	233	5	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	233	6	1116	1116	CD
work_izjlueimqneiljcxm4zmi6kuna	233	7	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	234	1	20	20	CD
work_izjlueimqneiljcxm4zmi6kuna	234	2	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	235	1	Gay	Gay	NNP
work_izjlueimqneiljcxm4zmi6kuna	235	2	F	F	NNP
work_izjlueimqneiljcxm4zmi6kuna	235	3	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	235	4	Hayman	Hayman	NNP
work_izjlueimqneiljcxm4zmi6kuna	235	5	SR	SR	NNP
work_izjlueimqneiljcxm4zmi6kuna	235	6	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	235	7	Lacy	Lacy	NNP
work_izjlueimqneiljcxm4zmi6kuna	235	8	MQ	MQ	NNP
work_izjlueimqneiljcxm4zmi6kuna	235	9	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	235	10	Buadi	Buadi	NNP
work_izjlueimqneiljcxm4zmi6kuna	235	11	F	F	NNP
work_izjlueimqneiljcxm4zmi6kuna	235	12	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	235	13	Gertz	Gertz	NNP
work_izjlueimqneiljcxm4zmi6kuna	235	14	MA	MA	NNP
work_izjlueimqneiljcxm4zmi6kuna	235	15	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	235	16	Ku-	Ku-	NNP
work_izjlueimqneiljcxm4zmi6kuna	235	17	mar	mar	NNP
work_izjlueimqneiljcxm4zmi6kuna	235	18	S	S	NNP
work_izjlueimqneiljcxm4zmi6kuna	235	19	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	235	20	Dispenzieri	Dispenzieri	NNP
work_izjlueimqneiljcxm4zmi6kuna	235	21	A	A	NNP
work_izjlueimqneiljcxm4zmi6kuna	235	22	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	235	23	Mikhael	Mikhael	NNP
work_izjlueimqneiljcxm4zmi6kuna	235	24	JR	JR	NNP
work_izjlueimqneiljcxm4zmi6kuna	235	25	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	235	26	Bergsagel	Bergsagel	NNP
work_izjlueimqneiljcxm4zmi6kuna	235	27	PL	PL	NNP
work_izjlueimqneiljcxm4zmi6kuna	235	28	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	235	29	Dingli	Dingli	NNP
work_izjlueimqneiljcxm4zmi6kuna	235	30	D	D	NNP
work_izjlueimqneiljcxm4zmi6kuna	235	31	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	235	32	Reeder	Reeder	NNP
work_izjlueimqneiljcxm4zmi6kuna	235	33	CB	CB	NNP
work_izjlueimqneiljcxm4zmi6kuna	235	34	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	235	35	Lust	Lust	NNP
work_izjlueimqneiljcxm4zmi6kuna	235	36	JA	JA	NNP
work_izjlueimqneiljcxm4zmi6kuna	235	37	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	235	38	Russell	Russell	NNP
work_izjlueimqneiljcxm4zmi6kuna	235	39	SJ	SJ	NNP
work_izjlueimqneiljcxm4zmi6kuna	235	40	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	235	41	Roy	Roy	NNP
work_izjlueimqneiljcxm4zmi6kuna	235	42	V	V	NNP
work_izjlueimqneiljcxm4zmi6kuna	235	43	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	235	44	Zeldenrust	Zeldenrust	NNP
work_izjlueimqneiljcxm4zmi6kuna	235	45	SR	SR	NNP
work_izjlueimqneiljcxm4zmi6kuna	235	46	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	235	47	Witzig	Witzig	NNP
work_izjlueimqneiljcxm4zmi6kuna	235	48	TE	TE	NNP
work_izjlueimqneiljcxm4zmi6kuna	235	49	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	235	50	Fonseca	Fonseca	NNP
work_izjlueimqneiljcxm4zmi6kuna	235	51	R	R	NNP
work_izjlueimqneiljcxm4zmi6kuna	235	52	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	235	53	Kyle	Kyle	NNP
work_izjlueimqneiljcxm4zmi6kuna	235	54	RA	RA	NNP
work_izjlueimqneiljcxm4zmi6kuna	235	55	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	235	56	Greipp	Greipp	NNP
work_izjlueimqneiljcxm4zmi6kuna	235	57	PR	PR	NNP
work_izjlueimqneiljcxm4zmi6kuna	235	58	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	235	59	Stew-	Stew-	.
work_izjlueimqneiljcxm4zmi6kuna	235	60	art	art	NN
work_izjlueimqneiljcxm4zmi6kuna	235	61	AK	AK	NNP
work_izjlueimqneiljcxm4zmi6kuna	235	62	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	235	63	Rajkumar	Rajkumar	NNP
work_izjlueimqneiljcxm4zmi6kuna	235	64	SV	SV	NNP
work_izjlueimqneiljcxm4zmi6kuna	235	65	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	236	1	Lenalidomide	lenalidomide	JJ
work_izjlueimqneiljcxm4zmi6kuna	236	2	plus	plus	CC
work_izjlueimqneiljcxm4zmi6kuna	236	3	dexametha-	dexametha-	XX
work_izjlueimqneiljcxm4zmi6kuna	236	4	sone	sone	NN
work_izjlueimqneiljcxm4zmi6kuna	236	5	versus	versus	IN
work_izjlueimqneiljcxm4zmi6kuna	236	6	thalidomide	thalidomide	NNP
work_izjlueimqneiljcxm4zmi6kuna	236	7	plus	plus	CC
work_izjlueimqneiljcxm4zmi6kuna	236	8	dexamethasone	dexamethasone	NN
work_izjlueimqneiljcxm4zmi6kuna	236	9	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	236	10	newly	newly	RB
work_izjlueimqneiljcxm4zmi6kuna	236	11	diagnosed	diagnose	VBN
work_izjlueimqneiljcxm4zmi6kuna	236	12	multiple	multiple	JJ
work_izjlueimqneiljcxm4zmi6kuna	236	13	myeloma	myeloma	NN
work_izjlueimqneiljcxm4zmi6kuna	236	14	:	:	:
work_izjlueimqneiljcxm4zmi6kuna	236	15	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	236	16	comparative	comparative	JJ
work_izjlueimqneiljcxm4zmi6kuna	236	17	analysis	analysis	NN
work_izjlueimqneiljcxm4zmi6kuna	236	18	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	236	19	411	411	CD
work_izjlueimqneiljcxm4zmi6kuna	236	20	patients	patient	NNS
work_izjlueimqneiljcxm4zmi6kuna	236	21	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	237	1	Blood	blood	NN
work_izjlueimqneiljcxm4zmi6kuna	237	2	2010	2010	CD
work_izjlueimqneiljcxm4zmi6kuna	237	3	;	;	:
work_izjlueimqneiljcxm4zmi6kuna	237	4	115(7):1343	115(7):1343	NNP
work_izjlueimqneiljcxm4zmi6kuna	237	5	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	237	6	1350	1350	CD
work_izjlueimqneiljcxm4zmi6kuna	237	7	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	238	1	21	21	CD
work_izjlueimqneiljcxm4zmi6kuna	238	2	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	239	1	Sashidharan	Sashidharan	NNP
work_izjlueimqneiljcxm4zmi6kuna	239	2	N	N	NNP
work_izjlueimqneiljcxm4zmi6kuna	239	3	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	239	4	Shenoy	Shenoy	NNP
work_izjlueimqneiljcxm4zmi6kuna	239	5	S	S	NNP
work_izjlueimqneiljcxm4zmi6kuna	239	6	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	239	7	Kishore	Kishore	NNP
work_izjlueimqneiljcxm4zmi6kuna	239	8	MK	MK	NNP
work_izjlueimqneiljcxm4zmi6kuna	239	9	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	239	10	Thanusubra-	Thanusubra-	NNP
work_izjlueimqneiljcxm4zmi6kuna	239	11	manian	manian	JJ
work_izjlueimqneiljcxm4zmi6kuna	239	12	H.	H.	NNP
work_izjlueimqneiljcxm4zmi6kuna	239	13	Comparison	Comparison	NNP
work_izjlueimqneiljcxm4zmi6kuna	239	14	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	239	15	Two	Two	NNP
work_izjlueimqneiljcxm4zmi6kuna	239	16	Therapeutic	Therapeutic	NNP
work_izjlueimqneiljcxm4zmi6kuna	239	17	Regimes	Regimes	NNPS
work_izjlueimqneiljcxm4zmi6kuna	239	18	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	239	19	Lenalidomide	lenalidomide	IN
work_izjlueimqneiljcxm4zmi6kuna	239	20	with	with	IN
work_izjlueimqneiljcxm4zmi6kuna	239	21	Dexamethasone	Dexamethasone	NNP
work_izjlueimqneiljcxm4zmi6kuna	239	22	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	239	23	Thalidomide	Thalidomide	NNP
work_izjlueimqneiljcxm4zmi6kuna	239	24	with	with	IN
work_izjlueimqneiljcxm4zmi6kuna	239	25	Dexamethasone	Dexamethasone	NNP
work_izjlueimqneiljcxm4zmi6kuna	239	26	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	239	27	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	239	28	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	239	29	Treatment	Treatment	NNP
work_izjlueimqneiljcxm4zmi6kuna	239	30	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	239	31	Multiple	Multiple	NNP
work_izjlueimqneiljcxm4zmi6kuna	239	32	Myeloma	Myeloma	NNP
work_izjlueimqneiljcxm4zmi6kuna	239	33	at	at	IN
work_izjlueimqneiljcxm4zmi6kuna	239	34	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	239	35	Tertiary	Tertiary	NNP
work_izjlueimqneiljcxm4zmi6kuna	239	36	Care	Care	NNP
work_izjlueimqneiljcxm4zmi6kuna	239	37	Hospital	Hospital	NNP
work_izjlueimqneiljcxm4zmi6kuna	239	38	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	239	39	India	India	NNP
work_izjlueimqneiljcxm4zmi6kuna	239	40	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	240	1	J	J	NNP
work_izjlueimqneiljcxm4zmi6kuna	240	2	Clin	Clin	NNP
work_izjlueimqneiljcxm4zmi6kuna	240	3	Diagn	Diagn	NNP
work_izjlueimqneiljcxm4zmi6kuna	240	4	Res	Res	NNP
work_izjlueimqneiljcxm4zmi6kuna	240	5	2015	2015	CD
work_izjlueimqneiljcxm4zmi6kuna	240	6	;	;	:
work_izjlueimqneiljcxm4zmi6kuna	240	7	9(5):XC01-XC04	9(5):xc01-xc04	CD
work_izjlueimqneiljcxm4zmi6kuna	240	8	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	241	1	22	22	CD
work_izjlueimqneiljcxm4zmi6kuna	241	2	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	242	1	Luo	Luo	NNP
work_izjlueimqneiljcxm4zmi6kuna	242	2	J	J	NNP
work_izjlueimqneiljcxm4zmi6kuna	242	3	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	242	4	Gagne	Gagne	NNP
work_izjlueimqneiljcxm4zmi6kuna	242	5	JJ	JJ	NNP
work_izjlueimqneiljcxm4zmi6kuna	242	6	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	242	7	Landon	Landon	NNP
work_izjlueimqneiljcxm4zmi6kuna	242	8	J	J	NNP
work_izjlueimqneiljcxm4zmi6kuna	242	9	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	242	10	Avorn	Avorn	NNP
work_izjlueimqneiljcxm4zmi6kuna	242	11	J	J	NNP
work_izjlueimqneiljcxm4zmi6kuna	242	12	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	242	13	Kesselheim	Kesselheim	NNP
work_izjlueimqneiljcxm4zmi6kuna	242	14	AS	as	IN
work_izjlueimqneiljcxm4zmi6kuna	242	15	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	243	1	Comparative	comparative	JJ
work_izjlueimqneiljcxm4zmi6kuna	243	2	effectiveness	effectiveness	NN
work_izjlueimqneiljcxm4zmi6kuna	243	3	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	243	4	safety	safety	NN
work_izjlueimqneiljcxm4zmi6kuna	243	5	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	243	6	thalidomide	thalidomide	NN
work_izjlueimqneiljcxm4zmi6kuna	243	7	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	243	8	lenalidomide	lenalidomide	VB
work_izjlueimqneiljcxm4zmi6kuna	243	9	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	243	10	patients	patient	NNS
work_izjlueimqneiljcxm4zmi6kuna	243	11	with	with	IN
work_izjlueimqneiljcxm4zmi6kuna	243	12	multiple	multiple	JJ
work_izjlueimqneiljcxm4zmi6kuna	243	13	myeloma	myeloma	NN
work_izjlueimqneiljcxm4zmi6kuna	243	14	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	243	15	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	243	16	United	United	NNP
work_izjlueimqneiljcxm4zmi6kuna	243	17	States	States	NNP
work_izjlueimqneiljcxm4zmi6kuna	243	18	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	243	19	America	America	NNP
work_izjlueimqneiljcxm4zmi6kuna	243	20	:	:	:
work_izjlueimqneiljcxm4zmi6kuna	243	21	A	a	DT
work_izjlueimqneiljcxm4zmi6kuna	243	22	population	population	NN
work_izjlueimqneiljcxm4zmi6kuna	243	23	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	243	24	based	base	VBN
work_izjlueimqneiljcxm4zmi6kuna	243	25	cohort	cohort	NN
work_izjlueimqneiljcxm4zmi6kuna	243	26	study	study	NN
work_izjlueimqneiljcxm4zmi6kuna	243	27	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	244	1	Eur	Eur	NNP
work_izjlueimqneiljcxm4zmi6kuna	244	2	J	J	NNP
work_izjlueimqneiljcxm4zmi6kuna	244	3	Cancer	Cancer	NNP
work_izjlueimqneiljcxm4zmi6kuna	244	4	2017	2017	CD
work_izjlueimqneiljcxm4zmi6kuna	244	5	;	;	:
work_izjlueimqneiljcxm4zmi6kuna	244	6	70:22	70:22	CD
work_izjlueimqneiljcxm4zmi6kuna	244	7	-	-	SYM
work_izjlueimqneiljcxm4zmi6kuna	244	8	33	33	CD
work_izjlueimqneiljcxm4zmi6kuna	244	9	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	245	1	23	23	CD
work_izjlueimqneiljcxm4zmi6kuna	245	2	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	246	1	Wang	Wang	NNP
work_izjlueimqneiljcxm4zmi6kuna	246	2	A	A	NNP
work_izjlueimqneiljcxm4zmi6kuna	246	3	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	246	4	Duan	Duan	NNP
work_izjlueimqneiljcxm4zmi6kuna	246	5	Q	Q	NNP
work_izjlueimqneiljcxm4zmi6kuna	246	6	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	246	7	Liu	Liu	NNP
work_izjlueimqneiljcxm4zmi6kuna	246	8	X	X	NNP
work_izjlueimqneiljcxm4zmi6kuna	246	9	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	246	10	Ding	Ding	NNP
work_izjlueimqneiljcxm4zmi6kuna	246	11	K	K	NNP
work_izjlueimqneiljcxm4zmi6kuna	246	12	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	246	13	Han	Han	NNP
work_izjlueimqneiljcxm4zmi6kuna	246	14	Y	Y	NNP
work_izjlueimqneiljcxm4zmi6kuna	246	15	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	246	16	Zhu	Zhu	NNP
work_izjlueimqneiljcxm4zmi6kuna	246	17	W	W	NNP
work_izjlueimqneiljcxm4zmi6kuna	246	18	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	246	19	Sun	Sun	NNP
work_izjlueimqneiljcxm4zmi6kuna	246	20	Z.	Z.	NNP
work_izjlueimqneiljcxm4zmi6kuna	247	1	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	247	2	Bortezomib	Bortezomib	NNP
work_izjlueimqneiljcxm4zmi6kuna	247	3	plus	plus	CC
work_izjlueimqneiljcxm4zmi6kuna	247	4	lenalidomide	lenalidomide	VB
work_izjlueimqneiljcxm4zmi6kuna	247	5	/	/	,
work_izjlueimqneiljcxm4zmi6kuna	247	6	thalidomide)-	thalidomide)-	NNS
work_izjlueimqneiljcxm4zmi6kuna	247	7	vs.	vs.	FW
work_izjlueimqneiljcxm4zmi6kuna	247	8	(	(	-LRB-
work_izjlueimqneiljcxm4zmi6kuna	247	9	bortezomib	bortezomib	NNP
work_izjlueimqneiljcxm4zmi6kuna	247	10	or	or	CC
work_izjlueimqneiljcxm4zmi6kuna	247	11	lenalidomide	lenalidomide	VB
work_izjlueimqneiljcxm4zmi6kuna	247	12	/	/	,
work_izjlueimqneiljcxm4zmi6kuna	247	13	thalidomide)-contain-	thalidomide)-contain-	NNP
work_izjlueimqneiljcxm4zmi6kuna	247	14	ing	ing	NNP
work_izjlueimqneiljcxm4zmi6kuna	247	15	regimens	regimen	VBZ
work_izjlueimqneiljcxm4zmi6kuna	247	16	as	as	IN
work_izjlueimqneiljcxm4zmi6kuna	247	17	induction	induction	NN
work_izjlueimqneiljcxm4zmi6kuna	247	18	therapy	therapy	NN
work_izjlueimqneiljcxm4zmi6kuna	247	19	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	247	20	newly	newly	RB
work_izjlueimqneiljcxm4zmi6kuna	247	21	diagnosed	diagnose	VBN
work_izjlueimqneiljcxm4zmi6kuna	247	22	multiple	multiple	JJ
work_izjlueimqneiljcxm4zmi6kuna	247	23	myeloma	myeloma	NN
work_izjlueimqneiljcxm4zmi6kuna	247	24	:	:	:
work_izjlueimqneiljcxm4zmi6kuna	247	25	a	a	DT
work_izjlueimqneiljcxm4zmi6kuna	247	26	meta	meta	JJ
work_izjlueimqneiljcxm4zmi6kuna	247	27	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	247	28	analysis	analysis	NN
work_izjlueimqneiljcxm4zmi6kuna	247	29	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	247	30	randomized	randomized	JJ
work_izjlueimqneiljcxm4zmi6kuna	247	31	controlled	controlled	JJ
work_izjlueimqneiljcxm4zmi6kuna	247	32	trials	trial	NNS
work_izjlueimqneiljcxm4zmi6kuna	247	33	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	248	1	Ann	Ann	NNP
work_izjlueimqneiljcxm4zmi6kuna	248	2	Hematol	Hematol	NNP
work_izjlueimqneiljcxm4zmi6kuna	248	3	2012	2012	CD
work_izjlueimqneiljcxm4zmi6kuna	248	4	;	;	:
work_izjlueimqneiljcxm4zmi6kuna	248	5	91(11):1779-	91(11):1779-	CD
work_izjlueimqneiljcxm4zmi6kuna	248	6	1784	1784	CD
work_izjlueimqneiljcxm4zmi6kuna	248	7	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	249	1	3	3	CD
work_izjlueimqneiljcxm4zmi6kuna	249	2	7	7	CD
work_izjlueimqneiljcxm4zmi6kuna	249	3	9	9	CD
work_izjlueimqneiljcxm4zmi6kuna	249	4	2	2	CD
work_izjlueimqneiljcxm4zmi6kuna	249	5	P	p	NN
work_izjlueimqneiljcxm4zmi6kuna	249	6	au	au	NNP
work_izjlueimqneiljcxm4zmi6kuna	249	7	m	m	NNP
work_izjlueimqneiljcxm4zmi6kuna	249	8	ga	ga	NNP
work_izjlueimqneiljcxm4zmi6kuna	249	9	rt	rt	NNP
work_izjlueimqneiljcxm4zmi6kuna	249	10	te	te	NNP
work_izjlueimqneiljcxm4zmi6kuna	249	11	n	n	NNP
work_izjlueimqneiljcxm4zmi6kuna	249	12	F	F	NNP
work_izjlueimqneiljcxm4zmi6kuna	249	13	JR	JR	NNP
work_izjlueimqneiljcxm4zmi6kuna	249	14	24	24	CD
work_izjlueimqneiljcxm4zmi6kuna	249	15	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	250	1	Garrison	Garrison	NNP
work_izjlueimqneiljcxm4zmi6kuna	250	2	Junior	Junior	NNP
work_izjlueimqneiljcxm4zmi6kuna	250	3	LP	LP	NNP
work_izjlueimqneiljcxm4zmi6kuna	250	4	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	250	5	Wang	Wang	NNP
work_izjlueimqneiljcxm4zmi6kuna	250	6	ST	ST	NNP
work_izjlueimqneiljcxm4zmi6kuna	250	7	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	250	8	Huang	Huang	NNP
work_izjlueimqneiljcxm4zmi6kuna	250	9	H	H	NNP
work_izjlueimqneiljcxm4zmi6kuna	250	10	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	250	11	Ba	Ba	NNP
work_izjlueimqneiljcxm4zmi6kuna	250	12	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	250	13	Mancini	Mancini	NNP
work_izjlueimqneiljcxm4zmi6kuna	250	14	A	A	NNP
work_izjlueimqneiljcxm4zmi6kuna	250	15	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	250	16	Shi	Shi	NNP
work_izjlueimqneiljcxm4zmi6kuna	250	17	H	H	NNP
work_izjlueimqneiljcxm4zmi6kuna	250	18	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	250	19	Chen	Chen	NNP
work_izjlueimqneiljcxm4zmi6kuna	250	20	K	K	NNP
work_izjlueimqneiljcxm4zmi6kuna	250	21	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	250	22	Korves	Korves	NNP
work_izjlueimqneiljcxm4zmi6kuna	250	23	C	C	NNP
work_izjlueimqneiljcxm4zmi6kuna	250	24	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	250	25	Dhawan	Dhawan	NNP
work_izjlueimqneiljcxm4zmi6kuna	250	26	R	R	NNP
work_izjlueimqneiljcxm4zmi6kuna	250	27	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	250	28	Cakana	Cakana	NNP
work_izjlueimqneiljcxm4zmi6kuna	250	29	A	A	NNP
work_izjlueimqneiljcxm4zmi6kuna	250	30	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	250	31	van	van	NNP
work_izjlueimqneiljcxm4zmi6kuna	250	32	de	de	NNP
work_izjlueimqneiljcxm4zmi6kuna	250	33	Velde	Velde	NNP
work_izjlueimqneiljcxm4zmi6kuna	250	34	H	H	NNP
work_izjlueimqneiljcxm4zmi6kuna	250	35	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	250	36	Corzo	corzo	NN
work_izjlueimqneiljcxm4zmi6kuna	250	37	D	d	NN
work_izjlueimqneiljcxm4zmi6kuna	250	38	,	,	,
work_izjlueimqneiljcxm4zmi6kuna	250	39	Duh	Duh	NNP
work_izjlueimqneiljcxm4zmi6kuna	250	40	MS	MS	NNP
work_izjlueimqneiljcxm4zmi6kuna	250	41	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	251	1	The	the	DT
work_izjlueimqneiljcxm4zmi6kuna	251	2	cost	cost	NN
work_izjlueimqneiljcxm4zmi6kuna	251	3	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	251	4	effective-	effective-	NN
work_izjlueimqneiljcxm4zmi6kuna	251	5	ness	ness	NN
work_izjlueimqneiljcxm4zmi6kuna	251	6	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	251	7	initial	initial	JJ
work_izjlueimqneiljcxm4zmi6kuna	251	8	treatment	treatment	NN
work_izjlueimqneiljcxm4zmi6kuna	251	9	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	251	10	multiple	multiple	JJ
work_izjlueimqneiljcxm4zmi6kuna	251	11	myeloma	myeloma	NN
work_izjlueimqneiljcxm4zmi6kuna	251	12	in	in	IN
work_izjlueimqneiljcxm4zmi6kuna	251	13	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	251	14	U.S.	U.S.	NNP
work_izjlueimqneiljcxm4zmi6kuna	251	15	with	with	IN
work_izjlueimqneiljcxm4zmi6kuna	251	16	bortezomib	bortezomib	NNP
work_izjlueimqneiljcxm4zmi6kuna	251	17	plus	plus	CC
work_izjlueimqneiljcxm4zmi6kuna	251	18	melphalan	melphalan	NNP
work_izjlueimqneiljcxm4zmi6kuna	251	19	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	251	20	prednisone	prednisone	NN
work_izjlueimqneiljcxm4zmi6kuna	251	21	versus	versus	FW
work_izjlueimqneiljcxm4zmi6kuna	251	22	thalidomide	thalidomide	NNP
work_izjlueimqneiljcxm4zmi6kuna	251	23	plus	plus	CC
work_izjlueimqneiljcxm4zmi6kuna	251	24	melphalan	melphalan	NNP
work_izjlueimqneiljcxm4zmi6kuna	251	25	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	251	26	prednisone	prednisone	NN
work_izjlueimqneiljcxm4zmi6kuna	251	27	or	or	CC
work_izjlueimqneiljcxm4zmi6kuna	251	28	lenalidomide	lenalidomide	VB
work_izjlueimqneiljcxm4zmi6kuna	251	29	plus	plus	CC
work_izjlueimqneiljcxm4zmi6kuna	251	30	melphalan	melphalan	NNP
work_izjlueimqneiljcxm4zmi6kuna	251	31	and	and	CC
work_izjlueimqneiljcxm4zmi6kuna	251	32	prednisone	prednisone	NN
work_izjlueimqneiljcxm4zmi6kuna	251	33	with	with	IN
work_izjlueimqneiljcxm4zmi6kuna	251	34	continuous	continuous	JJ
work_izjlueimqneiljcxm4zmi6kuna	251	35	lenalidomide	lenalidomide	JJ
work_izjlueimqneiljcxm4zmi6kuna	251	36	maintenance	maintenance	NN
work_izjlueimqneiljcxm4zmi6kuna	251	37	treatment	treatment	NN
work_izjlueimqneiljcxm4zmi6kuna	251	38	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	252	1	Oncologist	Oncologist	NNP
work_izjlueimqneiljcxm4zmi6kuna	252	2	2013	2013	CD
work_izjlueimqneiljcxm4zmi6kuna	252	3	;	;	:
work_izjlueimqneiljcxm4zmi6kuna	252	4	18(1):27	18(1):27	NN
work_izjlueimqneiljcxm4zmi6kuna	252	5	-	-	HYPH
work_izjlueimqneiljcxm4zmi6kuna	252	6	36	36	CD
work_izjlueimqneiljcxm4zmi6kuna	252	7	.	.	.
work_izjlueimqneiljcxm4zmi6kuna	253	1	Artigo	Artigo	NNS
work_izjlueimqneiljcxm4zmi6kuna	253	2	apresentado	apresentado	NNP
work_izjlueimqneiljcxm4zmi6kuna	253	3	em	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	253	4	05/12/2017	05/12/2017	CD
work_izjlueimqneiljcxm4zmi6kuna	253	5	Aprovado	Aprovado	NNP
work_izjlueimqneiljcxm4zmi6kuna	253	6	em	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	253	7	12/03/2018	12/03/2018	CD
work_izjlueimqneiljcxm4zmi6kuna	253	8	Versão	versão	JJ
work_izjlueimqneiljcxm4zmi6kuna	253	9	final	final	JJ
work_izjlueimqneiljcxm4zmi6kuna	253	10	apresentada	apresentada	NN
work_izjlueimqneiljcxm4zmi6kuna	253	11	em	-PRON-	PRP
work_izjlueimqneiljcxm4zmi6kuna	253	12	15/03/2018	15/03/2018	CD
work_izjlueimqneiljcxm4zmi6kuna	253	13	This	this	DT
work_izjlueimqneiljcxm4zmi6kuna	253	14	is	be	VBZ
work_izjlueimqneiljcxm4zmi6kuna	253	15	an	an	DT
work_izjlueimqneiljcxm4zmi6kuna	253	16	Open	open	JJ
work_izjlueimqneiljcxm4zmi6kuna	253	17	Access	access	NN
work_izjlueimqneiljcxm4zmi6kuna	253	18	article	article	NN
work_izjlueimqneiljcxm4zmi6kuna	253	19	distributed	distribute	VBN
work_izjlueimqneiljcxm4zmi6kuna	253	20	under	under	IN
work_izjlueimqneiljcxm4zmi6kuna	253	21	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	253	22	terms	term	NNS
work_izjlueimqneiljcxm4zmi6kuna	253	23	of	of	IN
work_izjlueimqneiljcxm4zmi6kuna	253	24	the	the	DT
work_izjlueimqneiljcxm4zmi6kuna	253	25	Creative	Creative	NNP
work_izjlueimqneiljcxm4zmi6kuna	253	26	Commons	Commons	NNP
work_izjlueimqneiljcxm4zmi6kuna	253	27	Attribution	Attribution	NNP
work_izjlueimqneiljcxm4zmi6kuna	253	28	LicenseBYCC	licensebycc	CD